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ABSTRACT
In this thesis, the synthesis of novel analogues of the second messenger D-myo­
inositol 1,4,5-trisphosphate is described.
1-0-Allyl-2,3,6-tri-0-benzyl-myoinositol was prepared by a known method. 
Isomerisation of the allyl group gave the 1-O-propenyl compound, which was 
phosphorylated at the 4- and 5-positions. Removal of the propenyl protecting 
group followed by phosphitylation of the 1-hydroxyl group and sulphoxidation of 
the phosphite furnished the fully protected 1-phosphorothioate analogue of 
lns(1,4,5)P3. Deblocking gave DL-myo-inositol 4,5-bisphosphate 1- 
phosphorothioate [lns(1,4,5)P3-1S].
A fluorescent chromophore was selectively attached to the 1-position of this 
lns(1,4,5)P3 analogue. The precursor DL-2,3,6-tri-Obenzyl-4,5-bis-[di-(2- 
cyanoethoxy)phospho]-myo-inositol was used to synthesise [35S]-labelled 
lns(1,4,5)P3-1S in co-operation with NEN-DuPont, USA.
Racemic 1-0-allyl-2,3,6-tri-0-benzyl-myoinositol was resolved into the optically 
active D- and L-isomers via the (-)-(co)-biscamphanates. The D-isomer was 
transformed as outlined above for the racemic compound to give D-myo-inositol
4,5-bisphosphate 1-phosphorothioate. The L-isomer was used in the synthesis 
of L-myo-inositol 1,4,5-trisphosphorothioate, which was found to be a potent non 
Ca2+-mobilising inhibitor of myo-inositol 1,4,5-trisphosphate 5-phosphatase. 
2 ,4 ,6-Tri-Opara-methoxybenzyl-/77yo-inositol was synthesised from myo-inositol 
via the orthoformate ester and was phosphitylated, sulphoxidised and de­
protected to give DL-myo-inositol 1,3,5-trisphosphorothioate, which was also 
found to be an effective 5-phosphatase inhibitor.
Routes to scyllo-inositol analogues of lns(1,4,5)P3 were studied. 1-0-Allyl-3,6-di-
0-benzyl-4,5-0-isopropylidene-myo-inositol was trifluoromethylsulphonylated at 
the free 2-position. Nucleophilic substitution of the triflate with caesium acetate 
gave 2-0-acetyl-1-0-allyl-3,6-di-0-benzyl-4,5-0-isopropylidene-scy//o-inositol. 
Successive removal of protecting groups gave 1-0-allyl-3,6-di-0-benzyl-scy//o- 
inositol and 1,4-di-Obenzyl-scy//o-inositol which were phosphorylated and 
deblocked yielding scyllo-inositol 1,4,5-trisphosphate and scyllo-inositol 1,2,4,5- 
tetrakisphosphate, respectively. These compounds were highly potent agonists 
in Ca2+-mobilisation. Thiophosphorylation and deprotection of 1,4-di-O-benzyl- 
scy//o-inositol gave scy//o-inositol 1,2,4,5-tetrakisphosphoro-thioate, which was 
found to be an effective partial agonist.
1-0-Allyl-3,6-di-0-benzyl-4,5-0-isopropylidene-scy//o-inositol, an intermediate in 
the previous synthesis, was isomerised to the 1-0 -(c/s-prop-1-enyl) derivative. 
The 2-position was trifluoromethylsulphonylated and then fluorinated using 
tetrabutylammonium fluoride to give 1-0-c/s-prop-1-enyl-3,6-di-0-benzyl-4,5-0- 
isopropylidene-myo-inositol. Removal of acid labile protecting groups, 
phosphorylation of the free hydroxyl groups and deblocking yielded 2-deoxy-2- 
fluoro-myo-inositol 1,4,5-trisphosphate, a potent full agonist.
The diastereoisomers of the valuable intermediate DL-4,5-di-0-acetyl-3-0-allyl- 
6-0 -benzyl-2-[(-)-co-camphanoyl]-1-0 -p-methoxybenzyl-A7?yo-inositol were
synthesised and separated by crystallisation.
Finally, methods to substitute the lns(1,4,5)P3 1-phosphate group with a car- 
boxymethylene moiety and to employ lactones as protecting groups were 
investigated. Thus, DL-1,4-di-0-benzyl-myoinositol was either directly, or via a 
three step route, converted into the six-membered l-Omethylene-2-O-lactone. 
The intermediate DL-3-0-carboxymethylene-1,4-di-O-benzyl-myo-inositol 
showed interesting 'thermosalient' properties.
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1.1 Signal Transduction in Cells
The cells in multicellular organisms must communicate with each other in order 
to be able to work together. They convey signals by using substances such as 
hormones and neurotransmitters. Lipophilic hormones like steroids can pass 
through the lipid bilayer of cell membranes and bind to their receptors within the 
cell, thereby effecting a response. Many messenger substances, however, are 
too hydrophilic to cross membranes. In order to deliver their message they have 
to bind to specific receptors on the outside of the cell membrane and activate 
mechanisms which transmit the signal into the cell.
There are several different classes of receptors: If the receptor is part of an ion- 
channel, the opening of this channel can trigger the influx or efflux of ions into or 
out of the cell. A change of ion concentrations in the cytosol will then activate 
cellular enzymes, evoking a response. Since the extracellular concentrations of 
Na+ and Ca2+-ions are 20 and 1000 fold higher, respectively, than the 
concentrations of these ions within the cell, they are particularly suitable for 
passive import through ligand-gated ion-channels. The K+-concentration, on the 
other hand, is higher in the cytosol, so this ion is exported after channel opening.
Tyrosine kinase receptors are intrinsically enzymes. They are embedded in the 
membrane and have binding sites able to recognise agonists on the outer 
surface, and active sites on the inside of the cell membrane. Binding of agonists 
activates the enzyme and leads to the phosphorylation of tyrosine residues on 
target proteins within the cell. This signal transduction mechanism is used by 
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Figure 1.1 Getting the message across the cell membrane
Most water soluble hormones, however, make use of a somewhat more complex 
signal transduction system. After binding to the ir receptor-protein on the cell 
surface, a membrane-bound GTP-binding protein (G-protein)f2'4], which is 
associated with the receptor, is activated. The family of G-proteins includes 
several members, regulating different intracellular pathways. G-proteins are 
composed of three subunits, designated a, p and 7 in order of decreasing mass. 
On activation, guanosine diphosphate (GDP) bound to the a-subunit is replaced 
by guanosine triphosphate (GTP) and the P7 subunit dissociates from the 
activated a-GTP subunit. The free subunits can now stimulate or inhibit other 
membrane bound enzymes acting as amplifiers (e.g. K+ channels, Ca2+ 
channels, adenylate cyclase (AC), guanylate cyclase (GC), Ptdlns(4,5)P2- 
specific phospholipase C (Ptdlns-PLC)), which in turn generate so-called 
'second messengers' on the cytosolic side of the cellu lar membrane. The 
intrinsic GTPase activity of the a  subunit then hydrolyses GTP to GDP, the a-
2
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Figure 1.2 GTP-binding proteins in signal transduction 
Second Messengers
The second messengers identified so far include cyclic adenosine 
monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), diacyl 
glycerol (DAG) and D-myo-inositol 1,4,5-trisphosphate [D-lns(1,4,5)P3] (in 
combination with Ca2+ ions). Recent studies suggest that cyclic adenosine 
diphosphate ribose (cADP-ribose), a metabolite of NAD+, may also have second 
messenger properties.
Compared to the large number of different hormones and neurotransmitters, 
there seem to be only few second messengers, suggesting that internal 
signalling pathways are surprisingly sim ilar in spite of the plentitude of 
biochemical and physiological processes to be regulated.
3
The Signal Transduction Pathway
Thus, the signal tranduction mechanism mediated by G-protein coupled 
receptors can be summarised as:






amplifier (e.g. adenylate cyclase, guanylate cyclase, Ptdlns-PLC)
1




__________ cellular response (growth, secretion, etc.)__________
1.2 The Role of Calcium in Signal Transduction
The first indication that calcium plays a role in the regulation of cellular events 
was an observation by Ringer in 1883 t5l. He examined muscle tissue and found 
that he could not induce the contraction of the tissue when he replaced the tap 
water in his medium with distilled water. The missing component was found to be 
calcium.
Today, it is known that a large number of different cellular processes are 
controlled by changes in the calcium concentration and the mobilisation of 
calcium has been found to be the primary function of many agonists. The 
cytosolic calcium concentration can be regulated by two different mechanisms:
1. Many agonists operate by inducing a change in the potential difference across 
the membrane. This causes voltage sensitive Ca2+ channels in the cell 
membrane to open. As most calcium within the cell is bound to membranes or
4
proteins the intracellular levels of free calcium are low and there is therefore a 
large gradient in favour of influx of ions into the cell. Thus, the cytosolic calcium 
concentration is increased.
2. Other agonists can mobilise sequestered calcium from intracellular stores. In 
each case, the calcium concentration in the cytosol is increased and Ca2+ 
dependent enzymes are activated. The cellular response depends on the type of 
cell targeted as well as the nature of the agonist.
1.3 Second Messengers
1.3.1 Adenosine 3',5'-cyclic monophosphate (cAMP)
In the late 1950's E.W. Sutherland and T.W. Rail discovered that the increased 
formation of phosphorylase in liver homogenates in the presence of epinephrine 
and glucagon was mediated by a heat-stable factor, which accumulated when 
the hormones were incubated with adenosine triphosphate and particulate 
fractions of liver homogenates. It was also observed that this factor stimulated 
the formation of phosphorylase in supernatant fractions in which the hormones 
had no effect. The factor was isolated and found to be the ribonucleotide 
adenosine 3',5'-cyclic monophosphate (cAMP) I-6-7].
The mechanism by which this second messenger operates has been intensively 
studied and is now well understood PI. Upon receptor stimulation cAMP is 
formed from adenosine 5'-triphosphate by the G-protein regulated enzyme 
adenylate cyclase. This enzyme is a large (185 kDa) integrated membrane 
protein. A wide variety of hormones have been found to activate adenylate 
cyclase, including corticotropin, adrenaline, noradrenaline, glucagon and 
vasopressin. There are two different types of receptors and G-proteins involved 
in the regulation of adenylate cyclase: stimulatory receptors (R s) which are 
linked to a stimulatory G-protein (Gs) and inhibitory receptors (Rj) which in turn 
are linked to an inhibitory G-protein (Gj).
In order to exert its effect in the cell, cAMP must activate a mechanism resulting 
in a cellular response. All the known effects of cAMP in animal cells are due to 
the stimulation of a protein kinase. This protein is comprised of two regulatory 
(49 kDa) and two catalytic (38 kDa) subunits and is inactive in its tetrameric 
R2C2 state. The catalytic activity of the protein kinase is however rapidly
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increased by cAMP binding to the regulatory subunits, which results in the 
dissociation of the R2C2 complex into a R2 subunit and two C subunits, which 
are catalytically active. cAMP is thus acting as an allosteric effector. Substrate 
proteins are phosphorylated by the kinase and their properties changed. As 
different cells contain different enzymes serving as substrates for the protein 
kinase, the response to increased concentrations of cAMP varies with the type of 
cell concerned. In liver cells for example, cAMP promotes glycogen breakdown 
and gluconeogenesis. In adrenal cortex cells it leads to an increase in steroid 
output and in stomach mucosa cells the secretion of hydrochloric acid is 
stimulated.
The action of cAMP is terminated by its hydrolysis to adenosine 5'- 
monophosphate (AMP) by a 3',5'-cyclic nucleotide phosphodiesterase (of which 
subtypes with different specifities for cAMP versus cGMP exist).
nh .











Figure 1.3 Formation and deactivation of cAMP
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1.3.2 Guanosine 3',5'-cyclic monophosphate (cGMP)
The role of cAMP in signal transduction was becoming widely accepted, when 
another compound with second messenger characteristics was discovered. 
Similar to cAMP, guanosine 3',5'-cyclic monophosphate (cGMP) is synthesised 
from GTP by a guanylate cyclase and is deactivated by hydrolysis to the 5'- 
monophosphate (GMP). In the photosensitive rod cells of the vertebrate retina, 
cGMP has been found to be the central regulatory molecule!1-9]. In contrast to 
cAMP, whose levels are low before activation of the signal tranduction process, 
the basal concentration of cGMP in rod cells is high. The cells respond to 
stimulation of the 'receptor' rhodopsin by photons with the activation of the G- 
protein transducin, which in turn mobilises a specific cGMP phosphodiesterase. 
The resulting decrease in cGMP levels leads to the closure of an ion-channel in 
the plasma membrane t1°], and the flow of both sodium and calcium ions is 
halted. Hyperpolarisation of the cells due to the reduced ion influx promotes the 
release of neurotransmitters into the synaptic gap, and the excited optical nerves 
transmit the signal to the brain. Deactivation of rhodopsin, regeneration of cGMP 
by guanylate cyclase and the re-opening of the. ion channel leads to the return 





Figure 1.4 Formation of cGMP
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1.3.3 Cyclic adenosine diphosphate ribose (cADP-ribose)
Recently, the involvement of pyridine nucleotide metabolites in the mobilisation 
of intracellular calcium in sea urchin eggs has been reported l11l  The active 
metabolite was identified as cyclic ADP-ribose (cADP-ribose)!12], derived from 
NAD+ by the action of the enzyme ADP-ribosyl cyclase t13l. It may be too early to 
categorise cADP-ribose as a novel second messenger, since the modulation of 
intracellular concentrations of this molecule by extracellular factors has not been 
demonstrated as yet. It has however, become clear that cADP-ribose is the most 
potent calcium mobilising agent described to date (EC50 for the release of Ca2+ 
from sea urchin microsomes 18 nM l11l). A specific binding site for cADP-ribose 
on sea urchin microsomes has been demonstrated and it appears that the 
release of calcium is regulated by a ryanodine-sensitive, but lns(1,4,5)P3- 
insensitive, Ca2+ channel of the endoplasmatic reticulum. The cADP-ribose 
sensitive and the lns(1,4,5)P3 sensitive calcium pools do however, seem to 
overlap substantially. cADP-ribose is very rapidly hydrolysed by cADP-ribose 
hydrolase, and this fast deactivation is another indication that cADP-ribose may 











Figure 1.5 Formation and deactivation of cADP-ribose
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1.3.4 Inositol 1,4,5-trisphosphate and Diacylglycerol
There are three major inositol-containing phospholipids present in animal cells: 
phosphatidylinositol (Ptdlns) 1 , usually accounting for more than 90 % of the 
total inositol phospholipids, phosphatidylinositol 4-phosphate [Ptdlns(4)P] 2 and 
phosphatidylinositol 4,5-bisphosphate [Ptdlns(4,5)P2] 3. Recently, the presence 
of phosphatidylinositol 3-phosphate [Ptdlns(3)P]l15l 4 and phosphatidylinositol
3,4,5-trisphosphate [Ptdlns(3,4,5)P3]I16] 5 has also been demonstrated. 
Together, these inositol phospholipids constitute less than 10 % of the total 
phospholipid of animal cells.
OR'
phospholipase C
1: R1 = R2 = R3 = H; Ptdlns
2: R1 = PO32', R2 = R3 = H; Ptdlns(4)P
3: R1 = R2 = PO32'; Ptdhs(4,5)P2
4: R1 = R2 = H, R3 = P O /' Ptdhs(3)P
5: R1 = R2 = R3 = PO32' Ptdlns(3,4,5)P3
Figure 1.6 Inositol Phospholipids
In 1953 Hokin and Hokin t17l reported that the stimulation of enzyme secretion in 
slices of pancreas and brain by the neurotransmitter acetylcholine was 
associated with the enhanced incorporation of 32Pj into the total phospholipid 
fraction. Later, I18), phosphatidylinositol was identified as the phospholipid 
showing the most enhanced incorporation of radioactive phosphate. This 
observation, named the "phosphoinositide effect" (PI effect) was the first 
indication that inositol phospholipids may be playing a role in signal 
transduction.
By the mid-1970s it was known that a phosphatidylinositol-specific 
phospholipase C (Ptdlns-PLC) catalysed the receptor-stimulated breakdown of 
inositol phospholipids I19!.
In 1975, Michell I2°l noted a correlation between the Ca2+ mobilising properties 
of certain agonists and the PI effect in various tissues, and the observation that 
the phosphoinositide breakdown was not controlled by changes in extracellular 
or intracellular calcium concentrations led him to suggest that the PI effect must 
precede the intracellular liberation of calcium or the opening of calcium gates. 
The phospholipid hydrolysed by the Ptdlns-PLC was then found to be 
phosphatidylinositol 4,5-bisphosphate I21l, which led to the identification of D- 
myo-inositol 1,4,5-trisphosphate [lns(1,4,5)P3] 6 as the Ca2+ mobilising second 








1,2-sn-Diacylglycerol (DAG) 7, the other product derived from the Ptdlns-PLC 
catalysed breakdown of Ptdlns(4,5)P2, has also been found to play a second
10
messenger role in cells. Diacylglycerol is lipophilic and remains in the cell 
membrane, where it exerts its function by activating a specialised protein kinase 
C (PKC). This signalling pathway initiated by DAG through the activation of PKC 
and the phosphorylation of various proteins by the kinase is separate from, but 
often synergistic to, the calcium signalling pathway.
Protein kinase C i23*24!, of which there are several subspecies I25l, was found to 
be highly stereospecific l26l. For activation, the diacylglycerol has to be in the
1,2-sn-configuration (sn stands for stereospecific numbering I27!), both 2,3-sn- 
and 1,3-DAG are inactive. It also seems to be essential that one of the fatty 
acids is unsaturated. The chain length of the fatty acid moieties, however, does 
not seem to be important for recognition by the kinase. The activation of PKC 
depends on the presence of calcium and phosphatidylserine as well as DAG.
It has been reported that tumor-promoting phorbol esters such as 12-0- 
tetradecanoylphorbol-13-acetate (TPA) 8, with molecular structures similar to 






Figure 1.7 Diacylglycerol and Phorbol ester
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Whilst DAG is degraded rapidly after formation, TPA is hardly metabolised. Thus 
TPA may extend a usually limited phase of cellular response, resulting in a 
distortion of the normal sequence of events leading eventually to tumor-growth. 
However, as PKC-stimulation by tumor promotors structurally unrelated to DAG 
has also been reported, this interpretation has to be treated with care. PKC has 
been found to be cleaved by calpain I in the presence of calcium, 
phosphatidylserine and DAG (or TPA). Thus the possibility of a sequential action 
of tumor promoters has been proposed: a short-term activation of PKC followed 
by the degradation of the enzyme over a longer period.
Deactivation of diacylglycerol is possible by two metabolic pathways: a) DAG is 
phosphorylated by a kinase to give phosphatidic acid, or b) the unsaturated fatty 
acid moiety from the 2-position of DAG is cleaved by phospholipase A2, giving 
monoacylglycerol and the eicosanoid precursor arachidonic acid, which is used 
in prostaglandin synthesis t29l.
1.4 The lns(1,4,5)P3 Receptor
The Ca2+ mobilising property of lns(1,4,5)P3 is mediated by an endoplasmic 
reticular receptor specific for D-lns(1,4,5)P3. Specific binding sites for 
lns(1,4,5)P3 have been identified in a number of peripheral tissues (see for 
example f30.31)) and in the brain, where sites are highly concentrated in the 
cerebellum [32.33],
The lns(1,4,5)P3 receptor has been isolated from rat cerebellar membranes by 
affinity chromatography on heparin-agarose I34). The fact that the receptor also 
binds to concanavalin A-sepharose and can be eluted with a- 
methylmannopyranoside indicates that the receptor is a glycoprotein. The native 
receptor was found to be a homo-tetramer, but co-operativity between the four 
subunits has not been demonstrated. However, binding of at least 3 molecules 
of lns(1,4,5)P3 is required to effect Ca2+ release I35l. The relative molecular 
mass (H ) of the monomer has been determined by electrophoretic analysis to 
be 260 KDa and the shape is globular with a Stokes' radius of ca. 10 nm. The 
receptor has now been cloned I36! and sequenced f37l. When reconstituted into
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liposomes, the receptor mediates Ca2+ release in response to lns(1,4,5)P3 
suggesting that the calcium channel is an intrinsic component of the receptor 
protein P®1. Two slightly different forms of the receptor were found (presumably 
generated by alternative splicing), comprising 2749 and 2734 amino acids, 
respectively. Hydrophobicity analyses have shown the presence of a cluster of 
hydrophobic sequences, there is however some disagreement about whether 
there are six P9l, seven t36l or eight P7! transmembrane regions forming the 
calcium channel.
The lns(1,4,5)P3 receptor is regulated by phosphorylation by a cAMP-dependent 
protein kinase, by changes in pH and in the cytosolic calcium concentration. 
Calcium reversibly inhibits ligand binding to the particulate and detergent- 
solubilised receptor I32], suggesting that the Ca2+ released by lns(1,4,5)P3 feeds 
back to inhibit further action of the second messenger, a process that may play a 
role in the calcium oscillations of many cells [40-43] Binding to the purified 
receptor protein was found to be unaffected by calcium I34!, suggesting the 
involvement of a distinct calcium binding protein conferring calcium sensitivity to 
the receptor I44l. Phosphorylation of the receptor on the other hand has no 
effect on ligand binding but prevents the ligand-induced opening of the calcium 
channel I45!. Changes in pH also regulate lns(1,4,5)P3 binding, with a sharp 
increase in binding throughout the physiologic range, tripling between pH 7.5 
and 8.5 l32l. The influence of growth factors and hormones as well as phorbol 
esters on signal transduction may be due to their ability to alter the intracellular 
pH.
Both Alzheimer's disease I46l and chronic ethanol consumption t47l have been 
linked to decreased brain [3H]-lns(1,4,5)P3 binding.
1.5 Nomenclature of Inositol Derivatives
The nine different stereoisomers of 1,2,3,4,5,6-cyclohexanehexol or inositol (Fig. 
1.6) are members of the family of cyclitols (by definition 'cycloalkanes containing 
one hydroxyl group on each of three or more ring atoms'). Only two of these nine 
isomers are optically active: D- and L-c/i/ro-inositol (16 and 17), all the other 







O H J  O H T













alio- inositol 15 D-c/7/Vo-inositol 16 L-c/7/ro-inositol 17
Figure 1.8 The nine inositol stereoisomers
The IUPAC commission has issued rules for the nomenclature of cyclitols I48!, 
the most important of which are summarised here:
the myo-inositol ring carbon bearing the only axial hydroxyl group in the 
chair conformation is C-2,
substituents are listed in alphabetical order prior to the term 'myo-inositol' 
unless they have to be named as suffixes (e.g. phosphates), 
when numbering substituents the lowest possible numbers have to be 
assigned according to which substituent has alphabetical priority, 
the prefix -O- is inserted between the numbering and the name of the 
substituent if the oxygen of the hydroxyl function has not been replaced in 
the substitution, (e.g. 1-O-benzyl-myo-inositol),
14
the prefix -C- is used in the same manner to denote substitution on the 
ring carbon without loss of the hydroxyl function,
'deoxy ' nomenclature is used if a hydroxyl group is replaced by another 
univalent substituent,
phosphoesters of inositol are termed inositol phosphates, the quantity of 
ester functions is denoted by using Greek numbers (e.g. myo-inositol 
1,3,4,5-tetrakisphosphate,
to differentiate between enantiomers, the suffixes D- and L- are added, 
the chiral centre used can also be stated (e.g. 1D-m yoinosito l 1,4,5- 
trisphosphate if C-1 is the chiral centre used).
M yoinosito l 10 itself is a m esocom pound, with a plane of symmetry going 
through C-2 and C-5. However, on substitution at one of the stereogenic carbon 
atoms (C-1, C-3, C-4 and C-6), a chiral derivative is obtained. In order to 
discrim inate between D- and L-configurations in such derivatives a numbering 
system applies: if the numbering proceeds anticlockwise around the ring, the 
compound has the D-configuration, if the numbering is clockwise, the compound 
is assigned the L-configuration (see Figure 1.9). As the 'lowest number' rule 
applies, substitution of the hydroxyl group at C-1 or C-3 by a phosphate group 
would in both cases give a mixture of D- and L-myo-inositol 1-phosphate, 
respectively.
D-/77yo-lns(1,4,5)P3 L-myo-lns(1,4,5)P3
Figure 1.9 The enantiomers of lns(1,4,5)P3
15
Recent recommendations for the numbering of atoms in myoinositol l49l propose 
that, as all naturally occuring inositol phosphates are of the D-configuration, they 
may all be numbered for biological purposes as the D-inositol derivatives, thus 
overriding the 'lowest number' rule. This new convention should make it easier 
to follow biochemical pathways. For example: according to the old IUPAC rules, 
D-myo-inositol 3,4-bisphosphate is converted into L-myo-inositol 1-phosphate by 
enzymatic hydrolysis. Use of the alternative name D-myo-inositol 3-phosphate 
for the product L-myo-inositol 1-phosphate clarifies the metabolic process 
involved, i.e. hydrolysis of the phosphate group at C-4.
Although the number of isomers of the different myoinositol phosphates is vast 
(there are 6 isomers of InsP and lnsP5, respectively, 15 isomers of lnsP2 and 
lnsP4, respectively, and 20 isomers of lnsP3), only a few of these isomers occur 
naturally.
1.6 The Inositol Phosphate Cycle
The discovery of the second messenger role of lns(1,4,5)P3 has stimulated the 
interest in the formation and metabolism of this compound. The biochemistry of 
inositol phosphates has recently been reviewed I5°l.
1.6.1 Biosynthesis of Inositol
The main source of myo-inositol for humans and animals is dietary intake, as 
inositol and inositol phosphates are present in many plants. De novo synthesis 
is however possible and involves the enzyme L-myo-inositol 1-phosphate 
synthetase, which isomerises glucose-6-phosphate 18 to L-lns(1)P 19 [= D- 
lns(3)P, see above] by an interesting sequence of chemical transformations [Fig. 
1.10]. The enzyme is very abundant in mammalian testis and brain and has been 
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Figure 1.10 Biosynthesis of L-/nyo-inositol 1-phosphate
L-lns(1)P is then hydrolysed to free myo-inositol by the enzyme inositol 
monophosphatase.
2o2po^7 
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myo-inositolP-glucose-6-phosphate L-myo-inositol-1-phosphate
Figure 1.11 De novo synthesis of myo-inositol
1.6.2 Inositol monophosphatase
Inositol monophosphatase (E.C. 3.1.3.25) I54’57! not only catalyses the 
dephosphorylation of D- and L-myo-inositol 1-phosphate but also D- and L-myo- 
inositol 4-phosphate and myo-inositol 5-phosphate. As the enzyme governs the 
production of inositol from inositol monophosphates arising either from agonist
17
activation of the cell or by de novo synthesis from glucose-6-phosphate it is one 
of the key enzymes in the inositol phosphate cycle.
lns(1,4,5)P3 lns(1,3>4>5)P4 Glucose-6-phosphate













Figure 1.12 Inositol monophosphatase, a key enzyme in the inositol 
phosphate cycle
Inositol monophosphatase is non-competitively inhibited by lithium [57-61] ancj the 
well known therapeutic effects of lithium in the treatment of manic-depressive 
patients can perhaps be attributed to its action on phosphoinositide signalling. 
However, as lithium does not only inhibit inositol monophosphatase but also has 
inhibitory effects on other metabolic enzymes of the inositol phosphate pathway, 
including lns(1,4)P2-phosphatase [62J and lns(1,3,4)P3-phosphatase I63-64], it is 
too early to say with certainty why lithium is effective in the treatment of manic 
depression. Lithium also affects the coupling of G-proteins to both muscarinic 
cholinergic and b-adrenergic receptors t65-66l, thus interfering with signal 
transduction at another crucial point.
In order to discrim inate between the different effects of lithium on signal 
transduction, more specific inhibitors of inositol monophosphatase would be 
helpful. Additionally, the narrow therapeutic index of lithium (constant monitoring
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of blood concentrations is necessary to maintain effective lithium levels and 
prevent overdosage) would make the substitution of this drug by more effective 
medications desirable. This explains the great current interest in alternative 
inhibitors of inositol monophosphatase. Synthetic efforts in this direction by the 
Merck, Sharpe and Dohme group I67-73] have shown encouraging results, and a 
number of inositol monophosphatase inhibitors have been prepared (Figure 
1.14), although they are not non-competitive in nature like lithium.
It was found that the two a-hydroxyl groups in the 2- and 6-position play very 
different roles in the hydrolysis of lns(1)P by inositol monophosphatase. The 2- 
hydroxyl group is important for recognition of the substrate by the enzyme [2- 
deoxy-lns(1)P is only a weak substrate], whereas the 6-hydroxyl group is 
involved in the mechanism of phosphate hydrolysis (thus 6-deoxy derivatives 
like 20 have inhibitory properties). The first approach to inhibitors was based on 
this observation, and by a 'hydroxyl group deletion' strategy D-3,5,6-tri-deoxy- 
lns(1)P 21 was synthesised and found to be a potent inhibitor I68], indicating that 
the 3- and 5-hydroxyl groups are not necessary for enzyme recognition.






Figure 1.13 Inositol monophosphatase: enzyme-substrate interaction
It is known that inositol monophosphatase is very substrate unspecific and that 
the enzyme is capable of hydrolysing 2'-nucleotides including adenosine-2'- 
monophosphate (2'-AMP)!55] as well as inositol monophosphates. After
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superimposing the molecular structures of 2'-AMP and D-3,5,6-tri-deoxy-lns(1 )P 
21 it was concluded that substituents in the 6-position (the purine heterocycle in 
2'-AMP) would be tolerated by the enzyme. This led to the synthesis of 6- 
substituted 3,5-di-deoxy-lns(1)P derivatives, amongst them 22, the most potent 
monophosphatase inhibitor reported to date I69l
However, phosphate esters are biologically labile and tend to have short half- 
lives due to hydrolysis by non-specific phosphatases. Therefore, attempts to 
improve the stability of the inhibitor by replacement of the phosphate ester with 
an isosteric, but stable, monophosphonate group were made. As myoinositol 1- 
methylenephosphonate did not show any inhibitory properties, the search for 
inhibitors was based on hydroxymethylene phosphonate, which had been 
identified as a weak inhibitor. In a series of analogues, the adamantyl ester 23 
was the most potent inhibitor with a Kj = 6.3 mM. Further studies on 
hydroxymethylene-bisphosphonic acid derivatives F11 showed that compounds 
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Figure 1.14 Inhibitors of Inositol Monophosphatase
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potent monophosphatase inhibitors. The 3-(3,4-dichlorobenzamido)benzyl 
derivative 25 is the most potent, non-hydrolysable inhibitor of myo-inositol 
monophosphatase reported to date l73L
1.6.3 Synthesis of Phosphatidylinositol 4,5-bisphosphate
The product of inositol monophosphatase activity, myo-inositol, is used for the 
synthesis of phosphatidylinositol 4,5-bisphosphate 3 (Figure 1.6), the precursor 
of the second messenger lns(1,4,5)P3: Phosphatidic acid, derived from DAG by 
phosphorylation of the free hydroxyl group by a kinase enzyme, can combine 
with cytidine monophosphate (CMP) to form CMP-phosphatidate. The enzyme 
Ptdlns synthetase (E.C. 2.7.8.11) can then fuse CMP-phosphatidate and myo­
inositol to form Ptdlns 1, releasing CMP in the process. Ptdlns is phosphorylated 
stepwise by specific kinases first to Ptdlns(4)P 2 and then to Ptdlns(4,5)P2, 
which can be used once more for signalling.
Once lns(1,4,5)P3 has mobilised Ca2+ and thus fulfilled its second messenger 
function, it has to be deactivated quickly so that the cell can return to a basal 
state in preparation for the next stimulus. Two enzymes are know to metabolise 
lns(1,4,5)P3: a 3-kinase and a 5-phosphatase, producing lns(1,3,4,5)P4 and 
lns(1,4)P2, respectively.
1.6.4 lns(1,4,5)P3 5-phosphatase
Different soluble and particulate subtypes of the 5-phosphatase have been 
characterised from brain I74-75]). The two soluble enzymes I74!, referred to as type 
1 and type 2 according to their order of elution from DEAE-Sepharose, show 
different substrate specifities with respect to lns(1,4,5)P3 and lns(1,3,4,5)P4. 
Type 1 5-phosphatase, a 60 kDa protein, has apparent Km values of 3 and 0.8 
pM for lns(1,4,5)P3 and lns(1,3,4,5)P4, respectively, and hydrolyses lns(1,4,5)P3 
ca. 12 times faster than lns(1,3,4,5)P4. The substrate of the type 2 phosphatase, 
a 160 kDa protein, seems to be primarily lns(1,4,5)P3 (Km 18 pM), the Km of this 
enzyme for lns(1,3,4,5)P4 is greater than 150 pM.
A recent report I76] shows a high similarity between a protein encoded by the 
Lowe's oculocerebrorenal syndrome (OCRL) gene and 5-phosphatase. OCRL is
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a genetic disorder affecting eyes, brain and kidneys, and there is strong 
evidence that OCRL may be an inherent defect of inositol phosphate 
metabolism. There are also indications that HIV-infected cell show defects of 
inositol polyphosphate-mediated signalling, and evidence has been presented 
showing that lns(1,4,5)P3 / lns(1,3,4,5)P4 5-phosphatase is the enzyme most 
affected I77!.
!ns(1,4)P2 does not seem to have any physiological role in this pathway, 
however it has been shown to act as an allosteric activator of 6-phosphofructo-1- 
kinase I78L lns{1,4)P2 is then further dephosphorylated to lns(1)P and/or lns(4)P 
and finally to inositol which is used for the re-synthesis of phosphoinositides.
1.6.5 lns(1,4,5)P3 3-kinase
The existance of a second pathway of lns(1,4,5)P3 metabolism was first 
suggested by the discovery of lns(1,3,4)P3 I79], which was found to be derived 
from lns(1,3,4,5)P4 via a 5-dephosphorylation. The source of lns(1,3,4,5)P4 was 
unclear at that time, and Ptdlns(3,4,5)P3, the possible parent phospholipid, could 
not be detected. An lns(1,4,5)P3 3-kinase activity was then demonstrated in 
various tissues t8°l and the enzyme has been purified from rat brain l81L The 3- 
kinase (molecular mass 150-160 kDa) is a dimeric protein comprised of two 
catalytic subunits (53 kDa each) plus calmodulin. Its activity is mediated by Ca2+, 
which is intriguing since it suggests that the lns(1,4,5)P3-induced rise of free 
cytosolic calcium acts as a regulator to promote the formation of lns(1,3,4,5)P4 
at the expense of lns(1,4,5)P3.
The physiological significance of lns(1,3,4,5)P4 182l is not quite clear yet. Binding 
sites for this molecule as distinct from those for lns(1,4,5)P3 have been identified 
in a variety of tissues l®3-86] |n contrast to the lns(1,4,5)P3 binding sites they 
seem to be associated with plasma membranes rather than the ER membrane 
I87L Suggestions I88*89! that the tetrakisphosphate may be involved in calcium 
homeostasis by regulating the influx of extracellular calcium ions through the 
plasma membrane and/or controlling calcium movement into various intracellular 
pools thus seem to be confirmed.
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Ins(1,3,4,5)P3 is hydrolysed to lns(1,3,4)P3 [79,82,90,9i]f possibly by the same 5- 
phosphatase that dephosphorylates lns(1,4,5)P3 [82.92]^  Alternatively,
dephosphorylation of lns(1,3,4,5)P4 to lns(1,4,5)P3 can occur I91l. Further 
hydrolysis of phosphates leads back to inositol.
lns(1,3,4)P3 is also known to be phosphorylated to lns(1t3,4l6)P4 l93l. This 
inositol tetrakisphosphate is capable of inducing Ca2+ release by interacting with 
the lns{1,4,5)P3 receptor I9 4 ] . In contrast to lns(1,4,5)P3 however, lns(1,3,4,6)P4 
appears to act as a partial agonist at the receptor, mobilising only 82 % of the 
calcium in the lns(1,4,5)P3-dependent store. Further phosphorylation of 
lns(1,3,4,6)P4 leads to the higher polyphosphates now found in mammalian 
cells.
1.6.6 Higher Inositol Phosphates
For a long time higher inositol phosphates have been known to exist in plants; 
as early as 1872 a highly phosphorylated substance later shown to be myo­
inositol hexakisphosphate (lnsP6, phytic acid) was isolated from seeds by Pfeffer 
l95l. lnsP6 is supposed to serve as a phosphorus and/or energy reservoir for the 
plant (it accounts for 60-90 % of the organically bound phosphorus in seeds), 
and enzymes (phytases) able to degrade lnsP6 and release the bound 
phosphorus for use by the organism have been discovered.
The presence of lns(1,3,4,5,6)P5 in avian erythrocytes has also been known for 
some time I96!, and it seems that it has a rather specialised function as a 
modulator of haemoglobin oxygen affinity in these cells I97l, a role performed 
normally in mammalian cells by 2,3-bisphosphoglycerate.
Ins(1,3,4,5,6)P5 and lnsP6 have now been found in a variety of cells, but their 
role is not clear. There is no evidence for rapid changes in the levels of these 
two compounds after agonist-stimulation of different receptors f98l, rendering an 
involvement of lns(1,3,4,5,6)P5 and lnsP6 in the lns(1,4,5)P3 signal transduction 
process unlikely. However, the possibility that these highly phosphorylated 
inositols are used as extracellular messengers has to be considered after the 
observation of dose-dependent, reversible changes of blood pressure and heart 
rate following the injection of lns(1,3,4,5,6)P5 and lnsP6 into rat nucleus tractus
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solitarius (a discrete brain stem nucleus implicated in cardio-vascular regulation) 
I"]. However, current opinion suggests that these observations should be 
treated with caution.
Reports (e.g. I1 0 0 !) that the activation of PLC is accompanied by increases in 
levels of lns(3,4,5,6)P4 and that these increases are not due to an increased 
metabolic flux from lns(1,4,5)P3 have led to suggestions that agonists evoke this 
particular effect by modulating the activity of enzymes that interconvert 
lns(1,3,4,5,6)P5 and lns(3,4,5,6)P4t101l, and that lns(1,3,4,5,6)P5 may provide a 
precursor pool for lns(3,4,5,6)P4. The function of the lns(3,4,5,6)P4 signal, 
however, is still unclear.
1.6.7 Inositol pyrophosphates
A number of higher inositol phosphates have been found in Dictyostelium [98,102]i 
and it was in this slime mould that inositol phosphates more polar than lnsP6 
were first demonstrated i103l. Recent studies l104l have shown that these 
compounds are pyrophosphates of lns(1,3,4,5,6)P5 and lnsP6. As the turnover 
between pyrophosphates and parent inositol phosphates is rapid, a role for 
these pyrophosphates as a new form of high-energy phosphates has been 
proposed I105).
1.6.8 Summary
The inositol phosphate cycle as it is known today is shown in Figure 1.9. 
Whereas the role of lns(1,4,5)P3 and the immediate metabolism of this second 
messenger is now relatively well understood, it is clear that there are still many 
questions to be answered before the complex metabolic network of inositol 







































1.7 GPI membrane anchors and putative insulin mediators
Many proteins are bound to biological membranes. Some of these proteins 
(called integral membrane proteins) have one or more hydrophobic domains and 
are embedded to a great extent in the lipid bilayer (e.g. ion channels). Other 
proteins are covalently attached to lipids which serve as anchors to the cell 
membrane. Many of these latter proteins are linked to the membrane by 
phosphatidylinositol anchors attached to the C-termina! amino acid of the protein 
through an intervening glycan structure [glycosyl-phosphatidylinositol (GPI) 
anchor] [106-I09]f (0n the biosynthesis of GPI anchors see I110!). More than 30 
different cell surface proteins with a GPI anchor have been identified, including 
hydrolytic enzymes (e.g. alkaline phosphatase and acetylcholinesterase t111]), 
mammalian antigens (e.g. Thy-1 I112]) and cell adhesion proteins. The generic 
structure of GPI anchors is Ptdlns - glucosamine - mannose3 - 
phosphoethanolamine - protein, however, modifications of the core mannosyl 
residues by additional side chains are common and other variations (e.g. in the 
fatty acid composition of PI) have also been observed.
Some metabolic fragments of the protein-GPI complex, formed by the combined 
actions of specific endogeneous proteases and a glycosyl-phosphatidylinositol 
specific phospholipase C (GPI-PLC) - a PLC distinct from the Ptdlns-PLC which 
hydrolyses Ptdlns, Ptdlns(4)P and Ptdlns(4,5)P2 and is located on the inner 
membrane rather than the cell surface - have displayed certain biochemical 
properties previously associated with crude preparations of putative insulin 
mediators (PIM). PIM are phosphorylated inositol-glycans which are generated 
following insulin cell surface receptor stimulation and can mimic some 
biochemical properties of insulin in vitro I113!.
The discovery of GPI anchors and putative insulin mediators has attracted the 
interest of bioorganic chemists [114-118]_
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Figure 1.17 Structure of the GPI anchor of the variant surface glycoprotein 
of Trypanosoma brucei
Efforts to synthesise the GPI anchor of the variant surface glycoprotein (VSG) of 
the parasitic protozoan Trypanosoma brucei i119l (Figure 1.17) have recently 
been successful I116l. The survival of African trypanosomes depends on the 
integrity of their cell-surface coat, which is formed by VSGs arranging into tightly 
packed monolayers and which protects the parasite from lytic factors of the host 
serum. By expressing different VSGs at different times the parasite is able to 
evade the host's immune response. This antigenic variation makes it difficult for 
the immune system to supply the appropriate antibodies at the right time and it 
also renders drugs against specific VSGs ineffectual.
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Inhibition of the biosynthesis of the VSG GPI-anchor however, or drugs targeting 
specific features of this GPI-anchor could prove successful. This explains the 
interest this particular GPI-anchor has attracted. Whereas the backbone 
structure of the VSG GPI-anchor is similar to other GPI-anchors, the a-galactose 
side chain of the VSG GPI-anchor seems to be parasite-specific, thus the design 
of drugs aiming at this side chain may prove successful.
The structures of other GPI anchors have been determined, including that of rat- 
brain Thy-1 glycoprotein I112l and human erythrocyte acetylcholinesterase
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2. The Synthesis of Inositol Phosphates
The inositol chemistry up to the mid-1960's is summarised in a book by 
Posternak I120]. In 1980 a comprehensive review of the chemistry and 
biochemistry of inositol phosphates was published by Cosgrove I121], which was 
concluded with the words: "The lower phosphoric esters of myo-inositol do not 
appear to exist in other than small amounts as transient intermediates in 
biochemical reactions". Renewed interest in inositol phosphate chemistry was 
stimulated by the discovery of the second messenger role of lns(1,4,5)P3 in 
1983. Two review articles I122,123] ancj books [124,125] summarise current 
developments this area. In 1992, Carbohydrate Research published a special 
issue on the synthesis of inositol derivatives [1261, which demonstrates the high 
degree of interest in this field today.
There are five major problems to be addressed when preparing inositol 
phosphates and analogues thereof. These problems are:
1 - synthesis of precursors with selectively protected hydroxyl functions,
2 - optical resolution of racemates,
3 - phosphorylation of free hydroxyl groups,
4 - deblocking of the fully protected compound,









Inositol Phosphate deprotection Protected Inositol
or Analogue Phosphate
Figure 2.1 Synthesis of Inositol Phosphates and Analogues
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2.1 Protecting Groups in the Synthesis of Inositol Phosphates
The starting material most commonly used in the synthesis of inositol 
phosphates is myo-inositol 1. In order to protect the six hydroxyl functions 
various blocking groups including ethers, esters, siloxanes, acetals have been 
employed. As all hydroxyl groups are secondary, they vary only slightly in 
reactivity, with the order of reactivity being 1- and 3-OH > 4- and 6-OH > 5-OH > 
2-OH. The selective protection of hydroxyl functions is therefore difficult to 
achieve, and often product mixtures are obtained.
2.1.1 Ether protecting groups
Benzyl ethers
Benzyl ethers are stable to oxidising agents and reducing agents such as 
sodium borohydride and lithium aluminium hydride. They are also not cleaved by 
the methods used to remove temporary acid or base labile protecting groups and 
are therefore usually employed as permanent protecting groups which are only 
deblocked together with the phosphate protecting groups (which are often 
benzyl groups as well, see below) in the final step of the synthetic sequence. 
The preparation of benzyl ethers is usually performed under rather drastic 
conditions (ROH + PhCH2CI, powdered KOH, 130-140°C), but there are milder 
options, e.g. use of sodium hydride, PhCH2Br and tetrabutyl ammonium iodide 
as phase transfer catalyst at r.t. t127l.
Removal of benzyl groups (as toluene) can be achieved by using palladium on 
carbon (platinum would hydrogenate the aromatic ring) as catalyst in catalytic 
hydrogenations or catalytic transfer hydrogenations with various hydrogen 
donors like cyclohexene I120], 1,4-cyclohexadiene t129l, formic acid I130), or 
ammonium formate t13i]. other methods for deprotection are bromination- 
hydrolysis t132]( acetolysis t133l or the use of sodium (or lithium) in liquid 
ammonia for chemical reduction I134].
para-Methoxybenzyl ethers
The preparation of p-methoxybenzyl ethers can be performed by using the 
methods described for benzyl ether formation. In contrast to unsubstituted
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benzyl ethers p-methoxybenzyl ethers are acid sensitive. Selective deprotection 
in the presence of other acid-labile protecting groups however, is possible with 
2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in dichloromethane-water
[135].
Allyl ethers
Allyl and to a lesser extent crotyl protecting groups have been widely used in the 
synthesis of inositol phosphates. Allyl ethers are usually formed by reacting free 
hydroxyl groups with allyl bromide in DMF at r.t. in the presence of a strong base 
such as NaH I136!. Allyl protecting groups are similar to benzyl ethers in their 
stability under acidic and basic conditions. At a very high pH however, 
isomerisation to the prop-1 -enyl group may occur.
Deprotection of allyl groups often involves their isomerisation to enol ethers by 
potassium fert.-butoxide in DMSO l137l (yielding the cis- isomer), 
tris(triphenylphosphine)rhodium(l) chloride [(Ph3P)3RhCI]l138! or PdCI2(PhCN)2 
(giving a mixture of c/s- and trans-isomers) or iridium complexes!139! (giving 
selectively the trans-isomer) and the subsequent acidic hydrolysis !14°1 of these 
prop-1-enyl compounds. With compounds containing acid sensitive groups, 
cleavage of the prop-1-enyl group by treatment with mercuric (II) chloride in the 
presence of mercuric (II) oxide is possible I141!. Like benzyl groups, allyl ethers 
can also be cleaved by the use of sodium in liquid ammonia I142,143] Recently 
the SmCI3-catalysed electrochemical cleavage of allyl ethers I144! and the 
employment of low-valent titanium I145! for the removal of benzyl and allyl ethers 
have been described.
Allyl deprotection methods have been reviewed I146!.
Silyl ethers
The regioselectivity of different reagents in the protection of 1,2-0- 
cyclohexylidene-myo-inositol was investigated l147l. It was found that selective 
protection of the 1-position can be achieved by employing sterically bulky 
reagents such as tert-butyldiphenylsilyl chloride (TBDPS-CI), whereas the 
selectivity was considerably reduced when smaller silyl groups such as tert- 
butyldimethylsilyl or trimethylsilyl were used. This observation was used in the
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synthesis of optically pure regioselectively silylated D-camphor dimethyl acetals 
of inositol. Reaction of ID ^.S-O -p-l'.y 'J '-trim ethyl^.llb icyclohept^ '- 
ylidene)-myoinositol with 1.1 equiv. of TBDPS-CI gave the 1-silyl derivative in 
88 % yield. When 2.1 equiv. of TBDPS-CI were used, the 1,4-di-O-silyl ether 
was obtained in 84 % yield. Desilylation was effected by treatment with 
tetrabutylammonium fluoride or acid hydrolysis.
2.1.2 Ester protecting groups
Base labile esters complement the acid labile protection groups in inositol 
phosphate synthesis. Most widely used are benzoyl and acetyl esters, although 
propionyl and butyryl esters have also been employed. Butyryl esters of inositol 
phosphates are interesting lipophilic analogues which may allow the delivery of 
inositol phosphate prodrugs across the intact cell membrane. The action of 
esterases within the cell may then hydrolyse the prodrug to liberate the active 
compound.
Acetate and butyrate esters have also been used in the synthesis of optically 
active intermediates by enzymatic catalysis (see below).
Benzoyl esters
Benzoylation is usually effected by reaction of the inositol derivative with 
benzoyl chloride in pyridine. Under suitable conditions, myo-inositol can be 
selectively benzoylated to give 1,3,4,5-tetra-O-benzoyl-myo-inositol or 1,3,5-tri- 
O-benzoyl-myo-inositol t148l. Removal of benzoates is possible under alkaline 
conditions.
2.1.3 Protection of diols
Isopropylidene and cyclohexylidene protecting groups
The use of these protecting groups allows the simultaneous protection of 1,2- 
diols. In several synthesis of inositol derivatives, the first step was the reaction of 
myoinositol with 2,2-dimethoxypropane l149l, cyclohexanone h50-152! or 1- 
ethoxycyclohexene [153.154] anc| an acjd catalyst in DMF to give a mixture of 
three di-acetals (1,2:3,4,1,2:4,5 and 1,2:5,6) or selectively the 1,2-mono-acetal,
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depending on the reaction conditions. Separation of the di-Ocyclohexylidene 
acetals is possible by column-chromatography and crystallisation. 1,2:4,5-Di-0  
isopropylidene-myo-inositol was obtained by Gigg et al. by converting the di-O  
isopropylidene acetals into the dibenzoates. 3,6-Di-Obenzoyl-1,2:4,5-di-0 
isopropylidene-myo-inositol was found to be insoluble in water, acetone and 
ether and could thus be separated from the two other isomers by washing with 
these solvents I149l. The same authors also succeeded in the isolation of 3,4-di- 
Obenzoyl-1,2:5,6-di-Oisopropylidene-/77yo-inositol by fractional crystallisation 
of a mixture of the soluble dibenzoates (giving access to 1,2:5,6-di-0  
isopropylidene-myo-inositol) and in the preparation of 1,2:3,4-di-0  
isopropylidene-myo-inositol via the 5,6-di-O-allyl ether i155].
The 1,2-mono-acetals are obtainable by hydrolysis of the di-acetals under mild 
acidic conditions, since the trans-acetals are less stable than the 1,2-c/'s-acetal 
l15°l. Direct syntheses of 1,2-cyclohexylidene-myo-inositol from myo-inositol 
using 1,1-dimethoxycyclohexane and a strongly acidic resin-bound sulphonic 
acid catalyst (45-50 % yield) I156! or cyclohexanone / PTSA in DMF / toluene 
followed by in situ ethanolysis of the trans-acetals (93 % yield) I152! have also 
been reported.
The 1,1,3,3-tetraisopropyldisiloxane (TIPS) protecting group
More recently, the tetraisopropyldisiloxane-1,3-diyl group has been used in the 
synthesis of different inositol phosphates including lns(1,3,4,5)P4 I157!. Reaction 
of myo-inositol with 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (TIPS-CI) in 
pyridine at r.t. afforded in 66 % yield the symmetrical 1,6:3,4-bis(disiloxane) 
derivative with only minor amounts of other inositol derivatives. The 1 ,2 -0  
cyclohexylidene acetal of myo-inositol gave selectively the 3,4-siloxane on 
treatment with TIPS-CI I157l. A number of enantibmerically pure regioselectively 
protected inositol derivatives have been synthesised by 1,2-acetalisation of myo­
inositol with D-camphor dimethyl acetal, protection of the 3,4-position with TIPS 
and various further protection/deprotection steps I147!. Removal of the TIPS 
protecting groups was effected with aqueous HF in acetonitrile.
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2.1.4 Orthoformate Esters
Simultaneous protection of the 1-, 3-, and 5-position of myo-inositol is possible 
by forming the orthoformate ester with triethylorthoformate and PTSA in DMSO 
[158] or preferably DMF I159!. The normal axial/equatorial relationship of the 
remaining free hydroxyl groups in this compound is reversed with the 2-position 
now equatorial and the 4- and 6-position axial. The spatial juxtaposition of the 
axial hydroxyl groups allows highly selective monoalkylations or 
monophosphorylations I160). This intermediate has been employed in the 
synthesis of racemic [160,161] as we|| as optically resolved myo-inositol 1,3,4,5- 
tetrakisphosphate I159!. Myoinositol orthoformate has also been used in the 
preparation of myoinositol 2-phosphate, myoinositol 4-phosphate and myo 
inositol 1,3-bisphosphate [160,161] Selective cleavage of the 2,4,6-tri-O-benzyl 
orthoester can be achieved by reduction with DIBAL or treatment with trimethyl 
aluminium, furnishing in high yields the 1,3-O-methylene and the 1,5-0- 
ethylidene derivative, respectively n 62.163] Rearrangement of the fully benzyl- 
protected 1,3-O-methylene derivative to the 1,2-acetal (with loss of the benzyl 
group in the 3-position) on treatment with stoichiometric amounts of Lewis acid 
(TiCI4) has been observed h 62,163]
Removal of the orthoformate ester is accomplished by acid hydrolysis.
2.1.5 The Use of Organotin Derivatives
As the differences between the reactivity of the equatorial hydroxyl groups in 
inositol derivatives are only small, attempts to selectively substitute one hydroxyl 
function often lead to a mixture of products. Organotin derivatives have proved 
to be useful to selectively activate hydroxyl groups I164!, thus allowing the 
synthesis of compounds only difficult to obtain by other routes. They are 
especially useful in directing the regiochemistry of substitution in axial/equatorial 
pairs of wodiols. An X-ray analysis of the 2,3-O-dibutylstannylene derivative of 
methyl-4,6-O-benzylidene-a-D-glucopyranoside showed a dimeric arrangement 
of the stannylenes (Figure 2.2). The two tin atoms are co-ordinated in a trigonal 
bipyramid structure with the butyl groups in equatorial positions and two sugar 
oxygen atoms each occupying the remaining equatorial and the apical positions.
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Figure 2.2 The trigonal bipyramidal structure of sugar-stannylene 
complexes
Tin reagents show a greater affinity for 1,2-diols in an axial-equatorial cis- 
conformation (i.e. the 1:2 or 2:3 position myo-inositol derivatives) than for 
diequatorial trans- hydroxy I groups (i.e. the 3:4, 4:5, 5:6 and 1 :6 positions), and it 
was for the selective allylation of the equatorial 1-hydroxyl group over the axial 
2-hydroxyl group of 1,2-diols that dibutylstannylene derivatives were first 
employed in inositol chemistry I165].
The efficiency of tin-mediated alkylation has been found to be enhanced by 
quaternary ammonium halides t166l and caesium fluoride t1671. Both modifications 
have been used in the synthesis of inositol derivatives [168,169] j h e observation 
that maximum yields in tin-mediated O-monoalkylations were obtained by the 
use of almost 2 equivalents of caesium fluoride [16?] has led to the suggestion 
that the salt may act in two diffent ways to assist in the reaction: a) by activating 
the alkyl halide through interaction of the polarisable caesium cation with the 
halogen atom, and b) by activating the S n -0  bond by the formation of a pentaco- 
ordinate complex.
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2.2 The Synthesis of Optically Active Inositol Derivatives
Chiral starting materials
If the meso-compound myo-inositol is used as starting material in the synthesis 
of inositol phosphates, optical resolution is required to separate D- and L- 
isomers of the inositol phosphate precursors. The problem of optical resolution 
can, however, be avoided by employing chiral starting materials, e.g. naturally 
occuring compounds such as L-quebrachitol (1L-2-(>methyl-ch/roinositol) 26 [in 
the synthesis of L-1-deoxy-1-fluoro-myoinositor I1 7 0 !, D-lns(1)P I1 7 1 !, L-lns(1)P 
l172l, L-lns(1,4,5)P3 I173i, L-lns(2,4,5)P3 and L-c/?/7olns(1,3,5)P3 I174], a number 
of 3-modified D-myoinositol analogues I175l, D-3-deoxy-lns(1,4,5)P3 and D-3- 
deoxy-lns(1,5,6)P3 t176l, as well as in the synthesis of L-ch/Volns(2,3,5)P3 t177!]. 
Other chiral starting materials which have been used are D-pinitol (1D-3-0- 
methyl-c/7/roinositol) 27 [in the synthesis of D-1-deoxy-1-fluoro-myoinositol and 
D-1,5-dideoxy-1,5-difluoro-neoinositol I178!, D-lns(1,4,5)P3 I173!, D-lns(2,4,5)P3 
and D-ch/7olns(1,3,5)P3 I1 7 4 !] , (-)-quinic acid 28 [in the synthesis of D- 
lns(1,4,5)P3 I179l and the 5-methylenephosphonate analogue thereof I180!], D- 
glucurono-6,3-lactone 29 [in the synthesis of precursors of D-lns(1,4,5)P3 I181l] 
and D-galactose 30 [in the synthesis of D-6-deoxy-lns(1,4,5)P3, D-6-deoxy- 
lns(1,2-cyclic-4,5)P3 and D-6-deoxy-lns(1,5)P2 via Ferrier rearrangement i182!]. 
Methyl a-D-glucopyranoside 31 has been employed in a biomimetic synthesis of 
enantiomerically pure D-myo-inositol derivatives I183], which were then used to 
prepare an inositol 1,3,4,5-tetrakisphosphate analogue carrying an affinity label 
at the 1-position l184l.
Enzymes in the synthesis of optically active inositol derivatives
In a number of studies, enzymes such as esterases, lipases and proteases have 
been examined for their ability to hydrolyse enantio- and regio-selectively 
racemic or meso-carboxylates of myo-inositol [159.185-187]| 3-deoxy-ep/-inositol 
and 1-deoxy-scy//oinositol I1 8 8 !. By employing the resolved precursors, D- 
lns(1,4,5)P3 [185,187]> D-lns(1,3,4)P3 [186,187] and D-lns(1,3,4,5)P4 [159,186,187] as 
well as L-lns(1,3,4,5)P4 I159l have been synthesised. A new method involving 
enzymes is the enzyme-catalysed selective esterification of myoinositol
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D-glucurono-6,3-lactone 29 D-galactose 30 methyl-a-D-glucopyranoside 31
Figure 2.3 Chiral starting materials in the synthesis of inositol 
phosphates
Chiral HPLC-columns
Chiral HPLC-columns have been used to resolve 4,5-di-0-benzyl-1,6-di-O-PMB- 
myo-inositol in the synthesis of lns(1,3,4)P3 l19°] and 1,3,4,5-tetra-O-benzoyl- 
myo-inositol in the synthesis of lns(1,3,4,5)P4 t148l.
Resolving Agents
Most optical resolutions in the synthesis of inositol phosphates rely on the 
conversion of racemic inositol derivatives into a pair of diastereoisomers, which 
is then separated by crystallisation or chromatography. Resolving agents used 
include D-mannose derivatives 32 I1 9 1 !, A(+)-0-acetyl-mandelic acid 33 [in the 
synthesis of 1D- and 1L-4-0-benzyl-/77yo-inositol l192J], camphanic acid 
chloride 34 and its A?-(+)-isomer, D- and L-camphor dimethyl acetals 35 [in the 
synthesis of lns(1,4,5)P3 and lns(1,4)P2 t193-194], where the camphor acetal has 
also been used as protecting group for the 1,2-position], Amenthyl chloroformate 
36 [1851, Amenthoxy acetylchloride 37 [in the synthesis of lns(1,4,5)P3 [195-197]
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and lns(1 ,3i4>5)P4 f197l] and f?-(+)-1-phenylethyl isocyanate 38 [in the synthesis 
of D-lns(1,3,4,5)P4 I159!]. Optical resolution via formation camphanate esters 
seems to be the most generally useful method available at the present time, both 
S-(-)- and A?-(+)-camphanic acid chloride (stable crystalline reagents, which are 
commercially available in high optical purity) have been employed to obtain 
optically active inositol derivatives.
/-menthyl chloroformate 36 /-menthoxyacetyl chloride 37 R-(+)-1 -phenylethyl isocyanate 38
Figure 2.4 Resolving agents used in the synthesis of optically pure 
inositol derivatives
3,4,6-tri-0-acetyl-1,2-O-ethylorthoacetyl- /-(+)-Oacetylmandelic acid 33 
p-D-mannopyranose 32
OMe
(1 S)-(-)-camphanic chloride 34 (1 R)-camphor dimethylacetal 35
CICCH20"
2.3 Phosphorylation Methodology
There are two different methods by which phosphorylation of free hydroxyl 
groups in suitably protected inositol derivatives can be achieved: employing a 
P(V) reagent in which the phosphorus is already on the phosphate oxidation 
level, or using a P(lll) approach, i.e. phosphitylation of the hydroxyl group and 
subsequent oxidation to give the protected phosphate ester.
2.3.1 P(V) reagents
The advantages of P(V) reagents for phosphorylation are the relative stability of 
reagent and products. Problems have however been encountered in the 
application of some P(V) reagents because of the low reactivity of the secondary 
hydroxyl groups of inositols; the phosphorylation of vicinal diols has proved to be 
especially difficult. The intermediate phosphate triesters formed upon 
phosphorylation at the first free hydroxyl group are prone to attack by the second 
hydroxyl group, thus affording a 5-membered cyclic phosphate rather than the 
desired bisphosphate. Since P(V) reagents are usually more bulky than P(lll) 
reagents, it may be sterically difficult for a second reagent molecule to gain 
access to the phosphorylation site after monosubstitution of the diol has taken 
place. Therefore cyclisation reactions are able to compete successfully with 
substitution reactions at the second hydroxyl group.
Phosphorochloridates
Phosphorochloridates are of the general structure: (R 0)3.XP(0)CIX, with x = 1 
and x = 2 for phosphoromonochloridates and phosphorodichloridates, 
respectively.
Phosphorus oxychloride (POCI3, x = 3) was first used as a phosphorylating 
reagent in 1857 I198] for the synthesis of methyl esters of phosphoric acid. More 
recently, it has been successfully employed in the regioselective synthesis of 5'- 
nucleotides from unprotected nucleosides t1"]. In this synthesis, POCI3 was 
used partially hydrolysed in trimethyl or triethylphosphate as solvent, and the 
active phosphorylating species was probably [(R0)3P-0-P(0)C I2]+Ch
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A stepwise phosphorylation of the vicinal 4,5-diol in myo-inositol derivatives with 
two P(V) reagents has recently been reported l20°]. Phosphorylation with 
bis(2,2,2-trichloroethyl) phosphorochloridate (see below) only gave a mixture of 
the 4- and 5-monophosphorylated inositols but not the bisphosphate presumably 
due to steric hindrance. By using POCI3 in pyridine followed by addition of 
methanol, the mixture of 4- and 5-monophosphorylated inositols could however 
be converted into 4,5-bisphosphate triesters with different protecting groups in 
the 4- and 5-position (i.e. 2,2,2-trichloroethyl and methyl esters).
Diphenyl phosphorochloridate can be easily prepared from phosphorus 
oxychloride and phenol [201,202] anc| has been employed in many phosphate 
ester preparations, including an early synthesis of D-myo-lns(2)P I203!, and the 
synthesis of L-myo-lns(1)P I172].
The oxidation of dibenzyl phosphite with A/-chlorosuccinimide furnishes dibenzyl 
phosphorochloridate, which was used in the first synthesis of a nucleotide 
coenzyme, adenosine 5'-diphosphate (ADP) I204], and later in the synthesis of 
adenosine 5'-triphosphate (ATP) I205!.
Other diaryl phosphochloridates have also been employed as phosphorylating 
agents. Bis(para-nitrobenzyl) phosphorochloridate and bis(para-nitrophenyl) 
phosphorochloridate have been used in the synthesis of 5'-amino-5'- 
deoxynucleosides [206l and thymidine nucleotides [2071, respectively, and 
bis(2,2,2-trichloroethyl) phosphorochloridate has been applied in the synthesis 
of nucleotides I208! as well as in the preparation of lns(1,4,5)P3 and its 5- 
phosphorothioate analogue [209-211]
Dianilino phosphorochloridate was employed in the first reported synthesis of D- 
lns(1,4,5)P3 [1951, this phosphorylation method and the removal of the protecting 
groups with isoamyl nitrate in pyridine/acetic acid/acetic anhydride was however 
considered to be unsatisfactory.
Phosphorodichloridates can react with two different partners, thus forming a 
phosphate-bridge between these moieties. As phosphodiester-links are common 
features of many biologically interesting compounds (e.g. oligonucleotides and 
phospholipids), a number of phosphorodichloridates have been developed for 
the synthesis of these compounds, including phenyl-, para-nitrophenyl- and 
methyl-phosphoro-dichloridate. Dichlorophosphoric acid has also been used for
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inter-nucleotide bond formation and in the synthesis of nucleoside 3',5'-cyclic 
phosphates l212l.
Anhydrides
Polyphosphates and mixed anhydrides are widely used as phosphorylating 
reagents, especially on an industrial scale, in spite of their non-specific nature, 
which often leads to the formation of cyclic phosphates or other side products. 
Phosphoric acid, potassium hydrogen phosphate and pyrophosphoric acid have 
all been employed in the synthesis of carbohydrate phosphates, the latter has 
also been used to phosphorylate epi- and muco-inositols I213l.
Tetrabenzyl pyrophosphate (TBPP) I214l is a commercially available crystalline 
solid formed by condensation of two molecules of dibenzyl phosphate with 
dicyclohexylcarbodiimide (DCC). It is the only P(V) reagent which has 
successfully been employed in inositol phosphate chemistry for the 
phosphorylation of vicinal diols [215-217]^  |n order to effect efficient 
phosphorylation with TBPP, it is neccessary to convert the free hydroxyl groups 
into alkoxides. This has been achieved by different methods, including the use of 
butyl lithium or lithium diisopropylamide (LDA) Pi5,2i8jf sodium hydride l216l, NaH 
and catalytic amounts of imidazole or 18-crown-6 I1 6°] or potassium hydride 
[217,219] The strongly basic conditions needed for efficient phosphorylation can 
however cause problems with some compounds leading to decomposition rather 
than formation of alkoxide ions. Once the protected phosphate has been formed 
the benzyl protecting groups can easily be removed by catalytic hydrogenolysis, 
treatment with trimethylsilyl bromide or sodium / liquid ammonia.
Phosphoramidates
Phosphoramidates of the general structure (R 0)2P(0)(N R '2) have been 
extensively employed in the synthesis of nucleoside di- and triphosphates. 
Phosphate monoesters can be activated for example by reaction with N,N'- 
carbonyldiimidazole, and the phosphoramidate formed can then react with 
another nucleophile to afford the product. Depending on whether the nucleophile 
used is an alcohol or another phosphate monoester, a phosphate diester or a 
pyrophosphate is obtained [220.221],
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2.3.2 P(III) reagents
P(lll) reagents are more reactive than most P(V) reagents, and good results by 
phosphitylation and subsequent oxidation have been reported in cases where 
P(V) reagents failed to give the desired products, e.g. phosphorylation of vicinal 
diols such as the free hydroxyl groups in the 4- and 5-position of precursors of 
lns(1,4,5)P3. The possibility that undesired cyclic phosphodiesters are formed 
[which is often encountered when P(V) reagents are used] is reduced.
Phosphorochloridites
Phosphorochloridites (RR'PCI) have the disadvantage of being unstable towards 
moisture. In spite of this they have been widely used and have also been 
employed in the synthesis of several inositol phosphates. Dimethoxy 
chlorophosphine in the presence of the base A/,A/-diisopropylethylamine was 
used in the synthesis of lns(1,4,5)P3, lns(1,3,4,5)P4 and lns(1,4,5,6)P4 I222l. 
Bis(2-cyanoethoxy)chlorophosphine was for example applied in the preparation 
of lns(1,3,4)P3 I223] and lns(1,4,5)P3 I224l.
Phosphoramidites
Phosphoramidites are more stable than phosphorochloridites and some can 
even be purified by flash chromatography. They are of the general type (RO)2P- 
N(R')2, with R being for example benzyl or cyanoethoxy and N(R')2 being 
diisopropylamine, diethylamine or morpholine.
Both A/,A/-diisopropylamino bis(2-cyanoethoxy) phosphine and N,N- 
diisopropylamino dibenzyl phosphine [225,226] have been widely used in inositol 
phosphate chemistry [159,169]| ancj A/,/V-diethyl bis(2-cyanoethoxy) phosphine [2271 
has also been used in the synthesis of lns(1,4,5)P3. The phosphitylating 
reagents have to be catalytically activated by a weak acid (1 -H  tetrazole). The 
benzyl reagent has the added advantage of giving phosphate triesters which 
readily crystallise.
The new o-xylylene phosphoramidite reagent 2-diethylamino-1,3,2- 
benzodioxaphosphepane, prepared by the reaction of hexaethylphosphorous
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triamide with 1,2-benzenedimethanol, has also been employed in the synthesis 
of inositol phosphates [196,228-232] f including lns(1,4,5)P3 and lns(1 ,3,4,5)P4.
o-xylylene dlethylphosphoramidite
Figure 2.5 O-xylylene diethylaminophosphine (OXDEP)
The efficiency of different methods for the oxidation of the phosphite triesters to 
the corresponding phosphate esters has been studied I226!; in inositol phosphate 
chemistry oxidation is usually effected with tert.-butyl hydroperoxide (f-BuOOH) 
[224,227] or m-chloroperoxybenzoic acid (mCPBA) I169l
A further advantage of using a two-step procedure is that the oxidation of the 
phosphite triesters can be replaced by sulphoxidation with elemental sulphur in 
pyridine I233l or phenacetyl disulfide I234), thereby making available not only 
phosphates but also phosphorothioate esters, which have been shown to be 
useful non-hydrolysable analogues of nucleotides t235l and inositol phosphates
[209,234,236]^
2.3.3 Conversion of H-Phosphonates into Phosphorothioates
Recently, a new approach towards the synthesis of phosphorothioate derivatives 
has been reported I237!. S-Benzyl and S-phenyl thiosuccinimides reacted with H- 
phosphonates and H-phosphonothioate diesters in the presence of N,N- 
diisopropylethylamine to give the corresponding S-benzyl(phenyl) 
phosphorothioates or phosphorodithioates, respectively. This method can be 
modified to give S,S-dibenzyl(phenyl) phosphorodithioates directly from 
hydroxylic compounds by reaction of the intermediate generated in situ from 
ammonium phosphinate, the thiosuccinimide and the activating reagent 2,4,6- 
triisopropylbenzenesulphonyl chloride. Thus, the 1-S,S-dibenzyl(phenyl) 
phosphorodithioates of DL-2,3,4,5,6-penta-0-benzyl-/77yo-inositol were prepared 
in a one-pot reaction from this derivative I237!.
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2.4 Deprotection and Purification of Final Compounds
Another problem to be addressed in the synthesis of inositol phosphates is 
phosphate migration, which can occur during deprotection when free hydroxyl 
groups are present adjacent to the phosphate ester moiety. Ideally, phosphate 
protecting groups should be removed prior to hydroxyl protecting groups. As the 
cleavage of benzylphosphate esters occurs much more rapidly than the 
deblocking of benzyl groups used for the protection of hydroxyl groups I238!, the 
use of benzyl groups has been proposed for the protection of phosphates as 
well as hydroxyl groups.
Purification of the deblocked inositol phosphates is usually achieved by ion- 
exchange h.p.I.c. After deprotection in sodium - liquid ammonia the compounds 
are accompanied by large amounts of salts, but the separation of the highly 
charged inositol phosphates is easily effected by the use of ion-exchange 
columns. If the pure fully protected inositol phosphate is subjected to catalytic 
hydrogenolysis, the inositol phosphate may be obtained without further 
purification.
The conventional method for detection and quantification of non-radiolabelled 
inositol phosphates relies on the complexation of free phosphate with molybdate 
ions I239].
Recently two h.p.I.c. on-line systems for the detection of organic phosphate have 
been described [240-242]. j h e  first system [2 4 0 .2 4 1 ] generates inorganic phosphate 
by an enzyme-loaded post-column reactor (alkaline phosphatase immobilised on 
phenoxyacetyl cellulose) which is then detected by complexation with molybdate. 
The disadvantage of this method is that relatively large samples are required 
and strong interferences of incompletely dephosphorylated higher inositol 
phosphates with the molybdate complex are observed.
The second system I242] does not require dephosphorylation. Here, the high 
affinity of tervalent transition-metal ions like Y3+ to both the cation-specific dye 4- 
(2-pyridylazo)resorcinol and polyanions has been exploited for picomolar-range 
detection of inositol polyphosphates.
Analysis of phosphorothioates is possible with 5,5'-dithiobis(2-nitrobenzoic acid) 
(DTNB), a reagent developed by Ellman for the detection of sulphydryl groups
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[243,244] The advantage of employing DTNB is that degradation of the 
phosphorothioate prior to analysis is not neccessary, allowing a quick 
identification of the column fractions containing the deprotected compound.
2.5 Synthetic Inositol Phosphates
2.5.1 Inositol Monophosphates
All six myo-inositol monophosphates (the meso 2- and 5-phosphates and the 
enantiomeric 1- and 4-phosphates) have been synthesised.
/nyo-lnositol 1-phosphate
The D- [171,231] anc| L-enantiomers l172l of lns(1)P have been prepared from 1L- 
quebrachitol via 1L-3,4:5,6-di-0-cyclohexylidene-2-0-methyl-c/7/ro-inositol. In 
order to synthesise D-lns(1)P this key compound was oxidised to the inosose 
(Ru02-N al04) and stereoselectively reduced with sodium borohydride to give L- 
1,2:5,6-di-Ocyclohexylidene-4-0-methyl-f77yo-inositol. Benzoylation of the 3- 
position, removal of methyl ether and trans-ketal with aluminium trichloride / 
sodium iodide, perbenzoylation, hydrolysis of the c/'s-ketal, selective silylation of 
the 1-position with triethylsilyl chloride and benzoylation of the remaining free 
hydroxyl group afforded the 1-silyl pentabenzoate. Deprotection of the silyl 
group with PTSA-acetic acid, phosphorylation with o-xylylene 
diethylphosphoramidite / mCPBA and successive deblocking of phosphates and 
hydroxyl groups gave D-lns(P)1.
An elegant three-step conversion of myo-inositol into D-lns(1)P has been 
reported t245]. Resolution of myo-inositol by formation of its 2,3-D-camphor 
acetal, selective phosphorylation of the 1-position of the acetal with dibenzyl or 
diethyl phosphorochloridate and subsequent hydrogenolysis and acid 
deprotection of the acetal afforded D-lns(1)P.
L-lns(1)P (= D-lns(3)P), the product of the enzyme glucose-6-phosphate inositol-
1-phosphate cyclase and the only primary source of inositol in nature, was 
obtained from 1L-3,4:5,6-di-0-cyclohexylidene-2-0-methyl-c/7/'ro-inositol by 
tosylation of the free hydroxyl group, removal of the other protecting groups with
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boron trichloride, perbenzoylation and detosylation with NaF (which proceeded 
with inversion of configuration). The 1D-1 ,2,4,5,6-penta-O-benzoyl-myo-inositol 
was then phosphorylated and deprotected to give L-lns(1)P.
Optically active lns(1)P has also been synthesised from 1,2,4,5,6-penta-O- 
benzyl-myo-inositol (resolved as the fl-(-)-camphanate) I238] and the 
corresponding pentaacetate (resolved as acid oxalates) I246!. The pentaacetate 
was also used in the synthesis of racemic lns(1)P and its phosphorothioate 
analogue l247l.
myo-lnositol 2-phosphate
lns(2)P was first synthesised by taking advantage of the highly selective 
oxidation of myoinositol to scy//oinosose by Acetobacter suboxydans. The 
inosose was peracetylated and the ketone reduced to give myoinositol
1,3,4,5,6-pentaacetate. Phosphorylation with diphenylchlorophosphate, removal 
of the phosphate protecting groups by hydrogenolysis and the acetates by 
catalytic saponification with sodium methylate in MeOH gave lns(2)P I203].
myoinositol 4-phosphate
Synthesis of lns(4)P was possible by selectively protecting the 3-position of
1,2:4,5-di-0-cyclohexylidene-myoinositol, followed by phosphorylation of the
remaining free hydroxyl group and deprotection [248,249] Racemic as well as
optically active lns(4)P has been synthesised from 1,2:4,5-di-Ocyclohexylidene-
3-O-benzyI-myoinositol, which was resolved using S-(-)-camphanic acid
chloride [238l. Reaction of 1,2-O-cyclohexylidene-myoinositol with 1,3-dichloro-
1,1,3,3-tetraisopropyldisiloxane (TIPS) gave selectively the 3,4-disiloxane, which
could be selectively benzoylated at the 6-position. Phosphorylation with TBPP
and base resulted in the migration of the benzoate and phosphorylation at the 6-
position. Removal of protecting groups afforded racemic lns(4)P I157l. A short
synthesis of racemic lns(4)P by chelation-controlled selective phosphorylation of




The mesocompound lns(5)P was first prepared from 2-amino-2-deoxy-/7eo 
inositol I249!, which can be obtained by hydrolysis of the antibiotic hygromycin A. 
Phosphitylation of 1,2-0-cyclohexylidene-3,4-disiloxane-myoinositol 6-benzoate 




lns(1,3)P2 is a mesocompound. A synthesis has been reported l16°] by 
regioselective diphenylchlorophosphate phosphorylation of 2,4,6-tri-O-benzyl- 
myo-inositol, obtained via the myoinositol orthoformate ester. The 1,3- 
bisphosphorylated product could be crystallised from the 82:18 mixture of 1,3- 
and 1,5-bisphosphorylated products. Deprotection with lithium in liquid ammonia 
gave lns(1,3)P2.
myoinositol 4,5-, 1,4-, and 3,4-bisphosphate
Racemic lns(4,5)P2, lns(1,4)P2 and lns(3,4)P2 have been synthesised by simply 
phosphorylating the three different di-cyclohexylidene or di-isopropylidene 
acetals of myoinositol [249,250] 1,2,3,4-Tetra-O-benzyl-myoinositol [251,252] ancj 
conduritol B derivatives t253! have also been used in the synthesis of lns(4,5)P2. 
The different enantiomers of these bisphosphates were obtained by employing 
the optically active bisacetals which can be obtained by resolution with 
orthoesters of D-mannose [248l or as bis-(-)-co-camphanates [2171.
myoinositol 1,5-bisphosphate
Both enantiomers of lns(1,5)P2 l254l have been prepared by phosphitylation of D- 
and L-1,2,4,6-tetra-0-benzyl-myoinositol with A/,A/-diethylamino bis(2- 
cyanoethoxy) phosphine, followed by oxidation and hydrogenolysis. Resolution 
of the tetrabenzyl compounds (obtained by selective benzylation of 2,4,6-tri-O-
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benzyl-myo-inositol derived from the orthoformate) could be effected as the 
mono-(-)-camphanic esters.
2.5.3 Inositol Trisphosphates 
myo-lnositol 1,4,5-trisphosphate
The first synthesis of D-lns(1,4,5)P3 using myoinositol as starting material was 
reported by Ozaki et a l in 1986 l195l (Figure 2.6). DL-1,2:4,5-di-0- 
cyclohexylidene-myoinositol 39 was benzylated to give 40. Selective removal of 
the 4,5-acetal with ethylene glycol and PTSA afforded 41. Allylation and 
cleavage of the remaining cis-acetal gave the 1,2-diol 43, which could be 
resolved after regioselective conversion into the diastereomeric 1-/- 
menthoxyacetyl esters 44a and 44b. Hydrolysis of the menthoxyacetyl ester 44a 
and regioselective allylation gave D-1,4,5-tri-0-allyl-3,6-di-0-benzyl-myoinositol 
45, which was benzylated and deallylated to 47. Phosphorylation with 
dianilidophosphoric chloride gave 48, and successive deblocking of phosphoryl 
and hydroxyl groups with isoamyl nitrite in pyridine / acetic acid / acetic 
anhydride and H2 / 5 % Pd-C, respectively, gave D-lns(1,4,5)P3 6. The 
phosphorylation and deprotection procedures, however, were not deemed to be 
satisfactory.
The second reported synthesis of lns(1,4,5)P3 f224l also employed 2,3,6-tri-O- 
benzyl-myo-inositol 47, obtained by a similar route I165l. The difficulties with 
phosphorylating this intermediate were overcome by the use of a P(lll) 
approach: treatment of the triol with diisopropylamino (2-cyanoethoxy) 
chlorophosphine followed by displacement of the diisopropylamino group with 2- 
cyanoethanol gave the trisphosphite, which was subsequently oxidised with 
/BuOOH to give the protected trisphosphate. Deblocking with sodium / liquid 
ammonia afforded racemic lns(1,4,5)P3. This approach was later modified by 
using sulphur in pyridine to sulphoxidise the trisphosphite, giving the 
trisphosphorothioate analogue of lns(1,4,5)P3 l236l.
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Figure 2.6 The first synthesis of D-/nyo-inositol 1,4,5-trisphosphate
Optically active D-lns(1,4,5)P3 was synthesised by using chiral 1,2:5,6-di-0- 
cyclohexylidene-myo-inositol [185,187^  which could be prepared either by 
conversion into the diastereomeric di-Amenthoxyacetic esters or by conversion
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into the diacetate or dibutyrate followed by deacylation with cholesterol esterase 
or porcine pancreatic lipase. The enzymes regio- and enantiospecifically remove 
the acyl functions, yielding mixtures of (-)-1,2:5,6-di-0-cyclohexylidene-/77yo- 
inositol and the mono- or diacylated enantiomer (depending on enzyme and 
substrate), which on chemical deacylation afford 1D-(+)-2,3:4,5-di-0L 
cyclohexylidene-myo-inositol. Tin-mediated benzylation of the 6-position, 
acetylation of the 1-position, PTSA-catalysed hydrolysis of the trans-acetal and 
saponification afforded D-2,3-0-cyclohexylidene-6-0-benzyl-/77yo-inositol. 
Phosphorylation with A/,A/-diisopropylamino bis(benzyloxy)phosphine and 
mCPBA, hydrogenolysis of the benzyl protecting groups and acid hydrolysis of 
the acetal gave D-lns(1,4,5)P3.
A short synthesis of racemic lns(1,4,5)P3 starting from 1,4-di-0-benzoyl-/77yo- 
inositol has been reported l222l  Phosphitylation of this tetrol at the 1-, 4-, and 5- 
positions with dimethyl chlorophosphite (3.3 equiv.) followed by acetylation at 
the 2-position and oxidation of the crude reaction mixture gave predominantly 
(94 %) the desired 1,4,5-tris(dimethyl phosphate). Demethylation and ester 
hydrolysis afforded lns(1,4,5)P3 contaminated with about 5 % bisphosphates.
The microbial oxidation of benzene by Pseudomonas putida affords cis-1,2- 
dihydroxycyclohexa-3,5-diene 49, which has been used in a synthesis of 
racemic lns(1,4,5)P3 l255l (Figure 2.7). The cyclic carbonate 50 derived from the 
diene by treatment with phosgene and triethylamine was stereoselectively 
oxidised to the a-epoxide 51 with mCPBA. Regioselective ring opening of the 
epoxide with benzyl alcohol and benzylation of the free hydroxyl group afforded 
the 4,5-di-0-benzyl-3-ene 53. The 1,2-carbonate was removed by hydrolysis, the 
double bond epoxidised and the c/s-1,2-diol reprotected as the isopropylidene 
acetal to give 54. The p-epoxide was opened with sodium-2p-propoxy-5,5- 
dimethyl-1,3-dioxane 55 to give 4,5-di-0-benzyl-6-0-[2-(5,5-dimethyl-1,3-dioxan- 
2-yl)ethyl]-2,3-0-isopropylidene-/77yo-inositol 56. Debenzylation and 
phosphorylation with TBPP afforded 57. Hydrogenolysis and treatment with 
moist trifluoroacetic acid afforded racemic lns(1,4,5)P3. This method has been 
modified to give D- and L-lns(1,4,5)P3 l256l by opening the a-epoxide 51 initially 
obtained with (R)-(+)-seophenethyl alcohol 58 rather than with benzyl alcohol, 
affording a mixture of diastereoisomers (59 a and 59 b) which could be 
separated by HPLC (Figure 2.7 b). The diastereoisomers were then processed 
analogous to the racemate to furnish the two enantiomers of lns(1,4,5)P3. This
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approach has also been used to give analogues of inositol and lns(1,4,5)P3 
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Figure 2.7 Synthesis of lns(1,4,5)P3 via the microbial oxidation of 
benzene
Benzene was also the starting material in another synthesis of racemic 
lns(1,4,5)P3 t253l (Figure 2.8). 7rans-1,2-dihydroxycyclohexa-3,5-diene 60 can 
be prepared from benzene in 40 % overall yield via Birch reduction, bromination, 
trans-hydroxylation, acetylation and dehydrobromination. Protection of the 
hydroxyl groups as MEM ethers and [4+2] addition to singlet oxygen followed by
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thiourea reduction affords 1,4-dihydroxy-2,3-di-Omethoxyethoxymethyl- 
cyclohexa-5-ene 61 l257l. Inversion at C-1 is achieved by oxidation with 
pyridinium chlorochromate yielding the desired 4-hydroxy-5-en-1-one 62 in 50 % 
yield. Reduction with sodium borohydride / cerium trichloride gave the 
symmetrical conduritol B derivative 63, which could also be obtained in 70 % 
yield by oxidation of the 1,4-diol 61 to the ene-1,4-dione and subsequent 
reduction. Benzylation of 63 and osmium tetroxide-catalysed cis hydroxylation of 
the double bond gave 3,6-di-0-benzyl-4,5-di-0-methoxyethoxymethyl-/77yo- 
inositol 64, which was regioselective methoxyethoxymethylated at the 1-position 
to give 65. Benzylation and demethoxyethoxymethylation furnished 2,3,6-tri-O- 
benzyl-myoinositol 47. Phosphorylation with TBPP followed by hydrogenolysis 
gave lns(1,4,5)P3.
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Figure 2.8 Synthesis of lns(1,4,5)P3 from benzene via trans-1,2- 
dihydroxy-cyclohexa-3,5-diene
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Chiral starting materials have also been employed in the synthesis of 
lns(1 >4,5)P3. Commercially available (-)-quinic acid 28 was converted to ester 66 
in four steps according to literature procedure. Sequential protection of the C-1 
alcohol as its p-(trimethylsilyl)ethoxymethyl (SEM) ether, diisobutylaluminium 
hydride (DIBAL-H) reduction of the ester, and selenylation of the resulting 
primary alcohol furnished 67. Rearrangement of the allylic selenoxide derived 
from 67 and benzylation generated a single stereoisomer 68. Transformation of 
68 to silyl enol ether 69 by low temperature ozonolysis and treatment with 
excess fert-butyldimethylsilyl (TBDMS) triflate proceeded with nearly complete 
regiospecifity. Hydroboration of the enol ether followed by alkaline peroxide
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Figure 2.9 Synthesis of D-lns(1,4,5)P3 starting from (-)-quinic acid
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oxidation furnished the alcohol 70, which on desilylation gave the known D-2,3- 
0-cyclohexylidene-6-0-benzyl-/77yo-inositol 71. Phosphorylation with TBPP and 
hydrogenolysis afforded D-lns(1,4,5)P3 I179).
Another synthesis of D- and L-lns(1,4,5)P3 made use of D-pinitol 27 and L- 
quebrachitol 26, respectively l173l. The naturally occuring starting materials were 
demethylated to give D- and L-cft/'ro-inositol 16 and 17, respectively. Formation 
of the more stable c/s,c/s-dicyclohexylidene acetal 72 (from 16), benzylation of 
the two remaining hydroxyl groups and hydrolysis of the acetals followed by 
selective benzoylation with 3 equivalents of benzoyl chloride gave mainly D-














Figure 2.10 Synthesis of D-lns(1J4l5)P3 from D-pinitol
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was converted into the triflate and the triflate displaced with inversion of 
configuration by sodium acetate /  acetic acid to give predominantly L-1,2,4-tri-O 
benzoyl-5,6-di-0-benzyl-myo-inositol 75 and some 1,3,4-tribenzoate due to 
migration of benzoyl groups. Debenzylation, phosphitylation of 76 with N,N- 
diisopropylamino bis(benzyloxy)phosphine, followed by oxidation with mCPBA 
and deprotection by hydrogenolysis gave D- and L-lns(1,4,5)P3, respectively.
Several other preparations of racemic I169! and optically active 
[191,197,217,219,227,230,258] ins(1,4,5)P3 have been published, including the 
synthesis of [3H]-labelled D- and L-lns(1,4,5)P3 l259l.
myo-lnositol 1:2-cyclic,4,5-trisphosphate
D-lns(1:2,4,5)P3 has been synthesised by treatment of D-3,6-di-0-benzyl-4,5- 
bis(dibenzylphospho)-myo-inositol with A/-methyl-pyridinium phosphodi- 
chloridate and subsequent deprotection I258]. It was also possible to obtain D- 
lns(1:2,4,5)P3 from D-lns(1,4,5)P3 by the action of water soluble 1-ethyl-3-(3- 
dimethylaminopropyl)carbodiimide t26°l.
myo-Inositol 2,4,5-trisphosphate
Racemic lns(2,4,5)P3 has been prepared from 3,6-di-0-benzyl-4,5-di-0-allyl- 
myo-inositol l165l, which was selectively benzylated at the 1-position. Deallylation 
to give the 2,4,5-triol, phosphorylation with TBPP and hydrogenolysis gave 
lns(2,4,5)P3 [216,217].
Another synthesis of lns(2,4,5)P3 using the benzyl-protected 2,4,5-triol of myo­
inositol (derived from benzylation of 3,6-di-0-benzyl-2,4,5-di-0-MEM-myo- 
inositol, a by-product obtained during the introduction of the MEM protecting 
group into the corresponding 1,2-diol) has been described I253!.
An attempted synthesis of D-lns(2,4,5)P3 t261! by resolution of a suitably 
protected precursor with Amenthoxyacetyl chloride and stepwise phosphorylation 
to give the fully protected precursor of D-lns(2,4,5)P3 was not concluded. 
However, the same authors t258! succeeded in the preparation of D-lns(2,4,5)P3 
by phosphorylating 1,2-Ocyclohexylidene-3,6-di-0-benzyl-myo-inositol with
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TBPP, removal of the acetal protecting group and resolution of this intermediate 
via the diastereomeric Amenthoxyacetic esters. Silylation of the 1-position, 
phosphorylation of the 2-position and hydrogenolysis afforded D-lns(2,4,5)P3
D- and L-lns(2,4,5)P3 were also prepared from L- and D-1,3,4-tri-O-benzoyl- 
myo-inositol, respectively [174L Partial benzoylation of the 3,4-dibenzyl ethers of 
D- and L-ch/ro-inositol gave the 1,2,5-tri-Obenzoyl-3,4-di-0-benzyl-c/7/ro- 
inositols, inversion of the free hydroxyl group and cleavage of the benzyl ethers 
by catalytic hydrogenolysis afforded D- and L-1,3,4-tri-O-benzoyl-myo-inositol.
myo- Inositol 1,3,4-trisphosphate
Several syntheses of racemic [217,223] ancj optically active [186,187,190] |ns(i ,3,4)P3 
have been reported:
1,6-Di-0-para-methoxybenzyl-4,5-di-Obenzyl-/77yo-inositol (derived from both 
1,2:3,4- and 1,2:5,6-di-0-cyclohexylidene-/7?yo-inositol) was resolved either by 
use of a chiral column or conversion into the diastereomeric Amenthoxyacetic 
esters. The remaining equatorial hydroxyl group was methoxymethylated and the
2-OH benzylated. Removal of methoxybenzyl and methoxymethyl protecting 
groups gave D-2,5,6-tri-0-benzyl-myo-inositol. Phosphorylation with TBPP and 
hydrogenolysis afforded D-lns(1,3,4)P3 [19°1.
Optically active 1,2:5,6-di-Ocyclohexylidene-A7?yo-inositol, obtained either by an 
enzymatic process or by conversion into the di-Amenthylcarbonates I185l was 
used in the synthesis of D-lns(1,3,4)P3 [186.187], Allylation of the free hydroxyl 
groups, selective removal of the trans-acetal, benzylation, deprotection of the 
cis-acetal, tin-mediated allylation of the 1-position, benzylation of the 2-position 
and removal of the allyl groups gave D-2,5,6-tri-0-benzyl-/77yo-inositol, which 




The first synthesis of lns(1l3,4,5)P4 employed the 1,3,5-orthoformate ester
[160,161]^  which could be selectively allylated at the 4-position. Benzylation of the 
remaining hydroxyl groups and removal of allyl group and orthoformate ester 
gave 2,4-di-O-benzyl-myo-inositol, which was phosphorylated using sodium 
hydride and TBPP and then deblocked by hydrogenolysis. Similar syntheses 
employing benzyloxymethyl ether rather than allyl ether for protection of the 4- 
position I216! and different phosphorylation methods t169l have also been 
published.
An even shorter route I14®] involves selective benzoylation of myo-inositol with
3.5 molar equivalents of benzoyl chloride in pyridine, myoinositol 1,3,4,5- 
tetrabenzoate is isolated as the major product in 34 % yield. Benzylation of the 
free hydroxyl groups with benzyl trichloracetimidate in the presence of 
trifluoromethanesulfonic acid and subsequent debenzoylation affords the 2,4- 
protected inositol, which was phosphitylated with oxylylene 
diethylphosphoramidite. Oxidation with mCPBA and hydrogenolysis afforded 
lns(1,3,4,5)P4. Resolution of the tetrabenzoate was accomplished by means of 
chiral column chromatography, thus giving access to optically active 
lns(1,3,4,5)P3.
The same authors have described the enantioselective acylation of inositol 
derivatives using tartaric acid monoester I228!. Thus symmetrical 1,3,5-tri-O- 
benzoyl-myo-inositol, obtained in modest yield by direct benzoylation of myo­
inositol, was enantioselectively transformed into the 4-tartrate and silylated at 
the 2- and 6-position. Resolution of the fully protected compound followed by 
deacylation with ethylmagnesium bromide, phosphorylation and hydrogenolysis 
afforded D-lns(1,3,4,5)P3 t23°l.
D-lns(1,3,4,5)P3 was also prepared from D-1,2:5,6-di-0-cyclohexylidene-myo 
inositol (186,187]^  which can be obtained by chemical or enzymatic means I185].
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Further syntheses of racemic f222l and optically active [159,197,262] ins(1,3 ,4 ,5 )P 3 
have been published.
myo- Inositol 1,2,4,5-tetrakisphosphate
Racemic lns(1,2l4,5)P4 has been prepared from 1,4-dibenzoyl-/77yoinositol by 
phosphitylation with dimethoxychlorophosphite followed by oxidation to the 
tetrakisphosphate with hydrogen peroxide. Removal of the phosphate methyl 
groups was effected with bromotrimethylsilane or HBr in acetic acid, and basic 
hydrolysis of the benzoates with lithium hydroxide gave lns(1,2,4,5)P4 as the 
octalithium salt.
In another method t253l 3,6-di-0-benzyl-4,5-di-0-(2-methoxyethoxy-methyl)-myo 
inositol, obtained from benzene via conduritol B derivatives was employed. 
Cleavage of the MEM ethers afforded 3,6-di-0-benzyl-/77yoinositol, which was 
phosphorylated with TBPP / sodium hydride and hydrogenolysed to give 
lns(1,2,4,5)P4.
myoinositol 1,3,4,6-tetrakisphosphate
The mesocompound lns(1,3,4>6)P4 was obtained by treatment of myoinositol 
with 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane, which regioselectively gave 
the symmetrical 3,4:6,1-bis(disiloxane) in 66 % yield. Benzoylation of the free 
hydroxyl groups followed by acidic removal of the siloxanes produced the
1,3,4,6-tetrol, which was phosphitylated with o-xylylene diethylphosphoramidite. 
Oxidation and hydrogenolysis afforded lns(1,3,4,6)P4 [1571.
myo- Inositol 1,4,5,6-tetrakisphosphate
Racemic lns(1,4,5,6)P4 I222] was synthesised from the 1,2-cyclohexylidene 
acetal of myoinositol by phosphitylation with dimethoxychlorophosphite followed 
by oxidation, removal of the methyl esters with bromotrimethylsilane and self­
catalysed hydrolysis of the acetal.
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3 Analogues of Inositols and Inositol Phosphates
Analogues of natural products have an established place in the array of tools 
the biochemist uses to investigate enzyme functions and mechanisms. 
Substrate analogues have for example been constructed as reversible or 
irreversible inhibitors, transition state analogues, suicide substrates and 
probes carrying reporter groups.
3.1 Phosphorothioates
3.1.1 Phosphorothioates as Phosphate Analogues
Phosphorothioates are analogues of phosphates in which a non-bridging 





Figure 3.1 Phosphate vs. Phosphorothioate
This replacement causes only a minimal change in the geometry of the 
molecule (van der Waals radii 1.4 A for oxygen and 1.9 A for sulphur). The 
electronegativities of oxygen and sulphur (Pauling index) are 3.5 and 2.5, 
respectively, and the second dissociation constant is reduced by ca. 0.5 units 
after substitition of oxygen for sulphur. At physiological pH, however, there is 
no difference in the number of formal negative charges associated with the 
phosphorus-containing group. The different dissociation energies (586 kJ 
mol’1 for the P=0 bond vs. 377 kJ mol-1 for the P=S bond) are a reflection of 
the decreased extent of rc-bonding in the P=S bond I263l, which is also the 
cause of the lower31P-NMR field resonance of phosphorothioates.
Many biologically interesting compounds contain phosphate groups. As 
phosphorothioates are generally more stable towards enzymatic cleavage 
than the corresponding phosphate (for example, AMP is hydrolysed 2000 
times faster than AMPS by alkaline phosphatase l264l), phosphorothioate
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analogues of naturally occuring phosphates are potential inhibitors of 
phosphatase enzymes. The phosphorothioate analogues of cAMP, (Sp)- and 
(flp)-cAMPS (the Sp-analogue carrying an axial and the Hp-analogue 
carrying an equatorial exocyclic sulphur atom)t have been used to probe the 
cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II 
I2 6 5 !, and (flp)-cGMPS was found to antagonise cGMP-dependent protein 
kinase l266l.
Figure 3.2 AMP and AMPS
Phosphorothioate analogues of nucleosides and nucleotides have played a 
major role in helping the biochemist and the molecular biologist to elucidate 
the properties of these molecules [235,267]
Some of these phosphorothioates are substrates for enzymes and can thus 
participate in metabolic reactions i.e. the synthesis of phosphorothioate 
containing DNA. They are also useful in determining the stereochemical 
course of enzymatic phosphorylation and nucleotidyl transfer reactions, as 
the replacement of a non-bridging oxygen by sulphur leads to chirality in a 
phosphodiester and so the existance of a pair of diastereoisomers [2351.
During the last five years phosphorothioate analogues of inositol phosphates 
have also found their place in the toolbox of the biochemist. The first 
synthetic lns(1,4,5)P3 analogue was myoinositol 1,4,5-trisphosphorothioate 
[lns(1,4,5)PS3] 77 t236], which was shown to be recognised with high affinity 
by intracellular sites mediating calcium release [268,269] ancj a specific D-
cAMP (Sp)-cAMPS (flp)-cAMPS
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Ins(1,4,5)P3 binding site in the cerebellum I27°]. Ins(1,4,5)PS3 is resistant to 
hydrolysis by the metabolic enzyme 5-phosphatase, inhibiting the enzyme 
potently with a Kj of 6 pM (for the racemic mixture) I271!. Because the 
phosphorothioate is not degraded as rapid.ly as lns(1,4,5)P3 it causes 
sustained calcium release from intracellular stores l272l.
6 : X = Y= Z = O; myo-lnositol 1,4,5-trisphosphate
77: X = Y = Z = S; myoinositol 1,4,5-trisphosphorothioate
78: X = Y = O;Z = S; myoinositol 1,4-bisphosphate 5-phosphorothioate
79: X = O; Y = Z = S; myoinositol 1 -phosphate 4,5-bisphosphorothioate
80: X = S; Y = Z = O; myoinositol 4,5-bisphosphate 1 -phosphorothioate
Figure 3.3 Phosphorothioate Analogues of lns(1,4,5)P3
lns(1,4,5)PS3 has now been supplemented by lns(1,4,5)P3-5S 78 [209-211] ancj 
lns(1 i4,5)P3-4,5S2 79 l273l. Both compounds are also 5-phosphatase resistant 
and very similar to lns(1,4,5)PS3 in calcium releasing properties.
The synthesis of phosphorothioate analogues also provides an excellent 
method to introduce radiolabels into inositol phosphates. Because the 
sulphoxidation is usually the final synthetic step before deprotection and can 
be effected with elementary sulphur, the handling of radioactive material can 
be kept to a minimum. Thus, D-[35S]lns(1,4,5)PS3 has been synthesised and 
used for enzyme t274l and receptor binding studies f275l, in which it was found 
to label two different sites, one of them being the lns(1,4,5)P3 receptor and 
the other one (which is showing only a low affinity for lns(1,4,5)P3) possibly 
being a different conformation of the receptor.
The phosphorothioate group is a good nucleophile I276! and as such reacts 
preferentially with soft acids such as transition metals, halogens and sp3 
hybridised carbons. In contrast, phosphate groups react preferentially with 
hard acids such as protons, carbonyl groups and tetrahedral phosphorus.
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Selective attachment of reporter groups to phosphorothioates in the presence 
of phosphates is thus possible by choosing appropriate reagents.
3.1.2 Phosphorothioate Analogues of Inositol Monophosphates 
DL-/nyo-lnositol 1 -phosphorothioate
Myo- Inositol 2,3,4,5,6-pentaacetate can be thiophosphorylated with 
thiophosphoryl chloride in acetonitrile solution containing traces of pyridine 
followed by hydrolysis with potassium hydroxide to form the phosphorothioate 
derivative. Removal of protecting groups and precipitation from solution gave 
the 1-phosphorothioate compound in 21% yield (2471.
An improved synthesis [277.278] has been reported by a different group. 
Racemic 2,3,4,5,6-penta-Obenzyl-myo-inositol produced the pentakis-O- 
benzyl myoinositol 1-phosphoramidite ester on reaction with N,N- 
diisopropylamino(2-cyanoethoxy)chlorophosphine. Treatment with 3- 
hydroxyproprionitrile and 1H-tetrazole afforded the phosphite triester which 
was dissolved in pyridine and treated with sulphur to give the 1- 
phosphorothioate triester. Deprotection produced myoinositol 1- 
phosphorothioate in 70% overall yield from the pentabenzyl-protected 
inositol.
D-/nyo-inositol 3-phosphorothioate
DL-l^^-tri-O-benzyl-S.O-O-isopropylidene-myoinositol was resolved using 
camphanic acid chloride and the D-enantiomer was converted to the 
protected 3-phosphorothioate by phosphitylation and oxidation using sulphur 
in pyridine. Deblocking produced the 3-phosphorothioate P79l.
DL-myo-inositol 1:2-cyclic-phosphorothioate
Direct thiophosphorylation of DL-M.S.e-tetra-O-acetyl-myo-inositol (or the 
respective tetrabutyryl or tetrabenzyl derivatives) with thiophosphoryl chloride 
in acetonitrile solution containing traces of pyridine afforded a 1:1 mixture of 
the endo and exo diastereoisomers of the protected cyclic thiophosphate
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which could be separated by reverse phase flash chromatography (yield 10 
% of each isomer). Deprotection with triethylamine / methanol and 
precipitation with potassium chloride produced endo and exo DL-myo-inositol 
1 :2-cyclic-phosphorothioate in quantitative yield I2 8 0 !.
3.1.3 Phosphorothioate Analogues of Inositol Bisphosphates 
/nyo-lnositol 1,4-bisphosphorothioate
DL-1,2:4,5-Di-0-isopropylidene-myo-inositol reacted with diisopropylamino- 
(2-cyanoethoxy) chlorophosphine forming the bisphosphoramidite. Formation 
of the bisphosphite triester occurred on reaction with tetrazole and 3- 
hydroxypropionitrile. Oxidation with sulphur in pyridine produced the 
protected bisphosphorothioate derivative which was deprotected and purified 
to yield myoinositol 1,4-bisphosphorothioate t25°].
myoinositol 4,5-bisphosphorothioate
The starting material for the preparation was 1,2,3,4-tetra-O-benzyl-myo 
inositol which was phosphitylated with diisopropylamino(2- 
cyanoethoxy)chlorophosphine forming the bisphosphoroamidite which was 
then converted to the tetracyanoethoxy bisphosphite triester. Sulphoxidation 
with sulphur in pyridine formed the bisphosphorothioate triester. Deblocking 
and purification produced the target compound t251l.
3.1.4 Phosphorothioate Analogues of Inositol Trisphosphates 
myo-lnositol 1,4,5-trisphosphorothioate
Myo-Inositol 1,4,5-trisphosphorothioate 77 [224,236] was the first lns(1,4,5)P3 
analogue synthesised and has proved to be a valuable instrument in the 
elucidation of the biochemical role of lns(1,4,5)P3. lns(1,4,5)P3 was 
synthesised from the protected precursor DL-1,2,4-tri-O-benzyl-myo-inositol, 
which was converted to the trisphosphoramidite by reaction with 
diisopropylamino(2-cyanoethoxy)chlorophosphine and then to the 
corresponding tris[di(2-cyanoethoxy)]phosphine on reaction with tetrazole 
and 2-cyanoethanol. Oxidation using sulphur in pyridine to the tris[di(2-
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cyanoethoxy)]phosphorothioate was followed by deprotection and purification 
produced the trisphosphorothioate.
A second synthesis which also uses 2,3,6-tri-O-benzyl-myoinositol has been 
reported t234l. Phosphitylation with bisbenzyldiisopropylaminophosphine in 
the presence of 1 -H  tetrazole in a CH2CI2 - CH3CN mixture gave the 
intermediate trisphosphite triester. Sulphurisation with phenacetyl disulfide 
rapidly produced the protected phosphorothioate which was then deblocked 
and purified to afford myo-inositol 1,4,5-trisphosphorothioate in 51% yield.
myoinositol 1,4-bisphosphate 5-phosphorothioate
The synthesis of the 5-phosphorothioate lns(1,4,5)P3-5S 78  [209,211] followed 
the same route as the lns(1,4,5)P3 synthesis reported starting with 2,3,6-tri- 
0-benzyl-4,5-Oisopropylidene-myoinositol which was phosphorylated using 
bis(2 ,2 ,2-trichloroethyl) phosphorochloridate to form the bis(2 ,2,2- 
trichloroethyl) phosphate group at the 1-position. The 4,5-isopropylidene 
group was removed and phosphorylation of the diol with bis(2 ,2,2- 
trichloroethyl) phosphorochloridate afforded a mixture of the 1,4- and 1,5- 
bisphosphate triesters. The 1,4-bisphosphate triester could be obtained from 
this mixture by crystallisation and was then phosphitylated at the free 5- 
hydroxyl group using A/,/V-diisopropylamino-(2-cyanoethoxy) 
chlorophosphine, oxidised with sulphur and deblocked as before to give the 
desired 5-phosphorothioate analogue.
A second synthesis l234J of 78 has been reported. A fully benzyl protected 
inositol 1,4-bisphosphate with a free 5-hydroxyl group was phosphitylated 
with bisbenzyldiisopropylaminophosphine. Sulphoxidation with phenacetyl 
disulphide produced the protected 5-phosphorothioate derivative. 




from phosphorylation of 2,3,6-tri-0-benzyl-4,5-0-isopropylidene-myoinositol 
followed by acid hydrolysis of the 4,5-acetal) was phosphitylated to form the
4,5-bisphosphite using either bis(2-cyanoethoxy)diisopropylaminophosphine 
or bisbenzyldiisopropylaminophosphine. Oxidation with sulphur in pyridine
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gave the respective protected 4,5-bisphosphorothioates. Deprotection and 
purification produced myo-inositol 1-phosphate 4,5-bisphosphorothioate in 
83% yield. The 4,5-bisphosphorothioate has been used in the synthesis of 
the pyrophosphate, which could be obtained by desulphurisation with N- 
bromosuccinimide (NBS) l273l.
myo- Inositol 4y5-bisphosphate 1-phosphorothioate
A second synthesis of this lns(1,4,5)P3 analogue was reported by Dreef et al. 
[2341 after work described in this thesis had been published. Thus, 2,3,6-tri-O- 
benzyl-4 ,5-di-0 -(fra/7s-prop-1-enyl)-myo-inositol 81 was reacted with 
(bisbenzyl)(diisopropylamino)phosphine followed by sulphurisation with 
phenacetyl disulfide to form the 1-phosphorothioate triester 82. Mild acidic 
hydrolysis of the 4- and 5-(prop-1-enyl) groups gave 83. Phosphitylation at 
the 4- and 5-positions with the phosphoramidite and oxidation of the 
intermediate phosphite triester with B^OOH afforded the fully benzyl- 
protected inositol 1-phosphorothioate 4,5-bisphosphate 84. Deblocking with 
sodium in liquid ammonia gave 80 in 74% yield.











Figure 3.4 Synthesis of lns(1,4,5)P3-1S (Dreef et al.)
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3.1.5 Phosphorothioate Analogues of Inositol Tetrakisphosphates
myo- Inositol 1,3,4-trisphosphate 5-phosphorothioate
Phosphitylation of 2,6-di-O-benzyM ,3,4-tris[(dibenzoxy)phospho]-n7yo- 
inositol with bisbenzyldiisopropylaminophosphine in the presence of 1AV- 
tetrazole was followed by in situ sulphurisation to produce the fully protected 
lns(1,3,4,5)P4-5S analogue. Removal of the benzyl protecting groups yielded 
the 5-phosphorothio-ate derivative (which acts as a competitive inhibitor of 3- 
kinase) in 68% yield I234l.
3.1.6 Phosphorothioate Analogues of Inositol Phospholipids
Syntheses of 1,2-dipalmitoyl-sn-glycero-3-thiophospho-myo-inositol (DPPsI) 
have been described by two groups [281-283]
In the first synthesis [281,282] iD-2,3:5,6-di-0-cyclohexylidene-4-0-methoxy- 
methyl-myo-inositol was phosphitylated with CIP(OCH3)N(Pr')2 and then 
converted directly to the protected 1,2-dipalmitoyl-sn-glycero-3-thiophospho- 
myo-inositol by reaction with 1,2-dipalmitoyl-s/i-glycerol and sulphoxidation 
with elemental sulphur. Deprotection with 80 % acetic acid afforded (Rp+Sp)- 
DPPsI as a mixture of diastereoisomers.
In the second approach 1,2-dipalmitoyl-sn-glycerol was reacted with chloro- 
A/,A/-diisopropylamino methoxyphosphine to produce the phosphoramidite 
which was then condensed with 1 D-2,3,4,5,6-penta-0-benzyl-A7?yo-inositol in 
the presence of tetrazole. Sulphoxidation afforded a mixture of the 
phosphorothioate diastereoisomers which could be separated by 
chromatography. Deprotection produced the individual diastereoisomers of 
1,2-dipalmitoyl-sr7-glycero-3-thiophospho-1-f77yo-inositol I283!.






(RP)- and (SP)-1,2-dipalmitoyl-sn-glycero-3-thiophospho-A77yo-inositol have 
been used to examine the stereochemical mechanism by which
phosphatidylinositol-specific PLC's cleave phosphatidylinositol (Ptdlns) 
[281,282] |n contrast to Ptdlns itself, these phosphorothioate diesters are chiral 
at the phosphorus atom, thus making the determination of enzyme 
stereospecifity possible. It was found that the RP isomer is the preferred 
substrate for Ptdlns-PLC and that the formation of cyclic
inositol(1:2)phosphate proceeds with inversion of configuration at 
phosphorus, suggesting that a direct attack of the 2-OH group (or in the case 
of non-cyclic products of water) on phosphorus affects the displacement of 
the diacylglycerol moiety, without involving a covalent enzyme-
phosphoinositol intermediate.
3.2 Other Phosphate Analogues
3.2.1 Phosphonates
One of the first lns(1,4,5)P3 analogues was DL-myo-inositol 1,4,5-tris-1-H- 
phosphonate 85 I284!, prepared by the reaction of the ammonium salt of 
benzyl-1-H-phosphonic acid with 2,3,6-tri-O-benzyl-myo-inositol and 
subsequent anionic debenzylation. However, no biological activity has been 
reported for this compound.
The 5-methylenephosphonate analogue of lns(1,4,5)P3 86 has been 
prepared from (-)-quinic acid I18°] and shown to be a long-lived agonist of 
calcium mobilisation.
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DL-lns(1 ^.SJa-tris-l -H-phosphonate 85 D-lns(1,4,5)P3-5-methylenephosphonate 86
lns(1,4,5)P3-5-methylphosphonate 87 lns(1,4,5)P3-5-(difluoromethyl)phosphonate 88
lns(1,3,4,5)P4-5-methylphosphonate 89 lns(1,3,4,5)P4-5-(difluoromethyl)phosphonate 90
Figure 3.6 Phosphonate analogues of lns(1,4,5)P3
Also synthesised were the 5-methylphosphonate analogues 87 and 89 and 
the 5-(difluoromethyl)phosphonate analogues 88 and 90 of lns(1,4,5)P3 and 
lns(1 i3 i4,5)P4, respectively, by employing the new bifunctional phosphonyla- 
ting agents b/s[6-(trifluoromethyl)benzotriazol-1-yl]methylphosphonate (for 
the preparation of the methylphosphonates) and (difluoromethyl)phosphonic- 
di(1,2,4-triazolide) (for the preparation of the difluoromethylphosphonate 
analogues) [285,286] §7 has been reported to act as a calcium antagonist in 
permeabilised human platelets.
The synthesis of the racemic 3-methylphosphonates analogues of lns(3,4)P2 
and lns(1,3,4)P3 has been described by the same group l287l.
The synthesis of racemic myo-inositol 5-methylphosphonate, myo-inositol
4,5-bismethylphosphonate and myo-inositol 1,4,5-trismethylphosphonate was 
accomplished using a phosphinate P(lll) approach followed by oxidation 
[288,289]  ^ a method which avoids the formation of undesired cyclic products.
Phosphonate analogues of inositol phospholipids have also been 
synthesised [290-293] j h e bifunctional phosphonylating agent bis[ 6- 
(trifluoromethyl)-benzotriazol-1-yl]methylphosphonate was employed in the 
synthesis of optically active phosphonate analogues of Ptdlns and Ptdlns(4)P 
I291] as well as in the preparation of the diastereomeric uncharged 
methylphosphonate analogues of Ptdlns I292l  The phosphonate analogue of 
Ptdlns has proved to be a potent anti-inflammatory and analgesic agent [29°1. 
Phosphonate derivatives of Ptdlns which have a single alkyl chain in place of 





91: R = H
92: R = P 03:2-
Figure 3.7 Methylenephosphonate Analogues of Ptdlns and Ptdlns(4)P 
3.2.2 Sulphates, Sulphonamides and Carboxylates
The preparation of racemic sulphonamide, sulphate and carboxymethyl 
analogues of lns(1,4,5)P3 has been described I289,294] However, none of 








Of the 10 million compounds that had been registered in Chemical Abstracts 
by February 1990, 6.2 % possess a carbon-fluorine bond. Every year more 
than 50000 novel organofluorine compounds are synthesised, the number of 
papers published in this area of research has reached 5000 per annum I295]. 
These numbers show the immense interest that organofluorine compounds 
attract. A number of reviews on the subject have appeared [295-298]^  including 
one on fluorinated carbohydrates £2961.
What is so special about fluorine? Fluorine has steric requirements very 
similar to hydrogen (van der Waals radius of fluorine 1.35 A, hydrogen 1.20 
A). Additionally, there are similarities in bond length and polarisation between 
C-F and C-OH (bond length for the carbon-fluorine bond 1.39 A, for the 
carbon-oxygen bond 1.43 A, electronegativity of fluorine 4 vs. 3.5 for 
oxygen). By replacing hydrogen or hydroxyl with fluorine, however, the 
chemical properties of a compound can be dramatically changed. Once 
introduced, the high carbon-fluorine bond energy (489 kJ / mol vs. 413 kJ / 
mol for a C-H bond and 358 kJ / mol for a C -0  bond) renders the substituent 
relatively resistant to metabolic transformations. These features can be 
exploited by the biochemist looking for analogues of naturally occurring 
compounds which may act as inhibitors of metabolic enzymes 
('antimetabolites'). As the overall steric 'appearance' of the molecule has 
only been moderately changed, the fluoro-analogue will still fit into the active 
site of the enzyme, but it will not be processed in the same way as the 
original metabolite.
3.3.1 Fluorinated Analogues of Natural Products
A good illustration for this mode of action is given by fluoroacetate. When 
cattle feed on the leaves of Dichapetalum cymosum, a poisonous African 
plant, the citrate cycle is blocked. Within an hour the citrate levels in many 
organs are raised more than 10 fold. The cattle develop spasms and die 
shorty afterwards. The substance in the leaves causing the poisoning is 
fluoroacetate. Fluoroacetate, once ingested, is activated as fluoroacetyl- 
coenzyme A and then condensed with oxaloacetate to give fluorocitrate, a 
potent inhibitor of the enzyme aconitase. The active centre of aconitase 
contains Fe2+ as coenzyme which forms a chelate complex with the hydroxyl 
oxygen and the two carboxylate oxygens of citrate prior to the dehydration
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step producing cis-aconitate. If the substrate is fluorocitrate, however, the 
fluorine atom replaces one of the carboxylate oxygens in the chelate complex 
with the Fe2+ ion. The high electonegativity of fluorine results in a strong 
interaction with the Fe2+, causing irreversible inhibition of the enzyme and 
blocking further steps in the metabolic pathway. In Australia thousands of 
cattle are lost every year due to the toxic effects of fluoroacetate even though 
it rarely exceeds 1% dry weight of the leaves or seeds of certain plants which 
the cattle feed on.
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Fluoroacetate Fluoroacetyl-Coenzyme A Fluorocitrate
Figure 3.9 Fluoroacetate is metabolised to fluorocitrate
The same principle was applied in cancer chemotherapy with the 
development of 5-fluorouracil [299.300] a s canqer cells proliferate faster than 
ordinary cells, they also require more deoxythymidine monophosphate 
(dTMP) for DNA synthesis. The metabolic precursor of dTMP is deoxyuridine 
monophosphate (dUMP), the transformation (methylation of the 5-position of 
uracil) is catalysed by the enzyme thymidylate synthetase. In vivo, 5-fluoro­
uracil is metabolised to 5-fluoro-2'-deoxyuridine-5'-monophosphate (F- 
dUMP), which irreversibly inhibits thymidylate synthetase. F-dUMP behaves 
like a normal substrate in the first step (formation of a covalent bond between 
C-6 and a sulphydryl group of the enzyme) and the second step (addition of 
methylene-tetrahydrofolate - the donor of the C  ^ unit required for methylation 
- to the 5-position) of the catalytic cycle. The next step (hydride-transfer to 
the methylene group and cleavage of the C-5 proton), however, is not 
possible with F-dUMP, where the C-5 proton has been replaced by fluorine.
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Thus, the catalytic process is blocked and the enzyme inactivated as it 
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F-dUMP complex with Thymidylate-Synthetase and Methylene-THF
Figure 3.10 Inhibition of Thymidylate Synthetase by F-dUMP
The effects of this inhibition are drastic. With thymidine no longer available, 
the DNA replication is stopped and with it the growth of any tumor. 
Unfortunately, the replacement of normal short-lived cells (e.g. leukocytes) is 
also affected by 5-fluorouracil, so that side effects common in cancer patients
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undergoing chemotherapy (weakening of the immune system, loss of hair) 
cannot be avoided.
3.3.2 The Synthesis of Fluorinated Analogues of Carbohydrates
The synthesis of fluoro-analogues of carbohydrates and inositols is not 
unprobiematic. In order to set up the desired hydroxyl group for the 
introduction of fluoride, protection of other hydroxyl functions in the molecule 
is necessary. The fluoride ion has only a low nucleophilicity, making 
substitution on a secondary carbon difficult unless good leaving groups like 
trifluoromethanesulphonates (triflates) are attached to the respective carbon 
atom. Another problem may arise from competing elimination reactions 
(which are catalysed by fluoride ion). It is therefore recommended to employ 
anhydrous fluoride salts with large counterions such as tetrabutylammonium 
(TBA+), tris(diethylamino)sulphur (TAS+) or Cs+ and use solvents which do 
not strongly solvate the fluoride ion (rendering the fluoride ion "naked") so as 
to maximise fluoride ion nucleophilicity, minimise elimination reactions and 
effect substitution under the mildest possible conditions.
In the synthesis of fluoro-analogues of inositol and inositol phosphates, 
diethylaminosulphur trifluoride [(C2H5)2NSF3, DAST) P°11 has been widely 
employed. DAST has the advantage of allowing direct replacement of a 
hydroxyl group by fluorine without prior activation of the hydroxyl function as 
a sulphonate. DAST is relatively mild, can be used on acid-sensitive 
substrates, and in the absence of neighbouring group participation, affords 
products resulting from Walden inversion. With some substrates DAST reacts 
regioselectively, so that protection of all the hydroxyl groups may not be 
required. Additionally, DAST can be employed to generate pem-difluoro 
compounds by reaction with inososes P02-307]
3.3.3 Fluorinated Analogues of Inositol
Pharmacologically active analogues of inositol phosphates have to be 
injected into intact cells in order to be effective, since these highly charged 
molecules are not able to cross the lipid bi-layer of the plasma membrane.
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The cellular inositol uptake system however, provides an alternative way of 
manipulating the lns(1,4,5)P3 signalling system. Analogues of myoinositol, 
which serve as substrates for Ptdlns synthetase, may be incorporated into the 
cellular phosholipid and inhibit the formation of lns(1,4,5)P3 or subsequent 
metabolic processes. Fluorinated inositol analogues are particularly suitable 
for this purpose because of the reasons mentioned above.
1D- and 1L-1-Deoxy-1-fluoro-/nyo-inositol
Different starting materials have been employed in the syntheses of 1D-1- 
deoxy-1-fluoro-myoinositol. Kozikowski et al. I178! were able to prepare the 
compound from optically active D-pinitol (3-O-methyl-D-ch/ro-inositol) in five 
steps by first converting pinitol into the 1,2:5,6-di-0-isopropylidene derivative 
(which is readily separable from the 1,2:4,5-diacetal also formed in the 
reaction). Methylation of the free 4-hydroxyl group, cleavage of the acetals 
and treatment of the 3,4-di-O-methyl-D-c/wro-inositol with DAST gave 
selectively 1D-1-deoxy-1-fluoro-4,5-di-0-methyl-myo-inositol with inversion of 
configuration on the fluorination site. Demethylation of this compound with 
BBr3 afforded 1D-1-deoxy-1-fluoro-myo-inositol.
The same group had earlier reported a 10-step synthesis of this fluorinated 
isostere from myo-inositol D 70,308]^  which involved fluorination at the 2- 
position of a suitably protected myo-inositol derivative and the optical 
resolution of the resulting protected fluoro-scy//o-inositol. Recovery of the 
myo-inositol configuration in the two enantiomers was achieved by Swern 
oxidation of the deprotected 1-hydroxyl group to give the 1-inosose followed 
by reduction of the keto-funtion with L-Selectride, which gave an axial alcohol 
(thus becoming the 2-position in the myo-inositol configuration) and afforded 
1D- and 1L-1-deoxy-1-fluoro-myo-inositol after deprotection of the respective 
enantiomeric intermediates.
A similar synthesis also starting from myo-inositol has been reported by Offer 
etal. [309,310] Here, the problems of recovery of the myo-inositol configuration 
and optical resolution were addressed efficiently in a single conversion, i.e. a 
tosylate group in a fluorinated scyllo-inositol intermediate was displaced with
S-(-)-caesium camphanate in 90% yield. The two resulting diastereoisomers 
were separated, deprotected and purified to produce the D- and L-1-fluoro 
analogues of myo-inositol.
An efficient synthesis of 1L-1-deoxy-1-fluoro-myo-inositol (= 1 D-3-deoxy-3- 
fluoro-myo-inositol) in two steps was possible by direct fluorination of L-
74
quebrachitol (L-3-0-methyl-c/?/'ro-inositol). Treatment with DAST resulted in 
selective fluorination of the 1-position (which proceeded with inversion to give 
the myo-inositol configuration) and subsequent demethylation with boron 
tribromide afforded the fluoro-inositol analogue I170!. This compound is 
capable of entering into the Ptdlns cycle and block the eventual production of 
both lns(1,3,4,5)P4 and lns(1>3l4)P3, since the 3-hydroxyl group is missing in 
this compound and phosphorylation at this position is therefore no longer 
possible. 1L-1-deoxy-1-fluoro-myo-inositol was found to inhibit growth of NIH 
3T3 cells even in the presence of myo-inositol I178l.
3-Deoxy-3-fluoro-myo-inositol inhibits cell growth in the presence of myo­
inositol on NIH 3T3 cells I178!, although the medium used contained relatively 
high levels of myo-inositol compared to other growth media. 3-Deoxy-3- 
fluoro-myo-inositol competitively blocks the uptake of myo-inositol which 
suggests that the 3-fluoro derivative acts as a substrate for the Ptdlns 
synthase enzyme incorporating myo-inositol into the cell phospholipid and so 
the 3-hydroxyl group is not required for activity but it is required for the action 
of the 3-kinase on lns(1,4,5)P3 I178!. The 1-deoxy-1-fluoro and the 1-deoxy-
1,1-difluoro compounds also inhibited cell growth but not as potently.
1 -Deoxy-1 -fluoro-scy//o-inositol
1-Deoxy-1-fluoro-scy//o-inositol was the first fluorinated analogue of inositol 
prepared P11l. DL-1-0-Benzoyl-3,4,5,6-tetra-0-benzyl-myo-inositol was 
reacted with DAST under rather drastic conditions (toluene, 70-80°C; 
attempted fluorination under conventional conditions - dichloromethane, 0- 
25°C - did not succeed) to give the protected fluorinated scy//o-inositol 
derivative, which was then deprotected by mild hydrolysis followed by 
hydrogenolysis to give the title compound.
1-Deoxy-1-fluoro-scy//o-inositol has also been synthesised by a method 
which allowed the incorporation of radioactive tritium through the 
stereoselective reduction of the intermediate 2,3,4,5,6-penta-0-benzyl-scy//o- 
inosose with sodium borotritide which produced mainly 1,3,4,5,6-penta-O  
benzyl-myo-[2-3H]-inositol. Reaction of the tritium labelled inositol with DAST 
and deprotection gave 1-deoxy-1-fluoro-scy//o-[1-3H]-inositol I312].




D-Pinitol reacted regioselectively with DAST to produce the difluoro 
compound 13 in 47% yield. Demethylation with boron tribromide then 
furnished 1 D-1,5-dideoxy-1,5-difluoro-neo-inositol I178L
2-Deoxy-2-fluoro-myo-inositol
A synthesis of [3H]-labelled and unlabelled 2-deoxy-2-fluoro-/77yo-inositol has 
been reported by Lowe and McPhee l312L Reaction with DAST usually occurs 
with inversion of configuration so in order to produce the 2-fluoro-myo-inositol 
derivative from 1,3,4,5,6-penta-0-benzyl-/77yo-inositol it was necessary to 
change the configuration at C-2 and convert the protected myo-inositol into
1,2,3,4,5-penta-0-benzyl-scy//o-inositol before fluorination. The inversion was 
effected by esterification of the free hydroxyl group with 
trifluoromethylsulphonic anhydride (triflic anhydride) and displacement of the 
triflate moiety with sodium trifluoroacetate. Base catalysed hydrolysis of the 
trifluoroacetate and reaction with DAST produced 1,3,4,5,6-penta-O-benzyl- 
2-deoxy-2-fluoro-/77yo-inositol, and deprotection with dry HBrgave 2-deoxy-2- 
fluoro-myo-inositol in 51% yield.
Oxidation of 1,3,4,5,6-penta-0-benzyl-/77yo-inositol with Jones' reagent 
(sodium dichromate / sulphuric acid) and reduction of the inosose with 
NaBH3T followed by treatment with DAST gave some 1,3,4,5,6-penta-O- 
benzyl-2-deoxy-2-fluoro-z77yo[2-3H]-inositol (with predominant formation of 
the scyllo-inositol analogue, see above). This compound was then 
deprotected as before to yield 2-deoxy-2-fluoro-myo-[2-3H]-inositol.
A further synthesis has been reported for 2-deoxy-2-fluoro-neo-inositol 
although the yield reported was low l313l.
2-Deoxy-2,2-difluoro-/nyo-inositol
1-0-Allyl-3,6-di-0-benzyl-4,5-0-isopropylidene-/77yo-inositol was oxidised to 
the 2-inosose. The ketone was fluorinated using DAST in dry 
dichloromethane at room temperature to form the pem-difluoro derivative. 
Deprotection was carried out by first removing the allyl and isopropylidene 




DL-1 -OBenzoyl-2-oxiranyl-3,4,5,6-tetra-0-benzyl-/77yo-inositol was converted 
into DL-2-C-fluoromethyl-3,4,5,6-tetra-Obenzyl-/77yo-inositol either by direct 
fluorination at the side chain with potassium hydrogen difluoride / 18-crown-6 
via epoxide ring opening (66 % yield) and subsequent removal of the 
benzoate ester with lithium aluminium hydride (51 % yield), or by 
saponification and fluorination of the 1-hydroxyl derivative (64 % overall 
yield). Hydrogenolysis afforded the title compound in 60 % yield I314l.
4-Deoxy-4-fluoro-/77yo-inositol
3-0-Benzyl-1,2:5,6-di-0-cyclohexylidene-myo-inositol reacted with DAST to 
give a mixture of the corresponding 4-fluoro-inositol derivatives in yields of 31 
% (for the retention product) and 8.8 % (for the product obtained by inversion 
at C-4), respectively. The fact that this fluorination reaction proceeds 
predominantly with retention of configuration is probably due to steric 
crowding by the substituents in the 1,2, 3, and 5,6-positions which renders 
the usually occuring backside attack of F_ more difficult and therefore 
disfavours the product of inversion. Deprotection of the major product 
furnished racemic 4-deoxy-4-fluoro-myo-inositol in 87% yield. Attempted 
deprotection of the minor ep/-inositol product led to decomposition products
[313].
5-Deoxy-5-fluoro-/T7yo-inositol
Several methods of synthesis of 5-deoxy-5-tluoro-myo-inositol have been 
published. The starting material for the first method I303! was 1,4,6-tri-O  
benzyl-2,3-0-cyclohexylidene-/?eo-inositol. Reaction with DAST and DMAP in 
toluene produced the 5-fluoro-/77yo-inositol derivative due to inversion at C-5 
in 61% yield followed by deprotection which produced the 5-deoxy-5-fluoro- 
myo- inositol.
6-0-Benzyl-1,2:3,4-di-0-cyclohexylidene-myo-inositol was employed as 
starting material for the preparation of 5-deoxy-5-fluoro-myo-inositol by two 
different groups. Fluorination of this compound with DAST gave a mixture of 
the products of inversion (35 %) and retention (14.5 %), the latter was 
hydrogenated to afford the deprotected 5-fluoro-/77yo-inositol [3131.
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The low yield obtained by this direct method was improved upon by inverting 
the 5-position prior to the DAST fluorination, which would then re-establish 
the myo-inositol configuration. This was accomplished by tosylation of the 5- 
hydroxyl group followed by nucleophilic displacement of the toluene 
sulphonate with caesium propionate in DMF to afford the neo-inositol 
derivative. The 5-hydroxyl function was recovered by base hydrolysis of the 
ester. Treatment with DAST gave the fluorinated derivative with the required 
conformation. Deprotection afforded the title compound in 73% yield from 6- 
0-benzyl-1,2:3,4-di-0-cyclohexylidene-myo-inositol P 0 9 ,3 io ].
5-Deoxy-5,5-difluoro-myo-inositol
Oxidation of 1,4,6-tri-0-benzyl-2,3-0-cyclohexylidene-myo-inositol with chro­
mium trioxide-dipyridine complex gave the corresponding 5-inosose in good 
yield. Fluorination was accomplished with DAST (51% yield) to give the gem-
5,5-difluoro derivative which was then deprotected to give the title compound 
in 83% yield P°31.
A number of 2-, 3-, 4-, and 5-modified inositol analogues have been 
evaluated as substrates and inhibitors of Ptdlns synthetase P15l. It was found 
that the enzyme has very stringent requirements for the cyclitol substrate. All 
compounds tested (including deoxy-, fluoro-, chloro-, bromo-, iodo- and 
amino-analogues) were less effective than lns(1,4,5)P3 as substrates for 
Ptdlns synthetase, with 5-deoxy-5-fluoro-myo-inositol, the best analogue 
found in this study, being incorporated into the cellular phospholipid at a rate 
equal to 26 % of that of myo-inositol. This analogue was then further 
phosphorylated to Ptdlns(4)P but not to Ptdlns(4,5)P2 as the compound lacks 
the 5-hydroxyl group neccessary for phosphorylation. Replacement of the 5- 
hydroxyl group with other halogens produced very poor or inactive 
substrates, however the 5-deoxy analogue was also found to be well 
recognised. In the inhibition assay, the rank order of analogues was similar to 
their effectiveness as substrates, with the exception of 5-deoxy-5,5-difluoro- 
myo-inositol which was inactive as a substrate for Ptdlns synthase but an 
effective inhibitor of the enzyme.
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3.3.4 Fluorine Analogues of Inositol Phosphates
2-Deoxy-2-fluoro-scy//o-inositol 1,4,5-trisphosphate
Reaction of l-Oallyl-S.e-di-O-benzyM.S-O-isopropylidene-myo-inositol 93 
(Figure 3.11) with DAST in dry dichloromethane at 0°C resulted in fluorination 
at the 2 position with inversion of configuration. Subsequent deprotections of 
95 to 3,6-di-0-benzyl-2-deoxy-2-fluoro-scy//o-iriositol 99 and phosphorylation 
with TBPP produced the fully protected fluorinated analogue 101, which was 
then deprotected by catalytic hydrogenolysis to give 2-deoxy-2-fluoro-scy//o- 





0Bn 97: X = H 
98: X = F
OAII
OBn
95:X  = H 
96: X = F
BnOBnO
0Bn 99: X = H 
100: X = F
OBn
101 :X  = H 
102: X = F
HOHO
'PO:OPO;
Figure 3.11 Synthesis of 2-F-scy//o-lns(1,4,5)P3 and 2,2-F2-lns(1,4,5)P3
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Sawyer and Potter reported the synthesis of 103 by a similar method P07l.
Reduction of the 2-inosose 94 with sodium borohydride resulted in the 
formation of a 2:1 mixture of myo- and scy//oinositol derivatives respectively, 
which could be separated by chromatography I1 6 8 !. When the scy//o-epimer 
was treated with DAST, fluorination surprisingly occured with retention of 
configuration yielding the same derivative which was obtained from the myo- 
epimer.
2-Deoxy-2,2-difIuoro-/nyo-inositol 1,4,5-trisphosphate
DL-2-deoxy-2,2-difluoro-lns(1,4,5)P3 [2,2-F2-lns(1,4,5)P3] 104 was
synthesised from the same precursor used in the synthesis of 2-deoxy-2- 
fluoro-scy//o-lns(1,4,5)P3 l306l  93 was oxidised to the 2-inosose 94 in 66% 
yield. The ketone was fluorinated using an excess of DAST in 
dichloromethane at 25°C to give the difluoro compound 96 in 60% yield. The 
same sequence of deprotection and phosphorylation reactions as in the 
synthesis of 2F-scy//o-lns(1,4,5)P3 produced the desired difluoro compound 
104.
Racemic 2F2-lns(1,4,5)P3 was also obtained by Sawyer and Potter using 
slightly different deprotection and phosphorylation procedures 1305,307]. j^ey  
succeeded in the optical resolution of 2-deoxy-2,2-difluoro-3,6-di-0-benzyl-
4,5-isopropylidene-/77yo-inositol by chromatographic separation of the 1 -(>[(- 
)-co-camphanyl] esters of this compound and were thus able to prepare D- 
and L-2,2F2-lns(1,4,5)P3 P 0 4 ,3 iq .
2-Deoxy-2-fluoro-scy//o-lns(1,4,5)P3 and 2-deoxy-2,2-difluoro-myo- 
lns(1,4,5)P3 act as full agonists for the release of Ca2+ with only slightly lower 
affinity for the receptor than lns(1,4,5)P3 1305]. Thus it has been proposed that 
the unique 2 axial hydroxyl group is relatively unimportant for activity at the 
receptor. Both fluoro analogues are weaker substrates for the lns(1,4,5)P3 3- 
kinase, with the difluoro compound better than the mono-fluoro compound, 
indicating that the 2-hydroxyl group is important for recognition by this 
enzyme although not essential. The mono-fluoro compound was a weak 
substrate for lns(1,4,5)P3 5-phosphatase whilst the difluoro analogue was not 
hydrolysed by the enzyme but inhibited its activity potently I305!. The difluoro 
compound was then resolved into the enantiomers P07l and it was found that
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D-2,2-F2-lns(1,4,5)P3 was a substrate for 5-phosphatase, whereas the L- 
enantiomer was an effective inhibitor of both 5-phosphatase and 3-kinase
[304,316]
1 D-3-Deoxy-3-fluoro-/77yo-inositol 1,4,5-trisphosphate
L-Quebrachitol was converted in two steps into D-3-deoxy-3-fluoro-myo- 
inositol as described above. Subsequent protection and phosphorylation at 
the hydroxyl groups gave the 3-fluorodeoxy analogue of lns(1,4,5)P3 P17l.
3-Deoxy-3-fluoro-lns(1 i4,5)P3 acts as a full agonist in releasing Ca2+ from 
NIH 3T3 cells and is equipotent to lns(1,4,5)P3. This shows the equatorial 3- 
hydroxyl group is not required for receptor recognition or activity. This 
compound promises to be valuable for studying the release of Ca2+ from the 
lns(1,4,5)P3 sensitive pools without interference from the lns(1f3,4,5)P4 
regulated Ca2+, as it will prevent the 3-kinase phosphorylating lns(1,4,5)P3 to 
lns(1,3,4,5)P4 I317l.
2-Deoxy-2-fluoro-scy//o-inositol 1,3,4-trisphosphate
Reaction of 1,3,4-tri-0-allyl-5,6-di-0-benzyl-/77yo-inositol with DAST resulted 
in monofluorination with inversion of configuration to give 2-deoxy-2-fluoro-
1.3.4-tri-0-allyl-5,6-di-Obenzyl-scy//o-inositol. Removal of the allyl protecting 
groups with Pd on carbon followed by phosphorylation with TBPP and 
removal of the benzyl protecting groups by catalytic hydrogenolysis afforded
2-deoxy-2-fluoro-scy//o-inositol 1,3,4-trisphosphate I318!.
2-Deoxy-2,2-difluoro-/77yo-inositol 1,3,4-phosphate
1.3.4-Tri-0-allyl-5,6-di-0-benzyl-myo-inositol was also used to prepare 2- 
deoxy-2,2-difluoro-A77yo-inositol 1,3,4-trisphosphate I318]. Oxidation of this 
compound with DMSO / acetic anhydride furnished the 2-inosose, which 
reacted with two equivalents of DAST to give the 2,2-difluoro compound. 
Deprotection and phosphorylation as before produced 2-deoxy-2,2-difluoro- 
myo- inositol 1,3,4-phosphate.
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3.4.4 Fluorinated analogues of inositol lipids
The first synthesis of a fluoro-analogue of an inositol lipid was described as 
early as 1982 P11l. 2-Deoxy-2-fluoro-1-phosphatidyl-scy//o-inositol was 
obtained by condensation of 2-fluoro-2-deoxy-3,4,5,6-tetra-0-benzyl-scy//o- 
inositol with the sodium salt of dipalmitoyl-L-a-phosphatidic acid, followed by 
hydrogenolysis.
Recently, the preparation of D-3-deoxy-3-fluoro-1-phosphatidyl-/77yo-inositol 
has been reported P19l. This Ptdlns analogue displayed cytostatic properties, 
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4. Structure-Activity Studies on lns(1,4,5)P3 Analogues
4.1 Structural Requirements for Calcium Release
The lns(1,4,5)P3 receptor shows great stereo- and regiospecifity and structural 
requirements for lns(1,4,5)P3 analogues, in order to effect Ca2+-release, are 
quite strict.
Whereas lns(1:2,4,5)P3> lns(4,5)P2 and GroPlns(4,5)P2 have been shown to be 
13-15 fold [320,321]^  650 fold l322l and 3-10 fold [321,323] weaker than lns(1,4,5)P3, 
respectively, most other natural inositol phosphates including lns(1)P, lns(1:2)P, 
lns(1,4)P2 [221, lns(1,3,4)P3 [269.324]f |ns(1,3,4,5,6)P5 [94«325J and lnsP6 (phytic 
acid) I269! are ineffective as agonists at the lns(1,4,5)P3 receptor.
The stereospecifity of the receptor is demonstrated by the fact that L- 
lns(1,4,5)P3, [ = D-lns(3,5,6)P3] is unable to mobilise calcium [269,326] Receptor- 
binding of this synthetic enantiomer is ca. 2000 times weaker than that of natural 
D-lns(1,4,5)P3 [324,327].
Modifications at the 1-position
A number of semisynthetic 1-substituted lns(1,4,5)P3 analogues [3231, able to 
release Ca2+, showed that large groups can be introduced at this position 
without major loss of activity.
Similarly, the 1-0-(3-aminopropyl) ester of lns(1,4,5)P3 and a photoaffintity 
analogue derived therefrom I328] were able to effect Ca2+ release, both being ca. 
8-fold weaker than lns(1,4,5)P3. Receptor binding of these derivatives was 
equally good, and the photoaffinity derivatives were successfully used to label 
lns(1,4,5)P3 binding sites I329).
Modifications at the 2-position
Similar to the 1-position, the introduction of large groups is tolerated at the axial
2-position (Figure 4.1) without affecting the ability of the analogue to act as a full 
agonist at the lns(1,4,5)P3 receptor [32°1. Removal of the hydroxyl group [in 2-
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deoxy-lns(1,4,5)P3] resulted in only a slight loss of activity [EC50 of racemic 2- 
deoxy-lns(1,4,5)P3 0.5 nM, D-lns(1,4,5)P3 0.2 |xM] i320i.
2-Deoxy-lns(1,4,5)P3
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Figure 4.1 lns(1,4,5)P3 analogues modified at the 2-position
Recently, DL-lns(1 l2 f4>5)P4 has been pharmacologically evaluated I3 3 0 !. This 
synthetic lns(1,4,5)P3 analogue with an additional phosphate group in the 2- 
position is the most potent inositol tetrakisphosphate described to date [EC50 = 
165 nM, compared with EC50 = 52 nM for lns(1,4,5)P3].
The stereospecifity of the lns(1,4,5)P3 receptor was confirmed by the different 
agonist properties of the enantiomers D- and L-2-deoxy-2,2-difluoro-lns(1,4,5)P3 
[304,316] D-2-deoxy-2,2-difluoro-lns(1f4,5)P3 was a full agonist, slightly less 
potent than lns(1,4,5)P3 in releasing Ca2+ from SH-SY5Y neuroblastoma cells 
[EC50 0.21 pM in comparison to an EC50 of 0.13 pM for D-lns(1,4,5)P3], whereas 
the L-enantiomer was only a very poor agonist (EC50 53 pM). 
DL-2-deoxy-2-fluoro-scy//o-lns(1,4,5)P3 was also a full agonist, somewhat less 
potent than D-lns(1,4,5)P3 with EC50 0.77 [305,331] j h e observation that 2,2-F2- 
lns(1,4,5)P3 was a more potent analogue than 2-F-scy//o-lns(1,4,5)P3 has led 
the authors to conclude that the axial fluorine atom in the first compound is able 
to make a more favorable interaction with the receptor protein than the axial 
hydrogen in the 2-position of the scyllo-analogue. This would imply that the 2- 
hydroxyl group of lns(1,4,5)P3 accepts rather than donates a hydrogen bond 
from the receptor: the less active 2-F-scy//o-lns(1,4,5)P3 is still able to donate 
but not to accept a hydrogen bond, whereas the axial fluorine of the more potent




Figure 4.2 Putative interaction of the 2-hydroxyl group with the 
lns(1,4,5)P3 receptor
These data appear to indicate that the 2 -position is relatively unimportant for 
receptor recognition.
Modifications at the 3-position
Both D-3-deoxy-lns(1,4,5)P3 i176l and D-3-deoxy-3-fluoro-lns(1,4,5)P3 t317l were 
shown to mobilise Ca2+ from permeabilised 3T3 cells as full agonists. These two 
compounds were almost equipotent to lns(1,4,5)P3.
L-c/7/'ro-lns(2,3,5)P3 [177.332]( an |ns(1,4,5)P3 analogue with an axial rather than 
equatorial 3-hydroxyl group, was found to be a potent agonist for the 
mobilisation of sequestered calcium from permeabilised human neuroblastoma 
cells with an EC50 only some 5  to 1 0 -fold higher than lns(1,4,5)P3 [331,333] j ^ e 
synthesis of racemic 6 -deoxy-6 -fluoro-c/7/'ro-lns(2 ,3 ,5 )P3 has been reported [334l, 
the pharmacological properties of this compound, however, are still due to be 
published.
Ins(1,3,4,5)P4, the product of 3-kinase action on lns(1,4,5)P3, has been shown to 
inhibit [3H]-lns(1,4,5)P3 binding to cerebellar membranes. The tetrakisphosphate 
has, however, a ca. 60 fold lower affinity to the receptor than lns(1,4,5)P3 t335!. A 
sim ilar decrease in potency has been observed in the ability to release calcium
[324] _
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These results show that the 3-hydroxyl group plays a relatively insignificant role 
in receptor binding and calcium release. An additional phosphate group in this 
position, however, reduces receptor binding properties considerably.
Modifications at the 4-position
No lns(1,4,5)P3 analogues selectively modified at the 4-position have yet been 
studied. The phosphate group in the 4-position appears, however, to be 
essential for recognition by the lns(1,4,5)P3 receptor, since all inositol 
phosphates lacking this moiety [e.g. Ins(1,3,5)P3 ] are inactive.
Modifications at the 5-position
D-myoinositol 1,4-bisphosphate 5-phosphorothioate [lns(1,4,5)P3-5S] [210,211] 
was found to be a full agonist at the lns(1,4,5)P3 receptor and a potent mobiliser 
of sequestered Ca2+ from permeabilised SH-SY5Y neuroblastoma cell, being 
only some 7-fold less potent than lns(1,4,5)P3 [EC50 values lns(1,4,5)P3 0.11 
pM, lns(1,4,5)P3-5S 0.8 pM]. Similar to the trisphosphorothioate analogue 
lns(1,4,5)PS3, lns(1,4,5)P3-5S is not dephosphorylated by the 5-phosphatase 
and is therefore able to evoke a sustained release of Ca2+. However, 
lns(1,4,5)P3-5S is a substrate for 3-kinase unlike lns(1,4,5)PS3.
Only preliminary evaluations have been carried out on the 5- 
methylenephosphonate analogue of lns(1,4,5)P3, but these initial studies 
showed that this compound releases calcium from bovine adrenal gland 
microsomes in a sustained fashion similar to other non-hydrolysable analogues 
of lns(1,4,5)P3 118°].
The racemic 5-methylphosphonate analogue of lns(1,4,5)P3 has been reported 
to antagonise lns(1,4,5)P3-stimulated calcium release in permeabilised human 
platelets in a pH-dependent manner, and to act as a competitive inhibitor of [3H]- 
lns(1,4,5)P3 binding to bovine adrenocortical microsomes [285,286] Full biological 
data for this compound and the 5-difluoromethylphosphonate analogue, which is 
also supposed to act as a weak antagonist [285,286]^  are stj|| f0 published and 
are awaited with interest, as this would represent the first small molecule 
antagonist of lns(1,4,5)P3 action.
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Modifications at the 6-position
D-6-Deoxy-lns(1,4,5)P3 was found to be a full agonist for calcium release in 
permeabilised SH-SY5Y human neuroblastoma cells some 70-fold less potent 
than lns(1,4,5)P3 (EC50 6.4 pM) [182],
DL-lns(1,4,5,6)P4 exhibited no Ca2+ releasing activity and did not appear to 
influence the lns(1,4,5)P3 mediated calcium release at concentrations up to 10 
pM t94I.
Other 6-modified lns(1,4,5)P3 analogues have been synthesised by Ley et al., 
including the 6-deoxy-6-fluoro-, the 6-deoxy-6-methyl-, and the 6-O-methyl- 
derivative [255,256,336,337] n 0 biological data of these compounds have been 
reported by this group to date. DL-6-0-methyl-lns(1,4,5)P3 was, however, 
evaluated by another group t324l and found to mobilise calcium with an EC50 of 
65 pM [lns(1,4,5)P3 0.3 pM].
Multiple Modifications
The unnatural inositol phosphates lns(2)P I338!, lns(2,4)P2, lns(1,2,6)P3 P39l, 
lns(1,3,5)P3 i324l and 3-deoxy-lns(1,5,6)P3 I176] are all unable to release calcium, 
as is myo-inositol.
D-myo-lnositol 1,2-cyclic 4,5-trisphosphate [lns(1:2,4,5)P3] was initially reported 
as being equipotent to lns(1,4,5)P3 in mobilising calcium [340,341]s ancj there were 
speculations that this cyclic inositol phosphate may be a second messenger in 
its own right [340L Further studies I321!, however, showed that lns(1:2,4,5)P3 is 
only a weak agonist more than an order of magnitude less potent than 
lns(1,4,5)P3 [EC50 3.6 pM, cf. Ins(1,4,5)P3 0.21 pM]. It was also demonstrated 
that treatment of lns(1:2,4,5)P3 with acid affords a mixture of lns(1,4,5)P3 and 
lns(2,4,5)P3 with receptor binding and calcium release properties similar to 
lns(1,4,5)P3, and it may therefore well be possible that the lns(1:2,4,5)P3 used in 
the initial experiments was contaminated with lns(1,4,5)P3 due to decomposition.
Synthetic lns(2,4,5)P3 was found to effect calcium release, being some 12-68 
fold less potent than lns(1,4,5)P3 [320-322,324,342] Tegge et al. [174,342] obtained
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the same EC50 value [4 pM; lns(1,4,5)P3 0.13 pM] for D-lns(2,4,5)P3 and for D- 
chiro-Inositol 1,3,4-trisphosphate, an analogue of lns(2,4J5)P3 with an axial 1- 
hydroxyl group. It thus appears that the difference between the two compounds, 
an equatorial versus an axial hydroxyl group at the 1-position, is insignificant 
with respect to Ca2+ mobilising activity. The L-enantiomers of both compounds 
were considerably less active than the D-isomers, and some 800 - 960 fold less 
active than lns(1,4,5)P3 [174,342]f this is another example for the stereospecificity 
of the lns(1,4,5)P3 receptor.
D-3-Azido-3-deoxy-lns(2,4,5)P3 was considerably less potent than lns(1,4,5)P3 
in calcium release studies I343]. The compound was found to mobilise 21 % of 
sequestered Ca2+ at a concentration of 100 pM, whereas lns(1,4,5)P3 released 
53 % at 10 pM. In binding experiments, the azide exhibited a Kj of 18.9 pM 
[lns(1,4,5)P3: K, = 10 nM] F43!.
DL-Cyclohexane 1,2,4-trisphosphate [= DL-2,3,6-trideoxy-lns(1,4,5)P3] was 
shown to effect Ca2+ release from permeabilised smooth muscle cells with an 
EC50 of 40 pM [lns(1,4,5)P3 0.3 pM] l324l. Benzene 1,2,4-trisphosphate was 
found to block lns(1,4,5)P3 binding to adrenal cortex microsomes competitively 
with an IC50 of 34 pM. The affinity of this compound to the receptor is about 
10000 fold lower than that of lns(1,4,5)P3 I344).
The racemic trissulphate, trissulphonamide, triscarboxy methyl and 
trismethylphosphonate analogues of lns(1,4,5)P3 did not show any biological 
activity [288,289^  neither did the 4,5-dimethylenephosphonate analogue of DL- 
lns(4,5)P2 l345I.
There has been a report by Schultz et al. I346l that cis,c/s-cyclohexane 1,3,5- 
trisphosphate and related analogues with a 1,5-bisphosphate arrangement are 
able to effect calcium release from isolated vacuoles of Neurospora crassa. This 
observation is however, to be treated with caution, as myo-inositol 1,3,5- 
trisphosphate has been shown not to act as an agonist in bovine aortic smooth 
muscle cells P24l. If these results were to be confirmed, it would imply that the 
vacuolar receptor of Neurospora crassa is different from mammalian receptors, 
which seems remarkable since lns(1,4,5)P3 receptors in different species have 
been found to be highly similar.
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Summary
The data given above suggest that the vicinal 4,5 bisphosphate moiety is 
essential for receptor recognition and that the presence of an additional 
phosphate group at the 1-position greatly enhances Ca2+ mobilising properties. 
The fact that lns(2,4,5)P3 is also a full and relatively potent agonist may possibly 
be explained by an interaction of the axial 2-phosphate with the receptor site 
normally occupied by the equatorial 1-phosphate of lns(1,4,5)P3.
relatively unimportant for receptor recognition: 
3-deoxy-lns(1,4,5)P3 and 3-F-lns(1,4,5)P3 as
well as L-c/?//o-lns(2f3,5)P3 were full agonists
essential for recognition, 
however, conservative modi­
fications are tolerated: 
lns(1,4,5)P3-4,5S and
kns(1,4,5)PS3 are active
not very important for receptor recognition: 
deoxy- and fluoro-analogues are active, as 
are compounds carrying large substituents 
in this position
essential for recognition by the receptor: 
lns(1,4)P2 is not an agonist, nor does it 
bind to the receptor 
analogues resistant to hydrolysis by 5- 
phosphatase like lns(1,4,5)P3-5S and
5-methylenephosphonate-lns(1,4,5)P3
can effect sustained calcium release
bulky substituents are tolerated 
in the 1 -position without major 
loss of activity, however, deletion 
reduces activity considerably
relatively important:
deletion as in 6-deoxy-lns(1,4,5)P3 or
substitution as in 6-0-methyl-lns(1,4,5)P3 
affords analogues which are still full agonists 
but less potent than lns(1,4,5)P3
Figure 4.3 Structure-activity relationship for the lns(1,4,5)P3-receptor
4.2 Partial Agonists at the lns(1,4,5)P3 Receptor
A number of partial agonists at the lns(1,4,5)P3 receptor have been identified: 
lns(1,3,4,6)P4 has been found to have a high affinity for the receptor and to give 
a maximal calcium release of 49.5±2.5 % [lns(1,4,5)P3: 60.5±3.3 %]. If the 
maximally effective Ca2+-releasing concentration of lns(1,3>4,6)P4 is 
administered together with lns(1,4,5)P3l the EC50 value for the dose-response 
curve is dramatically increased I94]. This has led to the conclusion that the Ca2+ 
released is not only from the same intracellular store, but it also strongly
89
indicates that lns(1,3,4,6)P4 and lns(1,4,5)P3 compete for the same receptor site 
[94,347]. a s |ns(1,3,4>6)P4 does not nominally possess the vicinal 4,5- 
bisphosphate moiety normally required for agonist activity (see above), it may 
not be obvious why this tetrakisphosphate should release calcium. However, two 
alternative binding conformations of lns(1,3,4,6)P4 to the lns(1,4,5)P3 receptor 
can be visualised (Figure 4.3), in which a number of important recognition 










Figure 4.4 Alternative binding conformations of lns(1,3y4,6)P4
Both of these alternative binding conformations of lns(1,3,4,6)P4 show an 
additional 2-phosphate moiety in the now equatorial 2-position. As discussed for 
analogues of lns(1,4,5)P3 with modifications at the 2-position, this should not 
cause a significant change in the binding and calcium release properties of the 
compound. The second feature that has changed is the 3-hydroxyl group (in the 
first alternative binding conformation) or 6-hydroxyl group (in the second binding 
conformation). In both cases the respective hydroxyl group is now axial rather 
than equatorial as in lns(1,4,5)P3.
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Partial agonist behaviour was also found for L-c/7/rolns(2,3,5)PS3 and 6-deoxy- 
lns(1,4,5)PS3 P4®]. They were able to mobilise only 34 % and 42 % of the 
calcium maximally mobilised by lns(1,4,5)P3, respectively. As very weak partial 
agonists [in comparison: lns(1,3,4,6)P3 releases 82 % of the lns(1,4,5)P3 
sensitive calcium, see above] they can be used to antagonise lns(1,4,5)P3 
induced Ca2+ release at relatively high concentrations (IC50 values of 26 pM and 
171 pM, respectively). It should be noted that both compounds are 3 or 6- 
modified analogues of lns(1,4,5)P3, respectively, in addition to carrying 
phosphorothioate groups rather than phosphates in the 1-,4-, and 5-positions.
4.3 lns(1,4,5)P3 Receptor Antagonists
Up to now, none of the lns(1,4,5)P3 analogues synthesised has shown any 
antagonistic properties apart from the 5-methylphosphonate analogue of 
lns(1,4,5)P3 [285,286] ancj L-cfr/rolns(2,3,5)PS3 P48l, the latter, however, has 
significant intrinsic activity. The only molecules which have been clearly 
demonstrated to potently inhibit lns(1,4,5)P3-receptor binding are heparin [32,349- 
354] and decavanadate [22,355-357]; neither of them, however, show specifity for 
the lns(1,4,5)P3-receptor [335,358^  ancj they are therefore of only limited use as 
pharmacological tools.
Heparin
Heparin is a polysulphated polysaccharide with a molecular weight between 
6000 and 20000, depending on origin and preparation. Its antagonistic action 
was first described in 1987 I32] and it was also found that the heparin fragment 
TV84558-51 (average Mr = 5100) is as potent as heparin itself in inhibiting [3H]- 
lns(1,4,5)P3 binding, whereas the smaller heparin fragment OAM51126 (average 
Mr = 2200) and less- or unsulphated glycosaminoglycans (chondroitin sulphate 
and hyaluronic acid) did not affect binding I32l. This is also the case for O- and 
N-desulphated N-reacetylated heparin, N-de$ulphated heparin showing a 
decreased inhibitory activity at the lns(1,4,5)P3-receptor [but not at the 
lns(1,3,4,5)P4 binding site], whilst pentosan polyphosphate is another potent but 
non-selective inhibitor at both lns(1,4,5)P3- and lns(1,3,4,5)P4-binding sites [3351. 
In contrast to the inhibitory effects of heparin and related substances observed
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in many animal and plant tissues, lns(1,4,5)P3-induced Ca2+-mobilisation in 
fungi is heparin-insensitive I359].
Heparin also inhibits lns(1,4>5)P3 3-kinase activity [but not lns(1,4,5)P3 5- 
phosphatase] P50!, the specific binding of lns(1,3,4>5)P4 to cerebellar 
membranes I335! and the ability of lns(1,3,4,5)P4 to release Ca2+ from cerebellar 
microsomes I325!.
It seems likely that the negatively charged sulphate groups of heparin interact 
with the hydrophilic pockets in the receptor binding site that usually 
accommodate the phosphate groups of lns(1,4,5)P3. However, it is interesting to 
note here that myo-inositol-1,4,5-trissulphate, in spite of carrying sulphate 
groups in the positions that are occupied by the phosphate groups in 
lns(1,4,5)P3 does not seem to have any antagonistic properties l289l.
Vanadate
Different species of vanadate have been examined for their ability to inhibit 
lns(1,4,5)P3-receptor binding and Ca2+ release, and it has been found that 
decavanadate (V10O286' at pH 7 P6°]) inhibits lns(1,4,5)P3-induced Ca2+ 
mobilisation in permeabilised rat insulinoma and PC12 cells (IC50 5 pM) I355) and 
SH-SY5Y cells (Kj=1.2 pM) I356! and inhibits the binding of [3H]-lns(1,4,5)P3 to its 
receptor in cerebellar and adrenal cortex membranes P56!.
Orthovanadate and oligovanadate on the other hand do not inhibit lns(1,4,5)P3 
receptor binding P55l, possibly because they are unable to bridge multiple 
lns(1,4,5)P3 binding sites suggested by Meyer etal. P51.
It is interesting to note here that tetravanadate has been shown to be an inhibitor 
of Pl-specific PLC P61l.
Decavanadate also suppresses lns(1,3,4,5)P4-induced Ca2+ release from 
permeabilised SH-SY5Y cells and inhibits lns(1,’4,5)P3 5-phosphatase, 3-kinase 
and lns(1,3,4,5)P4 5-phosphatase P56!.
Although decavanadate and heparin are potent and competitive antagonists at 
the lns(1,4,5)P3 receptor, the fact that their specifity is low may prevent them 
from becoming useful tools to investigate the second messenger role of 
lns(1,4,5)P3.
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4.4 Structure-Recognition Studies on lns(1,4,5)P3 3-kinase
The specifity of 3-kinase is in some respects greater than that of the lns(1 f4,5)P3 
receptor itself I272!, lns(1,4,5)P3 and lns(1,3,4,5)P3 being the only natural inositol 
polyphosphates known to be recognised with high affinity I324l.
Modifications at the 1-position
Removal of the 1-phosphate group greatly decreases the affinity of the 3-kinase, 
lns(4,5)P2 and lns(2,4,5)P3 are both very poor substrates for this enzyme
[362.363]^  ancj |ns(1:2,4,5)P3 is not phosphorylated by this enzyme l92l. The 1- 
phosphate group therefore appears to be essential for substrate recognition, 
which is in agreement with the observation that whilst both lns(1,4,5)P3-5S
[210.364] ancj ins(1,4,5)P3-4,5-S2 t348l are substrates for 3-kinase, an additional 
phosphoro-thioate substitution in the 1-position is not tolerated: lns(1,4,5)PS3 is 
not a substrate for 3-kinase t268-365],
Modifications at the 2-position
DL-2-deoxy-lns(1,4,5)P3 was shown to be recognised well by the kinase I32°l, the 
apparent K,- in calcium-free medium was 1.6 pM [lns(1,4,5)P3 1.0 pM]. Even the 
analogue 110 (Figure 4.1), carrying a rather bulky substituent in the 2-position, 
was recognised equally well as lns(1,4,5)P3. This analogue surprisingly showed 
an even greater affinity to the 3-kinase (Kj 0.36 pM) than lns(1,4,5)P3 in calcium 
free medium. However, no data indicating whether these analogues act as 
substrates or inhibitors were given.
Both DL-2-deoxy-2-fluoro-scy//o-lns(1,4,5)P3 and DL-2-deoxy-2,2-difluoro- 
lns(1,4,5)P3 appeared to be substrates for 3-kinase I305]. After resolution of the 
racemic gem-difluoride, however, the substrate properties of D- and L-2-deoxy-
2,2-difluoro-lns(1,4,5)P3 were found to be quite different. Whereas the D-isomer 
was a substrate for 3-kinase (apparent Kj = 10.2 pM), the L-isomer was a potent 
inhibitor of this enzyme (Kj 11.9 pM) I316!. The reason for this inhibitory activity is 
not yet known, however, L-2,2-F2-lns(1,4,5)P3 represents a novel lead in the 
design of further effective inhibitors for the pharmacological intervention in the 
polyphosphoinositide pathway.
93
Modifications at the 3-position
As can be expected with 3-modified lns(1,4,5)P3 analogues, both D-3-deoxy-3- 
fluoro-lns(1,4,5)P3 [176,317] ancj |_-ch/ro-lns(2,3,5)P3 h 77.332] f a D-lns(1,4,5)P3 
analogue with inverted hydroxyl stereochemistry at the 3-position, are resistant 
to phosphorylation by the 3-kinase, and they are potent inhibitors of this enzyme 
(Kj values of 7.1 and 8.6  pM respectively) P33J.
Figure 4.5 3-position modified lns(1,4,5)P3 analogues
lns(1,3,4,5)P4, the product of lns(1,4,5)P3 phosphorylation by 3-kinase, is a 
weak inhibitor of the enzyme (IC50 90 pM). However, based upon the IC50 data it 
seems unlikely that sufficient lns(1,3,4,5)P4 can accumulate to affect the rate of 
lns(1,4,5)P3 phosphorylation significantly, suggesting that it plays no role in any 
"feedback" mechanism t324l.
Modifications at the 4-position
No compounds with selective modifications at the 4-position have been 
pharmacologically evaluated to date. However, recognition of the 4,5- 
bisphosphorothioate analogue of lns(1,4,5)P3 [lns(1,4,5)P3-4,5S] was attenuated 
in comparison to lns(1,4,5)P3-5S (K m = 5 pM and 46 pM, respectively) I348!, 
indicating that the 4-phosphate group is important for substrate recognition.
L-c/7/ro-lns(2,3,5)P3 D-3-F-(1,4,5)P3
94
Modifications at the 5-position
DL-lns(1,4>5)P3-5S was a substrate for the 3-kinase with Km = 5 fiM P48l, but 
phosphorylation of this compound occured considerably more slowly than that of 
the natural substrate [ca. 15 % the rate of lns(1>4,5)P3]. The 5- 
methylenephosphonate analogue of lns(1,4,5)P3, reported to evoke a sustained 
release of calcium [285,286^ jS presumably not a substrate for 3-kinase, although 
biological details on this compound have not been published. It appears 
therefore that only conservative modifications are tolerated in this position.
Modifications at the 6-position
6-Deoxy-lns(1,4,5)P3 is one of the few compounds that is recognised by the 
highly selective 3-kinase l182l. The kinetics of its metabolism indicate that is a 
substrate for this enzyme, and the phosphorylation of lns(1,4,5)P3 is inhibited 
competitively by 6-deoxy-lns(1,4,5)P3 with an apparent Kj of 5.7 pM [Km for 
lns(1,4,5)P3, 3.2 mM]. It appears that hydroxyl group deletion remote from the 
site of action of the 3-kinase has no major effect on the binding properties of the 
substrate.
In contrast to the 6-deoxy analogue, DL-6-methoxy-lns(1,4,5)P3 shows a marked 
drop in affinity (ca. 120-fold) for the 3-kinase I324!. Since the hydrogen bonding 
potential at the 6-position is removed in both analogues, it seems likely that the 
increased steric bulk at the 6-position of DL-6-methoxy-lns(1,4,5)P3 is the cause 
for the low affinity of this analogue for the enzyme.
Multiple modifications
DL-Cyclohexane 1,2,4-trisphosphate was only a weak inhibitor of [3H]- 
lns(1,4,5)P3 phosphorylation (IC50 327 pM) t324].
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Summary
site of enzyme action: 3-deoxy-lns(1,4 ,5)P3 
3-F-lns(1,4,5)P3 and L-cA)/7o-lns(2,3,5)P3 
are all potent inhibitors
conservative modifications are tolerated: 
ins(1,4,5)P3-5S is phosphorylated
not important for recognition by 
3-kinase, 2-deoxy-lns(1,4,5)P3 and
2-fluoro analogues are good substrates 
some analogues carrying bulky groups 
show an even greater affinity than 
lns(1,4,5)P3
the 1 -phosphate group appears 
to be an important but not essen­
tial feature:
lns(4,5)P2 is a weak substrate
deletion as in 6-deoxy-lns(1,4,5)P3 is
tolerated, bulky substituents however 
appear to reduce the affinity
Figure 4.6 Structure-recognition relationship for 3-kinase
4.5 Structure-Recognition Studies on lns(1,4,5)P3 5-phosphatase
In contrast to the lns(1,4,5)P3 receptor and the lns(1,4,5)P3 3-kinase, the 
lns(1,4,5)P3 5-phosphatase seems to be relatively non-specific. However, whilst 
many analogues bind to the phosphatase, only a few are substrates.
Modifications at the 1-position
The 1-phosphate group appears to be an important feature in substrate 
recognition by 5-phosphatase. lns(4,5)P2 is a very poor substrate (Km = 215 pM)
[348].
Modifications at the 2-position
A number of racemic lns(1,4,5)P3 analogues modified at the 2-hydroxyl group 
were examined for their ability to interact with erythrocyte ghost and brain 
cytosol 5-phosphatase t32°l (Figure 4.1). It was found that all compounds were 
competitive inhibitors of the enzyme and that they could serve as substrates for
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5-phosphatase, although the extent of hydrolysis varied. Surprisingly, 2-deoxy- 
lns(1,4,5)P3 and most of the other 2-modified analogues showed an even 
greater affinity for 5-phosphatase than lns(1,4,5)P3.
2-Deoxy-2-fluoro-scy//o-lns(1,4,5)P3 was found to be well recognised by the 
phosphatase but to be a weaker substrate than lns(1,4,5)P3 I305!
The 5-phosphatase substrate properties of D- and L-2-deoxy-2,2-difluoro- 
lns(1,4,5)P3 are quite different. Whereas D-2-deoxy-2,2-difluoro-lns(1,4,5)P3 is a 
good substrate for the 5-phosphatase, the L-enantiomer was found to be a 
potent inhibitor of the enzyme (Kj 19.0 pM) P 16l. Since 5-phosphatase is known 
to be specific for the D-isomer of lns(1,4,5)P3, and analogues in the L- 
conformation are usually not recognised very well by this enzyme [cf. L- 
lns(1,4,5)P3, Kj = 124 pM I271!], this result is surprising. There have however 
been reports on the interaction of 2-substituted analogues in the L-configuration 
who also display inhibitory properties with respect to 5-phosphatase I366! and the 
L-isomer of 109 (Figure 4.1) was found to be a surprisingly potent inhibitor with 
Kj = 3.8 pM [D-lns(1,4,5)P3: Kj = 13.1 pM].
Thus, it may be concluded that the 2-hydroxyl group may be involved in 
substrate recognition by the lns(1,4,5)P3 5-phosphatase, altough it does not 
appear to be an essential feature.
Modifications at the 3-position
3-Deoxy-lns(1,4,5)P3 was found to be a good substrate, binding with a slightly 
higher affinity than lns(1,4,5)P3 itself.
3-Deoxy-3-fluoro-lns(1,4,5)P3 was a substrate for erythrocyte 5-phosphatase 
and inhibited the dephosphorylation of [3H]-lns(1,4,5)P3 with an apparent Kj of 
3.9 pM P33l.
L-c/7/rolns(2,3,5)P3, which can be visualised as lns(1,4,5)P3 with an inverted 3- 
hydroxyl group, was found to be a very potent inhibitor of 5-phosphatase (Kj 7.7 
pM) [177,332,333] j h j s js somewhat surprising, since the modification of the 
stereochemisty of the 3-hydroxyl group in this molecule is remote from the site of 
attack of the enzyme. Two possible explanations for this phenomenon have 
been given (Figure 4.7):
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a) the conformation of L-c/7/ro-lns(2,3,5)P3 in solution and / or bound to 5- 
phosphatase is sufficiently different from lns(1,4,5)P3 to interfere with the 
catalytic mechanism of the enzyme, but nevertheless the analogue binds to the 
enzyme in a similar mode to lns(1,4,5)P3 or;
b) the inhibition may be the result of non-productive binding of L-chiro- 
lns(2,3,5)P3 in an inverted and rotated mode. In this arrangement the analogue 
would mimic four elements of lns(1,4,5)P3 correctly, namely the ring pucker, the 
crucial vicinal 4,5-bisphosphate moiety (as the 2;3-bisphosphate pair) and the 3- 
hydroxyl group (as the 4-hydroxyl group). The 5-phosphate group of L-chiro- 
lns(2,3,5)P3 in this mode mimics an equatorial 2-phosphate group of an 
lns(1,4,5)P3 analogue, and such a phosphate could presumably still bind 
reasonably well to the hydrophilic pocket of the enzyme usually interacting with 
the equatorial 1-phosphate group of lns(1,4,5)P3 [lns(2,4,5)P3 is also a substrate 
for the 5-phosphatase I320!]. In this inverted binding mode the axial 1-hydroxyl 
group of L-c/7/'ro-lns(2,3,5)P3 now mimics the axial 6-hydroxyl group of an 
lns(1,4,5)P3 analogue. As discussed below (Modifications at the 6-position), the 
equatorial 6-hydroxyl group of lns(1,4,5)P3 may play an important role in the 
mechanism of 5-phosphatase catalysed hydrolysis and the inhibitory properties 
of L-c/7/ro-lns(2,3,5)P3 may possibly be ascribed to the pseudo axial 6-hydroxyl 
group in the inverted binding conformation b).
a) b)
lns(1,4,5)P3 L-c/?/ro-lns(2,3,5)P3
Figure 4.7 Alternative binding conformations of L-c/)/ro-lns(2,3,5)P3 to 5- 
phosphatase
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Modifications at the 5-position
It has been demonstrated by the 5-phosphorothioate analogue lns(1,4,5)P3-5S> 
that modification at the 5-position creates a potent inhibitor of the enzyme 
lns(1,4,5)P3-5-phosphatase (Kj 6.8 pM) [210,211] •
The 5-methylenephosphonate analogue of D-lns(1,4,5)P3 is another long-lived 
agonist of calcium mobilisation [18°). The sustained release of calcium by this 
compound indicates that it is not dephosphorylated and thus deactivated by the 
5-phosphatase nor phosphorylated at the 3-position by the kinase. No data on 
interactions with the enzyme have however been published as yet.
The synthesis and preliminary biological data of the 5-methylphosphonate and
5-difluoromethylphosphonate analogues of lns(1,4,5)P3 have been published, 
however no details on interactions of these 5-modified lns(1,4,5)P3 analogues 
with the 5-phosphatase have been reported to date.
Modifications at the 6-position
D-6-deoxy-lns(1,4,5)P3 [1821 inhibited the dephosphorylation of [32P]-lns(1,4,5)P3 
by erythrocyte 5-phosphatase with a Kf of 76 pM [Km for lns(1,4,5)P3 40 pM]. D-
6-deoxy-lns(1,4,5)P3 is therefore a relatively potent inhibitor of this enzyme. 
Both the only ca. 2-fold lower affinity of D-6-deoxy-lns(1,4,5)P3 and the 
approximately 4-fold lower affinity of DL-6-methoxy-lns(1,4,5)P3 for the aortic 
smooth muscle 5-phosphatase [3241 underline the non-selectivety of this enzyme. 
The resistance of these two analogues to dephosphorylation confirmed that the 
minimal structural requirements for substrate hydrolysis by the 5-phosphatase 
include the vicinal 4,5-bisphosphate moiety and a free 6-hydroxyl group P24l. It is 
possible that the role of the 6-hydroxyl group of lns(1,4,5)P3 is similar to the role 
that the 6-hydroxyl group of lns(1)P plays in the dephosphorylation of this 
compound by inositol monophosphatase, i.e. the absence of this group has no 
significant effect on binding, but its presence is essential for the enzyme to act 
on the substrate (mechanistic hydroxyl group, see Chapter 1.6.2).
Multiple modifications
DL-lns(1,4,5)PS3 was resistant to degradation by 5-phosphatase [27°1. DL- 
Cyclohexane 1,2,4-trisphosphate was a weak competitive inhibitor of 5-
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phosphatase (Kj 124 pM ), and no inorganic phosphate release due to hydrolysis 
by the enzyme was detected P24l.
Summary
3-deoxy-lns(1,4,5)P3 and 3-F-lns(1,4 ,5)P3 
are good substrates, however, inversion at 
this position creates a potent inhibitor, 
L-c/)/ro-lns(2,3,5)P3
analogues modified at the 
5-position like lns(1,4,5)P3-5S and 
5-methylenephosphonate-lns(1,4 ,5)P3 
are potent inhibitors of 5-phosphatase
not important for recognition by
5-phosphatase, 2-deoxy-lns(1,4,5)P3
and other 2-modified analogues are 
good substrates
the 1 -phosphate group appears 
to enhance recognition but not 
to be an essential feature: 
lns(4,5)P2 is a weak substrate
mechanistic hydroxyl group: 
deletion as in 6-deoxy- and
6-Omethyl-lns(1,4,5)P3 gives 
inhibitors of 5-phosphatase
Figure 4.8 Structure-recognition relationship for 5-phosphatase
RESULTS AND DISCUSSION
5 Aims of this work
As outlined in the General Section, there is currently great interest in the second 
messenger D-myo-inositol 1,4,5-trisphosphate. as well as in other inositol 
phosphates involved in signal transduction, and in the interactions of these 
compounds with receptors and metabolic enzymes. To investigate the roles of 
the different components in this complex network, analogues of the naturally 
occurring inositoi phosphates are needed which can, for example, serve to label 
relevant proteins or act as enzyme inhibitors.
In this thesis, the synthesis of novel analogues of the second messenger D-myo- 
inositol 1,4,5-trisphosphate is reported. These analogues were prepared with 
different objectives in mind:
The first target compound was the 1-phosphorothioate analogue of lns(1,4,5)P3, 
myo-inositol 4,5-bisphosphate 1-phosphorothioate lns(1,4,5)P3-1S, which was to 
be prepared initially in racemic, and then in optically active form. This analogue 
was then to be used to link a fluorescent chromophore selectively to the 1- 
position of lns(1,4,5)P3. It was also thought that this method might be used to 
link lns(1,4,5)P3 to other reporter groups, e.g. spin labels, affinity and 
photoaffinity probes and affinity column matrices. An intermediate in the 
synthesis of lns(1,4,5)P3-1S was to be employed in the preparation of [35S]- 
lns(1,4,5)P3-1S, a novel radioligand for the lns(1,4,5)P3 receptor which would 
allow the synthesis of radioactive S-alkyl reporter group adducts.
The trisphosphorothioate analogues of the moderately potent 5-phosphatase 
inhibitors lns(1,3,5)P3 and L-lns(1,4,5)P3 were then to be synthesised and 
evaluated as potential inhibitors of this enzyme. The aim here was to explore 
whether the improved binding of phosphorothioate analogues could be exploited 
to produce high affinity inhibitors which would not mobilise Ca2+.
The next objective was the preparation of analogues of lns(1,4,5)P3 modified at 
the 2-position in order to investigate the contribution of this position towards
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receptor binding and interaction with metabolic enzymes. For this purpose, the 
scyllo-inositol analogue DL-scy//o-inositol 1,2,4-trisphosphate as well the 
fluorinated analogue DL-2-deoxy-2-fluoro-myo-iiiositol 1,4,5-trisphosphate were 
to be synthesised.
Two other scyllo-inositol derivatives, scyllo-inositol 1,2,4,5-tetrakisphosphate 
and scyllo-inositol 1,2,4,5-tetrakisphosphorothioate, were then to be prepared 
with the aim to mimick the phosphate arrangement of the known partial agonist 
lns(1,3,4,6)P4 and to find out more about structural requirements for compounds 
with these characteristics, with the overall aim of antagonist development.
A route to the novel proposed lns(1,3,4,5)P4 3-phosphatase inhibitor, myo­
inositol 1,4,5-trisphosphate-3-phosphorothioate, lns(1,3,4,5)P4-3S was devised. 
A key step included the optical resolution of a valuable intermediate in the 
synthesis of 3-position modified lns(1,4,5)P3 and lns(1,3,4,5)P4 analogues, DL-
3-0-allyl-6-0-benzyl-1-0-p-methoxybenzyl-4,5-0-isopropylidene-myo-inositol, 
which was to be attempted via the camphanate ester method. The resolved 
intermediate was then to be applied in the preparation of D-lns(1,3,4,5)P3-3S.
Methods to replace the lns(1,4,5)P3 1-phosphate group with a carboxymethylene 
moiety (which should mimic a phosphate to some extent) and to employ lactones 
as protecting groups in the synthesis of inositol derivatives were to be 
investigated. We were also interested in ring-fused lacto-derivatives of inositol 
phosphates since compounds with a second ring fused to the inositol ring should 
be more rigid than ordinary inositol phosphates. Analogues with less flexibility 
than the natural substrates may display antagonistic or inhibitory properties and 
would help to define structure-activity parameters.
Finally, routes to C-allyl inositol derivatives via Claisen rearrangements of 
elimination products with a C=C bond in the inositol ring were to be studied. This 
new class of compounds was of interest to us because by oxidative cleavage of 
the allyl double bond the synthesis of derivatives with a -CH2-COOH group 
linked directly to an inositol ring carbon should be possible. Sterically, the -CH2- 
COOH moiety might appear to be a better surrogate for a phosphate group than 
a carboxymethylene group, and such compounds, when phosphorylated, may 
show novel activity.
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6 Synthesis of DL-myo-inositol 4,5-bisphosphate 1-phosphorothioate, 
and its fluorescent and radio-labelling
The few structure-activity studies which have been performed on lns(1l4J5)P3 
analogues show that the vicinal 4,5-bisphosphate moiety of lns(1,4,5)P3 is 
essential for Ca2+-re leasing activity I272!, the 1-phosphate group being thought to 
provide enhanced affinity for the receptor. Semisynthetic lns(1,4,5)P3 analogues 
with modifications at the 1-phosphate position have been prepared from the 
deacylated polyphosphoinositide phospholipid and are biologically potent in 
effecting calcium release l323l. It was thought that introduction of a nucleophilic 
phosphorothioate group into the lns(1,4,5)P3 molecule should permit the facile 
attachment of reporter groups to lns(1,4,5)P3> such as photoaffinity labels, spin 
labels and fluorescent probes. Previously synthesised inositol 
phosphorothioates like the trisphosphorothioate lns(1,4,5)PS3 and the 5- 
phosphorothioate lns(1,4,5)P3-5S have been shown to be highly potent 
analogues of lns(1,4,5)P3. Consequently, the synthesis of the novel lns(1,4,5)P3 
analogue myo-inositol 4,5-bisphosphate 1-phosphorothioate [lns(1,4,5)P3-1S] in 
racemic and optically active form has been devised and its use in the fluorescent 
labelling of lns(1,4,5)P3 has been demonstrated. Whilst these studies were in 
progress other groups have also addressed the problem of attaching reporter 
groups to lns(1,4,5)P3 [328,367] or related compounds [368l, and lns(1,4,5)P3 to 
affinity matrices [320,368,369]
Myo-inositol was chosen as a cheap (£ 18.50 for 250 g I370!) and readily 
available starting material for the synthesis of the 1-phosphorothioate analogue 
of lns(1,4,5)P3. In order to set up the inositol molecule for the introduction of 
phosphate groups at position 4 and 5 and a phosphorothioate group at position 
1, it was necessary to synthesise a compound with protected 2-, 3- and 6- 
hydroxyl functions. It was also required that either the 4- and 5-hydroxyl groups 
or the 1-position of this intermediate were blocked (depending on whether the 
phosphorothioate group or the phosphate groups were introduced first). The 
protecting group(s) chosen to block the 1-position (or the 4- and 5-positions) had 
to be easily removable without affecting the blocked 2-, 3- and 6-positions, or the 
phosphate (phosphorothioate) triester functions or the protecting groups used 
for the 2-, 3- and 6-position.
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The selected key intermediate that fulfilled the requirements outlined above, was
2,3,6-tri-0-benzyl-1-0-(prop-1-enyl)-/77yo-inositol. The 4- and 5-positions in this 
compound are free and can be selectively phosphorylated because all the other 
hydroxyl functions are protected. The prop-1-enyl ether at the 1-position can 
then be cleaved without affecting the benzyl ethers or the protected phosphate 
groups. Additionally, the compound is easily prepared by isomerisation of the 
known 1-O-allyl ether t168!.
6.1 Synthesis of DL-2,3-6-Tri-0-benzyl-1-0-(prop-1-enyl)-myo-mositol
1-0-Allyl-2,3,6-tri-0-benzyl-myo-inositol was synthesised essentially according 
to the procedure of Gigg etal. [149,168]
Myo-inositol was treated with 2,2-dimethoxypropane in DMF and PTSA to give a 
mixture of the three bis-acetals. The desired 1,2:4,5-di-0-isopropylidene-/77yo- 
inositol was isolated by converting the three isomers into the dibenzoates with 
benzoyl chloride / pyridine. In contrast to the other two dibenzoates, 1,2:4,5-di- 
0-isopropylidene-3,6-di-0-benzoyl-myo-inositol is insoluble in pyridine, water, 
acetone and ether and was obtained from the reaction mixture by washing with 
these solvents. Removal of the benzoyl groups by treatment with methanolic 
sodium hydroxide solution and benzylation with benzyl chloride, potassium 
hydroxide and the phase-transfer catalyst 18-crown-6 (the reaction is a 
modification of Gigg's procedure, who used benzyl bromide and sodium hydride 
in A/,A/-dimethylformamide) gave 3,6-di-Obenzyl-1,2:4,5-di-0-isopropylidene- 
myo-inositol 123, with 'permanent' benzyl protecting groups in the 3- and 6- 
position as required.
After acid hydrolysis of the two acetals, the hydroxyl group in the 1-position of 
124 was allylated. Selective allylation of the tetrol was accomplished by first 
forming a tin-complex I164] with dibutyltin oxide by heating under reflux in toluene 
with azeotropic removal of water of condensation by means of a Dean and Stark 
apparatus. The tin-complex reacted with allyl bromide in DMF to give selectively 
the 1-O-allyl ether. A cleaner reaction with higher yields was achieved by adding 
caesium fluoride (rather than tetrabutylammonium iodide I168!) to the reaction 
mixture prior to the addition of allyl bromide t167l. The role of caesium fluoride in 
this reaction is discussed in Chapter 2.1.5.
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Figure 6.1 Synthesis of 1-0-Allyl-2,3,6-tri-0-benzyl-/77ya-inositol
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The 1-, 3- and 6-positions were now protected: the next objective was to 
introduce a benzyl group at the 2-position. This was effected by simultaneous 
protection of the 4- and 5-positions as the isopropylidene acetal using 2,2- 
dimethoxypropane and PTSA, followed by benzylation of the remaining free 2- 
hydroxyl group with benzyl chloride /  KOH / 18-crown-6. The acetal was cleaved 
by acid hydrolysis to give DL-1-0-allyl-2,3,6-tri-0-benzyl-/77yo-inositol 127, which 
could be obtained in crystalline form (m.p. 73-75°C) from ethanol / water. Gigg et 
al. obtained this compound only as a syrup after column chromatography on 
silica gel I168].
Isomerisation of the allyl ether to the corresponding prop-1-enyl derivative 128 
was accomplished either by employing tris(triphenylphosphine)rhodium (I) 
chloride (Wilkinson's catalyst) in the presence of 1,4-diazabicyclo[2.2.2]octane 
(DABCO) (to prevent premature hydrolysis of the propenyl ether) in 7:3:1 
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Figure 6.2 Isomerisation of the 1-O-allyl group
Yields were found to be higher when Bu!OK was used; additional advantages 
are the easier work-up and the fact that a homogenous product is obtained as 
only the c/s-isomer is formed, whereas the use of Wilkinsons's catalyst gave a 
mixture of ca. 5:1 cis.trans prop-1-enyl isomers. The cis.trans ratio was
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determined by the integration of the 1H-NMR signals at 1.56 ppm (0.5 H, dd, J 
6.8, 1.55, trans-CH=CH-CH3) and 1.68 ppm (2.5 H, dd, J 6.8, 1.6, cis-CH=CH- 
CH3). The CH=CH-CH3 and the CH=CH-CH3 signals were part of multiplets and 
could therefore not be used to determine the exact amounts of the isomers 
present in the mixture. It was however clear from the CH=CH-CH3 signal at 6.07- 
6.15 ppm that the cis-isomer (J 6.2 and 1.65 Hz) was the major component. The 
assignment of the 1.68 ppm signal to the cis-isomer was confirmed when pure
2,3,6-tri-O-benzyM-0-(cis-prop-1 -enyl)-myo-inositol was prepared.
6.2 The Synthesis of bis(2-cyanoethoxy)(diisopropy!amino) phosphine
The next step in the synthesis of lns(1,4,5)P3-1S was the phosphorylation of the
4- and 5-positions of 128. The P(lll) reagent bis(2- 
cyanoethoxy)(diisopropylamino) phosphine was chosen to phosphitylate the free 
hydroxyl groups of the protected inositol derivative. P(lll) reagents are more 
reactive than P(V) reagents and allow phosphorylation of the vicinal 4,5-diol 
without formation of cyclic phosphates (see Chapter 2.3). They have the 
additional advantage of providing access to both phosphates and 
phosphorothioates as the phosphite triesters obtained may be oxidised to give 
the corresponding phosphate triesters or sulphoxidised to give the protected 
phosphorothioates. The removal of the 2-cyanoethoxy protecting groups by (3- 
elimination in sodium / liquid ammonia occurs faster than the deblocking of the 
benzyl protecting groups on the inositol ring hydroxyl functions. Undesirable 
phosphate migrations which may occur when free hydroxyl groups are present 
next to a protected phosphate, are therefore avoided.
The phosphitylating reagent 131 was synthesised in three steps from
phosphorus trichloride according to the procedure of Bannwarth and Trzeciak
[226];
1) Phosphorus trichloride was treated under nitrogen with 3-hydroxypropionitrile 
and pyridine (1 equivalent each) in dry ether to give dichloro(2- 
cyanoethoxy)phosphine 129 after removal of the pyridine hydrochloride 
precipitate. 31P-NMR showed a single signal at 5 = 179.77 ppm. The compound 
was very moisture sensitive and partly decomposed during attempted distillation
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at reduced pressure. It was therefore used without further purification to prepare 
the alkoxybis(dialkylamino)phosphine 130.
2) (2-Cyanoethoxy)bis(diisopropylamino)phosphine 130 was prepared by adding 
9 equivalents of /V,/V-diisopropylamine slowly to an ethereal solution of the 
alkoxydichlorophosphine 129 (addition of only 2 equivalents of secondary amine 
will give the A/,/V-diisopropylamino(2-cyanoethoxy)chlorophosphine P72l). The 
crude product was obtained after filtering the precipitated amine hydrochloride. 
This compound is quite stable and was purified by distillation under reduced 
pressure from calcium hydride. 31P-NMR: 5 = 122.56 ppm.
The strong p^-d  ^ interaction between phosphorus and the nitrogen atoms I127l 
makes alkoxybis(dialkylamino)phosphines easily susceptible to protonation by 
very weak acids (such as diisopropylammonium tetrazolide), leading to an 
activated species which can react with another alcohol to give the 
dialkoxy(dialkylamino)phosphine. In this class of compounds the p^-d* 
interaction is reduced due to the newly introduced alkoxy function, they are 
therefore less susceptible to protonation and behave like monofunctional 
reagents. Activation can still be achieved under slightly more acidic conditions 
(e.g. by employing 1H-tetrazole), allowing the reaction with a hydroxyl group 
bearing substrate to give the desired phosphite triester.
✓Cl
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131 130
Figure 6.3 Synthesis of bis(2-cyanoethoxy)(diisopropylamino)phosphine
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3) The phosphitylating reagent bis(2-cyanoethoxy)(diisopropylamino)phosphine 
131 was prepared by adding 1.1 equivalents of 3-hydroxypropionitrile to a 
solution of 130 and diisopropylammonium tetrazolide (prepared in quantitative 
yield by treatment of a solution of tetrazole in acetonitrile with an excess of 
diisopropylamine, followed by filtration and drying under vacuum P73l) in 
dichloromethane. The product was stable enough to allow purification by flash 
chromatography.
6.3 DL-myo-lnositol 4,5-bisphosphate 1-phosphorothioate
Phosphorylation of the vicinal 4,5-diol of 128 was effected using a P(lll) 
approach, thus avoiding difficulties which can arise by direct phosphorylation of 
the vicinal diols with P(V) reagents (e.g. the formation of undesirable cyclic 
phosphates). 2,3,6-Tri-0-benzyl-1-0(prop-1-enyl)-A77yo-inositol was treated with 
bis(2-cyanoethoxy)-/V,A/-diisopropylaminophosphine I226l and 1H-tetrazole in dry 
dichloromethane to give the bisphosphite triester. 31P-NMR showed signals at 
148 ppm (excess phosphitylating agent), 139.21 and 138.64 ppm (inositol 4- and
5-phosphite) and 127 ppm (phosphitylating reagent-tetrazolide).
The protected P(lll) bisphosphite was oxidised to the P(V) bisphosphate by the 
addition of excess tert.-butyl hydroperoxide (B^OOH) I236] to the cooled reaction 
mixture. The 31P-NMR spectrum showed a minor peak at 8 ppm (phosphonate) 
and two signals at -5.52 and -5.65 ppm. Although the oxidation of the phosphite 
was complete within a few minutes, stirring was usually continued overnight 
because it was found to make the chromatographic purification of the product 
easier, presumably because H-phosphonate by-products of a polarity similar to 
the product were oxidised to more polar derivatives.
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Figure 6.4 Synthesis of DL-/nyo-inositol 4,5-bisphosphate 1- 
phosphorothioate
The prop-1-enyl ether was cleaved by acidic hydrolysis with methanolic 
hydrochloric acid I140! or HgO-HgCI2 t141l to give DL-2,3,6-tri-0-benzyl-4,5- 
bis[di(2-cyanoethoxy)phospho]-A77yo-inositol. Initially, cleavage of the propenyl 
ether with HgO-HgCI2 was chosen in order to avoid any deprotecting of the 
sensitive phosphate triesters. It proved however, very difficult to separate the 
mercury compounds from the reaction product even by chromatographic means, 
so that in later experiments mild acidic hydrolysis was used which was found not 
to affect the protected phosphates and also to give cleaner products. The 1H- 
NMR signals of the inositol ring protons of this compound were assigned to the 
individual protons by coupling constants and correlation spectroscopy (COSY, 
Figure 6.5).
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Figure 6.5 COSY spectrum of 133
The free hydroxyl group was then phosphitylated and the phosphite 
sulphoxidised with an excess of sulphur in pyridine t233J to give DL-2,3,6-tri-0- 
benzyl-4,5-bis[di(2-cyanoethoxy)phospho]-1-[bis(2-cyanoethoxy)thiophospho]- 
myo-inositol. 31P-NMR spectroscopy showed signals at 66.83 ppm for the 
phosphorothioate triester and peaks at -2.83 and -3.10 ppm for the phosphate 
triester.
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Deblocking of benzyl and cyanoethoxy protecting groups was accomplished 
using sodium in liquid ammonia l236l to give the lns(1,4,5)P3 analogue DL-myo- 
inositol 4,5-bisphosphate 1-phosphorothioate [DL-lns(1,4,5)P3-1S] 80, which 
was purified by ion-exchange chromatography on DEAE Sephadex A-25. DL- 
lns(1,4,5)P3-1S was eluted at ca. 800 mmol dm’3 triethylammonium hydrogen 
carbonate (TEAB) buffer (yield 46 % as determined by quantitative phosphate 
analysis). 31P-NMR spectroscopy (Figure 6.6) showed that the product 
possessed a single phosphorothioate group (8P 42.1 ppm) and two phosphate 
groups (5P 4.6, 3.5 ppm). The signals in the proton NMR were assigned by their 
chemical shift and their coupling constants as well as their COSY spectrum 
(Figure 6.7).
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Figure 6.7 COSY spectrum of 80
6.4 [35S]-DL-/77yo-inositol 4,5-bisphosphate 1-phosphorothioate
The synthesis of the metabolically stable radioligand D-[35S(U)]-myo-inositol
1,4,5-trisphosphorothioate [35S]-lns(1,4,5)PS3 and its application in binding 
studies has been reported (275l. This radioligand was shown to label two different 
sites in rat cerebellar membranes: the lns(1,4,5)P3 receptor and another site that 
displayed only low affinity for lns(1,4,5)P3.
In cooperation with NEN-DuPont, racemic 1,2,4-tri-0-benzyl-5,6-bis[di(2- 
cyanoethoxy)phospho]-myo-inositol was used to synthesise the radiolabelled 
DL-[35S]-lns(1,4,5)P3-1S, which is a novel radioligand for the lns(1,4,5)P3 
receptor.
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This radiolabelled analogue was used in binding experiments with rat cerebellar 
membranes, the assay conditions are described in t275l. DL-[35S]-lns(1,4,5)P3-1S 
was supplied by NEN-DuPont with a specific activity of ~ 81 Ci / mmol. Thus
1.03 nM of [35S]-lns(1,4,5)P3-1S in an assay volume of 120 pi is equivalent to 
22112 dpm. Figure 6.8 shows the displacement of [35S]-lns(1,4,5)P3-1S by 













t-  4000 •
.E co
rti d.O (/><u c
CL —






0 i . i . i . i
- 9 - 8 - 7 - 6 - 5
Concentration
lnsP3-1 S (log M)
Figure 6.8 Displacement of [35S]-lns(1,4,5)P3-1S by lns(1,4,5)P3-1S
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Figure 6.9 Scatchard transformation of [35S]-lns(1,4,5)P3-1S binding data
These results indicate that the displacement of lns(1,4,5)P3-1S from cerebellar 
membranes is monophasic in contrast to lns(1 ,4,5)PS3i which has been found to 
be displaced in a biphasic mode I275!. This observation led to the suggestion that 
[35S]-lns(1,4,5)PS3 labels two different sites with equal affinity: the lns(1,4,5)P3 
receptor and a site that displays low affinity for lns(1,4,5)P3. [35S]-lns(1,4,5)P3- 
1S on the other hand, being structurally closer to the natural ligand lns(1,4,5)P3 
than [35S]-lns(1,4,5)PS3, appears to be specific for the lns(1,4,5)P3 receptor and 
does not interact with the low affinity binding site. This novel radioligand may 




Fluorescent labelling methodology has already shown its versatility in the 
nucleic acid field l374l, where it is established as a valuable alternative to the use 
of radioactivity. The semisynthetic preparation of a fluorescent Ptdlns analogue 
has been reported (3751, however, no fluorescent lns(1,4I5)P3 analogue has yet 
been synthesised. We reasoned that such a compound may provide 
environmental information concerning receptor binding.
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Figure 6.10 Synthesis of fluorescently labelled DL-lns(1,4}5)P3-1S
Nitrobenzoxadiazole (NBD) derivatives, such as the iodoacetate A/-{2- 
(iodoacetoxy)ethyl]-A/-methyl}amino-7-nitro-2,1,3-benzoxadiazole (IANBD), are 
unique in having long-wavelength fluorescein-like fluorescence spectral
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properties, but with high environmental sensitivity of the quantum yield, coupled 
with a relatively small molecular size t376l  Such a probe appeared ideal to study 
the interactions of a fluorescently tagged lns(1,4,5)P3 with the intracellular 
receptor and the metabolic enzymes 5-phosphatase and 3-kinase.
Reaction of the phosphorothioate analogue DL-lns(1,4,5)P3-1S with IANBD 
proceeded smoothly to give the adduct 135, which was purified by ion exchange 
chromatography on DEAE Sephadex A-25, and was eluted at ca. 800 mmol dm-3 
TEAB (yield 57 % of a dark orange glass). 31P-NMR spectroscopy (Figure 6.11) 
clearly showed that the signal for the 1-phosphorothioate group (5P 42.1 ppm) of 
80 had disappeared. Instead, a new signal at 8P = 19.9 ppm was found for 135.
OH
HO
2 0 2P 0 ‘
.Me■O—P—S
0 H  135
NO-
0 ppm
Figure 6.11 1 H-coupled 31P-NMR spectrum of 135
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Chemical shifts of about 20 ppm in the 31P-NMR are typical for S-alkyl 
phosphorothiolates. The signal appeared as a quartet with J = 9.5 Hz, indicating 
coupling of the phosphorus nucleus to both C-1-H and the S-methylene protons. 
The two signals for the phosphate groups in positions 4 and 5 at 1.7 and 3.0 
ppm remained unchanged (d, J 8.5), proof that the alkylation was indeed 
selective at the more nucleophilic phosphorothioate.
The adduct 135 exhibited a UV spectrum consistent with the presence of an 
NBD chromophore and when excited at 460 nm showed the expected 
fluorescence at 540 nm.
excitation spectrum 
X em = 600 nm
fluorescence 
spectrum 
X Pv = 460 nm
£30 £90 550 nm £80 5£0 600 nm
Figure 6.12 UV fluorescence spectrum of 135
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Compound 135 was potent at mobilising ATP-sequestered intracellular Ca2+ 
from permeabilised cells and was recognised by the lns(1,4,5)P3 receptor with 
surprisingly high affinity [only ca. 6 fold less than lns(1,4,5)P3] in spite of the 
bulky additional group. The synthesis of 135 thus provides the first example of a 
biologically active lns(1,4,5)P3 analogue labelled with a fluorescent reporter 
group.
Preliminary experiments on receptor site localisation with this probe were 
disappointing, the main problem was the lack of sensitivity of the NBD 
chromophore, which did not show any fluorescence enhancement on binding to 
the receptor protein. An explanation for this lack of sensitivity could be that after 
receptor binding the NBD probe is found in a hydrophilic environment (possibly 
the cytosol), which seems plausible since other 1-modified lns(1,4,5)P3 
analogues with relatively bulky groups in this position (see Chapter 4.1) were 
also almost equipotent to lns(1,4,5)P3 in binding and calcium release studies, 
indicating that substituents at the 1-phosphate group show only little interaction 
with the receptor protein. To improve the fluorescence of 1-modified probes it 
would therefore be necessary to replace the enviromentally sensitive NBD group 
with another chromophore like fluorescein whose fluorescence properties are 
only to a small degree dependent on the polarity of the solvent.
6.6 Pharmacology
All compounds whose synthesis is described in this chapter have now been 
pharmacologically evaluated:
Figure 6.13 summarises the Ca2+-release studies on DL-lns(1,4,5)P3-1S 80 and 
the fluorescent probe 135 (IP3-1S-NBD). The assays were performed on 
electrically permeabilised SH-SY5Y neuroblastoma cells as described in t3643, 
except that the cells were permeabilised using 3 pulses of a 3 pF capacitor 
rather then 12 pulses. The EC50 values obtained under these conditions were 
0.21 ± 0.02 pM for 80 and 0.64 ±  0.15 pM for 135. These results have to be seen 
in relation to the potency of the natural agonist D-lns(1,4,5)P3, which has EC50 = 
0.08 ± 0.02 pM. Considering that 80 was applied in racemic form and assuming
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that the L-isomer is not biologically active, D-80 is almost equipotent to 
lns(1,4,5)P3.
The kinetics of the Ca2+-release were consistent with lns(1,4,5)P3-1S being a 
substrate for lns(1,4,5)P3 5-phosphatase and 3-kinase.











The Ca2+ mobilising properties of lns(1,4,5)P3-1S have also been studied in 
platelets. For this assay, rabbit platelets were isolated and washed according to 
Murphy et al. I377l. The platelets (109 / ml) were suspended in an "intracellular 
like" buffer containing 5 mM ATP and permeabilised by treatment with saponin 
(40 pg / ml) for 1 min. The washed platelets were loaded with 45Ca2+ for 60 min 
and stimulated with the inositol phosphate analogue for 3 min at r.t. The 
remaining cell-associated 45Ca2+ was then determined by rapid filtration. The 
results for lns(1,4,5)P3-1 S are shown in Figure 6.14.
Dose response  curve to  m yo —ino s ito l —4 ,5 —bis













Figure 6.14 Ca2+ mobilisation of lns(1,4,5)P3 and lns(1,4,5)P3-1S in 
platelets
The results of binding studies are shown in Figure 6.15. [3H]-lns(1,4,5)P3 was 
displaced from cerebellar membranes by adding either lns(1,4,5)P3 or
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Ins(1,4,5)P3-1S. The IC50 values obtained in this isotope dilution experiment 
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7 Synthesis of D-lns(1,4,5)P3-1S
7.1 Optical Resolution of 1-0-Allyl-2,3,6-tri-0-benzyl-/nyo-inositol
Myo-inositol, a meso-compound, was used as starting material in the synthesis 
of lns(1,4f5)P3-1S, and this analogue was initially obtained as the mixture of D- 
and L-enantiomers. In order to prepare the optically pure analogue of naturally 
occurring D-lns(1,4l5)P3l it was neccessary to resolve a precursor to synthesise 
1D-lns(1,4,5)P3-1S.
Thus racemic 1-0-allyl-2,3,6-tri-0-benzyl-/77yoinositol 127 was converted into its
4,5-bis-(-)-co-camphanate ester using (-)-camphanic acid chloride /  pyridine. The 
camphanate method was chosen because (-)-camphanic acid chloride is 
commercially available in high optical purity (98 %) and camphanates are often 
highly crystalline, thus making separation of the diastereoisomers by 
crystallisation rather than by tedious chromatographic means possible. 
Camphanate esters have already been successfully employed for the resolution 
of various inositol derivatives [1 2 2 ,1 23,248,378-380]_ with (+)-camphanic acid 
chloride now commercially available, the diastereoisomers which can not be 
crystallised from (-)-camphanate mixtures are now also accessible, making this 
route even more generally applicable. However, (+)-camphanic acid chloride is 
markedly more expensive than (-)-camphanic acid chloride (£ 25.70 for 250 mg 
vs. £ 8.60 for 1 g l37°l).
The biscamphanate 136 of the protected D-isomer 137 readily crystallised 
initially from the diastereomeric mixture, however the crystalline biscamphanate 
143 of the protected inositol, 144, could also be obtained by keeping the mother 
liquor left from the crystallisation of 136 at -20°C for several days. The 
supernatant was then filtered off and the solid that had formed was dissolved in 
hot ether. After leaving the solution in the refrigerator for two days crystals had 
appeared which were collected to give 143.
The 1H-NMR resonances (Figure 7.1) of the camphanate methyl groups were 
used as an initial guide to the efficiency of this resolution. After base-deblocking 






myo-inositol were obtained. The absolute configuration of these enantiomers 
was assigned by conversion of one of them (144) to the known triol D-(-)-1,2,4- 
tri-O-benzyl-myo-inositol 146 I168l by isomerisation of the allyl group and 
subsequent removal of the c/'s-prop-1-enyl group with acid.
The melting point (97-98°C) and optical rotation ([a]D18 = +21.5°) of 1D-1 -O-allyl-
2,3,6-tri-O-benzyl-myo-inositol 137 are in good agreement with data for this 
compound (m.p. 98°C, [a]D18 = +20°) measured by Gigg e t a i , who reported the 
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Figure 7.2 Optical resolution of 127 and synthesis of D-lns(1,4,5)P3-1S
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7.2 Synthesis of D-myo-inositol 4,5-bisphosphate 1-phosphorothioate
The 1D-isomer was used to prepare optically active 1D-lns(1,4>5)P3-1S, by 
following the route outlined for the racemic compound. Thus, D-1-Oallyl-2,3,6- 
tri-O-benzyl-myo-inositol 137 was isomerised to the c/s-1-0-prop-1-eny I 
derivative 138 (m.p. 116-118°C, [a]D11 = +40.6°) using BukDK / DMSO and the 
product was phosphorylated to give the corresponding optically active protected
4,5-bisphosphate 139 (m.p. 131-132°C, [a]D19 = +11.5°). Removal of the 
propenyl group with 1 M HCI / methanol (1:5) and thiophosphorylation of the 
resulting alcohol 140 generated D-2,3,6-tri-0-benzyl-1-0-[bis(2- 
cyanoethoxy)thiophospho]-4,5-bis[di(2-cyanoethoxy)phospho]-myo-inositol 141 
(neither 140 nor 141 could be crystallised). 141 was then deblocked with sodium 
in liquid ammonia to furnish 1 D-myo-inositol 4,5-bisphosphate 1- 
phosphorothioate 142 in 44 % yield after ion-exchange chromatography. The 
optical rotation for this compound was found to be [a]D21 = -42.7° at pH 9.4.
7.3 Pharmacology
The pharmacological properties of D-lns(1,4,5)P3 are currently being evaluated. 
The optically active precursor 140 is now being applied in the preparation of 
radiolabelled [35S]-D-lns(1,4,5)P3-1S in cooperation with NEN-DuPont.
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8 Synthesis of Novel lns(1,4,5)P3 5-Phosphatase Inhibitors
Inhibitors of the metabolic enzymes 5-phosphatase and 3-kinase are of great 
current interest to the biochemist. Especially valuable for metabolic studies are 
inhibitors that selectively block the enzyme activity and do not interact with the 
lns(1,4,5)P3 receptor. Such compounds have not been prepared before, 
although in parallel with these studies Dr. Changsheng Liu in our group 
synthesised L-ch/ro-lns(1,4,6)PS3 I381], an analogue that showed similar 
characteristics. Thus, our aim was to develop potent 5-phosphatase inhibitors 
unable to release calcium by improving the binding properties of compounds 
known to be moderately potent, non calcium-mobilising inhibitors.
The cytosolic 5-phosphatase is relatively non-specific and recognises not only 
D-lns(1,4,5)P3 and D-lns(1,3,4,5)P4, which are the natural substrates of this 
enzyme, but also synthetic inositol phosphates such as L-lns(1,4,5)P3, 
lns(1,3,5)P3 and DL-lns(2,4,5)P3 1324]. Unlike D-lns(1,4,5)P3, DL-lns(2,4,5)P3 and 
DL-lns(1,3,4,5)P4 however, L-lns(1,4,5)P3 [= D-lns(3,5,6)P3] and lns(1,3,5)P3 
are competitive inhibitors of this enzyme with Kj values of 39 and 45 pM, 
respectively. In another study using human erythrocyte 5-phosphatase L- 
lns(1,4,5)P3 has also been found to inhibit the enzyme with a Kj of 124 pM I271).
Cooke etal. l271l observed that the trisphoshorothioate analogue of lns(1,4,5)P3, 
DL-lns(1,4,5)PS3, acted as a potent competitive inhibitor of 5-phosphatase (Kj 6 
pM, cf. Ins(1,4,5)P3: Km = 40 pM). Thus the substitution of phosphate groups by 
phosphorothioate moieties resulted in increased binding properties (i.e. 
decrease of the Kj value) of the analogue. Racemic lns(1,4,5)PS3 does however 
mobilise intracellular calcium [269,326] ancj was therefore considered 
unsatisfactory with regard to the objective outlined above.
Considering the effect that replacement of phosphate groups by 
phosphorothioate groups had on lns(1,4,5)P3, we reasoned that 
phosphorothioate analogues of the competitive non calcium-mobilising, but weak 
5-phosphatase inhibitors L-lns(1,4,5)P3 and lns(1,3,5)P3 would prove to be more 
potent inhibitors than the parent compounds and this idea was pursued by the 
synthesis of these analogues.
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8.1 Synthesis of L-/nyo-inositol 1,4,5-trisphosphorothioate
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Figure 8.1 Synthesis of L-lns(1,4,5)P3
The L-enantiomer of l-O-allyl^.S.e-tri-O-benzyl-myo-inositol 144 was 
isomerised to the corresponding 1-0-c/s-(prop-1-enyl) derivative 145 and 
deprotected to give 1D-1,2f4-tri-0-benzyl-myo-inositol 146. Melting point (116- 
118°C) and optical rotation ([a]D18 = -10.1°) measured for this previously 
described triol were in good agreement with the reported values (m.p. 118- 
120°C, [a]D18 = -9.0°) I168l. 146 was then thiophosphorylated, generating 1L-
2,3,6-tri-O-benzyM >4,5-tris-[di(2-cyanoethoxy)thiophospho]-/77yo-inositol 147. 
Deblocking with sodium / liquid ammonia furnished 1L-lns(1,4,5)PS3 148, which
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was purified by ion-exchange chromatography. The 31P-NMR spectrum of 148 
showed as expected signals at 44.82, 44.69 and 42.06 ppm for the three 
phosphorothioate groups.
It was observed that treatment of the crude reaction product with Dowex 50 
cation-exchange resin (H+-form, added to reduce the ionic strength of the 
solution and thus facilitate purification by ion-exchange chromatography) 
resulted in decomposition of the deprotected phosphorothioate. Since 
decomposition was not reported for Dowex treatment of deblocked phosphates 
I382] and a strong smell of sulphur could be noticed after Dowex treatment of the 




Figure 8.2 31P-NMR spectrum of 148
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8.2 Synthesis of 2,4,6-tri-0-butyryl-/nyo-inositol
Myo-inositol was used as starting material to prepare 2,4,6-tri-0-butyryl-/77yo- 
inositol, a compound which was of interest to us for studies on the 
enantiospecific deacylation of inositol derivatives by enzymes. Selective 
protection of the 1-, 3- and 5-hydroxyl groups of myo-inositol can be effected by 
converting the starting material into its orthoformate ester 150 by Billington's 
modification [1611 of the method devised by Lee and Kishi I158!, i.e. DMF rather 
than DMSO was used as solvent for the reaction.
Figure 8.3 Synthesis of the orthoformate ester of myo-inositol
Thus, the orthoformate was converted into the orthoformate tributyrate 151 by 
treatment with butyric anhydride in pyridine with DMAP as acylation catalyst. 
This compound was then treated with 80% trifluoroacetic acid to remove the 
orthoformate ester. Tic (ether / hexane 2:1) showed the conversion of the 
starting material (Rf 0.74) into a major and a minor product (Rf 0.12 and 0.28, 
respectively). Separation of the product mixture gave the desired tributyrate 152 
as the major product (63 %) and the minor product 153 (14 %).
The 1H-spectrum of 153 showed the presence of 3 butyrate esters (with 
corresponding signals in the 13C-spectrum at 173.11,173.30,174.66 ppm for the 
butyrate carbonyl group). It was also obvious from the 1H-NMR spectrum that 
unlike 152, 153 was not a symmetrical compound. Only two D20-exchangeable 
protons were found, which excluded the possibility that a migration of the 
butyrate esters had occurred and implied the presence of a substituent in the 
1 (3)-position (substitution at the 5-position would have given a symmetrical 
compound). The only two NMR signals unaccounted for were assigned to this 




Figure 8.4 1H-NMR spectrum of 153
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Figure 8.5 13C-NMR spectrum of 153
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assigned as an aldehyde proton signal) and a 13C-NMR doublet at 159.61 ppm 
(which was assigned as an aldehyde carbonyl signal). From this, it was 
concluded that the additional substituent in the 1-position was a formyl group 
derived from incomplete deprotection of the orthoformate ester.
After the presence of a formyl group in the 1-position had been established, the 
ring protons had to be assigned. The 1H-signal at 5.08 ppm, a dd with coupling 
constants of 10.4 Hz and 2.7 Hz, is found considerably further downfield than 
the other proton signal (3.85 ppm) showing axial / axial and axial / equatorial 
coupling (J = 10.1, 2.9 Hz). These signals were therefore assigned to C-1-H and 
C-3-H, respectively, the formate moiety causing the downfield shift of C-1-H. The 
signal at 3.65 ppm (dd, J 9.8, 9.8 Hz), which sharpened after D20  exchange 
(indicating the presence of a hydroxyl group on the same ring carbon), was 
assigned to C-5-H. The C-2-H peak at 5.62 ppm was easily identified by the 
small J values, and the remaining two signals at 5.2 and 5.4 ppm (shifted 
downfield because of butyrate ester substitution) can be ascribed to C-4-H and
C-6-H.
■ ^  llOCPr" »ii 'J
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Figure 8.6 Preparation of 2,4J6-tri-0-butyryl-n7yo-inositol
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The Cl-mass spectrum, showing an (M+H)+ peak at m/z 419, is in agreement 
with the assignment of 153 as DL-2,4,6-tri-0-butyryl-1-0-formyl-/77yo-inositol.
Obviously, if this deprotection can be controlled it could be very useful as a way 
of partially deprotecting the orthoformate, thus affording a protected inositol 
which could be used for further manipulations.
Enzymes have been used by a number of groups to prepare optically active 
inositol derivatives (see Chapter 2.2). Baudin et al. t159) succeeded in 
enantioselectively converting 4,6-di-0-butyryl-/77yo-inositol orthoformate into the 
(-)-monobutyrate (ee > 95 %, yield 83 %) by employing porcine liver esterase 
(PLE). We wanted to investigate whether the major product obtained by 
deprotection of the tributyrate orthoformate, 2,4,6-tri-O-butyryl-myo-inositol 152, 
is also a substrate for this enzyme, and whether the enzyme would 
stereoselectively deacylate this compound to give either the D-2,4-di-Obutyrate 
or the D-2,6-di-Obutyrate, the latter being a useful intermediate in the synthesis 
of optically active D-lns(1,3,4,5)P4. This project was conducted in co-operation 
with Stephen J. Mills in our group.
152 was thus digested with porcine liver esterase (Sigma) in 0.1 M phosphate 
buffer, pH 7. However, even after several days of incubation, no deacylation 
product could be detected by tic or NMR and the project was abandoned.
8.3 Synthesis of Bis(benzyloxy)(diisopropylamino) phosphine
For the phosphitylation of compounds prepared during the later stages of this 
study bis(benzyloxy)(diisopropylamino)phosphine I225l was preferred to the 
corresponding 2-cyanoethoxy phosphine because the resulting benzyl 
phosphate and phosphorothioate triesters tend to be more crystalline. 
Bis(benzyloxy)- (diisopropylamino)phosphine was easily accessible in two steps 
from phosphorus trichloride and was applied to the synthesis of inositol 
phosphates by Yu and Fraser-Reid t169] after initially having been developed for 
use in oligonucleotide chemistry and automated DNA synthesis I225].
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Diisopropylamino dichlorophosphine 156 was prepared by the method of Tanaka 
et al. P83l by adding two equivalents of diisopropylamine to a solution of PCI3 in 
dry ether at -78°C. The crude product was purified by distillation under reduced 
pressure (5P 166.4).
Reaction of 156 with two equivalents of benzyl alcohol in the presence of two 
equivalents of triethylamine then gave bis(benzyloxy)(diisopropylamino)- 
phosphine 157 (8P 145.24) which could be purified by flash chromatography.
C k  BnCk
PCI3    c|> - N ( P r ' ) 2    Bno ')2
156 157
Figure 8.7 Synthesis of bis(benzyloxy)(diisopropylamino)phosphine
8.4 The synthesis of myo-inositol 1,3,5-trisphosphorothioate
Myo-inositol orthoformate 150 was then also used as the starting material for the 
synthesis of lns(1 >3,5)PS3:
The remaining free hydroxyl groups of 150 were protected as p-methoxybenzyl 
ethers using p-methoxybenzyl chloride / sodium hydride in DMF. The orthoester 
was removed by treatment of the fully protected compound 154 with 80% 
trifluoroacetic acid yielding the desired 2>4>6-tri-Op-methoxybenzyl-/77yo-inositol. 
This compound was thiophosphorylated with bis(benzyloxy)(diisopropylamino)- 
phosphine 157 to give the fully protected trisphosphorothioate 158, which was 
then deprotected with sodium in liquid ammonia to give lns(1,3,5)PS3 159 as the 
triethylammonium salt after ion-exchange chromatography. 31P-NMR of this 
symmetrical trisphosphorothioate showed two signals at 47.74 and 46.55 ppm 
integrating for one and two P-nuclei, respectively (Figure 8.9). Both signals were 
doublets with J = 10.1 Hz. The corresponding 3JH_P coupling constants were also 
observed in the 1H-NMR spectrum for the signals at 4.08 ppm (1 H, ddd, J 10.3, 
9.2, 9.2, C-5-H), and 4.19 ppm (2 H, ddd, J 10.3, 10.3, 2.5, C-1-H, C-3-H). The
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13C-NMR spectrum of 159 showed 2J c .0 .p  coupling constants of 6.6 Hz for the 























Figure 8.8 Synthesis of myo-inositol 1,3,5-trjsphosphorothioate
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Figure 8.9 31P-NMR spectrum (1H-coupled) of 159 
8.5 Pharmacology
The potential 5-phosphatase inhibitors L-myo-inositol 1,4,5-trisphosphorothioate 
148 and myo-inositol 1,3,5-trisphosphorothioate 159 have now been 
pharmacologically evaluated. The results showed that both 148 and 159 are 
highly potent inhibitors of the metabolic enzyme lns(1,4,5)P3 5-phosphatase 
from human erythrocyte membranes, with submicromolar Kj values of 0.43 pM 
and 0.50 pM, respectively l348J.
As our objective was to prepare non-calcium mobilising 5-phosphatase 
inhibitors, the two trisphosphorothioates were also examined for their Ca2+ 
releasing abilites. Figure 8.10 shows the effect of 148 and 159 on the 
concentration of free calcium in platelets in comparison to lns(1,4,5)P3. It is 
surprising to see 159 causing any mobilisation of calcium in this system, since
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studies on calcium mobilisation in T-cells showed that lns(1,3,5)PS3 did not 
release any calcium in this system.
The Calcium releasing abilities of 














Figure 8.10 Calcium mobilisation of 148 and 159 in platelets
Both compounds were also assayed for their interactions with lns(1,4,5)P3 3- 
kinase. However, whereas L-lns(1,4,5)PS3 is recognised surprisingly well by the 
enzyme (apparent Kj = 1.46 pM), lns(1,3,5)PS3 shows hardly any interaction 
(apparent Kj 247 pM). Thus, whilst both L-lns(1,4,5)PS3 and lns(1,3,5)PS3 are 
potent 5-phosphatase inhibitors, lns(1,3,5)PS3 has the advantage of being 
selective for this enzyme.
The pharmacological data of 5-phosphatase inhibitors are summarised below:
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inhibitor /substrate 5-phosphatase 3-kinase lns(1,4,5)Pa-receptor
D-2,3-diphosphoglycerate 350 or 978 pM inhibitor no interaction
L-cMro-lns(1,4,6)Pa 44 pM no interaction no interaction
L-c/)/ro-lns(1,4,6)PSa 0.3 pM no interaction no interaction
lns(1,3,5)P«j 45 pM no interaction no interaction
lns(1,3,5)PSo 159 0.5 pM no interaction no interaction
DL-lns(1,4,5)PSa 1.7 pM inhibitor agonist
DL-lns(1,4,5)Pa-4,5S 1.4 pM substrate agonist
DL-lns(1,4,5)Pr 5S 6.8 pM substrate agonist
L-lns(1,4,5)PQ 39 or 124 pM 40.3 pM no interaction
L-lns(1,4,5)PS,148 0.43 pM 1.46 pM no interaction
D-lns(1,4,5)Pa, Km 19 pM substrate agonist
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9 The Synthesis of Scylio-Inositol Analogues
Modified analogues of lns(1>4,5)P3 are of great current interest as potential 
lns(1 >4,5)P3 receptor antagonists and enzyme inhibitors. We chose to pursue 
scy//o-inositol analogues in this regard, where the hydroxyl group at C-2 has a 
configuration inverse to that of the corresponding myo-inositol, i.e. the 2- 
hydroxyl group is in an equatorial rather than an axial position. 2-Modified 
lns(1,4,5)P3 analogues including 2-fluoro and 2-deoxy derivatives have already 
been shown to have interesting properties (see Chapter 4).
The most obvious target compound was scyllo-lns(1,2,4)P3, the scyllo-analogue 
of lns(1,4,5)P3. In addition to the preparation of scyllo-lns(1,2,4)P3> the synthesis 
of scy//o-lns(1,2,4,5)P4 and its tetrakisphosphorothioate analogue was devised, 
but for a different reason: both compounds are analogues mimicking the 
phosphate arrangement in lns(1,3,4,6)P4, which has been shown to act as a 
partial agonist at the lns(1,4,5)P3 receptor. We were therefore interested in 
these scy//o-inositol analogues to find out more about structural requirements for 
compounds acting as partial agonists.
9.1 Synthesis of 1-0-Allyl-3,6-di-0-benzyl-scy//o-inositol
Thus, 1-0-allyl-3,6-di-Obenzyl-4,5-0-isopropylidene-/77yo-inositol 93, an inter­
mediate with a free 2-hydroxyl group used to synthesise 1-0-allyl-2,3,6-tri-0- 
benzyl-myo-inositol, was employed to generate scyllo-inositol compounds.
The axial 2-hydroxyl group was substituted in two steps: first, by action of 
trifluorosulphonic anhydride in pyridine to afford the triflate 160. This compound 
was only partially purified and characterised because of its instability (triflates 
have been reported to decompose on silica gel columns). Secondly, the triflate 
moiety was then displaced by substitution with caesium acetate in DMF in a 
reaction which proceeded with inversion of configuration at the 2-position of the 
inositol ring to give the scyllo-inositol derivative 161. 1H-NMR (Figure 9.1) 
showed that the signal for the C-2 proton at 5.15 ppm (easily assigned to C-2-H 
by its downfield shift from all the other ring proton signals due to acetate- 
substitution on C-2) is a dd with J1 = J2 = 8.8. The coupling constants arise from 
axial-axial coupling to C-1-H and C-3-H, which made the assignment of the
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compound as being of the scyllo-configuration safe. The C-2-Heq - C-^{3)-Hax 
arrangement found in myo-inositol derivatives usually results in J values in the 
order of 2 - 5 Hz according to the Karplus equation.
T~ ------
Figure 9.1 1H-NMR spectrum of 161 (expansion 3.4 ppm to 5.3 ppm)
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Removal of acetate and isopropylidene protecting groups by saponification 
followed by acid hydrolysis gave 1-0-allyl-3,6-tri-0-benzyl-scy//o-inositol 164 
either v/a162 or 163.
The synthesis of 1-0-allyl-3,6-di-0-benzyl-4,5-0-isopropylidene-scy//o-inositol 
162 had previously been reported by Gigg et al. I168!, who obtained this 
compound as a by-product (30 % yield) in the reduction of the 2-inosose 
derivative with sodium borohydride (the major product in this reaction was 1-0- 
allyl-3,6-di-0-benzyl-4,5-0-isopropylidene-/77yo-inositol 93). The compound was 
presumed to be the scyllo-inositol derivative and melting point (105-106°C) and 
microanalysis data were reported. This derivative was, however, not further 
investigated by the authors.
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Figure 9.2 Synthesis of DL-scy//o-inositol 1,2,4-trisphosphate 166
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Phosphitylation of 164 with bis(benzyloxy)(diisopropylamino)phosphine / 1H- 
tetrazole followed by oxidation with Bi^OOH furnished 165. The 1H-coupled 31P- 
NMR spectrum for this fully protected trisphosphate showed a quartet integrating 
for 2 P at -1.72 (J = 7.9 Hz) and a second quartet with the same coupling 
constant which integrated for 1 P at -1.47. The corresponding signals in the 1H- 
NMR could not be observed due to overlapping signals from the CH2Ph and 
CH2CH=CH2 protons.
Figure 9.3 1H-coupled 31P-NMR spectrum of 165
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Treatment with sodium-liquid ammonia deblocked both the benzyl and allyl t143l 
protecting groups in one step. Ion-exchange chromatography on Q Sepharose 
Fast Flow gave pure 166.
9.3 Scyllo- lns(1,2,4,5)P4 and Scyllo-lns(1,2,4,5)PS4
We were interested in scyllo-inositol 1,2,4,5-tetrakisphosphate and its 
phosphorothioate analogue for two different reasons:
As mentioned in Chapter 4.2, lns(1,3,4,6)P4 has been found to be a good partial 
agonist at the lns(1,4,5)P3 receptor P4^4?]. We wanted to establish the individual 
contributions made by the 1,3,4,6-phosphate arrangement of this compound 
[which is also present in scyllo-lns(1,2,4,5)P4] and the axial hydroxyl group 
(which is missing in the scy//o-inositol analogues) towards this partial agonist 
behaviour.
The second motive to prepare these scyllo-inositol derivatives was the fact that 
myo-inositol 1,2,4,5-tetrakisphosphate has been found to be a very potent 
inhibitor of 5-phosphatase with a Kj of 2.9 pM P3°J. We reasoned that the 
symmetrical scyllo-inositol analogue of this compound may show inhibitory 
properties similar to lns(1,2,4,5)P4 and that enzyme binding may be increased 
by replacing the phosphate groups with phosphorothioate moieties (see Chapter 
8).
The synthesis of scy//o-lns(1,2,4,5)P4 170 and scyllo-lns(1,2,4,5)PS4 172 was 
relatively straightforward (Figure 9.4). 1-OAIIyl-3,6-di-0-benzyl-scy//o-inositol 
164 was isomerised to the c/s-prop-1-enyl derivative 167 using BulOK / DMSO. 
The propenyl group of this intermediate was then removed by acidic hydrolysis 
to give the mesocompound 1,4-di-0-benzyl-scy//o-inositol 168. Phosphitylation 
with bis(benzyloxy)(diisopropylamino)phosphine followed by oxidation or 
sulphoxidation gave the fully protected tetrakisphosphate and phosphorothioate, 
respectively. Both compounds showed a single peak in the 31P-NMR spectrum 
(at -3.74 and 67.77 ppm, respectively), which was to be expected for these 
highly symmetrical derivatives. Deprotection with sodium in liquid ammonia 
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Figure 9.4 Synthesis of scyllo-inositol 1,2,4,5-tetrakisphosphate 170 and 
scyllo- inositol 1,2,4,5-tetrakisphosphorothioate 172
9.5 Pharmacology 
DL-Scy//o-lnositol 1,2,4-trisphosphate
The ability of DL-scy//o-inositol 1,2,4-trisphosphate to mobilise sequestered 
calcium has now been studied in various tissues. Results for SH-SY5Y cells 
showed that this analogue is a full agonist almost equipotent to lns(1,4,5)P3 with 
EC50 = 130 nM.
The dose response curves obtained using T-cells (Figure 9.5) and rabbit 
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Figure 9.5 Calcium mobilisation of DL-scy//o-inositol 1,2,4-trisphosphate 
(□) and DL-2-deoxy-2-fluoro-myoinositol 1,4,5-trisphosphate 
(o) in T-cells
The fact that scyllo-inositol 1,2,4-trisphosphate is of a potency sim ilar to 
lns(1,4,5)P3 is not surprising since other 2-modified lns(1,4,5)P3 analogues have 
also been found to be good agonists (see Chapter 4.1). The loss of activity 
observed when substituting the axial 2-hydroxyl group with an equatorial 
hydroxyl group is comparable to the effect caused by the deletion of this group 
[in 2-deoxy-lns(1,4,5)P3]. In each case, the modified compound in racemic form 
is ca. 2.5 times less active than D-lns(1,4,5)P3. Assuming that the L-isomers are 
not biologically active, the differences in activity between 2-modified analogues 
and lns(1,4,5)P3 are indeed minute, indicating that the 2-hydroxyl group does 
not contribute significantly towards receptor binding.
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Figure 9.6 Ca2+ mobilisation of scy//o-lns(1,2,4)P3 in platelets
The interactions of DL-scy//o-inositol 1,2,4-trisphosphate 166 with lns(1,4,5)P3 3- 
kinase and 5-phosphatase have also been examined. 166 was found to be a 
good substrate for 3-kinase (Kj 4.0 pM) and a moderately potent inhibitor of 5- 
phosphatase (Kj 24.2 pM).
Scyllo- Inositol 1,2,4,5-tetrakisphosphate
Scy//o-lns(1,2,4,5)P4 was a very potent full agonist (EC50 = 82.56 nM) at the 
lns(1,4,5)P3 receptor [cf. Ins(1,4,5)P3: EC50 = 52 nM], and binding data for this 
compound (obtained by displacing [3H]-lns(1,4,5)P3 from specific sites on bovine 
adrenal cortex membranes) are equally good (IC50 = 14.37 nM, Kj = 10.82 nM).
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compound (obtained by displacing [3H]-lns(1,4,5)P3 from specific sites on bovine 
adrenal cortex membranes) are equally good (IC50 = 14.37 nM, Kj = 10.82 nM). 
The fact that unlike lns(1,3,4>6)P4> scy//o-lns(1,2,4,5)P4 does not show any 
partional agonist properties, is clearly due to the only difference between these 
two molecules, i.e. the stereochemistry of the 2-hydroxyl group of lns(1,3,4,6)P4, 
which is equatorial rather than axial in scyllo-lns(1,2,4,5)P4. Keeping in mind the 
alternative binding conformations that have been suggested for lns(1,3,4,6)P4 
(Chapter 4.2), it is evident that the axial pseudo-3(6)-hydroxyl group 
arrangement does indeed contribute significantly to the partial agonist properties 
of this compound [but see below for lns(1,3,4,6)PS4].
Scyllo- Inositol 1,2,4,5-tetrakisphosphorothioate
Scy//o-lns(1,2,4,5)PS4 was found to be a partial agonist at the lns(1,4,5)P3 
receptor in saponin-permeabilised SH-SY5Y cells with EC50 = 1.6 (iM. This 
compound is able to mobilise some 80 % of lns(1,4,5)P3 sensitive calcium.
It is very surprising that scyllo-lns(1,2,4,5)PS4 is a partial agonist, since the 
parent compound scy//o-lns(1,2,4,5)P4 does not share these pharmacological 
characteristics. From what is known to date, one can only speculate as to why 
scyllo-lns(1,2,4,5)PS4 displays partial agonist properties. Comparison with the, 
now established, partial agonists L-c/7/ro-lns(2,3,5)PS3 and 6-deoxy- 
lns(1,4,5)PS3 (which mobilise 34 % and 42 % of lns(1,4,5)P3 sensitive calcium, 
respectively) P84] shows that all compounds are'phosphorothioate analogues of 
phosphate derivatives who are relatively potent full agonists. It therefore 
appears that substitution of phosphate groups with phosphorothioate moieties is 
a major element in creating compounds with partial agonist characteristics. 
However, since lns(1,4,5)PS3 is a full agonist, it can also be concluded that by 
replacing the 1-, 4-, and 5-phosphate groups with phosphorothioates alone, one 
does not obtain a partial agonist. Of considerable importance is also the 
observation that lns(1,3,4,5)PS4 is not a partial agonist.
Binding and Ca2+ release data for scy//o-lns(1,2,4,5)P4 and scyllo- 
lns(1,2,4,5)PS4 are summarised below:
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scyllo-1 ns(112,4I5)P4 scyllo-1 ns(1,2,4,5)PS4
Binding IC50 14.37 ±2.41 nM 430.58 ±46 .44  nM
Ki 10.82 ±2 .00  nM 312.77 ±34 .60  nM
slope 0.852 ±0 .037 1.007 ±0 .078
Ca2+ release e c 50 82.56 ± 18.79 nM 1.606 ±0 .056  pM
slope 1.068 ±0.021 0.7019 ±0 .048
The results of calcium release studies performed on saponin-permeabilised 
rabbit platelets and T-cells are shown in Figure 9.7 and Figure 9.8.
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Figure 9.8 Calcium mobilisation of lns(1,4,5)P3 (o), scyllo-lns(1,2,4,5)P4 (•) 
and scyllo-lns(1,2,4,5)PS4 (+) in T-cells
The interactions of these lns(1,4,5)P3 analogues with 5-phosphatase and 3- 
kinase are currently being investigated.
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10 DL-2-Deoxy-2-fluoro-/nyo-inositol 1,4,5-trisphosphate
10.1 The Synthesis of DL-2-Deoxy-2-fluoro-lns(1,4,5)P3
A number of fluorinated analogues of lns(tJ4,5)P3 have been prepared, 
including the 2-fluoro analogues 2-deoxy-2-fluoro-scy//olns(1,4,5)P3 103 and 2- 
deoxy-2,2-difluoro-lns(1,4,5)P3 104 (see Chapter 3.3).
The synthesis of 2-deoxy-2-fluoro-lns(1,4,5)P3 [2-F-lns(1,4,5)P3]> the 2-fluoro 
analogue most similar to lns(1,4,5)P3> has however not been reported as yet. 
With regard to the interesting properties that both 103 and 104 displayed, we 
reasoned that an analogue resembling lns(1,4,5)P3 even closer like 2-F- 
lns(1,4,5)P3 may show improved characteristics as compared to the former 
analogues.
2-F-scy//o-1ns(1,4,5)P3 2,2-F2-lns(1,4,5)P3 2-F-/nyo-lns(1,4,5)P3
Figure 10.1 Analogues of lns(1,4,5)P3 fluorinated at the 2-position
1-0-Allyl-3,6-di-0-benzyl-4,5-0-isopropylidene-scy//oinositol, an intermediate in 
the synthesis of scyllo-inositol analogues of lns(1,4,5)P3 (see above), was 
chosen as the starting material to synthesise 2-F-lns(1,4,5)P3. An earlier attempt 
to synthesise 2-F-lns(1,4,5)P3 from the same precursor by fluorination with 
DAST failed P06! because the reaction unexpectedly proceeded with retention of 
configuration, yielding the same 2-deoxy-2-fluoro-scy//oinositol derivative which 
was obtained by DAST fluorination of the corresponding myoinositol derivative. 
This may be an indication for steric effects or neighbouring group participation in 
the reaction mechanism, as DAST fluorinations usually give an inverted product 
and, in the special case of the reaction of 1,2,3,4,5-penta-0-benzyl-scy//o 
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Figure 10.2 Retention of configuration in the DAST fluorination of 162
DL-1-0-Allyl-3,6-di-0-benzyl-4,5-isopropylidene-scy//o-inositol 162 was isomeri- 
sed to the 1-Oc/s-prop-1-enyl derivative 173 with BulOK / DMSO and converted 
into the triflate 174 by treatment with trifluoromethanesulfonic anhydride in 
pyridine. Substitution of the sulphonate at the 2-position with dry 
tetrabutylammonium fluoride gave 3,6-di-0-benzyl-2-deoxy-2-fluoro-4,5- 
isopropylidene-1-0-(c/s-prop-1-enyl)-n?yo-inositol 175.
Observation of 2JHF = 50.0 Hz and 3JHF = 29.5 Hz in the 1H-NMR (Figure 10.3) 
and the 19F-NMR (Figure 10.4) spectra of this compound confirmed the 
presence of an axial 2-fluorine atom. The 2JHF and 3JHF coupling constants 
measured are in good agreement with those reported for 2-deoxy-2-fluoro-myo- 
inositol I312!, where 2JHF and 3JHF were found to be 52.1 Hz and 28.8 Hz, 
respectively. Inositol derivatives bearing equatorial fluorine atoms (e.g. 1-deoxy-
1-fluoro-scy//o-inositol P07,311]) show similar coupling constants for 2JHF (50.4 
Hz), but 3Jhf is much smaller (12.6 Hz) than the J value found in compounds 
with an axial fluorine.
Additional proof for the myo-inositol conformation of the product obtained are the 
3J constants (2.4 Hz) found in the coupling between C-2-H and C-1(3)-H, which 
indicate an equatorial-axial arrangement of the respective protons.
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Figure 10.3 1H-NMR spectrum of 175 (expansion 1.4 - 5.1 ppm)
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k -  100 Hz - 4
Figure 10.4 19F-NMR spectrum of 175 (signal at -210.21 ppm)
Removal of the acid labile propenyl and isopropylidene protecting groups gave 
176, which was phosphitylated with bis(benzyloxy)(diisopropylamino) phosphine 
and oxidised to furnish 177. Deprotection with sodium / liquid ammonia furnished
2-deoxy-2-fluoro-myo-inositol 1,4,5-trisphosphate 178. Marecek and Prestwich 
[306] had reported that 2-fluoro-scy//o-lns(1,4,5)P3 underwent slow defluorination 
(ty2 « 2 weeks) at pH 13 and 50°C, whereas the difluoro analogue was stable 



























Figure 10.5 Synthesis of DL-2-deoxy-2-fluoro-lns(1,4,5)P3 178
The 31P-NMR spectrum of 178 (Figure 10.6) showed three doublets integrating 
for 1 phosphorus each at 1.96, 1.56, and 0.37 ppm with J = 10.1, 6.7, and 10.1 
Hz, respectively, and the 19F-spectrum of this compound showed a dt at -211.8 
ppm with J 2 -h ,f  51 -3 H z  a n d  J 1(3)-H, f  29 7  Hz- The signals in the 1H-NMR 
spectrum could be assigned easily by their chemical shifts and 1H-1H-, 1H-31P-, 
and 1H-19F-coupling constants.
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Figure 10.6 1H-coupled 31P-NMR spectrum of 178
10.2 Pharmacology
The new fluorinated lns(1,4,5)P3 analogue 178 is now being evaluated, and 
prelim inary results have shown it to be equipotent to lns(1,4,5)P3 in mobilising 
sequestered calcium assuming that only the D-isomer of 178 displays biological 
activity [EC50 of 178 = 0.10 pM, EC50 of D-lns(1,4,5)P3 = 0.05 pM]. Comparison 
of the calcium mobilising properties of 178 with those of 2F-scy//o-lns(1,4,5)P3 
103 (EC50 = 0.77 pM) and 2,2-F2-lns(1,4,5)P3 104 (EC50 = 0.41 pM) show that
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the closer structural similarity of 178 to lns(1f4,5)P3 is reflected in its biological 
activity. The assumption [305,331] (see Chapter 4.1, Figure 4.2) that the 2-hydroxyl 
group of lns(1,4,5)P3 interacts with the receptor by accepting rather than 
donating a hydrogen bond thus appears to be confirmed: the 2-fluorine of 178 is 
still able to accept hydrogen bonds, but can no longer donate them, and the 
compound is nevertheless as potent as lns(1,4,5)P3.
178 is also a good substrate for 3-kinase, acting as a potent competitive inhibitor 
of the phosphorylation of [3H]-lns(1,4,5)P3 by this enzyme (apparent Kj = 3.0 pM; 
for comparison: 2-F-scy//o-lns(1,4,5)P3 103 and 2,2-F2-lns(1,4,5)P3 104 have Kj 
values of 8.8 pM and 11.0 pM, respectively).
Interactions of racemic 2-F-myo-lns(1,4 ,5 )P 3 with 5-phosphatase have also been 
studied, and the fluorinated derivative was found to be a moderately potent 
competitive inhibitor of this enzyme (Kj 14 .4  pM ). It may tentatively be assumed 
that by analogy with the difluoro-analogue 104 the inhibitory effect of DL-178 is 
due to the presence of L-2-F-lns(1,4 ,5 )P 3 in the racemic mixture, whereas the D- 
isomer is probably a substrate for this enzyme like D-104. It will however, be 
necessary to resolve the enantiomers of this novel fluorinated analogue to 
determine the contributions made by the individual enantiomers towards the 
overall data obtained for the racemic compound.
The pharmacological results obtained for the different fluorinated lns(1,4,5)P3 
analogues are summarised and compared to D-lns(1,4,5)P3 (= D-6) below:
DL-103 DL-104 L-104 D-104 DL-178 D-6
0.77 0.41 53 0.21 0.10 0.05
5-phosphatase, Kt 0-7 (S) 26.0 (I) 19(1) 60 (S) 14.4 (I) 16-40
3-kinase, Kj 8.8 (S) 11.0 (S) 11.9 (I) 10.2 (S) 3.0 (S) 0.85-3.2
S = substrate, I = inhibitor, all values in pM.
Figure 10.7 Pharmacological activity of fluorinated lns(1,4,5)P3 analogues
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11 A synthetic route to optically active myo-inositol 1,4,5-trisphosphate
3-phosphorothioate: resolution of DL^S-di-O-acetyl-S-O-allyl-e-O 
benzyM-O-p-methoxybenzyl-myo-inositol
The fully protected inositol derivative DL-S-O-allyl^.e-di-ObenzyM.S-di-O  
isopropylidene-1-Op-methoxybenzyl-/77yo-inositol would allow the selective 
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Figure 11.1 Route to lns(1,4,5)P3-3S from 3-0-allyl-2,6-di-0-benzyl-4,5-di- 
O-isopropylidene-l-O-p-methoxybenzyl-myo-inositol
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Therefore this versatile compound represents a key intermediate in the 
synthesis of 1- and 3-modified analogues of the second messenger lns(1,4,5)P3 
and of lns(1,3,4,5)P4> which is supposed to play an important role in calcium 
homeostasis I89l.
Since the biochemical properties of enantiomers of the same derivative can be 
very different, it was thought essential to attempt the synthesis of this 
intermediate in optically pure form to gain access to the individual D- and L- 
lns(1,4,5)P3 and lns(1,3,4,5)P4 analogues, including the derivative we were most 
interested in, i.e. the 3-phosphorothioate analogue of D-lns(1,3,4,5)P4 (Figure
11.1), which would be resistant to hydrolysis by lns(1,3,4,5)P4 3-phosphatase. 
For this purpose, the camphanate method (see Chapter 2.2), which had already 
proved to be effective in the optical resolution of 1-0-allyl-2,3,6-tri-0-benzyl- 
myo-inositol (Chapter 7.1), was chosen. Thus the precursor to the key 
intermediate DL-3-0-allyl-2,6-di-0-benzyl-4,5-di-0-isopropylidene-1-0-p-
methoxybenzyl-myo-inositol, DL-3-Oallyl-2-0-benzyl-4,5-di-0-isopropylidene-1-
O-p-methoxybenzyl-myo-inositol 184 was synthesised by a 5-step route from 
DL-1:2,4:5-di-Oisopropylidene-/77yo-inositol 122 I149] (Figure 11.2). Optical 
resolution was then attempted by forming the 2-0-(-)-(co)-camphanate ester of 
184.
Treatment of 1,2:4,5-di-0-isopropylidene-/77yo-inositol 122 with 1 equivalent of 
allyl bromide and excess sodium hydride in DMF according to the procedure of 
Gigg et at. I165l gives the 3-allyl ether 179 in only 30 % yield. When a strong 
base like sodium hydride is used, the small differences in reactivity between the 
free 3- and 6-hydroxyl groups cannot be exploited to achieve selective alkylation 
at the more reactive 3-position. Therefore this procedure gives a product mixture 
of the two monoallylated inositols in a ratio of 1:1 and a minor amount of the 
bisallylated inositol.
If however 1,2:4,5-di-Oisopropylidene-/77yo-inositol is treated with allyl bromide 
under mild conditions using barium oxide /  barium hydroxide I385J rather than 
sodium hydride as base, selective alkylation of the 3-position is possible. The 
desired DL-3-0-allyl-1,2:4,5-di-0-isopropylidene-/77yo-inositol 179 was obtained 
in 63 % yield and only minor amounts of DL-3,6-di-0-allyl-1,2:4,5-di-0
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isopropylidene-myo-inositol 180 and DL-6-0-allyl-1,2:4,5-di-0-isopropylidene- 
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Figure 11.2 Optical resolution of DL-4,5-di-0-acetyl-3-0-allyl-6-0-benzyl-
1 -O-p-methoxybenzyl-myo-inositol
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Benzylation of the free 6-position of 179 was effected with benzyl chloride, KOH 
and 18-crown-6 as phase transfer catalyst. DL-3-0-Allyl-6-0-benzyl-1,2:4,5-di- 
Oisopropylidene-myo-inositol 181 thus obtained was then converted into DL-1-
0-allyl-4-O-benzy I-myo-inositol 182 by acidic removal of the isopropylidene 
protecting groups.
Selective p-methoxybenzylation of 182 was achieved by first forming a 
stannylene complex with dibutyltin oxide, which was then Oalkylated with p- 
methoxybenzyl chloride with the assistance of caesium fluoride. Although 
several less polar by-products were also formed in this reaction as shown by tic 
analysis, the major product DL-3-0-allyl-6-0-benzyl-1-Op-methoxybenzyl-myo 
inositol 183 was isolated in 81 % yield. The 4- and 5-positions of triol 183 were 
then simultaneously protected with an isopropylidene group by reaction with 2- 
methoxypropene and PTSA in DMF to give DL-3-0-allyl-6-0-benzyl-1-0-p- 
methoxybenzyl-4,5-di-Oisopropylidene-myoinositol 184.
Resolution of 184 was attempted by conversion into the diastereomeric S-(-)- 
camphanate esters using S-(-)-camphanic chloride /  pyridine.
Tic and high performance tic (hptlc) analysis of the mixture of the D- and L- 
isomers of 3-0-allyl-6-0-benzyl-2-0-[(-)-(co)-campanoyl]-1 -O-p-methoxybenzyl-
4,5-di-0-isopropylidene-/77yo-inositol 185 showed only one single product spot 
for the two diastereoisomers, suggesting that chromatographic separation of the 
mixture would not be feasible. Efforts to crystallise selectively one
diastereoisomer from polar (methanol) and non-polar (ether / petrol ether)
solvents were unsuccessful. In each case a 1:1 mixture of the two
diastereoisomers (as determined by the 1H-NMR signals of the camphanate 
methyl groups) was obtained.
Since the separation of D- and L-3-0-allyl-6-0-benzyl-2-0[(-)-(co)-camphanoyl]-
1-0-p-methoxybenzyl-4,5-0-isopropylidene-myoinositol 185 was found to be 
impossible by conventional methods, it was decided to remove the
isopropylidene group by mild acidic hydrolysis to give the 4,5-diol 186. 
Resolution of this more polar derivative was then to be attempted.
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Separation of the diastereomers of 186 by flash chromatography on silica gel 
and by crystallisation proved to be impossible. However, as hptlc revealed two 
product spots for this compound, we reasoned that acetylation of 186 to give the
4,5-di-O-acetate 187 might afford a compound easier to crystallise than the diol. 
187 was indeed highly crystalline and the two isomers showed up as two 
discrete spots on hptlc (chloroform : methanol 60:1, Rf 0.58 and 0.63). It was 
possible to obtain the less polar diastereoisomer in optically pure form by 
recrystallisation from ether. This compound had a melting point of 142-143°C 
and [a]D27 was found to be +19.0° (c = 4 in CHCI3). The 1H-NMR spectrum 
showed no detectable contamination of (+)-187 with the other isomer (Figure 
11.3).
In order to establish the absolute configuration of this compound, attempts were 
made to obtain single crystals for X-ray analysis. Recrystallisation from several 
different solvents (ether, methanol, ethanol) however, gave long thin needles of 
(+)-187 unsuitable for X-ray analysis in each case. Since the removal of the 
base labile protecting groups was necessary in order to prepare the optically 
active, fully protected key intermediate 3-0-allyl-2,6-di-0-benzyl-4,5-di-0- 
isopropylidene-1-Op-methoxybenzyl-myo-inositol, both the camphanate and the 
acetate esters were cleaved by alkaline hydrolysis to give 188. This compound, 
with a sharp melting point of 157.5-158°C and [a]D20 = +19.0°C, was obtained 
from ethyl acetate in beautiful crystals. Lack of time, however, precluded the 




Figure 11.3 1H-NMR spectrum of (+)-187
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12 Novel ring-fused inositol- lactones and O-methylene carboxylates
A synthesis of the racemic triscarboxymethyl analogue of lns(1,4,5)P3 has been 
reported by Westerduin et al. I289l. This isosteric compound did, however, not 
shown any affinity for the lns(1,4,5)P3 receptor, nor did it induce platelet 
aggregation. Carboxymethyl substitution for phosphates is, however, in principle 
a useful substitution and we reasoned that a better chance for novel activity 
might come from mixed phosphate /  carboxymethyl analogues.
We anticipated that an lns(1,4,5)P3 analogue with only a single carboxymethyl 
group in the 1-position and the 4,5-bisphosphate pair unchanged would be 
sufficiently close to lns(1,4,5)P3 to show biological activity. Comparison of the 
pharmacological properties of the 1-O-methylenecarboxylate analogue with 
those of lns(1,4,5)P3 and lns(4,5)P2 would then allow us to determine the effect 
of the modification, and give an indication of whether the same substitution 













Figure 12.1 Introduction of fluorescent reporter groups into the 1-position 
of lns(1}4y5)P3 analogues via amide links
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Such an analogue would also allow the introduction of reporter groups into the 
molecule by linking them selectively to the 1 -carboxylate (e.g. fluorescent labels 
containing amino groups could be attached to the inositol ring via a stable amide 
link, Figure 12.1). This might be an alternative to our alkylphosphorothioate 
route to biologically active probes (see Chapter 6.4).
We also wanted to explore the possibility of using the formation of a lactone 
between the 1-O-methylenecarboxylate and 2-hydroxyl group as a means to 
temporarily protect the 2-position and to introduce a degree of rigidity into the 
structure of phosphorylated analogues. Lactone polyphosphates would be a new 
class of lns(1,4,5)P3 analogues.
The 1,2-O-methylene lactone 191 of DL-3,6-di-0-benzyl-A77yo-inositol 124 was 
prepared by two different methods (Figure 12.2). Direct synthesis albeit in low 
yield (16 %) was possible by treatment of 1,2-0-dibutylstannylene-3,6-di-O 
benzyl-myo-inositol with ethyl bromoacetate in DMF.
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Figure 12.2
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The second route involved three steps, however, the overall yield was higher 
than that obtained by the direct method. Thus, DL-1-0-cyanomethylene-3,6-di- 
O-benzyl-myo-inositol 189 was prepared by tin-mediated alkylation of 1,4-di-O- 
benzyl-myo-inositol with bromoacetonitrile in 58 % yield. 13C-NMR showed 
signals at 56.24 ppm (t) for CH2CN and at 116.21 ppm (s) for CN, and in the 1H- 
NMR spectrum the AB-system at 3.83 and 3.89 ppm was assigned to the CH2CN 
group. The v(CH2-CA/) IR band (which may be found between 2260 and 2240 
cm-1 and is usually weak or even absent in unconjugated nitriles) was not 
observed in the IR spectrum of this compound.
Treatment of 189 with sodium hydroxide in ethanol followed by acidification 
resulted in conversion into DL-3,6-di-0-benzyl-1-Ocarboxymethylene-myo- 
inositol 190 (81 %), which showed a strong carbonyl signal in the IR-spectrum at 
1720 cm-1. 1H-NMR (broad COOH signal at 12.6 ppm) and 13C-NMR (COOH 
singlet at 172.2 ppm) confirmed the presence of a carboxylate moiety.
DL-1-O-carboxymethylene-3,6-di-O-benzyl-/?7y0-inositol: a jumping crystal
The 1-O-carboxymethylene derivative was found to display an interesting 
"thermosalient" behaviour, i.e. on heating, the crystals jumped over a range of 
90-120°C before melting at 185-187°C. After the crystals had been warmed to 
140°C the same phenomenon could be observed on cooling: the crystals jumped 
between 60-40°C. Similar properties have been reported by Gigg et al. for a 
different compound, DL-3,4-di-Oacetyl-1,2,5,6-tetra-O-benzyl-myo-inositol l155l. 
It was suggested after preliminary studies in polarised light that the crystals "may 
be in a form of a bundle or parallel fibres or leaves ... with crystallographically 
non-identical faces in contact... and that a composite crystal of this sort may act 
in the same way as a bimetallic strip at different temperatures".
The properties of DL-3,4-di-0-acetyl-1,2,5,6-tetra-Obenzyl-myo-inositol have 
been further investigated by calorimetric methods I380], where it was found that 
this compound underwent even two reversible solid / solid phase transitions, and 
by solid state magic angle spinning NMR studies I387!, which led to the 
conclusion that there are no large differences in the structure or dynamic 
properties of the three solid phases of the diacetate, and that the thermosalient
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behaviour may be the consequence of the cooperative effect of a number of 
subtle intermolecular interactions.
Lactonisation of the carboxymethylene derivative with a catalytic amount of acid 
and removal of water of condensation to shift the reaction equilibrium to the 
product side gave 191 identical to 191 prepared by the direct route in 92 % yield 
(43 % overall yield). The 1H-NMR spectrum of 191 showed unusually small H^- 
Hgx J values (5.9 and 6.0 Hz) for the coupling between C-1-H and C-6-H and a 
relatively large H ^ -H ^  coupling between C-1-H and C-2-H (3.3 Hz) (coupling 
constants of other inositol ring protons could not be measured because the 
signals were part of multiplets). This observation may be explained by the 
presence of the 1,2-lactone ring causing the inositol ring to adopt a slightly 
twisted position.
The lactone 191 was converted into the 4,5-diacetate 192 for characterisation. 
The 1H-NMR signals for C-5-H and C-4-H were found at 5.09 and 5.39 ppm, as 
expected shifted considerably downfield in comparison to the signals for these 
protons in the spectrum of the 4,5-diol.
In order to investigate whether the 'jumping crystal' behaviour of DL-1-0- 
carboxymethylene-3,6-di-0-benzyl-myo-inositol 190 was a property shared by 
the different enantiomers of this compound, the optical resolution of this 
compound was attempted. 191 was converted into the 4,5-bis-(-)-co-camphanate 
193, and one diastereoisomer crystallised readily from methanol. Removal of the 
camphanate moieties by base hydrolysis followed by acidification gave the 
optically resolved 1-O-carboxymethylene derivative 194. This compound had a 
surprisingly high melting point (308-310°C) and showed a phase transition 
between 240 and 255°C, but in contrast to the racemic 190 no 'thermosalient' 
properties could be observed for 194.
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13 Novel C-allyl inositols by Claisen rearrangement of inositol O-allyl 
ethers
Inositols linked via C-C bonds to other groups are not common (with the 
exception of methylenephosphonates) and are worth of investigation as 
analogues in the context of inositol phosphate synthesis. We devised a new 
approach to these derivatives as follows:
We anticipated that elimination rather than substitution reactions on 1-O-allyl-
3 ,6-di-0 -benzyl-4 ,5-0 -isopropylidene-2-0 -trifluoromethylsulphoxy-/77yo-inositol 
160 followed by Claisen-rearrangement of the resulting enol ether would give 
access to novel inositol analogues with a C-allyl group. By oxidation with 
ruthenium trichloride - sodium periodate such compounds could then be 
converted into C-methylenecarboxylates. Sterically, the -CH2-COOH moiety 
might be a better phosphate surrogate than the -0-CH2-C 00 H  group obtained 
by oxidative cleavage of allyl ethers. Like compounds with an -0-CH2-C 00H  
group (see Chapter 12), C-methylenecarboxylates could be employed in the 
preparation of analogues carrying reporter groups linked to the 1-position of the 
inositol ring via a stable amide bond. Replacement of the 4- and / or 5- 
phosphate with a C-methylenecarboxylate may lead to derivatives with potential 
antagonistic properties.
Elimination products have been obtained in SN2 displacement reactions on 
chiro-\nos\Xo\ triflates, with potassium benzoate and 18-crown-6 catalyst in DMF 
at 80°C giving 85 % elimination product versus 18 % (sic !) substitution product 
I231]. We therefore attempted to eliminate the triflate group of 160 by using the 
same reaction conditions. The sole product isolated was however, 1-0-a lly l-2-0  
benzoyl-3,6-di-0-benzyl-4,5-0-isopropylidene-scy//o-inositol 195 (yield 67 %, 
Figure 13.2), the substitution product. That this compound is indeed in the 
scy//o-configuration and that the displacement of the triflate moiety therefore 
proceeded with inversion at C-2 is obvious from the 1H-NMR spectrum (Figure
13.1): the signal for C-2-H at 5.43 ppm (the downfield shift as compared to the 
signals for the other ring protons at 3.57-3.81 ppm is caused by the benzoate 
ester group at C-2) is a dd with J1 = J2 = 8.9 Hz. Coupling constants this large 
are only found for ring protons in an axial-axial arrangement.
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Figure 13.2
195 was then converted into the diol 196 by acid hydrolysis of the 4,5-0- 
isopropylidene group. Removal of the allyl protecting group by isomerisation with 
Wilkinson's catalyst and in situ hydrolysis of the prop-1-enyl ether gave 197, a 
precursor for the synthesis of scyllo-inositol analogues of lns(1,4,5)P3.
It was then attempted to effect elimination by treating the triflate with sodium 
carbonate in DMSO at 120°C. This however lead to the decomposition of 160. 
No reaction products could be isolated from the black tar obtained.
Elimination of the triflate group from 160 was finally successfully performed by 
employing the non-nucleophilic hindered base 1,8-diazabicyclo[5.4.0]undec-7- 
ene (DBU) P88l. After stirring the reaction mixture for 24 h at r.t., tic (petrol ether 
b.p. 60-80°C / ether 2 :1) showed that the starting material (Rf 0.35) had 
disappeared and two major products (198, Rf 0.54 and 199, Rf 0.46) had been 
formed in a ratio of ca. 1:1. These compounds were isolated and characterised:
According to their mass spectra, both 198 and 199 had a molecular mass of M = 
422. Both compounds showed the presence of two benzyl groups, an allyl group 
and the isopropylidene group in their 1H-NMR spectra (see Figure 13.4 and 
13.5). It was also evident from the 1H-NMR that there were only 5 protons
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attached to the inositol ring in each compound, which was confirmed by the 13C- 
NMR spectra which showed only 5 doublets in the region between 70 and 100 
ppm corresponding to the 5 C-H ring carbons. The signals for the remaining ring 
carbon were found to be singlets at 154.55 and 153.84 ppm, respectively.
It was thus safe to conclude that 198 and 199 corresponded to the two possible 
elimination products with a double bond between C-1 and C-2 or C-2 and C-3. 
The assignment of structures to the two products obtained proved to be 
impossible by reference to their spectroscopic data alone. The structures of 198 
and 199 could, however, be assigned by chemical transformation: only 198 
rearranged on heating for 15 min at 200°C to give a mixture of 200 and 201. In 
contrast, 199 decomposed under the same conditions. It may thus be tentatively 
assumed that the correct structure for 198 is the one drawn out in Figure 13.6, 
since 199 cannot undergo Claisen rearrangements.
Another way of structural assignment would be acid treatment of each product. 
In each case the enol ether should decompose to give an inosose with loss of 
either a benzyl or an allyl group, thus allowing the direction of ongoing 
elimination to be deducted:
Figure 13.3
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Figure 13.4 1H-NMR spectrum of 198
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Figure 13.5 1H-NMR spectrum of 199
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Figure 13.6 Elimination and Claisen rearrangement
It should be mentioned here that 199 was also obtained as a by-product (7 % 
yield) in the reaction of 160 with tetrabutylammonium fluoride, which gave 1-0- 
allyl-2-deoxy-2-fluoro-3,6-di-0-benzyl-4f5-0-isopropylidene-scy//o-inositol 202 
as the main product (Figure 13.7). The melting point measured for 202 (111- 
112°C, from hexane) differs considerably from the value reported by Sawyer (98-
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100°C) I389!, who obtained this compound by DAST fluorination of 1 -O-allyl-3,6- 
di-0-benzyl-4,5-0-isopropylidene-A77yo-inositol 93.
\  BnO T
O S O 2C F 3
\  BnO
OAII + 199
OBn 160 OBn 202
Figure 13.7 Reaction of 160 with tetrabutylammonium fluoride
The assignment of the scy//o-configuration to the main product 202 is based on 
the 1H-NMR signal for C-2-H at 4.50 ppm, which appears as a dt with Jh-c-f = 
49.3 Hz and Jh-ci(3)-h = 7-9 Hz- The ,ar9e J value measured for the coupling 
between the vicinal hydrogens at C-2 and C-1 / C-3 is typical for an axial-axial 
arrangement of the protons, thus the fluorine has to be found in an equatorial 
position. Further proof for the structure is provided by the proton signal at 3.71 
ppm (1 H, ddd, J 12.8, 9.7, 7.9), which can be assigned to C-1-H (or C-3-H). The 
3J h _ p  value of 12.8 Hz (and the corresponding coupling constant of 14.7 Hz 
found in the 19F spectrum) are typical for proton and fluorine in an axial- 
equatorial relationship. 3JH_F coupling constants in a 2-fluoro derivative with 
myo-inositol configuration can be expected to be much larger (« 29 Hz, see 
Chapter 10.1).
Claisen rearrangement:
When the product obtained by heating 198 for 15 min at 200°C was examined, it 
was originally thought to be a homogenous compound, since tic (petrol ether b.p. 
60-80°C /  ether 2:1) showed complete conversion of the starting material (Rf 
0.54) into what appeared to be a single product (Rf 0.45). The 1H- (Figure 13.8) 
and 13C-NMR spectra revealed however that it was a mixture of two compounds. 
Attempts to isolate these two products chromatographically were not successful. 
It was however clear from the 13C-NMR spectra of the product mixture that both 
compounds contained carbonyl groups (8C 203.69 and 205.31), and it thus 
appears safe to conclude that the reaction mixture contained DL-2-deoxy-2-C-
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ally l-3,6-d i-0-benzyl-4 I5-Oisopropylidene-/7?yo-1-inosose 200 and DL-2-deoxy- 
2-C-allyl-3,6-di-0-benzyl-4,5-0-isopropylidene-scy//o-inosose 201.
Figure 13.8 1H-NMR of the Claisen rearrangement product (200 and 201)
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Two explanations for this result can be imagined: as shown in Figure 13.9, the 
Claisen rearrangement can, in principle, proceed via two different transition 
states to yield either 200 or 201 or a mixture of both products.
Figure 13.9 Possible transition states in the Claisen rearrangement of 198
Alternatively, either 200 or 201 could be formed selectively in the 
rearrangement. Epimerisation via the enol 203 (Figure 13.10) would then give 
rise to a mixture of the tautomers 200 and 201, since the addition of a proton to 










Figure 13.10 Possible epimerisation of 200 and 201 via end  203
If separation of 200 and 201 was possible, selective reduction of the respective 
inososes using either sodium borohydride or the sterically hindered lithium 
trisiamylborohydride ('LS-Selectride' i394i), which affords predominantly the axial 
alcohol, would make available a number of new C-allyl inositol derivatives (204 - 
207, Figure 13.11). Stereospecific reduction of the 1-position of 200 would 
transform this position either into the equatorial 1-OH of the 2-deoxy-2-C-allyl- 
myo-inositol system 204 or into the axial 1-OH of the 6-deoxy-6-C-allyl-c/?/ro- 
inositol system 205. The same conversions performed on 201 would afford the 
C-allyl-scy//oinositol derivative 206 and the 1-deoxy-1-C-allyl-myo-inositol 207, 
respectively.
As outlined above, there is considerable potential for the preparation new 
inositol phosphate analogues by employing the synthetic sequence of triflate 
elimination, Claisen rearrangement and stereoselective reduction of the resulting 
inososes. Whilst the first steps into this direction have now been made, there 
are, however, still a number of problems (such as optimising the yield of the 1,2- 
eliminated product and the separation of the Claisen rearrangement products 

















Figure 13.11 Derivatives accessible by selective reduction of 200 and 201
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14 Outlook
W ithin the last decade, polyphosphoinositide research has been one of the most 
rapidly expanding fields in biochemistry. The number of research publications 
per annum in this area (Figure 14.1) increased almost 10-fold between 1983 
(when the second messenger role of D-myo-inositol 1,4,5-trisphosphate was 
discovered) and 1988, and the average number of articles appearing is now at 
500 per year.
The Growing Interest in Inositol Biochemistry and
C h e m i s t r y
as measured by research publications
#  600
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Figure 14.1 Publications on inositol research
Since 1983, the important role that inositol phosphates play in signal 
transduction has become increasingly clear. However, whilst the function of 
lns(1,4,5)P3 is now fairly well known, there are still many questions to be 
answered before the complex biochemical processes involved in the generation 
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Apart from the most prominent inositol phosphate lns(1 f4,5)P3, interest is now 
increasingly focussed on other biologically active inositol phosphates and 
phospholipids. The recent discovery that activation of a Ptdlns(4,5)P2 3-kinase 
by certain growth factors leads to the formation of Ptdlns(3,4,5)P3 I390!, and that 
this inositol phospholipid can in turn stimulate the £ isozyme of protein kinase C 
l391J is only one example of the important role that other inositol derivatives play 
in signal transduction and other physiological processes.
During this last decade, tools provided by pharmaceutical chemists have made a 
considerable contribution to unravelling various aspects in the lns(1,4,5)P3 
signalling pathway:
Analogues of lns(1,4,5)P3 and lns(1,3,4,5)P4 have helped to elucidate structural 
requirements for receptor binding and enzyme interaction. A number of inhibitors 
for metabolic enzymes in the phosphoinositide pathway have been developed. 
Synthetic derivatives of lns(1,4,5)P3 have been used to prepare affinity matrices 
for the purification of receptor proteins. Radioactive analogues and photoaffinity 
derivatives have been employed to label lns(1,4,5)P3 and lns(1,3,4>5)P4 binding 
sites. The use of 'caged' lns(1,4,5)P3 l392l has allowed the study of calcium 
mobilisation in intact cell preparations. The first lipophilic lns(1,4,5)P3 analogue 
has now been reported I393], making possible the delivery of active substances 
across the cell membrane.
Impressive as this list of achievements may seem, there are many tasks ahead 
for the pharmaceutical chemist in inositol phosphate research:
The most interesting challenge for the future is arguably the preparation of 
lns(1,4,5)P3 antagonists. Heparin and decavanadate have already been 
identified as antagonists, but they are of only limited use in inositol phosphate 
research because of their lack of specificity, and the search for a specific small 
molecule lns(1,4,5)P3 antagonist continues. Analogues with partial agonist 
properties have given first indications on how this goal may be achieved, and the 
day may not be far when the synthesis of the first lns(1,4,5)P3 antagonist will be 
reported.
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It may take considerably longer to find applications of inositol phosphate 
research in medicine, but one can imagine that cell-penetrating antagonists or 
inhibitors of metabolic enzymes may be devised who are able to serve as drugs.
The discovery of novel biologically active inositol phosphates and phospholipids 
like Ptdlns(3,4>5)P3 is likely to lead to equally strong efforts in the synthesis of 
analogues of these compounds as has been seen for lns(1,4,5)P3. Work in this 
area has only just started.
The concluding words of Potter's review from 1990 I123! still apply: "If the current 
pace of progress is maintained we can expect an exciting future".
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EXPERIMENTAL SECTION
15 Materials and Methods
Chemicals were purchased from Aldrich, Fluka and Lancaster. IANBD was 
purchased from Molecular Probes. Diethyl ether was dried over sodium wire and 
distilled. Dichloromethane, triethylamine and dimethylformamide were dried over 
calcium hydride, distilled and stored over 4 A molecular sieves. Pyridine was 
dried by refluxing with sodium hydroxide pellets, followed by distillation, and 
stored over 5 A sieves.
Triethylammonium bicarbonate (TEAB) buffers (1 or 2 M) were prepared by 
bubbling carbon dioxide through a 1 or 2 M solution of triethylamine in de­
ionised water until a pH of 8 was obtained.
Thin layer chromatography (tic) and high performance tic (hptlc) was performed 
on pre-coated plates (Merck tic aluminium sheets silica 60 F254, Art. no. 5554 
and Merck hptlc plates silica 60 F254, Art. no. 5635). Products were visualised by 
spraying phosphomolybdic acid in methanol followed by heating. Flash 
chromatography refers to the method of Still etal. P95l and was carried out using 
Sorbsil C60 silica gel.
1H- and 13C-NMR spectra were recorded on either Bruker AM-300 or Jeol JNM
GX-270 NMR spectrometers. Chemical shifts were measured in ppm relative to
tetramethylsilane (TMS). 31P-NMR and 19F-NMR spectra were recorded on a
Jeol FX-90Q spectrometer. 31P- and 19F-NMR chemical shifts were measured in
ppm relative to external 85 % H3P 04 and internal CFCI3, respectively. J values
are given in Hz. Melting points (uncorrected) were determined using a Reichert-
Jung Thermo Galen Kofler block. Microanalysis was carried out at Butterworth
Laboratories Ltd. and the University of Bath microanalysis service. Mass spectra
were recorded at the SERC Mass Spectrometry Service Centre, Swansea, and
at the University of Bath. Optical rotations were measured using a Optical
Activity Ltd. AA-10 polarimeter. Ion exchange chromatography was performed
on an LKB-Pharmacia Medium Pressure Ion Exchange Chromatograph using
DEAE Sephadex or DEAE Sepharose with gradients of triethylammonium
bicarbonate (TEAB) as eluent.
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Column fractions were assayed for phosphate by a modification of the Briggs 
test t239l as follows:
A molybdate solution (12.5 g of ammonium molybdate dissolved in 250 ml water 
and 35 ml conc. H2S 04), a hydroquinone solution (0.5 g hydroquinone dissolved 
in 100 ml water and a drop of conc. H2S 0 4) and a sulphite solution (20 % w/v 
sodium sulphite in water) were prepared. Aliquots (usually 250 pi) of the 
fractions to be assayed were transferred into test tubes and conc. H2S 04 (3 
drops) was added to these samples. The samples were heated at 150°C for 1 h. 
After cooling, water (500 pi), molybdate solution (500 pi), hydroquinone solution 
(250 pi) and sulphite solution (250 pi) were added to each of the test tubes. The 
samples were then boiled for 7 seconds and allowed to cool. Phosphate 
containing fractions could be identified by their blue colour.
For quantitative analysis, samples containing known amounts of potassium 
dihydrogen phosphate were co-assayed with samples of unknown phosphate 
contents. After being processed as above, the test tube fractions were 
transferred to 10 ml volumetric flasks and water was added to give 10 ml of 
solution. The UV absorbance at 340 nm was recorded using 3 ml quartz cells. 
The concentration of the unknown samples was calculated from a standard 
curve derived from the absorbances of the reference samples.
Compounds containing phosphorothioates were assayed by a modification of the 
Ellman test I243] for sulphydryl groups as follows. To 250 pi aliquots of the ion- 
exchange column fractions was added 1 ml of a buffered solution of Ellman's 
reagent [100 ml 10 mM Tris buffer, pH 8, containing 40 mg of 5’,5-dithio-b/s(2- 
nitrobenzoicacid)]. The fractions containing phosphorothioates were identified 
their deep yellow colour.
16 Synthesis of myo-inositol 4,5-bisphosphate 1-phosphorothioate
16.1 DL-3,6-Di-0-benzoyl-1,2:4,5-di-0-isopropylidene-myoinositol 121
This compound was prepared according to the method of Gigg etal. I149l.
A mixture of myoinositol 10 (250 g, 1.39 mol), A/,A/-dimethylformamide (1 litre), 
2,2-dimethoxypropane (750 ml) and toluene-p-sulphonic acid (5 g) was heated 
under reflux for 2 h, after which only little solid remained. Triethylamine (50 ml)
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was added to the cooled solution and the solid removed. Toluene (125 ml) was 
added to the filtrate and the low-boiling solvents were evaporated at 40°C. 
Pyridine (750 ml) was added to the A/,A/-dimethylformamide solution followed by 
benzoyl chloride (1 I) dropwise with stirring and cooling during 30 min. After a 
further 2 h, the solid was collected and washed successively with pyridine, 
water, acetone and ether to give DL-3,6-di-0-benzoyl-1,2:4,5-di-0- 
isopropylidene-myo-inositol 121 (167 g, 357 mmol, 26% of reacted inositol).
m.p. 285-310°C (Lit. t149L 328-330°C)
8h (CDCI3, 300 MHz) 1.30, 1.42, 1.51, 1.63 (12 H, 4 s, 4 CH3), 3.73 (1 H, dd, 
J10.5, 9.75, C-5-H), 4.40 (2 H, m, C-1,4-H), 4.80 (1 H, dd, J 4.5, 4.5, C-2-H),
5.44 (1 H, dd, J 10.5, 4.5, C-3-H), 5.61 (1 H, dd, J 10.8, 7.2, C-6-H), 7.23-7.63 (6 
H, m, C(O)Ph), 7.82-8.19 (4 H, m, C(O)Ph)
16.2 DL-1,2:4,5-Di-0-isopropylidene-/nyo-inositol 122
This compound was prepared according to the method of Gigg etal. I149L 
A mixture of 121 (167 g, 357 mmol), sodium hydroxide (64 g) and methanol (4 
litres) was heated under reflux for 30 min. The resulting clear solution was 
cooled, neutralised with solid carbon dioxide, diluted with water (3.2 litres) and 
evaporated to dryness. The title compound was extracted with dichloromethane, 
and after evaporation of the solvent 79 g (304 mmol, 85 %) of DL-1,2:4,5-di-0- 
isopropylidene-myo-inositol 122 were obtained.
m.p. 164-165°C (from ethyl acetate, Lit. t149]; 171-173°C)
5h (CDCI3, 270 MHz) 1.39, 1.46, 1.49, 1.54 (12 H, 4 s, 4 CH3), 2.60-2.70 (2 H, 
brd, OH), 3.05-2.85 (2 H, brd, OH), 3.33 (1 H, dd, J 10.6, 9.5, C-5-H), 3.84 (1 H, 
dd, J 9.7, 9.7, C-H), 3.90 (1 H, dd, J 10.6, 6.4, C-H), 4.05 (1 H, dd, J 9.8, 4.5, C- 
H), 4.08 (1 H, d, J 6.0, C-H), 4.48 (1 H, dd, J 4.8,.4.8, C-2-H)
16.3 DL-3,6-Di-0-benzyl-1,2:4,5-di-0 -isopropylidene-/77yo-inositol 123
DL-1,2 :4,5-Di-Oisopropylidene-A77yoinositol 122 (15.6 g, 60 mmol), 18-crown-6 
(795 mg, 3 mmol), potassium hydroxide (40 g) and benzyl chloride (85 ml) were 
heated with vigorous stirring up to 120°C, at which time the reaction became 
exothermic. Heating was removed, and after 2 h the reaction mixture had cooled
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to room temperature. Toluene (70 ml) was added and the mixture was washed 
with 1 M sodium chloride solution, until the aqueous phase remained neutral. 
The toluene layer was dried over magnesium sulphate and evaporated at 95°C 
(high vacuum) to remove remaining benzyl chloride. Recrystallisation of the 
product from ethanol gave DL-3,6-di-Obenzyl-1,2 :4,5-di-Oisopropylidene-/77yo- 
inositol 123 (25.7 g, 58 mmol, 98 %).
m.p. 151-153°C (Lit. I149l: 153-155°C)
SH (CDCI3, 300 MHz): 1.32, 1.39, 1.45, 1.48 (12 H, 4 s, 4 CH3), 3.34 (1 H, dd, J
10.5, 9.4, C-5-H), 3.67 (1 H, dd, J 10.6, 6.5, C-3-H), 3.74 (1 H, dd, J 10.1, 4.2, C-
1-H), 3.98-4.07 (2 H, m, C-4-H, C-6-H), 4.30 (1 H, dd, J 4.6, 4.6, C-2-H), 4.81 (2 
H, AB, CH2Ph), 4.79, 4.88 (2 H, AB, JAB 12.6, CH2Ph), 7.22-7.42 (10 H, m, 
CH2P/7)
16.4 DL-1,4-Di-0-benzyl-/nyo-inositol 124
This compound was prepared according to the method of Gigg etal. i149L 
A solution of 123 (68.6 g, 156 mmol) in 80% acetic acid (1340 ml) was heated 
under reflux for 15 min, cooled and diluted with the same volume of water. The 
product was collected to give DL-1,4-di-O-benzyl-myoinositol 124 (53 g, 147 
mmol, 95%).
m.p. 203-204°C (Lit. [149,396]: 205-207°C, 203-204°C)
5h (d6-DMSO, 270 MHz) 3.09-3.19 (2 H, m, C-1,5-H), 3.30 (1 H, ddd, J 9.7, 4.2,
2.4, C-3-H), 3.45 (1 H, dd, J 9.3, 9.3, C-4-H), 3.62 (1 H, ddd, J 9.3, 9.3, 4.8, C-6- 
H), 3.98 (1 H, ddd, J 3.3, 2.8, 2.8, C-2-H), 4.58, 4.65 (2 H, AB, JAB 12.1, CH2Ph), 
4.67 (1 H, d, J 6.8 , D20  ex, OH), 4.76, 4.79 (2 H, AB, JAB 11.4, CH2Ph), 4.76 (1 
H, d, J 5.0, D20  ex, OH), 4.79 (1 H, d, J 4.6, D20  ex, OH), 4.83 (1 H, d, J 5.0, 
D20  ex, OH), 7.23-7.44 (10 H, m, CH2Ph)
16.5 DL-1-0-Allyl-3,6-di-0-benzyl-/nyo-inositol 125
This compound was prepared by a modification of the method of Gigg et al. 
[168,155]^  ,• e caesium fluoride rather than tetrabutylammonium iodide was used. 
DL-1,4-Di-0 -benzyl-/77yo-inositol 124 (12 g, 33.3 mmol) and dibutyltin oxide (9 g, 
36 mmol) were heated under reflux in toluene (300 ml) in a Dean and Stark
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apparatus overnight. The solution was evaporated to complete dryness in vacuo. 
Cesium fluoride (7 g, 46 mmol) was added to the resulting white solid and the 
mixture was dried in vacuo for 2 h, and then suspended in a solution of allyl 
bromide (8 ml, 42 mmol) in dry dimethylformamide (200 ml). The mixture was 
stirred at r.t. for 20 h and evaporated to dryness. The residue was taken up in 
ethylacetate, washed with 1 M HCI, brine and saturated NaHC03 and the 
precipitated tin derivatives removed by filtration through Celite. The filtrate was 
concentrated and chromatographed on silica gel using ether as eluent to give
10.4 g (26 mmol, 78 %) of 125.
m.p. 103-104°C (Lit. I168]: 107-108°C) 
tic (ether) Rf 0.3
5h (CDCI3, 300 MHz) 2.53 (1 H, s, OH), 2.74-2.75 (1 H, d, J 2.2 , OH) 2.79 (1 H, 
d, J 2.3, OH), 3.25 (1 H, dd, J 9.5, 2.8, C-3(1)-H), 3.30 (1 H, dd, J 9.45, 2.8, C- 
1 (3)-H), 3.39 (1 H, ddd, J 9.4, 9.4, 2.0, C-5-H), 3.77 (1 H, dd, J 9.4, 9.4, C-6-H), 
3.95 (1 H, ddd, J 9.4, 9.4, 2.0, C-4-H), 4.14, 4.18 (2 H, AB, ddd, JAB 12.6, J 5.7,
1.4, 1.4, CH2-CH=CH2), 4.24 (1 H, dd, J 2.8, 2.8, C-2-H), 4.69, 4.74 (2 H, AB, 
Jab 11.7, CH2Ph), 4.74, 4.93 (2 H, AB, J 11.2, CH2Ph), 5.19 (1 H, ddt, J 10.4,
1.4, 1.4, c/s-CH2-CH=CH2), 5.29 (1 H, ddt, J 17.2, 1.6, 1.6, trans-CH2-CH=CH2), 
5.92 (1 H, ddt, J 17.2, 10.4, 5.7, CH2-CH=CH2), 7.25-7.40 (10 H, m, CH2P/7)
16.6 DL-1 - 0 -Allyl-3,6-di-0 -benzyl-4 ,5- 0 -isopropylidene-/i7yo-inositol 93
This compound was prepared according to the method of Gigg etal. I168]. 
DL-1-0 -Allyl-3 ,6-di-0 -benzyl-/7?yo-inositol 125 (4.1 g, 10 mmol), 2 ,2-dimethoxy- 
propane (41 ml) and toluene-p-sulphonic acid (410 mg) were stirred for 2 h in 
100 ml dry acetone, when tic (ether-petrol ether b.p.40-60°C) showed a product 
(Rf 0.6). After cooling, 5 ml of triethylamine were added and stirring continued for 
30 min. The solvents were evaporated and the crude product chromatographed 
on silica gel in ether / petrol ether (b.p. 40-60°C) to give DL-1-0-allyl-3,6-di-0- 
benzyl-4,5-0-isopropylidene-myo-inositol 93 (3.27 g, 7.4 mmol, 74 %).
m.p. 102-103°C (Lit. I168!: 103-105°C)
5h (CDCI3, 300 MHz) 1.46 (3 H, s, CH3), 1.47 (3 H, s, CH3), 2.63 (1 H, s, OH), 
3.25 (1 H, dd, J 8.4, 3.4, C-3(1)-H), 3.37 (1 H, dd, J 10.1, 10.1, C-5-H), 3.57 (1 
H, dd, J 10.1, 3.1, C-1(3)-H), 3.93 (1 H, dd, J 9.7, 9.7, C-4(6)-H), 4.08 (1 H, dd, J
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9.8, 9.8, C-6(4)-H), 4.16-4.21 (2 H, m, Ctf2-CH=CH2), 4.22 (1 H, dd, J 2.9, 2.9, 
C-2-H), 4.72, 4.86 (2 H, AB, JAB 11.6, CH2Ph), 4.76, 4.88 (2 H, AB, JAB 12.0, 
Ctf2Ph), 5.17 (1 H, ddt, J 10.25, 1.4, 1.4, c/s-CH2-CH=CH2), 5.26 (1 H, ddt, J
17.2, 1.65, 1.65, trans-CH2-CH=CH2), 5.90 (1 H, ddt, J 17.2, 10.25, 5.5, CH2- 
CH=CH2), 7.28-7.41 (10 H, m, CH2Ph)
16.7 DL-1-0-Allyl-2,3,6-tri-0-benzyl-4,5-0-isopropylidene-/77yo-inositol 126
DL-1-0-Allyl-3,6-di-0-benzyl-4,5-0-isopropylidene-myo-inositol 93 (8.9 g, 20.2 
mmol), 18-crown-6 (4.54 g, 1.7 mmol), potassium hydroxide (25 g, 446 mmol) 
and benzyl chloride (50 ml, 55 g, 434 mmol) were heated with vigorous stirring 
up to 120°C. After 30 min heating was removed, and the solution allowed to cool 
to room temperature. Toluene (70 ml) was added and the mixture was washed 
with 1 M sodium chloride solution, until the aqueous phase remained neutral. 
The toluene layer was dried (MgS04) and evaporated at 95°C (high vacuum) to 
remove volatile benzylation by-products. Recrystallisation from ethanol gave 126 
(10.5 g, 19.8 mmol, 98%).
m.p. 81-83°C (Lit. t155L 82-84°C)
tic (ether-petrol ether b.p.40-60°C 1:1): Rf 0.9
6h (CDCI3j 300 MHz) 1.46 (6 H, s, 2 CH3), 3.27 (1 H, dd, J 9.5, 3.2, C-3(1)-H), 
3.41 (1 H, dd, J 9.8, 9.8, C-5-H), 3.57 (1 H, dd, J 9.7, 3.2, C-1(3)-H), 3.93 (1 H, 
dd, J 9.7, 9.7, C-4(6)-H), 4.08 (1 H, dd, J 9.8, 9.8, C-6(4)-H), 4.14-4.19 (2 H, m, 
CH2-CH=CH2), 4.18 (1 H, dd, J 2.7, 2.7, C-2-H), 4.56, 4.67 (2 H, AB, JAB 11.8, 
CH2Ph), 4.71, 4.85 (2 H, AB, JAB 11.8, CH2Ph), 4.76, 4.88 (2 H, AB, JAB 11.9, 
CH2Ph), 5.17 (1 H, ddt, J 10.25, 1.4, 1.4, c/s-CH2-CH=CH2), 5.26 (1 H, ddt, J
17.2, 1.65, 1.65, trans-CV\2-CH=CH2), 5.90 (1 H, ddt, J 17.2, 10.25, 5.5, CH2- 
CH=CH2), 7.28-7.41 (15 H, m, CH2Ph)
16.8 DL-1-0-Allyl-2,3,6-tri-0-benzyl-/nyo-inositol 127
This compound was prepared according to the method of Gigg etal. I168!.
126 (10 g, 18.8 mmol) was heated under reflux in a solution of methanol (360 ml) 
and 1 M hydrochloric acid (40 ml) for 30 min. After cooling, an excess of 
NaHC03 was added and the solvents were evaporated. The product was 
extracted from the residue with ether, the extract was dried over magnesium
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sulphate, and the solvent was evaporated to give 127 (8.6 g, 17.5 mmol, 93 %).
m.p. 73-75°C (from ethanol /  water, Lit. l168l: 'syrup')
5h (CDCI3, 270 MHz) 2.56, 2.60 (2 H, 2 br s, D20  ex, OH), 3.20 (1 H, dd, J 9.7,
2.2, C-3-H), 3.28 (1 H, dd, J 9.7, 2.2 , C-1-H), 3.42 (1 H, dd, J 9.3, 9.3, C-5-H),
3.87 (1 H, dd, J 9.4, 9.4, C-6-H), 4.04 (1 H, dd, J 9.5, 9.5, C-4-H), 4.06 (1 H, dd, 
J 2.5, 2.5, C-2-H), 4.10 (2 H, ddd, J 5.3, 1.4,1.4, CH2CH=CH2), 4.55, 4.61 (2 H, 
AB, Jab 11.7, CW2Ph), 4.75, 4.96 (2 H, AB, Jab 11.9, CH2Ph), 4.79, 4.89 (2 H, 
AB, Jab 11-2, CH2Ph), 5.19 (1 H, ddt, J 10.4, 1.4, 1.4, c/s-CH2CH=CH2), 5.31 (1
H, ddt, J 17.2, 1.6, 1.6, frans-CH2CH=CH2), 5.91 (1 H, ddt, J 17.2, 10.4, 5.3, 
CH2CH=CH2), 7.25-7.42 (15 H, m, CH2Ph);
8C (CDCI3, 68 MHz) 71.45, 72.26, 74.02, 75.35 (4 t, CH2CH=CH2 and CH2Ph),
72.20, 73.53, 74.60, 79.95, 80.76, 80.83 (6 d, inositol ring C), 116.73 (t, 
CH2CH=CH2), 127.37, 127.63, 127.70, 127.79, 127.96, 128.12, 128.38, 128.44 
(8 d, CH2Ph), 134.67 (d, CH2CH=CH2), 137.85, 138.76 (2 s, CH2P/i); 
m/z (70 eV El) 399 [(M - C7H7)+, 2 %], 307, 181 (5), 131 (10), 109 (5), 91 
[(C7H7)+, 100];
mlz (Cl, Isobutane) 491 (M+H)+, 399 (10), 309, 181 (20), 131 (20), 107 (100), 91 
(80), 69 (20)
16.9 DL-2,3,6-Tri-0-benzyl-1-0-(prop-1-enyl)-myo-inositol 128 (mixture of 
els- and frans-isomers)
A solution of 127 (1.55 g, 3.16 mmol) and diazabicyclo[2.2.2]octane (71 mg, 0.65 
mmol) in a mixture of ethanol /  toluene /  water (7:3:1, v/v/v) was heated. When 
the solution had reached reflux temperature, tris(triphenylphosphine)rhodium 
chloride (202 mg, 0.22 mmol) was added and the mixture was heated under 
reflux for 30 min. After cooling, the mixture was diluted with water and extracted 
twice with ether. The combined organic layers were dried over magnesium 
sulphate and the solvent was evaporated. Chromatography on silica gel (ether / 
hexane 2:1) gave 128 as a mixture of ca. 5:1 cis:trans prop-1 -enyl isomers. Yield
I.2 7  g (82% ).
§H (CDCI3, 300 MHz) 1.56 (0.5 H, dd, J 6.8 , 1.55, trans-CH=CH-CH3), 1.68 (2.5 
H, dd, J 6.8, 1.6, c/s-CH=CH-CH3), 2.67 (1 H, d, J 2.0, D20  ex, OH), 2.70 (1 H, 
d, J 1.8, D20  ex, OH), 3.22 (1 H, dd, J 9.7, 2.4, C-3-H), 3.46 (1 H, dd, J 9.3, 9.3,
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C-5-H), 3.57 (1 H, dd, J 9.7, 2.3, C-1-H), 3.93 (1 H, dd, J 9.4, 9.4, C-6-H), 4.04 
(1 H, dd, J 9.5, 9.5, C-4-H), 4.07 (1 H, dd, J 2.4, 2.4, C-2-H), 4.46-4.98 (7 H, m, 
CH=CH-CH3 and 3 CH2Ph), 6.07-6.15 (1 H, m, CH=CH-CH3), 7.25-7.42 (15 H, 
m, CH 2Ph)\
16.10 DL-2,3,6-Tri-0-benzyl-1-0-(c/s-prop-1-enyl)-/nyo-inositol 128
A solution of 127 (2 g, 4.08 mmol) and freshly sublimed potassium tert-butoxide 
(2.28 g, 20 mmol) in dry DMSO (50 ml) was stirred for 3 h at 50°C when hptlc 
(ether) showed complete conversion of the starting material (Rf 0.78) to a single 
product (Rf 0.80). Water (50 ml) was added to the brown solution, which was 
then extracted with ether (2 x 100 ml). The combined organic layers were dried 
over anhydrous magnesium sulphate and evaporated to dryness to give 128 
(1.97 g, 4.02 mmol, 98%).
m.p. 101-103°C (from ethanol / water)
Found: C, 73.28; H, 6.93. Calc for C30H34O6 (490.60): C, 73.45; H, 6.99 %.
5h (CDCI3i 270 MHz) 1.67 (3 H, dd, J 6.9, 1.65, CH=CH-CH3), 2.76 (1 H, d, J
2.4, D20  ex, OH), 2.79 (1 H, d, J 2.0, D20  ex, OH), 3.21 (1 H, dd, J 9.7, 2.4, C-3- 
H), 3.42 (1 H, ddd, J 9.2, 9.2, 2.2, D20  shake gives dd, 9.2, 9.2, C-5-H), 3.55 (1 
H, dd, J 9.7, 2.4, C-1-H), 3.92 (1 H, dd, J 9.5, 9.5, C-6-H), 4.03 (1 H, ddd, J 9.5,
9.5, 2.0Hz, D20  shake gives dd, J 9.5, 9.5, C-4-H), 4.07 (1 H, dd, J 2.4, 2.4, C-2- 
H), 4.49 (1 H, dq, J 6.7, 6.7, CH=CH-CH3), 4.49, 4.56 (2 H, AB, 11.6, 
CH2Ph), 4.70, 4.88 (2 H, AB, JAB 11.6, CH2Ph), 4.77, 4.88 (2 H, AB, JAB 11.6, 
CH2Ph), 6.08 (1 H, dd, J 6.2, 1.65, CH=CH-CH3), 7.23-7.42 (15 H, m, CH2Ph)\
5C (CDCI3, 68 MHz) 9.44 (q, CH=CH-CH3), 74.44, 75.35 (2 t, CH2Ph), 72.07, 
74.24, 74.96, 79.43, 80.28, 83.23 (6 d, inositol ring C), 100.97 (d, CH=CH-CH3), 
127.50, 127.66, 127.79, 128.18, 128.28, 128.41, 128.48 (7 d, CH2Ph), 137.60, 
138.43 (2 s, CH2P/7), 145.34 (d, CH=CH-CH3);
m/z (+ve ion FAB) 489 [(M-H)+, 0.5 %], 399 (3), 181 (15), 91 (100);
m/z (-ve ion FAB) 979 [(2M-H)-, 30 %], 643 [(M+NBA)-, 60], 489 [(M-H)-, 100],
399 (20), 381 (20)
16.11 Dichloro(2-cyanoethoxy)phosphine 129
This compound was prepared according to the procedure of Bannwarth and
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Trzeciak [2261, except that a larger volume of solvent (800 ml of ether rather than 
200 ml) was used.
To a solution of PCI3 (137.33 g, 85.5 ml, 1 mol) and dry pyridine (81 ml, 1 mol) in 
800 ml of ether under N2 at -78°C was added 3-hydroxypropionitrile (71.05 g, 68 
ml, 1 mol) dropwise over a period of 90 min. After cooling had been removed, 
stirring was continued overnight at r.t. The precipitate was removed by filtration 
under N2 and washed twice with 100 ml of ether. After evaporation of ether, the 
oily residue was dried for 3 h, giving crude 129 (104 g, 0.6 mol, 60 %). Since 
129 decomposed partly during distillation, the crude product was used for the 
preparation of 130.
SP (CDCI3; 36 MHz) 179.77
16.12 (2-Cyanoethoxy)bis(diisopropylamino)phosphine 130
This compound was prepared according to the procedure of Bannwarth and 
Trzeciak t226!.
To a solution of crude 129 (104 g, 0.6 mol) in 1 litre of dry ether under N2, 
diisopropylamine (753 ml, 5.3 mol) was added over a period of 1 h at - 10°C with 
stirring, which was continued overnight at r.t. The precipitated hydrochloride was 
removed by filtration under N2 and washed twice with 300 ml of ether. The 
combined ether solutions were evaporated, and the oily residue was distilled 
under vacuum after the addition of 1.5 g of calcium hydride to give 130 (117 g, 
388 mmol, 56 %, Lit. I226] 64 %).
b.p. 120°C / 0.8 hPa (Lit. t226l 117°C / 0.5 Torr)
5P (CDCI3; 36 MHz) 122.56
16.13 Bis(2-cyanoethoxy)(diisopropylamino)phosphine 131
This compound was prepared according to the procedure of Bannwarth and 
Trzeciak I226!.
To a solution of 130 (117 g, 388 mmol) and diisopropylammonium tetrazolide 
(33.4 g, 194 mmol) in 1400 ml dry dichloromethane, 3-hydroxypropionitrile (29 
ml, 30.3 g, 427 mmol) was added dropwise under N2 with stirring. After complete 
addition, stirring was continued for another 2 h. The mixture was poured into
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1200 ml of saturated aqueous sodium bicarbonate, which was then extracted 
with dichloromethane (3 x 600 ml). The combined organic layers were dried 
over sodium sulphate and evaporated. Flash chromatogaphy of the crude 
material (eluting with ether / pentane 3:1) gave 131 (72 g, 265 mmol, 68 %, Lit. 
I226! 81 %).
8h (CDCI3; 300 MHz) 1.14 (12 H, d, J 6 .8 , CH(CH3)2), 2.62-2.57 (4 H, t, J 6.2, 
OCH2CH2CN), 3.47-3.65 (2H, m, CH(CH3)2), 3.68-3.93 (4 H, m, OCF/2CH2CN)
5P (CDCI3; 36 MHz) 149.15
16.14 DL-2,3,6-Tri-0-benzyl-4,5-bis[di-(2-cyanoethoxy)phospho]-1-0-(c/s- 
prop-1-enyl)-/77yo-inositol 132
A solution of bis(2-cyanoethoxy)(diisopropylamino)phosphine 131 (7 g, 26 mmol) 
in dichloromethane (50 ml) was added to a solution of 128 (1.24 g, 2.6 mmol) 
and tetrazole (2.19 g, 31.2 mmol) in dichloromethane (50 ml). The mixture was 
stirred at r.t. for 1 h (5P 140.70, 140.47 ppm). 10% water in THF (20 ml) was 
added and stirring continued for 30 min. 2,6-Lutidine (2 ml) followed by terf-butyl 
hydroperoxide (20 ml, 70 % in water) was then added and stirring continued 
overnight. The solution was washed with saturated aqueous sodium hydrogen 
carbonate (2 x 100 ml) and dried over magnesium sulphate. The solvents were 
evaporated and the residue chromatographed on silica gel with 0 % to 100 % 
ethyl acetate in hexane and then 0 % to 10 % ethanol in ethyl acetate. The 
product was recrystallised from ethanol to give 132 (1.43 g, 64 %).
m.p. 118-120°C (from ethanol) 
tic (ethyl acetate:ethano19:1) Rf 0.76
Found: C, 58.49; H, 5.57; N, 6.52. Calc for C42H48N40 12P2 (862.81): C, 58.47; 
H, 5.61; N, 6.49% .
6h (CDCI3, 270 MHz) 1.63 (3 H, dd, J 6.8 , 1.6, CH2=CH-CH3), 2.16-2.39 (4 H, m, 
CH2CH2CN), 2.65-2.69 (4 H, m, CH2CH2CN), 3.50 (1 H, dd, J 9.5, 2.0, C-3-H), 
3.66 (1 H, dd, J 9.7, 2.0, C-1-H), 3.89-4.31 (10 H, m, CH2CH2CN, C-2-H, C-6-H), 
4.38-4.99 (9 H, m, CH2Ph, C-4-H, C-5-H, CH=CH-CH3), 6.06 (1 H, dd, J 6.8 , 1.6, 
CH=CH-CH3), 7.26-7.40 (15 H, m, CH2P/7);
8C (CDCI3, 68 MHz) 9.34 (q, CH=CH-CH3), 18.97, 19.10, 19.23, 19.33 (4 t,
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CH2CH2CN), 62.11, 62.70 (2 t, CH2CH2CN), 71.97, 74.70 (2 t, CH2Ph), 73.76, 
74.83, 78.10, 78.52, 79.60, 82.48 (6 d, inositol ring C), 102.04 (d, CH=CH-CH3) 
116.60, 116.83, 116.93 (3 S, CN), 126.85, 127.31, 127.60, 127.70, 127.92, 
128.12, 128.22, 128.34, 128.51 (9 d, CH2Ph), 137.01, 137.85, 138.21 (3 s, 
CH2P/7), 144.66 (d, CH=CH-CH3);
5P (CDCI3, 36 MHz) -3.57, -3.70;
m/z (+ve ion FAB) 863 [(M+H+), 1.3 %], 771 (0.3), 181 (6), 144 (8), 91 [(C7H7)+, 
100];
m/z (-ve ion FAB) 808 [(M - CH2CH2CN)-, 55 %], 718 (12), 203 (100), 150 (85), 
97 (70);
Accurate mass calc for C42H49012N4P2 (M+H)+ 863.2822, found 863.2822 
132 (mixture of c/s- and trans-isomers):
6h (CDCI3i 270 MHz) 1.51 (0.5 H, dd, J 6.8 , 1.6, trans-CH2=CH-CH3), 1.63 (2.5 
H, dd, J 6.8 , 1.6, c/s-CH2=CH-CH3), 2.10-2.45 (4 H, m, CH2CH2CN), 2.56-2.76 
(4 H, m, CH2CH2CN), 3.50 (1 H, dd, J 9.5, 2.0, C-3-H), 3.66 (1 H, dd, J 9.7, 2.0, 
C-1-H), 3.89-4.31 (10 H, m, CH2CH2CN, C-2-H, C-6-H), 4.38-4.99 (9 H, m, 
CH2Ph, C-4-H, C-5-H, CH=CH-CH3), 6.03-6.13 (1 H, m, CH=CH-CH3), 7.26-7.40 
(15 H, m, CH2P/7);
16.15 DL-1,2,4-Tri-0-benzyl-5,6-bis[di(2-cyanoethoxy)phospho]-/nyo- 
inositol 133
a) A solution of mercuric chloride (300 mg, 1.1 mmol) in acetone / water (10:1 
(v/v), 4 ml) was added dropwise with stirring to a mixture of 132 (949 mg, 1.1 
mmol) and yellow mercuric oxide (300 mg) in acetone /  water (10:1 (v/v), 10 ml). 
After the addition was complete, stirring was continued for a further 5 min. The 
mercuric oxide was removed by filtration through Celite, the solvents evaporated 
and the residue taken up in ethyl acetate (50 ml). The solution was washed with 
semisaturated aqueous potassium iodide solution (50 ml), dried and evaporated. 
Chromatography on silica gel using hexane -» ethyl acetate ethyl acetate / 
ethanol (9:1, v/v) gave the pure title compound (786 mg, 87 %) as a syrup.
b) A solution of 132 (470 mg, 0.54 mmol) in 30 ml 1 M HCI:methanol (1:5) was 
heated under reflux for 30 min when tic (ethyl acetate:ethanol 9:1) showed 
complete conversion of the starting material (Rf 0.76) into a single product (Rf
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0.71). After cooling, the mixture was treated with an excess of sodium hydrogen 
carbonate and the solvents were evaporated. The title compound was extracted 
with ether (2 x 50 ml) and the solvent was evaporated to give 133 (426 mg, 95%) 
as a syrup which could not be crystallised.
5h (CDCI3, 300 MHz) 2.14-2.46 (4 H, m, CH2CH2CN), 2.60-2.72 (5 H, m, 
CH2CH2CN, OH, OH D20  ex), 3.53 (1 H, dd, J 9.9, 2.1, C-3-H), 3.62 (1 H, ddd, J 
9.9, 7.3, 2.4, D20  ex gives dd, J 9.9, 2.4, C-1-H), 3.86 (1 H, dd, J 9.4, 9.4, C-4- 
H), 4.06 (1 H, dd, J 2.3, 2.3, C-2-H), 3.90-4.37 (8 H, m, CH2CH2CN), 4.43 (1 H, 
q, J 9.1, C-5-H), 4.56, 4,67 (2 H, AB, JAB 11.3, CH2Ph), 4.75, 4,93 (2 H, AB, JAB
11.6 , CH2Ph), 4.79, 4,92 (2 H, AB, JAB 11.4, CH2Ph), 4.83 (1 H, q, J 9.3, C-6-H), 
7.22-7.41 (15 H, m, CH2P/j);
5C (CDCI3, 68 MHz) 18.65, 18.78, 18.84 (3 1, CH2CH2CN), 62.02, 62.08, 62.66 (3 
t, CH2CH2CN), 71.97, 74.05, 74.86 (3 t, CH2Ph), 71.55, 75.80, 77.65, 78.40, 
79.23, (5 d, inositol ring C), 116.64, 116.86, 116.99 (3 s, CN), 127.08, 127.50, 
127.57, 127.63, 127.86, 128.15, 128.22, 128.31 (8 d, CH2Ph), 136.91, 137.85,
138.04 (3 s, CH2Ph);
8P (CDCI3, 36 MHz) -5.52, -5.65;
m/z (+ve ion FAB) 823 [(M+H)+, 1.3 %], 222 (8), 181 (6), 144 (8), 91 [(C7H7)+, 
100];
m/z (-ve ion FAB) 768 [(M - CH2CH2CN)-, 45 %], 203 (100), 150 (95), 97 (80); 
Accurate mass calc for C39H45012N4P2 (M+H)+ 823.2509, found 823.2509
16.16 DL-2,3,6-Tri-0-benzyl-4,5-bis[di(2-cyanoethoxy)phospho]-1-[di(2- 
cyanoethoxy)thiophospho]-/nyo-inositol 134
Bis(2-cyanoethoxy)diisopropylamino phosphine (670 mg, 2.5 mmol) was added 
to a solution of 133 (412 mg, 0.5 mmol) and tetrazole (210 mg, 3 mmol) in 
dichloromethane (25 ml). The mixture was stirred at r.t. for 1 h. Dry pyridine (5 
ml) and sulphur (320 mg, 10 mmol) was added and the solution stirred for 
another 24 h. The solvent was evaporated and the residue chromatographed on 
silica gel (eluent hexane -» ethyl acetate -> ethanol /  ethyl acetate 10 % v/v) to 
give pure 134 as a syrup, yield 405 mg (79 %).
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5|_| (CDCI3> 270 MHz) 2.03-2.47 (6 H, m, CH2CH2CN), 2.49-2.79 (6 H, m, 
CH2CH2CN), 3.61 (1 H, dd, J 9.9, 1.8, C-3-H), 3.82-4.46 (14 H, m, CH2CH2CN, 
C -1-H, C-6-H), 4.40 (1 H, br s, C-2-H), 4.52 (1 H, q, J 9.2, C-5-H), 4.67, 4.75 (2 
H, AB, 11.3, CH2Ph), 4.87 (2 H, AB, CH2Ph), 4.85 (1 H, q, J 8.6 , C-4-H), 
4.84, 4.92 (2 H, AB, JAB 11.7, CH2Ph), 7.27-7.44 (15 H, m, CH2Ph)
8C (CDCI3, 68 MHz) 18.78, 18.91, 19.14, 19.20, 19.27 (5 t, CH2CH2CN), 62.08, 
62.18, 62.24, 62.37, 62.44, 62.53, 62.63, 62.79,'62.83 (9 t, CH2CH2CN), 72.33, 
74.34, 77.26 (3 1, CH2Ph), 74.63, 75.25, 78.04, 78.36, 78.46, 79.17 (6 d, inositol 
ring C), 116.41, 116.51, 116.57, 116.83, 116.96 (5 s, CN), 126.40, 127.60, 
127.76, 128.05, 128.18, 128.31, 128.48 (7 d, CH2Ph), 136.86, 137.72, 137.85 (3 
s, CH2P/7);
8P (CDCI3, 36 MHz) 66.83, -2.83, -3.10;
m/z (+ve ion FAB) 1025 [(M+H)+, 1.3 %], 181 (6), 144 (10), 91 [(C7H7)+, 100]. 
m/z (-ve ion FAB) 970 [(M - CH2CH2CN)-, 45 %], 219 (30), 203 (100), 150 (90), 
97 (80);
Accurate mass calc for C45H520 14N6P3S (M+H)+ 1025.2475 found 1025.2475
16.17 DL-/nyo-lnositol 4,5-bisphosphate 1-phosphorothioate 80
Ammonia was condensed into a three neck flask at -78°C. An excess of sodium 
was added to dry the liquid ammonia which was then distilled into a second 
three neck flask and kept at -78°C. Sodium was added until the solution 
remained blue. Compound 134 (120 mg, 117 pmol) was dissolved in dry dioxane 
(2 ml) and added to the sodium-liquid ammonia mixture. After stirring for 15 min 
the reaction was quenched by adding ethanol to the mixture, which became 
colourless. The ammonia was evaporated and the crude product taken up in 
water. The aqueous solution was treated with Dowex resin (H+) until a pH of 6 
was reached. The resin was filtered off and washed well with water. A few drops 
of triethylamine were added to the filtrate which was then evaporated to dryness. 
The crude product was purified by ion-exchange chromatography on DEAE 
Sephadex A-25 eluting with a gradient of triethylammonium bicarbonate buffer 
(0.1 M to 1 M), pH 8.0. The triethylammonium salt of 80 eluted at approx. 800 
mM and after evaporation of TEAB the product was obtained as a glass. Yield 54 
pmol (46%).
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5H (D20 , pH 8 , 300 MHz) 3.62 (1 H, dd, J 9.8, 2.5, C-3-H), 3.78 (1 H, dd, J 9.5,
9.5, C-6-H), 4.01 (1 H, q, J 9.2, C-5-H), 4.20-4.11 (2 H, m, C-2-H, C-1-H), 4.25 (1 
H, q, J 9.4, C-4-H);
5P (D20 , pH 8, 36 MHz) 42.13, 4.58, 3.50;
m/z (+ve ion FAB) 538 [(M+Et3NH)+, 10%], 436 (M+, 3), 102 (Et3NH+, 100) 
Accurate mass calc for C12H310 14NP3S (M+Et3NH)+ 538.0678 found 538.0678
1 6 .1 8  Fluorescent Labelling of ln s (1 ,4 ,5 )P 3- 1S
S-{2-[N-Methyl-/V-(7-nitro-2,1,3-benzoxadiazole-4-yl)amino]- 
ethoxycarbonylmethyl}-DL-myo-inositol 4,5-bisphosphate 1- 
phosphorothioate 135
A mixture of 8 0  (30 pmol) and 4-{A/-[2-(iodoacetoxy)ethyl]-A/-methylamino}-7- 
nitro-2,1,3-benzoxadiazole (15 mg, 33pmol) in ethanol was protected from light 
and stirred for 2 h at 0°C. The product was purified by ion-exchange 
chromatography on DEAE Sephadex A-25 eluting with a gradient of 
triethylammonium bicarbonate buffer (0.1 M to 1 M), pH 8.0. 135 eluted at ca. 
800 mM and was obtained as a dark orange glass after evaporation of TEAB. 
Yield 17 pmol (57%).
8P (D20 , 36 MHz, 1H-coupled) 1.72 (d, J 8.5, 0 P 0 32'), 3.01 (d, J 8.5, 0 P 0 32-), 
19.86 (q, J 9.1, O PS02_);
m/z (+ve ion FAB) 815 [(M+Et3NH)+, 3 %], (799 [(M+Et3NH - 0)+, 5], 714 (M+, 
12), 698 [(M - 0 )+, 14], 596 [(lns(1,4,5)P3S-CH2C 0 2 + Et3NH)+, 27], 102 
(Et3NH+, 100)
17 Synthesis of 1 D-myo-lnositol 4,5-bisphosphate 1-phosphorothioate
17.1 1D-(+)-1-0 -Allyl-2,3,6-tri-0 -benzyl-4,5-di-0 -[(-)-o)-camphanoyl]-/r7yo-
inositol 136
A mixture of DL-1-0 -allyl-2 ,3 ,6-tri-0 -benzyl-/7?yo-inositol (3.432 g, 7 mmol) and (- 
)-co-camphanic acid chloride (6.067 g, 28 mmol) in dry pyridine (50 ml) was 
stirred for 12 h at r.t. The solution was cooled in ice-water then water (0.5 ml)
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was added, and the solution was stirred for another 1 h at r.t., after which hptlc 
(ether:petroleum ether 1:1) showed two products (R, 0.52 and 0.42). Ether (100 
ml) and dichloromethane (50 ml) were added and the organic phase was washed 
successively with saturated aqueous potassium chloride, ice-cold M-hydrochloric 
acid, saturated aqueous potassium chloride and saturated aqueous sodium 
hydrogen carbonate (200 ml each) and then dried over magnesium sulphate. 
Evaporation of the solvents gave a syrup, which was taken up in ether (40 ml) 
and kept at -20°C overnight. The crystals formed (1.2 g) were filtered, the mother 
liquor evaporated, and the residue was dissolved in a mixture of ether (20 ml) 
and methanol (5 ml) to give more crystals (1 g). Overall yield: 2.2 g (2.6 mmol, 
74%) of 136.
m.p. 142-143°C (from ethyl acetate /  hexane):
[a]D21 = +19.4° (c = 5 in CHCI3);
Found C, 70.4; H 6.73. Calc for C50H58O12 (851.00): C, 70.57; H, 6.87 %.
5h (CDCI3, 300 MHz) 0.75 (6 H, 2 s, CH3), 0.91 (3 H, s, CH3), 0.95 (3 H, s, CH3),
1.03 (6 H, s, 2 CH3), 1.59-1.67 (2 H, m, CH2), 1.77-1.88 (4 H, m, 2 CH2), 2.27- 
2.39 (2 H, m, CH2), 3.44 (1 H, dd, J 9.7, 2.1, C-3-H), 3.55 (1 H, dd, J 10.7, 2.1, 
C-1-H), 3.96-4.09 (2 H, m, CH2CH=CH2), 4.14 (1 H, dd, J 2.0, 2.0, C-2-H), 4.17 
(1H, dd, J 9.6, 9.6, C-6-H), 4.45, 4.59 (2 H, AB, Jab 11.5, CH2Ph), 4.85, 4.87 (2 
H, AB, Jab 12.1, CH2Ph), 4.62, 5.02 (2 H, AB, Jab 11-3, CH2Ph), 5.18 (1 H, ddt, J
10.4, 1.4, 1.4, c/s-CH2CH=CH2), 5.27 (1 H .'ddt, J 17.2, 1.6, 1.6, trans- 
CH2CH=CH2), 5.34 (1 H, dd, J 9.6, 9.6, C-5-H), 5.76 (1 H, dd, J 9.9, 9.9, C-4-H),
5.83 (1 H, ddt, J 17.2,10.4, 5.7, CH2CH=CH2), 7.20-7.42 (15 H, m, CH2P/j);
5C (CDCI3, 68 MHz) 16.28,16.54, 16.64 (3 q), 28.80, 30.76 (2 1), 54.00, 54.78 (2 
s), 71.39, 71.84, 74.15 (3 t, CH2CH=CH2 and CH2Ph), 72.82, 73.37, 74.08,
78.07, 78.23, 80.18 (6 d, inositol ring C), 91.05 (s), 117.45 (t, CH2CH=CH2), 
126.85, 127.24, 127.34, 127.708, 127.83, 127.96, 128.18, 128.28, 128.39 (9 d, 
CHzPh), 134.12 (d, CH2CH=CH2), 137.04, 138.17 (3 S, CH2Ph), 166.36, 166.62, 
177.91 (3 s);
m/z (+ve ion FAB) 851 [(M+H)+, 7%], 181 (13), 109 (8), 91 (100)
17.2 1D-(+)-1-0-Allyl-2,3,6-tr!-0-benzyl-/nyo-inositol 137
The (+)-biscamphanate 136 (1.26 g, 1.48 mmol) was dissolved in 100 ml 
methanol containing 1.3 g NaOH. The solution was heated under reflux for 1 h
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when tic (ether) showed complete conversion of the starting material (Rf 0.79) to 
a single product (Rt 0.59). After cooling, the solution was neutralised with solid 
C 0 2. Water (100 ml) was added and the solution extracted twice with 100 ml 
chloroform each. The organic layers were dried over magnesium sulphate and 
the solvent evaporated to give 137 (703 mg, 1.44 mmol, 97 %).
m.p. 97-98°C (Lit. t168l: m.p. for the enantiomer 96-98 °C)
Found: C, 73.4; H, 6.92. Calc for C30H34O6 (490.60): C, 73.45; H, 6.99 %.
[“ Id18 = +21 -5° (c = 4 in CHCI3), (Lit. t168l: [a]D for the enantiomer - 20.5 °)
8h (CDCI3, 270 MHz) 2.56, 2.60 (2 H, 2 br s, D20  ex, OH), 3.20 (1 H, dd, J 9.7,
2.2, C-3-H), 3.28 (1 H, dd, J 9.7, 2.2, C-1-H), 3.42 (1 H, dd, J 9.3, 9.3, C-5-H),
3.87 (1 H, dd, J 9.4, 9.4, C-6-H), 4.04 (1 H, dd, J 9.5, 9.5, C-4-H), 4.06 (1 H, dd, 
J 2.5, 2.5, C-2-H), 4.10 (2 H, ddd, J 5.3, 1.4,1.4, CH2CH=CH2), 4.55, 4.61 (2 H, 
AB, 11.7, CH2Ph), 4.75, 4.96 (2 H, AB, 11.9, CH2Ph), 4.79, 4.89 (2 H, 
AB, Jab 11.2, CH2Ph), 5.19 (1 H, ddt, J 10.4,1.4, 1.4, cfe-CH2CH=CH2), 5.31 (1 
H, ddt, J 17.2, 1.6, 1.6, frans-CH2CH=CH2), 5.91 (1 H, ddt, J 17.2, 10.4, 5.3, 
CH2CH=CH2), 7.25-7.42 (15 H, m, CH2Ph);
6C (CDCI3, 68 MHz) 71.45, 72.26, 74.02, 75.35 (4 t, CH2CH=CH2 and CH2Ph),
72.20, 73.53, 74.60, 79.95, 80.76, 80.83 (6 d, inositol ring C), 116.73 (t, 
CH2CH=CH2), 127.37, 127.63, 127.70, 127.79, 127.96, 128.12, 128.38, 128.44 
(8 d, CH2P/j), 134.67 (d, CH2CH=CH2), 137.85,138.76 (2 s, CH2Ph); 
m/z (70 eV El) 399 [(M - C7H7)+, 2 %], 307, 181 (5), 131 (10), 109 (5), 91 
[(C7H7)+, 100];
m/z (Cl, Isobutane) 491 (M+H)+, 399 (10), 309,181 (20), 131 (20), 107 (100), 91 
(80), 69 (20)
17.3 1D-(+)-2,3,6-Tri-0-benzyl-1-0-(c/s-prop-1-enyl)-myo-inositol 138
137 (840 mg, 1.71 mmol) and freshly sublimed potassium ferf-butoxide (778 mg,
6.84 mmol) in dry DMSO (30 ml) was stirred for 3 h at 50°C. The solution was 
worked up as described for the racemic compound to give 138 (815 mg, 1.66 
mmol, 97%).
m.p. 116-118°C (from ethanol /  water)
Found: C, 73.3; H, 7.02. Calc for C30H34O6 (490.60): C, 73.45; H, 6.99 %.
[a]D11 = +40.6° (c = 4 in CHCI3)
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Mass spectra and NMR data were identical to 128.
17.4 1D-(+)-2,3,6-Tri-0-benzyl-4,5-bis[di(2-cyanoethoxy)phospho]-1-0- 
(c/s-prop-1-enyl)-/nyo-inositol 139
To a mixture of 138 (348 mg, 0.71 mmol) and tetrazole (615 mg, 8.8 mmol) in dry 
dichloromethane (20 ml) was added bis(2-cyanoethoxy)diisopropylamino 
phosphine (1.9 g, 7.1 mmol). After stirring at r. t. for 1 h, water in THF (10% v/v) 
was added and the solution was stirred for another 30 min. 2,6-Lutidine (0.5 ml) 
and tert-butyl hydroperoxide (5 ml) was then added and stirring continued 
overnight. Work-up as for 132 gave 139 (485 mg, 0.57 mmol, 80%).
m.p. 131-132°C (from ethanol)
Found: C, 58.6; H, 5.65; N, 6.51. Calc for (862.81) C, 58.47; H,
5.61 ;N , 6.49% .
[a]D19 = +11.5° (c = 3.5 in CHCI3)
Mass spectra and NMR data were identical to 132.
17.5 1D-(+)-2,3,6-Tri-0-benzyl-4,5-di-[bis-(2-cyanoethoxy)phospho]-/nyo- 
inositol 140
139 (200 mg, 232 pmol) was heated under reflux with 10 ml 1 M HCIimethanol 
(1:5) and work-up as for the racemic compound gave 140 (183 mg, 96 %) as a 
syrup.
[a]D15 = + 8.5° (c = 4.5 in CHCI3, Lit. P79! [a]D = +5)
Mass spectra and NMR data were identical to 133.
17.6 1D-(+)-2,3,6-Tri-0-benzyl-4,5-bis[di(2-cyanoethoxy)phospho]-1-[bis- 
(2-cyanoethoxy)thiophospho]-myo-inositol 141
Compound 140 (152 mg, 185 pmol) was phosphitylated and sulphoxidised 
analogously to the racemic compound to give 141 (140 mg, 137 pmol) after 
column chromatography.
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[a]D16 = +10.5° (c = 2.5 in CHCI3)
Mass spectra and NMR data were identical to 134.
17.7 1 D-(-)-myo-lnositol 4,5-bisphosphate 1-phosphorothioate 142
141 (50.6 mg, 49.4 pmol) was deprotected as for the racemic compound to give 
pure 142 (21.5 pmol, 44 %) after ion-exchange chromatography.
[a]D21 = -42.7° (c = 0.19 in H20 , pH = 9.4)
Mass spectra and NMR data were identical to 80.
18 Synthesis of 1 L-myo-lnositol 1,4,5-trisphosphorothioate
18.1 1 L-(-)-1 -0-Allyl-2,3,6-tri-0-benzyl-4,5-di-0-[(-)-co-camphanoyl]-/nyo-
inositol 143
The mother liquor left from the crystallisation of 136 was kept at -20°C for 
several days when a solid had formed at the bottom of the flask. The 
supernatant was filtered off and the solid dissolved in hot ether. After leaving the 
solution in the fridge for two days crystals had formed which were collected to 
give 143 (2.4 g, 2.8 mmol, 80 %).
m.p. 174-177°C (from ethyl acetate / hexane);
[a]D18 = -25.0° (c = 4.2 in CHCI3);
Found: C , 70.7; H 6.82. Calc for C 5oH580 12 (851.00): C, 70.57; H, 6.87 %.
5h (CDCI3, 270 MHz) 0.81 (3 H, s, CH3), 0.82 (3 H, s, CH3), 0.96 (3 H, s, CH3), 
0.98 (3 H, s, CH3), 1.04 (6 H, s, 2 CH3), 1.57-1.65 (2 H, m, CH2), 1.76-1.98 (4 H, 
m, 2 CH2), 2.16-2.26 (2 H, m, CH2), 3.39 (1 H, dd, J 9.9, 2.0, C-3-H), 3.56 (1 H, 
dd, J 9.9, 2.0, C-1-H), 4.01 (2 H, d, J 5.3, CH2CH=CH2), 4.05 (1 H, dd, J 1.5, 1.5, 
C-2-H), 4.16 (1H, dd, J 9.8, 9.8, C-6-H) 4.47, 4.54 (2 H, AB, JAB 11.7, CH2Ph), 
4.63, 4.95 (2 H, AB, JAB 11.2, CH2Ph), 4.86, 4.86 (2 H, AB, JAB 12.4, CH2Ph),
5.18 (1 H, ddt, J 10.4, 1.4, 1.4, c/s-CH2CH=CH2), 5.27 (1 H, ddt, J 17.2, 1.6, 1.6, 
fra/7S-CH2CH=CH2), 5.34 (1 H, dd, J 9.6, 9.6, C-5-H), 5.76 (1 H, dd, J 9.9, 9.9, 
C-4-H), 5.83 (1 H, ddt, J 17.2, 10.4, 5.7, CH2CH=CH2), 7.22-7.42 (15 H, m, 
CH2P/7);
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8C (CDCI3, 68 MHz) 16.28, 16.44, 16.54 (3 q), 28.70, 31.10 (2 t), 53.58, 53.74, 
54.56, 54.62 (4 s), 71.42, 71.97, 72.26, 74.79 (4 t, CH2CH=CH2 and CH2Ph) 
72.26, 73.56, 74.21 77.81, 78.49, 80.02 (6 d, inositol ring C), 90.66 (s), 117.16 
(t, CH2CH=CH2), 126.95, 127.42, 127.53, 127.66, 127.86, 128.12, 128.31 (7 d, 
CH2Ph), 134.21 (t, CH2CH=CH2), 137.23, 138.17, 138.24 (3 s, CH2P/?), 166.65,
177.87, 178.00 (3 s); 
m/z as 136
18.2 1 L-(-)-1-0-Allyl-2,3,6-tri-0-benzyl-/nyo-inositol 144
The (-)-biscamphanate 143 (2.37 g, 2.79 mmol) in 200 ml methanol containing
2.4 g NaOH was heated under reflux for 1 h. Work-up as for 137 gave 144 (1.36 
g, 2.78 mmol, 100 %).
m.p. 96-98°C (from ethanol, Lit. l168L 96-98 °C)
Found: C, 73.5; H, 6.94. Calc for C 3oH340 6 (490.60): C , 73.45; H, 6.99 %.
[a]D19 = -21.9° (c = 4.3 in CHCI3, Lit. l168L [a]D - 20.5 °)
Mass spectra and NMR data were identical to 127.
18.3 1 L-(-)-2,3,6-Tri-0 -benzyl-1- 0 -(c/s-prop-1-enyl)-/77yo-lnositol 145
144 (546 mg, 1.11 mmol) and freshly sublimed potassium tert-butoxide (505 mg,
4.44 mmol) in dry DMSO (20 ml) was stirred for 3 h at 50°C. The solution was 
worked up as described for the racemic compound to give 145 (536 mg, 1.09 
mmol, 98%).
m.p. 117-119°C (from ethyl acetate / hexane)
Found: C, 73.6; H, 6.98. Calc for C30H34O6 (490.60): C, 73.45; H, 6.99 %.
[a]D19 = -41.1° (c = 4.3 in CHCI3)
Mass spectra and NMR data were identical to 128.
18.4 1 D-(-)-1,2,4-tri-0-benzyl-/nyo-inositol 146
145 (413 mg, 843 pmol) was heated under reflux for 30 min after which tic 
(ether) showed complete conversion of the starting material (Rf 0.90) to a single 
product (Rf 0.59). The solution was allowed to cool and an excess of NaHC03
201
was added. The solvent was evaporated and the residue was extracted with 
chloroform, dried over magnesium sulphate and the solvent evaporated to give 
146 (329 mg, 731 pmol, 87 %).
m.p. 116-118°C (from ethanol / water, Lit. I168! 118-120°C, Lit. I396l 117-119°C for 
the enantiomer)
[a]D18 = -10.1° (c = 2.5 in CHCI3, Lit. I168] -9.0°, Lit. I396! +15.5° for the 
enantiomer)
5h (CDCI3, 400 MHz) 2.3-2.7 (3 H, br s, D20  ex, 3 OH), 3.27 (1 H, dd, J 9.7, 2.6, 
C-1-H), 3.46 (1 H, dd, J 9.1, 9.1, C-5-H), 3.52 (1 H, dd, J 9.5, 2.6, C-3-H), 3.68 
(1 H, dd, J 9.2, 9.2, C-4-H), 4.01 (1 H, dd, J 9.5, 9.5, C-6-H), 4.07 (1 H, dd, J 2.6,
2.6, C-2-H), 4.58, 4.68 (2 H, AB, JAB 11.7, CH2Ph), 4.83, 4.87 (2 H, AB, JAB
11.5, CH2Ph), 4.72, 4.92 (2 H, AB, JAB 11.3, CH2Ph), 7.28-7.33 (15 H, m, 
CH2P/7)
m/z (+ve ion FAB) 901 [(2M+H)+, 2 %], 499 [(M-H)+, 9], 181 (20), 91 (100) 
m/z (-ye ion FAB) 603 [(M+NBA)-, 100 %], 449 [(M-H)-, 70]
18.5 1 L-(-)-2,3,6-tri-0-benzyl-1,4,5-[bis(2-cyanoethoxy)thiophospho]-/nyo- 
inositol 147
Bis(2-cyanoethoxy)(diisopropylamino)phosphine (1.27 g, 4.74 mmol) was added 
to a solution of 146 (142 mg, 316 pmol) and tetrazole (399 mg, 5.69 mmol) in 
dichloromethane (15 ml). The mixture was stirred at r.t. for 1 h, after which tic 
(chloroform / acetone 9:1) showed complete conversion of the starting material 
(Rf 0.24) into a product (Rf 0.38) and 31P-NMR showed three phosphite triester 
peaks at 141.13, 140.53 and 139.65 ppm. Dry pyridine (5 ml) and sulphur (500 
mg, 15.6 mmol) was added and the suspension stirred overnight. Tic showed 
conversion of the triphosphite into a new product (Rf 0.37). The solvent was 
evaporated and the residue chromatographed on silica gel to give 147 (332 mg, 
314 pmol, 99 %) as a syrup.
[a]D17= -15.9° (c = 3.5 in CHCI3)
5h (CDCI3i 270 MHz) 1.95-2.41 (4 H, m, CH2CH2CN), 2.58-2.62 (2 H, m, 
CH2CH2CN), 2.73-2.82 (6 H, m, CH2CH2CN), 3.64 (1 H, dd, J 9.9, 2.8, C-3-H), 
3.68-3.89 (2 H, m, CH2CH2CN), 3.98-4.55 (14 H, m, CH2CH2CN, C-2-H, C-6-H, 
C-5-H, C-1-H), 4.60, 4.78 (2 H, AB, JAB 11.7, CH2Ph), 4.88 (2 H, AB, CH2Ph),
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4.81, 4.95 (2 H, AB, JAB 11.6, CH2Ph), 5.19 (1 H, q, J 9.5, C-4-H), 7.34-7.43 (15 
H, m, CH2P/7)
5C (CDCI3, 68 MHz) 18.36, 18.52, 18.81, 18.94, 19.23, 19.40, 19.53 (7 t, 
CH2CH2CN), 62.44, 62.63, 62.73, 62.79, 62.86, 62.99, 63.09 (7 t, CH2CH2CN), 
72.16, 73.92, 75.22 (3 t, CH2Ph), 74.57, 77.42, 77.78, 78.69, 78.78, 79.63 (6 d, 
inositol ring C), 116.38, 116.44, 116.60, 116.73, 116.96, 117.03 (6 s, CN),
125.88, 127.24, 127.53, 127.73, 127.83, 127.99, 128.44, 128.60 (8 d, CH2Ph), 
137.17, 137.88, 138.21 (3 s, CH2Ph)
8P (CDCI3, 36 MHz) 66.70, 66.43, 66.25
m/z (+ve ion FAB) 1057 [(M+H)+, 5.4 %], 91 (100)
m/z (-ve ion FAB) 1001 [(M - CH2CH2CN)-, 30 %], 219 (100)
18.6 1 L-myo-lnositol 1,4,5-trisphosphorothioate 148
Ammonia was condensed into a three neck flask at -78°C. An excess of sodium 
was added to dry the liquid ammonia which was then distilled into a second 
three neck flask and kept at -78°C. Sodium was added until the solution 
remained blue. 147 (150 mg, 142 pmol) was dissolved in dry dioxane (1 ml) and 
added to the sodium-liquid ammonia mixture. After stirring for 15 min the 
reaction was quenched by adding ethanol to the mixture (the colour of the 
solution turned white). The ammonia was evaporated and the crude product was 
purified by ion-exchange chromatography on DEAE Sephadex A-25 eluting with 
a gradient of triethylammonium bicarbonate buffer (0.1 M to 1 M), pH 8.0. The 
triethylammonium salt of 148 eluted at a buffer concentration of ca. 800 mM. 
Yield 129 pmol (91 %).
5h (D20 , pH 8 ; 400 MHz) 3.76 (1 H, dd, J 9.5, 2.8, C-3-H), 3.98 (1 H, dd, J 9.5,
9.5, C-6-H), 4.16-4.34 (2 H, m, C-1.5-H), 4.39 (1 H, dd J 2.8, 2.8, C-2-H), 4.54 (1
H, m, C-4-H).
8P (D20 ; pH 8 ; 36 MHz) 44.82, 44.69, 42.06 
m/z (-ve ion FAB) 467 [(M-H)-, 100 %]
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19 Synthesis of myo-Inositol 1,3,5-trisphosphorothioate
19.1 (1 R, 3 S, 5 S, 6 R, 7 S, 8 S, 9 S)-2,4,10-trioxatricyclo [3.3.1.13»7] 
decane-6,8,9-triol [ = myo-lnositol orthoformate] 150
This compound was prepared according to the method of Billington et al. l161l.
Purification by flash chromatography was performed according to Baudin et al. 
[159].
To a suspension of myoinositol (50 g, 278 mmol) and toluene-/>sulphonic acid 
(13.83 g, 73 mmol) in dry DMF (700 ml), triethyl 'orthoformate (83 ml, 500 mmol) 
was added dropwise under N2 at 140°C. The solution was stirred for 3 h at 
140°C and then allowed to cool. DMF was distilled off at reduced pressure at 70° 
to 80°C. The residue was treated with 100 ml of 10 % sodium 
hydrogencarbonate solution, stirred for 15 min at r.t., diluted with water (1 litre) 
and extracted 3 times with 250 ml of CHCI3. The aqueous phase was lyophilised, 
the residue treated with methanol (2 litres) at 50°C, and the suspension filtered. 
Methanol was evaporated under vacuum. Flash chromatography with acetonitrile 
(crude product dissolved in water) gave 40.47 g (77 %) of 150.
m.p. 297-300°C (Lit. [161.158] 300-302°C,
8h (CD3OD, 270 MHz) 4.06-4.09 (2 H, m), 4.12-4.17 (2 H, m), 4.40-4.44 (2 H, 
m), 5.41 (1 H, d, J 1.3 Hz, OOOCH)
8C (CD3OD, 68 MHz) 61.33 (d), 69.35 (2 d), 70.84 (d), 76.25 (2 d), 104.21 (d, 
HCOOO)
m/z (Cl, Isobutane) 191 [(M+H)+, 80 %], 173 [(M : OH)+, 30], 73 (100)
19.2 2,4,6-Tri-O-butyryl-myo-inositol orthoformate 151
A mixture of 10 (1.9 g, 10 mmol), DMAP (50 mg, 4.1 mmol), butyric anhydride (8 
ml, 0.1 mol) and dry pyridine (50 ml) was stirred at r.t. for 1 h, after which tic 
(hexane /  ethyl acetate 3:1) showed complete conversion of the starting material 
(Rf 0.00) into a single product (Rf 0.66). Methanol (50 ml) was added to the 
solution and stirring continued for another 30 min. The solvents were evaporated 
and the residue taken up in chloroform (50 ml). The solution was washed 
successively with 1 M HCI, sat. NaHC03 solution (2 x 50 ml) and water (50 ml 
each) and then dried over magnesium sulphate. Evaporation of the solvent gave
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a syrup which was recrystallised from petrol ether (b.p. 60-80°C) to give 151 
(3.58 g, 89 %).
m.p. 68-68.5°C
Found: C, 57.0; H, 7.10. Calc for C19H280 9 (400.43): 56.99; H, 7.05 %.
8H (CDCI3, 270 MHz) 0.97 (6 H, t, J 7.4, 2 butyrate CH3), 0.99 (3 H, t, J 7.4, 
butyrate CH3),1.70 (6 H, tq, J 7.5, 7.5, 3 butyrate Ctf2CH3), 2.21-2.40 (4 H, m, 2 
butyrate COCH2), 2.45 (2 H, t, J 7.4, butyrate COCH2), 4.31-4.33 (2 H, m, C-1-H, 
C-3-H), 4.55 (1 H, tq, J 1.7, 1.7, C-5-H), 5.17 (1 H, d, J 1.5, C-2-H), 5.54 (2 H, t, 
J 3.8, C-4-H, C-6-H), 5.60 (1 H, d, J 1.1, HCOOO)
8C (CDCI3, 68 MHz) 13.56 (3 q, butyrate CH3), 18.16 (2 t, butyrate CH2CH3), 
18.29 (t, butyrate CH2CH3), 35.84 (2 t, butyrate COCH2), 35.94 (t, butyrate 
COCH2), 62.83 (d, C-5), 66.72 (2 d, C-1, C-3), 67.43 (2 d, C-4, C-6), 69.15 (d, C- 
2), 103.05 (d, HCOOO), 171.81 (2 s, CO), 173.14 (s, CO) 
m/z (Cl, Isobutane) 401 [(M+H+), 75 %], 71 (100)
19.3 2,4,6-Tri-0-butyryl-/nyo-inositol 152 and DL-2,4,6-Tri-0-butyryl-1-0- 
formyl-myo-inositol 153
A solution of 151 (400 mg, 1 mmol) in 80% trifluoroacetic acid (10 ml) was stirred 
for 4 h at r.t. after which tic (ether / hexane 2:1) showed conversion of the 
starting material (Rf 0.74) into a major and a minor product (Rf 0.12 and 0.28, 
respectively). The solvents were evaporated at 45°C and the residue partitioned 
between chloroform and sat. NaHC03 solution. The organic layer was dried over 
magnesium sulphate, the solvent evaporated and the product mixture separated 
by flash chromatography (petrol ether / ether 1:1) to give 152 (246 mg, 63 %) 
and 153 (59 mg, 14%).
DL-2,4,6-Tri-0-butyryl-/nyo-inositol 152:
m.p. 112-114°C (from ethyl acetate / hexane)
Found: C, 55.1; H, 7.83. Calc for C18H30O9 (390.43): C, 55.37; H, 7.74 %.
8h (CDCI3, 270 MHz) 0.95 (6 H, t, J 7.5, 2 butyrate CH3), 0.98 (3 H, t, J 7.5, 
butyrate CH3), 1.59-1.75 (6 H, m, 3 butyrate CH2CH3), 2.37 (4 H, t, J 7.3, 
butyrate COCH2), 2.47 (2 H, t, J 7.4, butyrate COCH2), 3.08 (1 H, d, J 7.0, D20
205
ex, OH), 3.26 (2 H, d, J 5.9, D20  ex, 2 OH), 3.56 (1 H, brd dd, J 9.7, 9.7, D20  ex 
gives dd, J 9.5, 9.5, C-1-H), 3.75-3.79 (2 H, m, D20  ex gives dd, J 10.0, 2.7, C- 
3-H, C-5-H), 5.14 (2 H, dd, J 9.9, 9.9, C-4-H, C-6-H), 5.49 (1 H, dd, J 2.8, 2.8, C-
2-H)
8C (CDCI3, 68 MHz) 13.30 (q, butyrate CH3), 18.13 (t, butyrate CH2CH3), 35.91 
(t, butyrate COCH2), 68.66 (2 d, C-1, C-3), 71.23 (d, C-5), 73.50 (d, C-2), 74.70 
(2 d, C-4, C-6), 174.27 (s, butyrate CO), 174.53 (2 s, butyrate CO) 
m/z (+ve ion FAB) 781 [(2 M + H)+, 1.2 %], 391 [(M+H)+, 9], 373 [(M - OH)+, 100], 
303 [(M - OH - COCH2CH2CH3)+, 37]
m/z (-ve ion FAB) 543 [(M + NBA)-, 54 %], 389 [(M - H)-, 78], 122 (45), 87 (100) 
DL-2,4,6-Tri-0-butyryl-1-0-formyl-/nyo-inositol 153:
8h (CDCI3, 270 MHz) 0.93, 0.96, 0.99 (9 H, 3 1, J 7.3, 3 butyrate CH3), 1.56-1.75 
(6 H, m, butyrate CH2CH3), 2.32, 2.40, 2.45 (6 H, 3 t, J 7.5, butyrate COCH2), 
2.80, 2.92 (2 H, 2 brd s, D20  ex, 2 OH), 3.65 (1 H, brd dd, D20  ex gives dd, J
9.8, 9.8, C-5-H), 3.85 (1 H, brd d, J 9.2, D20  ex gives dd, J 10.1, 2.9, C-3(1)-H),
5.08 (1 H, dd, J 10.4, 2.7, C-1(3)-H, 5.20 (1 H, dd, J 10.0, 10.0, C-6(4)-H), 5.40 
(1 H, dd, J 10.1, 10.1, C-4(6)-H), 5.62 (dd, 1 H, J 2.8, 2.8, C-2-H), 7.94 (1 H, s, 
OCOH)
5C (CDCI3, 68 MHz) 13.36 (q, butyrate CH3), 13.43 (2 q, 2 butyrate CH3), 18.29 
(2 1, 2 butyrate CH2CH3), 18.36 (t, butyrate CH2CH3), 35.94 (t, butyrate COCH2), 
36.00 (t, butyrate COCH2), 68.57, 68.63, 70.29, 71.32, 71.55, 74.66 (6 d, inositol 
ring C), 159.61 (d, formyl CO), 173.11,173.30,174.66 (3 s, butyrate CO) 
m/z (Cl, Isobutane) 419 [(M+H)+, 5 %], 401 [(M - OH)+, 60], 331 [(M - OH - 
COCH2CH2CH3)+, 31), 89 (45), 71 (100)
19.4 2,4,6-Tri-Op-methoxybenzyl-/nyo-inositol orthoformate 154
NaH (5.33 g of a 60 % dispersion, 113 mmol) was added to a stirred solution of 
149 (5 g, 26 mmol) in anhydrous DMF (250 ml) at r.t. The mixture was stirred for 
20 min, after which p-methoxybenzyl chloride (17.6 ml, 20.36 g, 130 mmol) was 
added. The suspension was stirred overnight, after which tic (hexane / ethyl 
acetate 1:1) showed a product (Rf 0.41). The reaction was quenched with water 
(10 ml), the solvents were evaporated and the residue partitioned between 
chloroform (200 ml) and water (50 ml). The organic phase was washed with
206
brine, dried over magnesium sulphate and evaporated to give a syrup which was 
chromatographed on silica gel (eluent ether / hexane 2:1) to give 154 (11.2 g,
20.3 mmol, 78 %)
m.p. 47-48°C (from ethanol / water)
Found: C, 67.4; H, 6.13. Calc for C31H3409 (550.61): C, 67.62; H, 6.22 %.
5h (CDCI3i 270 MHz) 3.76 (3 H, s, OCH3), 3.79 (6 H, s, 2 OCH3), 4.00 (1 H, brd 
s, C-5-H), 4.24 (2 H, brd s, 2 C-H), 4.29 (2 H, brd s, 2 C-H), 4.35 - 4.54 (5 H, m, 
2 CH2Ph, C-2-H), 4.58 (2 H, s, CH2Ph), 5.51 (1 H, s, 0 3CH), 6.80 (4 H, d, J 8.4, 
arom.), 6.83 (2 H, d, J 8.6, arom.), 7.10 (4 H, d, j  8.2, arom.), 7.28 (2 H, d, J 8.4, 
arom.)
8C (CDCI3, 68 MHz) 55.07 (q, OCH3), 66.65 (d, 2 inositol ring C), 68.08 (d, 
inositol ring C), 70.48 (d, 2 inositol ring C), 71.00 (t, CH2PhOMe), 73.66 (d, 
inositol ring C), 103.08 (d, 0 3CH), 113.62 (d, 6 PhOMe C), 129.12 (d, 4 P/OMe  
C), 129.58 (d, 2 PhOMe C), 134.57 (s, 3 PhOMe C), 159.16 (s, 3 P/OMe C) 
m/z (+ve ion FAB) 551 [(M + H)+, 2 %], 429 [(M - CH2C6H4OCH3)+, 6], 121 
[(CH2C6H4OCH3)+, 100]
m/z (-ve ion FAB) 703 [(M + NBA)-, 25 %], 535 (30), 322 (55), 188 (100)
19.5 2,4,6-Tri-0-p-methoxybenzyl-/nyo-inositol 155
154 (5.6 g, 10.2 mmol) was heated under reflux in a mixture of 2M HCI (10 ml) 
and methanol (200 ml) for 30 min, when tic (hexane / ethyl acetate 1:2) showed 
conversion of the starting material (Rf 0.67) into a product (Rf 0.35). The solution 
was cooled to r.t. and adjusted to pH 8 with ammonia solution. The solvents 
were evaporated and the residue extracted with ethyl acetate (2 x 200 ml). The 
combined extracts were evaporated and the crude product was 
chromatographed on silica gel using ether -> ether / ethyl acetate 1:1 as eluent 
to give 155 (4.7 g, 8.7 mmol, 85 %).
m.p. 110-112°C (from ethyl acetate / hexane)
Found: C, 66.7; H, 6.77. Calc for C30H36O9 (540.61): C, 66.65; H, 6.71 %.
5h (CDCI3, 270 MHz) 2.45 (2 H, d, J 5.7, D20  ex, 2 OH), 2.66 (1 H, brd s, D20  
ex, OH), 3.40 - 3.55 (3 H, m, C-1,3,5-H), 3.61 (2 H, dd, J 9.25, 9.25, C-4.6-H), 
3.77 (6 H, s, 2 OCH3), 3.80 (3 H, s, OCH3), 3.90 (1 H, dd, J 3.0, 3.0, C-2-H), 
4.73 (2 H, s, CP2Ph), 4.76 (4 H, s, 2 CH2Ph), 6.87 (4 H, d, J 8.6, CH2P/?OMe),
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6.89 (2 H, d, J 8.6, CH2P/70Me), 7.24 (2 H, d, J 8.6, CH2P/?OMe), 7.29 (4 H, d, J
8.6, CH2P/rOMe)
8C (CDCI3, 68 MHz) 55.14 (q, OCH3), 72.33 (d, 2 C, inositol ring C), 74.47 (t, 
CH2Ph), 74.79, 78.95 (2 d, 2 C, inositol ring C), 81.48 (d, 2 C, inositol ring C),
113.78 (d, 2 PhOMe C), 113.85 (d, 4 PhOlAe C), 129.45 (d, 2 P/rOMe C), 129.61 
(d, 4 PhOMe C), 130.58 (s, PhOMe), 159.22 (s, P/rOMe) 
m/z(+ve ion FAB) 539 [(M-H)+, 1.5 %], 419 (5), 121 [(CH2C6H4OCH3)+, 100] 
m/z (-ve ion FAB) 706 (36 %), 693 [(M + NBA)-, 57], 539 [(M -H)-, 100], 419 [(M - 
CH2C6H4OCH3)-, 38]
19.6 Diisopropylaminodichlorophosphine 156
This compound was prepared according to the method of Tanaka etal. I382l.
A solution of diisopropylamine (350.5 ml, 2.5 mol) in dry ether (350 ml) was 
added dropwise over 1 h to a stirred solution of PCI3 (109 ml, 1.25 mol) in dry 
ether (350 ml) at -78°C. After the addition the mixture was stirred a further 1 h at 
-78°C and then allowed to warm to room temperature. The precipitate was 
filtered and the solvent was evaporated. The crude product was distilled at 
reduced pressure to give 156 (158 g, 0.78 mol, 63 %).
b.p. 52°C / 0.6 mbar (Lit. P82] 72-73°C / 7 mmHg)
8P (CDCI3; 36 MHz) 166.44
19.7 Bis(benzyloxy)(diisopropylamino)phosphine 157
156 (50.5 g, 0.25 mol) and triethylamine (69.7 ml, 50.6 g, 0.5 mol) were stirred in 
dry CH2CI2 (250 ml) at -78°C. Benzyl alcohol (51.7 ml, 54.1 g, 0.5 mol) in dry 
CH2CI2 (35 ml) was added dropwise over a period of 30 min. Cooling was 
removed and stirring continued for a further 4 h. The precipitate was filtered and 
the solvent was evaporated. The crude product was chromatographed on silica 
gel (hexane / triethylamine 10:1) to give 157 (72.1 g, 0.21 mol, 83 %).




A mixture of 155 (541 mg, 1 mmol) and tetrazole (1.26 g, 18 mmol) was stirred at 
r.t. in dichloromethane (30 ml). 157 (6.2 g, 15 mmol) was added and stirring 
continued for 1 h. Pyridine (5 ml) and sulphur (500 mg) were added and stirring 
continued overnight. Tic (ethyl acetate / hexane 2:1) showed one product (Rf 
0.81). The solution was partitioned between. chloroform and sat. aqueous 
NaHC03> the organic phase was dried over magnesium sulphate and the 
solvents evaporated. The residue was chromatographed on silica gel to give to 
give 158 (835 mg, 61 %) as a syrup.
8H (CDCI3, 270 MHz) 3.70 (6 H, 2 s, OCH3), 3.76 (3 H, s, OCH3), 4.07 (2 H, dd, J
9.5, 9.5, C-4.6-H), 4.43 (2 H, ddd, J 10.3, 10.3, 2.2, C-1,3-H), 4.60-5.10 (20 H, 
m, 9 CH2Ph, C-2-H, C-5-H), 6.71 (4 H, d, J 8.6, CH2P/TOMe), 6.80 (2 H, d, J 8.8, 
CH2PftOMe), 6.98 (4 H, dd, J 7.6, 1.9, CH2P/70Me), 7.11-7.35 (32 H, m, 
CH2PhOMe and CH2Ph).
8C (CDCI3, 68 MHz) 54.16 (q, OCH3), 68.56, 68.73, 68.89, 69.02, 72.71, 74.14 (6 
t, CH2Ph), 76.12 (d, 1 inositol ring C), 76.54 (d, 2 inositol ring C), 76.70 (d, 2 
inositol ring C), 78.91 (d, 1 inositol ring C), 112.38 (d, 4 PhOMe C), 112.54 (d, 2 
PhOMe C), 126.89, 126.95, 127.21, 127.27, 127.34, 127.43, 127.56, 127.66, 
127.76, 128.05 (10 d, CH2P/7and PhOMe), 129.35 (s, 2 PhOMe C), 129.67 (s, 1 
PhOMe C), 134.54, 134.67, 134.80, 134.93 (4 s,C H 2Ph), 157.73 (s, PhOMe C) 
8P (CDCI3, 36 MHz)
m/z (+ve ion FAB) 1370 [(M + H)+, 0.17 %], 1247 (0.3), 121 [(CH2C6H4OCH3)+, 
100], 91 [(CH2C6H5)+, 37]
m/z (-ve ion FAB) 1277 [(M - C7H7)-, 10 %), 293 [(OP(S)(OCH2C6H5)2-, 100], 95 
(55)
19.9 /tfyo-inositol-1,3,5-trisphosphorothioate 159
Ammonia was condensed into a three neck flask at -78°C. An excess of sodium 
was added to dry the liquid ammonia which was then distilled into a second 
three neck flask and kept at -78°C. Sodium was added until the solution 
remained blue. Compound 158 (237 mg, 173 pmol) was dissolved in dry dioxane 
(2 ml) and added to the sodium in liquid ammonia. After stirring for 15 min the
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reaction was quenched with ethanol. Ammonia and ethanol were evaporated 
and the crude product was purified by ion-exchange chromatography on 
Pharmacia Q Sepharose Fast Flow eluting with a gradient of triethylammonium 
bicarbonate buffer (0.1 M to 1 M), pH 8.0. The triethylammonium salt of 159 
eluted between 450 mM and 530 mM. Yield: 157 pmol (91%).
5h (D20 , 270 MHz) 3.87 (2 H, dd, J 9.3, 9.3, C-4-H, C-6-H), 4.08 (1 H, ddd, J
10.3, 9.2, 9.2, C-5-H), 4.19 (2 H, ddd, J 10.3, 10.3, 2.5, C-1-H, C-3-H), 4.62 (1 H, 
brd s, C-2-H)
8C (D20 , 68 MHz) 69.63 (1 C, d, C-2), 70.83 (2 C, d, C-4, C-6), 74.29 (2 C, dd, J 
c-O-p 6.6, C-1, C-3), 78.41 (1 C, dd, J C_0 .P 6.6, C-5)
5P (D20 , 36 MHz) 47.74 (1 P, d, J 10.1, 5-P), 46.55 (2 P, d, J 1 0 .1 ,1-P, 3-P)
m/z (-ve ion FAB) 466 [100 %, (M - H)-J, 432 (15), 238 (15), 113 (17), 95 
[(PS02)-. 40]
Accurate mass calc for C6H140 12P3S3 (M - H)- 466.886, found 466.886;
20 Synthesis of scyllo-Inositol 1,2,4-trisphosphate
20.1 DL-1-0-Allyl-3,6-di-0-benzyl-4,5-0-isopropylidene-2-0-trifluoro- 
methylsulphoxy-myo-inositol 160
A solution of 1-0-Allyl-3,6-di-Obenzyl-4,5-Oisopropylidene-/77yo-inositol 93 
(8.604 g, 19.5 mmol) and dry pyridine (10 ml) in dry dichloromethane (50 ml) 
was cooled to -78°C. Trifluoromethylsulphonic anhydride (6 ml, 10 g, 35.4 mmol) 
was added dropwise to the mixture. After the addition, cooling was removed and 
stirring continued for 2 h at r.t., after which tic (petrol / ether 1:1) showed 
complete conversion of the starting material (Rf 0.39) to a product (Rf 0.62). The 
reaction was quenched with water (10 ml), diluted with dichloromethane (50 ml) 
and washed successively with sat. NaHC03, water and brine (100 ml each). The 
organic layer was dried over magnesium sulphate and the solvents evaporated 
in vacuo. Toluene was added to the orange syrup in order to remove the 
remaining pyridine, which was then evaporated to give 160 as a yellow solid in 
quantitative yield.
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5h (CDCI3; 270 MHz) 1.45 (3 H, s, CH3), 1.49 (3 H, s. CH3), 3.39 (1 H, t, J 10.1, 
C-5-H), 3.43 (1 H, dd, J 8.8, 3.1, C-3(1)-H), 3.68 (1 H, dd, J 10.5, 2.8, C-1(3)-H),
3.86 (1 H, dd, J 9.9, 9.0, C-4(6)-H), 3.88 (1 H, dd, J 10.4, 9.3, C-6(4)-H), 4.10- 
4.25 (2 H, m, CH2-CH=CH2), 4.78 (2 H, AB, JAB 12.5, CH2Ph), 4.76, 4.88 (2 H, 
AB, Jab 11.5, CH2Ph), 5.23 (1 H, t, J 2.9, C-2-H), 5.17-5.32 (2 H, m, CH2- 
CH=CH2), 5.99 (1 H, ddt, J 17.3, 10.35, 5.9, CH2-CH=CH2), 7.25-7.37 (10 H, m, 
CH2P/j);
8C (CDCI3; 68 MHz) 26.87 (q, CH3), 71.86, 73.06, 73.54 (3 t, 2 CH2Ph and 
CH2CH=CH2), 73.57, 76.88, 77.70, 78.08, 78.93, 85.84 (6 d, 6 inositol ring C), 
112.40 (S, (CH3)2C), 118.21 (t, CH2CH=CH2), 125.28 (CF3), 127.52, 127.58, 
127.78, 128.23, 128.36, 128.59, 129.01 (7 d, CH2P/?), 133.78 (d, CH2CH=CH2), 
137.15,138.28 (2 s, CH2Ph);
m/z (+ve ion FAB) 573 [(M + H)+, 2 %], 502 [(M - HCF3)+, 13), 91 (100)
20.2 DL-2-0-Acetyl-1 -0-allyl-3,6-di-0-benzyl-4,5-isopropylidene-scy//o- 
inositol 161
A mixture of crude 160 (5.73 g, 10 mmol) and caesium acetate (2.78 g, 15 mmol) 
in dry DMF (150 ml) was stirred at r.t. for 2 h after which tic (petrol /  ether 1:1) 
showed conversion of the starting material (R, 0.62) into a product (Rf 0.70). The 
solution was concentrated in vacuo and the residue was partitioned between 
water and chloroform (100 ml each). The organic layer was dried over 
magnesium sulphate and evaporated. The crude product was purified by 
chromatography (ether /  petrol 1:1) to give 161 (4.39 g, 9.1 mmol, 91 %).
m.p. 108-110°C (from hexane)
Found: C, 69.5; H, 7.07. Calc, for C28H340 7 (482.57): C, 69.69; H, 7.10 %.
8h (CDCI3; 270 MHz) 1.47 (6 H, s, 2 CH3), 2.03 (3 H, s, COCH3), 3.45 (1 H, dd, J
9.3, 8.2, C-H), 3.49-3.63 (3 H, m, C-H), 3.71 (1 H, dd, J 9.2, 8.2, C-H), 4.05,
4.29 (2 H, AB, dt, 12.6, J 5.7, 1.5, CH2CH=CH2), 4.61, 4.85 (2 H, AB,
12.4, CW2Ph), 4.71, 4.88 (2 H, AB, JAB 11.7, CH2Ph), 5.08-5.22 (2 H, m, 
CH2CH=CH2), 5.15 (1 H, t, J 8.8, C-2-H), 5.81 (1 H, ddt, CH2CH=CH2, J 17.2,
10.4, 5.6), 7.24-7.39 (10 H, m, CH2Ph)
8C (CDCI3; 68 MHz) 20.92 (q, COCH3), 26.95 (2 q, CH3), 72.07, 72.98, 74.11 (3 
t, CH2Ph and CH2CH=CH2), 74.66, 76.77, 78.56, 78.88, 79.34, 81.61 (6 d,
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inositol ring C), 112.58 (s, (CH3)2C), 116.77 (t, CH2CH=CH2), 127.44, 127.50, 
127.70, 128.18, 128.22 (5 d, CH2Ph), 134.67 (d, CH2CH=CH2), 138.30 (s, 
CH2P/j), 169.70 (s, CO);
m/z (+ve ion FAB) 483 [(M + H)+, 4.5 %], 91 (100)
m/z (-ve ion FAB) 635 [(M + NBA)-, 60 %], 485 (50), 212 (100)
20.3 DL-1 -0-Allyl-3,6-di-0-benzyl-4,5-0-isopropylidene-scy//o-inositol 162
A mixture of 161 (3.19 g, 6.6 mmol) in methanol (50 ml) and 1 M aqueous 
sodium hydroxide (6 ml) was heated under reflux for 30 min after which tic 
(petrol /  ether 1:1) showed complete conversion of the starting material (Rf 0.70) 
into a product (Ftf 0.63). The solution was allowed to cool and neutralised with 
solid carbon dioxide. The solvent was evaporated and the residue partitioned 
between water and chloroform. The organic phase was dried over magnesium 
sulphate and evaporated to give 162 as a white solid (2.46 g, 5.6 mmol, 85 %).
m.p. 101-103°C (from hexane, Lit. t168i 105-106°C)
Found: C, 70.7; H, 7.26. Calc, for C26H320 6 (440:54): C; 70.89; H, 7.32 %.
8h (CDCI3; 270 MHz) 1.46 (6 H, s, 2 CH3), 2.73 (1 H, d, J 2.4, D20  ex, OH), 3.39 
(1 H, t, J 8.5, C-H), 3.51-3.64 (5 H, m, 5 C-H), 4.28, 4.39 (2 H, AB, dt, 12.5, 
3J 5.8, 4J 1.5, CH2CH=CH2), 4.72, 4.90 (2 H, AB, 11.7, CH2Ph), 4.72, 4.93 (2 
H, AB, Jab 11.7, CH2Ph), 5.16 (1 H, ddt, J 10.3, 1.4,1.4, os-CH2-CH=CH2), 5.26 
(1 H, ddt, J 17.2, 1.5, 1.5, frans-CH2-CH=CH2), 5.94 (1 H, ddt, J 17.2, 10.4, 5.7, 
CH2-CH=CH2), 7.24-7.40 (10 H, m, CHzPh)
Sc (CDCI3; 68 MHz) 26.92 (q, CH3) 72.65, 72.95, 74.37 (3 t, CH2Ph and 
CH2CH=CH2), 75.90, 78.43, 78.49, 79.11, 79.37, 83.39 (6 d, inositol ring C),
112.29 (S, (CH3)2C), 116.96 (t, CH2CH=CH2), 127.44, 127.60, 127.66, 127.83, 
128.22, 128.31 (6 d, CH2P/j), 134.99 (d, CH2CH=CH2), 138.27, 138.43 (2 s, 
CH 2Ph)
m/z (+ve ion FAB) 441 [(M +H)+, 8 %], 91 (100)
m/z (-ve ion FAB) 593 [(M + NBA)-, 100 %], 440 (M-, 30)
20.4 DL-2-0-Acetyl-1-0-allyl-3,6-di-0-benzyl-scy//o-inositol 163
A solution of 161 (3.57 g, 7.4 mmol) in methanol /  1 M HCI 9:1 (100 ml) was 
heated under reflux for 20 min after which tic (ethyl acetate /  hexane 1:1)
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showed complete conversion of the starting material (Rf 0.85) into a product (Rf 
0.44). The mixture was allowed to cool and neutralised with NaHC03. The 
solution was concentrated and then partitioned- between water and chloroform 
(100 ml each). The organic phase was dried over magnesium sulphate and 
evaporated to give 163 (2.7 g, 6.1 mmol, 83 %).
m.p. 142-143°C (from ethyl acetate / hexane)
Found: C, 67.8; H, 6.80. Calc, for C25H3o07 (442.51): C, 67.86; H, 6.83 %.
8h (CDCI3; 270 MHz) 2.00 (3 H, s, COCH3), 2.87 (1 H, d, J 2.4, D20  ex, OH),
3.03 (1 H, d, J 2.4, D20  ex, OH), 3.32-3.57 (5 H, m, C-1,3,4,5,6-H) 4.09, 4.28 (2 
H, AB, dt, JAB 12.5, 3J 5.7, 4J 1.5, CH2CH=CH2), 4.67, 4.76 (2 H, AB, JAB 11.6, 
CH2Ph), 4.76, 4.87 (2 H, AB, JAB 11.1, CH2Ph), 5.10 (1 H, dd, J 9.7, 9.7, C-2-H),
5.14 (1 H, ddt, J 10.4, 1.3, 1.3, c/s-CH2CH=CH2), 5.22 (1 H, ddt, J 17.2, 1.5, 1.5, 
trans-CH2CH=CH2), 5.84 (1 H, ddt, J 17.2, 10.4, 5.7, CH2CH=CH2), 7.24-7.37 
(10 H, m, CH2P/7)
5C (CDCI3; 68 MHz) 20.98 (q, COCH3), 73.66 (2 d, 2 inositol ring C), 73.76, 
79.98, 80.34, 81.80 (4 d, inositol ring C), 74.15, 74.70, 75.38 (3 t, 2 CH2Ph and 
CH2CH=CH2), 116.96 (t, CH2CH=CH2), 127.70, 127.76, 127.89, 127.99, 128.44, 
128.51 (6 d, CH2P/7), 134.46 (d, CH2CH=CH2), 138.11, 138.21 (2 s, CH2Ph), 
169.90 (s, CO);
m/z (+ve ion FAB) 443 [(M + H)+, 4 %], 91 (100)
m/z (-ve ion FAB) 883 [(2 M - H)-, 19 %], 553 [(M + NBA)-, 100], 441 [(M - H)-, 
50]
20.5 DL-1-OAIIyl-3,6-di-0-benzyl-scy//o-inositol 164
a) A solution of 162 (1.414 g, 3.21 mmol) in 80 % acetic acid (50 ml) was heated 
under reflux for 15 min, cooled and diluted with water (50 ml). After keeping the 
mixture at - 20°C overnight the precipitate was collected to give 164 (1.155 g, 
2.88 mmol, 90%).
b) A mixture of 163 (2.24 g, 5.06 mmol) in methanol (100 ml) and 1 M aqueous 
sodium hydroxide (12 ml) was heated under reflux for 30 min after which tic 
(ethyl acetate / hexane 2:1) showed complete conversion of the starting material 
(Rf 0.63) into a product (Rf 0.40). The solution was cooled and neutralised with 
solid carbon dioxide. The solvent was evaporated and the residue partitioned
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between water and ethyl acetate. The organic phase was dried over magnesium 
sulphate and evaporated to give 164 as a white solid (1.76 g, 4.4 mmol, 87 %).
m.p. 180°C (from ethyl acetate)
Found: C, 69.0; H, 7.05. Calc, for C23H2806 (400.47): C; 68.98; H, 7.05 %.
5h (d6-DMSO; 270 MHz) 3.05-3.21 (5 H, m, 5 C-H), 3.32-3.37 (1 H, m, D20  ex 
gives dd, J 9.0, 9.0, C-H), 4.20, 4.32 (2 H, AB, brd d, 12.8, 3J 5.5, 
CH2CH=CH2), 4.71, 4.81 (2 H, AB, JAB 11.4, CH2Ph), 4.79 (2 H, AB, JAB 11.5, 
CH2Ph), 5.00 (1 H, d, J 3.7, D20  ex, OH), 5.04-5.06 (2 H, m, D20  ex gives 1 H, 
d, J 10.4, c/s-CH2CH=CH2, OH), 5.13 (1 H, d, J 5.5, D20  ex, OH), 5.21 (1 H, ddt,
J 17.4, 1.65, 1.65, trans-CH2CH=CH2), 5.94 (1 H, ddt, J 17.2, 10.4, 5.5,
CH2CH=CH2), 7.23-7.45 (10 H, m, CH2Ph)
5C (d6-DMSO; 68 MHz) 73.40, 73.82, 74.21 (3 t, CH2Ph and CH2CH=CH2),
73.75, 73.92, 74.34, 82.48, 82.54, 82.90 (6 d, inositol ring C), 115.60 (t,
CH2CH=CH2), 127.11, 127.21, 127.60, 127.69, 127.99, 128.08 (6 d, CH2Ph),
136.42 (d, CH2CH=CH2), 139.53, 139.79 (2 s, CH2Ph)
m/z (+ve ion FAB) 401 [(M + H)+, 4 %], 91 (100)
m/z (-ve ion FAB) 553 [(M + NBA)-, 80 %], 399 [(M - H)-, 100]
20.6 DL-1-0-Allyl-3,6-di-0-benzyl-2,4,5-tris[di(benzyl)phospho]-scy//o- 
inositol 165
A solution of bis(benzyloxy)(diisopropylamino)phosphine 157 (19.9 g, 26 mmol) 
in dichloromethane (50 ml) was added to a solution of 164 (1 g, 2.5 mmol) and 
tetrazole (3.15 g, 45 mmol) in dichloromethane (50 ml). The mixture was stirred 
at r.t. for 1 h. Water (2 ml) in THF (20 ml) was added and the mixture was stirred 
for further 30 min. 2,6-Lutidine (2 ml) followed by tert-butyl hydroperoxide (20 
ml) was then added and stirring continued overnight. The solution was washed 
with saturated aqueous sodium hydrogen carbonate (2 x 100 ml) and dried over 
magnesium sulphate. The solvents were evaporated and the residue 
chromatographed on silica gel with 0 % to 100 % ethyl acetate in hexane. The 
product was recrystallised from ethanol to give 165 (1.294 g, 1.5 mmol, 58 %).
tic (ethyl acetate / hexane 1:1) Rf 0.38 
m.p. 103-105°C
Found: C, 66.1; H, 5.72. Calc, for C65H670 15P3 (1181.16): C, 66.10; H, 5.72 %.
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5h (CDCI3; 270 MHz): 3.58 (1 H, dd, J 8.4, 8.4, C-H), 3.67 (1 H, dd, J 8.4, 8.4, C- 
H), 3.73 (1 H, dd, J 8.4, 8.4, C-H), 4.12-4.26 (2 H, m, CH2CH=CH2), 4.55-5.15 
(21 H, m, 8 CH2Ph, CH2CH=CH2, 3 C-H), 5.78 (1 H, ddt, J 17.2, 10.4, 5.5, 
CH2CH=CH2), 6.97-7.35 (40 H, m, 8 CH2Ph).
5C (CDCI3; 68 MHz): 69.18, 69.28, 69.38, 69.44 (4 1, 4 PO-CH2Ph), 73.56, 73.79,
74.31 (3 1, 2 CH2Ph and CH2CH=CH2), 77.71, 78.14, 78.98, 79.08, 79.43, 79.66 
(6 d, 6 inositol ring C), 117.09 (t, CH2CH=CH2), 127.11, 127.24, 127.79, 127.99, 
128.09, 128.25 (6 d, CH2Ph), 134.25 (d, CH2CH=CH2), 135.71, 137.85, 137.91 
(3 s, CH2P/j)
8P (CDCI3, 162 MHz, 1H-decoupled): -1.75 (2 P), -1.52 (1 P)
8P (CDCI3, 162 MHz, iH-coupled): -1.72 (q, 2 P, J 7.9), -1.47 (q, 1 P, J 7.9) 
m/z (+ve ion FAB) 1181 (1 %), 1090 [(M - C7H7)+, 0.3], 181 (12), 91 (100) 
m/z (-ve ion FAB) 1088 [(M - C7H7 - 2 H)-, 7 %), 998 (2.5), 277 (100), 187 (16)
20.7 DL-scy//o-inositol 1,2,4-trisphosphate 166
Ammonia was condensed into a three neck flask at -78°C. An excess of sodium 
was added to dry the liquid ammonia which was then distilled into a second 
three neck flask and kept at -78°C. Sodium was added until the solution 
remained blue. Compound 165 (311 mg, 263 pmol) was dissolved in dry dioxane 
(2 ml) and added to the sodium-liquid ammonia mixture. After stirring for 15 min 
the reaction was quenched with ethanol. Ammonia and ethanol were evaporated 
and the crude product was purified by ion-exchange chromatography on 
Pharmacia Q Sepharose Fast Flow eluting with a gradient of triethylammonium 
bicarbonate buffers (0.1 M to 1 M), pH 8.0. The triethylammonium salt of 166 
eluted at between 320 mM and 460 mM. Yield 240 pmol (91%).
8h (D20 , pH=8, 270 MHz) 3.48-3.52 (2 H, m, 2 C-H), 3.58 (1 H, dd, J 9.3, C-H), 
3.84-4.07 (3 H, m, 3 C-H)
8C (D20 , pH=8, 68 MHz)
8P (D20 , pH=8, 162 MHz, 1H-decoupled) 0.50 (1 P), 0.72 (2 P)
m/z (+ve ion FAB) 623 [(M + 2 Et3NH)+, 1.1 %], 522 [(M + Et3NH)+, 1.4], 102
(Et3NH+, 100)
m/z (-ve ion FAB) 839 [(2 M)-, 15 %], 419 (M-, 100), 97 (10)
Accurate mass calc for C6H140 15P3 (M - H)- 418.9546, found 418.9550;
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21 Synthesis of scyllo-Inositol 1,2,4,5-tetrakisphosphate and scyllo-
Inositol 1,2,4,5-tetrakisphosphorothioate
21.1 DL-3,6-Di-0-benzyM-0-(c/s-prop-1-enyl)-scy//o-inositol 167
A solution of 164 (443 mg, 1.106 mmol) and freshly sublimed potassium tert- 
butoxide (570 mg, 5 mmol) in dry DMSO (20 ml) was stirred for 3 h at 50°C after 
which tic (ethyl acetate / hexane 2:1) showed complete conversion of the starting 
material (Rf 0.67) into a product (Rf 0.73). Water (50 ml) was added and the 
mixture was extracted with ether (2 x 50 ml). The organic phase was dried over 
magnesium sulphate and evaporated and the crude product was purified by 
flash chromatography (ether / hexane 1:1) to give 167 (430 mg, 97 %).
m.p. 140°C (from ethanol / water)
Found: C, 68.6; H, 7.13. Calc, for C23H280 6 (400.47): C; 68.98; H, 7.05 %.
8h (DMSO; 270 MHz) 1.53 (3 H, d, J 6.8, CH3), 3.07-3.15 (1 H, m, C-H), 3.22-
3.29 (3 H, m, C-H), 3.41-3.49 (2 H, m, C-H), 4.18 (1 H, dq, J 6.6, CH=CH-CH3),
4.66, 4.75 (2 H, AB, 11.2, CH2Ph), 4.79, 4.79 (2 H, AB, JAB 12.1, CH2Ph), 
5.04 (1 H, br s, D20  ex, OH), 5.13 (1 H, br s, D20  ex, OH), 5.26 (1 H, d, J 5.3, 
D20  ex, OH), 6.21 (1 H, dd, J 6.4, 1.5, CH=CH-CH3), 7.21-7.45 (10 H, m, 
CH2P/7)
8C (DMSO; 68 MHz) 9.24 (q, CH=CH-CH3), 72.43, 73.50, 73.79, 81.45, 82.52,
85.05 (6 d, 6 inositol ring C), 73.60, 73.92 (2 t, CH2Ph), 96.24 (d, CH=CH-CH3),
126.89, 127.05, 127.47, 127.54, 127.80 (5 d, CH2Ph), 139.05, 139.47 (2 s,
CH2P/7), 148.13 (d, CH=CH-CH3)
m/z (+ve ion FAB) 401 [(M + H)+, 4 %], 181 (8), 91 (100)
m/z (-ve ion FAB) 799 [(2 M -H)-, 13 %], 566 (49), 553 [(M + NBA)-, 77], 399 [(M -
H)-, 100), 341 (38)
21.2 1,4-Di-0-Benzyl-scy//o-inositol 168
167 (190 mg, 474 pmol) was heated under reflux in a mixture of methanol /1  M 
HCI (5:1) for 15 min after which tic (ethyl acetate / hexane 2:1) showed complete 
conversion of the starting material (Rf 0.73) into a product (Rf 0.43). The solvent 
was evaporated and the residue collected to give 168 (124 mg, 344 pmol, 73 %).
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m.p. 309-310°C (from ethanol) with a phase transition between 240-260°C 
Found: C, 66.6; H, 6.71. Calc, for C2oH2406 (360.41): C, 66.65; H, 6.71 %.
6h (d6-DMSO; 270 MHz) 3.03-3.07 (2 H, m, C-1,4-H), 3.18-3.21 (4 H, m, C- 
2,3,5,6-H), 4.76 (2 H, AB s, CH2Ph), 4.96, 4.97 (2 H, AB d, CH2Ph), 7.21-7.41 
(10 H, m ,CH2P/7)
8C (d6-DMSO; 68 MHz) 73.79 (2 t, 2 CH2Ph), 74.27 (4 d, 4 C-OH), 82.90 (2 d, 2 
C-O-benzyl), 127.14 (2 d, CH2Ph), 127.69,128.05 (2 x 2 d, CU2Ph), 139.89 (2 s, 
CH 2Ph).
21.3 3,6-Di-O-benzyM ^ ^S-tetrakisIdKbenzyOphosphoJ-scy/Zo-inositol 
169
168 (307 mg, 852 pmol) and tetrazole (1.19 g, 17 mmol) were stirred at r.t. in dry 
dimethylformamide (15 ml). 157 was added to the mixture and stirring continued 
for 1 h, after which 31P-NMR showed a single peak at 141 ppm. 2,6-Lutidine (2 
ml) followed by tert-butyl hydroperoxide (6 ml) was then added and stirring was 
continued overnight. The solution was partitioned between chloroform and 
saturated aqueous sodium hydrogen carbonate (50 ml each). The organic phase 
was dried over magnesium sulphate, the solvents were evaporated and the 
residue chromatographed on silica gel with 0 % to 100 % ethyl acetate in 
hexane. The product was recrystallised from ethanol to give 169 (885 mg, 632 
mmol, 74 %).
tic (hexane / ethyl acetate 1:1) Rf 0.46 
m.p. 110-111 °C (from methanol)
Found: C, 65.2; H, 5.45. Calc, for C76H760 18P4 (1401.32): C, 65.14; H, 5.47 %. 
5h (CDCI3; 270 MHz): 4.01 (2 H, t, C-3.6-H), 4.66 (4 H, brd s, C-1,2,4,5-H), 4.73-
5.02 (10 H, m, CH2Ph), 7.06-7.30 (60 H, m, CH2Ph)
8C (CDCI3; 68 MHz): 69.51, 73.14 (2 t, CH2Ph), 77.55, 79.73 (2 d, 6 inositol ring 
C), 127.37, 127.47, 127.86, 128.12, 128.25, 128.35 (6 d, CH2Ph), 135.55,
135.64, 135.77, 137.53 (4 s, Cb\2Ph)
8P (CDCI3; 36 MHz; 1H-decoupled): -3.71
m/z (+ve ion FAB) 1401 [(M+H)+, 0.5 %], 1310 [(M+H - C7H7)+, 0.2]
m/z (-ve ion FAB) 1309 [(M - C7H7)-, 2.3 %], 1218 [(M - 2 C7H7)-, 0.6], 277
[ ( 0 P ( 0 ) ( 0 C 7H 7)2)-, 100]
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21.4 Scyllo-inositol 1,2,4,5-tetrakisphosphate 170
Ammonia was condensed into a three neck flask at -78°C. An excess of sodium 
was added to dry the liquid ammonia which was then distilled into a second
three neck flask and kept at -78°C. Sodium was added until the solution
remained blue. Compound 169 (252 mg, 180 pmol) was dissolved in dry dioxane 
(4 ml) and added to the sodium-liquid ammonia mixture. After stirring for 15 min 
the reaction was quenched with ethanol. Ammonia and ethanol were evaporated 
and the crude product was purified by ion-exchange chromatography on 
Pharmacia Q Sepharose Fast Flow eluting with a gradient of triethylammonium 
bicarbonate buffers (0.1 M to 1 M), pH 8.0. The triethylammonium salt of 170 
eluted between 560 mM and 650 mM. Yield 74 pmol (41 %).
5|_| (D20 ; 270 MHz): 3.48 (2 H, dd, J 9.3, 9.3, C-3.6-H), 3.87 (4 H, ddd, J 12.2,
9.3, 9.3, C-1,2,4,5-H)
5C (D20 ; 100 MHz): 73.61 (2 C), 77.09 (4 C)
5P (D20 ; 36 MHz; 1H-coupled): 2.83 (d, J 8.3)
m/z (+ve ion FAB) 804 (1 %), 703 (2.5), 102 (100)
m/z (-ve ion FAB) 998 (4.5 %), 555 (4.5), 499 [(M - H)-, 100],
Accurate mass calc for C6H150 18P4 (M - H)- 498.9209, found 498.9191.
21.5 3,6-Di-O-benzyM ,2,4,5-tetrakis[di(benzyl)thiophosphoro]-scyllo- 
inositol 171
168 (522 mg, 1.45 mmol) and tetrazole (2.02 g, 29 mmol) were stirred at r.t. in 
dry dimethylformamide (25 ml). 157 was added to the mixture and stirring 
continued for 1 h when 31P-NMR showed a single peak at 141 ppm. Pyridine and 
an excess of sulphur was then added and stirring continued for 10 min. The 
solution was separated between chloroform and saturated aqueous sodium 
hydrogen carbonate (50 ml each). The organic phase was dried over magnesium 
sulphate, the solvents were evaporated and the residue chromatographed on 
silica gel (hexane / ether 3:1). The product was recrystallised from ethanol to 
give 171 (1.8 g, 1.23 mmol, 85 %).
tic (hexane / ether 1:1) Rf 0.63
m.p. 91-93°C (from ethyl acetate / ethanol)
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Found: C, 61.9; H 5.23. Calc, for C76H76014P4S4 (1465.57): C, 62.29; H, 5.23 %. 
SH (CDCI3; 270 MHz): 4.15 (2 H, t, C-3.6-H), 4.58 (4 H, brd, C-1,2,4,5-H), 4.75- 
5.23 (10 H, m, CH2Ph), 7.08-7.23 (60 H, m, CH2P/j)
8C (CDCI3; 68 MHz): 70.03, 72.59 (2 t, CH2Ph), 77.97, 79.92 (2 d, inositol ring 
C), 127.43, 127.99, 128.05, 128.12, 128.22, 128.34 (6 d, CH2Ph), 135.56,
135.64, 135.71, 137.53 (4 s, CH2Ph)
8P (CDCI3, 36 MHz; 1H-decoupled): 67.77
m/z (+ve ion FAB) 1465 [M+, 0.1 %], 1035 (0.1), 945 (0.2), 91 (100)
m/z (-ve ion FAB) 1373 [(M - C7H7)-, 9 %], 1282 [(M - 2 C7H7)-, 3], 1249 [(M - 2
OC7H7)-, 4), 293 [OP(S)(OC7H7)2-, 100]
21.6 Scy//o-inositol 1,2,4,5-tetrakisphosphorothloate 172
Ammonia was condensed into a three neck flask at -78°C. An excess of sodium 
was added to dry the liquid ammonia which was then distilled into a second 
three neck flask and kept at -78°C. Sodium was added until the solution 
remained blue. 171 (205 mg, 140 pmol) was dissolved in dry dioxane (3 ml) and 
added to the sodium-liquid ammonia mixture. After stirring for 15 min the 
reaction was quenched with ethanol. Ammonia and ethanol were evaporated 
and the crude product was purified by ion-exchange chromatography on
Pharmacia Q Sepharose Fast Flow eluting with a gradient of triethylammonium
bicarbonate buffers (0.1 M to 1 M), pH 8.0. The triethylammonium salt of 172 
eluted between 850 mM and 950 mM. Yield: 25 pmol (18% )
8h (D20 ; 270 MHz): 3.46 (2 H, dd, J 9.1, 9.1, C-3.6-H), 3.83 (4 H, ddd, J 11.8, 
9.1, 9.1, C-1,2,4,5-H)
8C (D20 ; 68 MHz): 80.41 (2 C), 84.97 (4 C)
8P (D20 ; 36 MHz): 43.48 (d, J 11.0)
m/z (-ve ion FAB) 563 [(M-H)-, 95 %], 529 (18), 188 (47), 154 (32), 113 (28), 95 
[(PS02)-, 100]
Accurate mass calc for C6H150 14P4S4 (M - H)‘ 562.8295, found 562.8273.
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removed and stirring continued for 2 h at r.t.f after which tic (ether / petrol ether 
b.p. 40-60°C 1:1) showed conversion of the starting material (Rf 0.53) to a 
product (Rf 0.67). The reaction was quenched with water (10 ml), diluted with 
dichloromethane (50 ml) and washed successively with sat. NaHC03, water and 
brine. The organic layer was dried over magnesium sulphate and the solvents 
evaporated in vacuo. Toluene was added to the orange syrup in order to remove 
the remaining pyridine, which was then evaporated to give the title compound as 
a yellow solid in quantitative yield.
m/z (+ve ion FAB) 863 (1.8 %), 650 (1.5), 502 [(M - HCF3), 1.6], 212 (85), 91 
(100)
m/z(-ve ion FAB) 931 (1%), 149 (100)
22.3 DL-3,6-Di-0-benzyl-2-deoxy-2-fluoro-4,5-isopropylidene-1-0-(c/s- 
prop-1-enyl)-/77yo-inositol 175
Tetrabutylammonium fluoride (15 ml of a 1.1 M solution in THF) was added to 
crude 174 (2.15 g, 3.75 mmol) in THF (20 ml) at r.t. The colour of the reaction 
mixture turned to red / brown and tic (ether / petrol ether b.p. 40-60°C) showed 
conversion of the starting material (Rf 0.67) to a product (Rf 0.56). Stirring was 
continued for a further 1 hour. The solvent was evaporated and the brown 
residue taken up in chloroform. After washing with water, the organic phase was 
dried over magnesium sulphate and evaporated and the crude product purified 
by flash chromatography (hexane / ether 3:1) to give 175 (1.143 g, 2.58 mmol, 
69 %).
m.p. 70-72°C (from ethanol)
Found: C, 70.4; H, 7.03. Calc, for C26H310 5F (442.53): C, 70.57; H, 7.06 %.
5h (CDCI3; 270 MHz) 1.47 (3 H, s, CH3), 1.48 (3 H, s, CH3), 1.64 (3 H, dd, J 7.0, 
1.65, OCH=CH-CH3), 3.41 (1 H, t, J 9.6, C-H), 3.54 (1 H, ddd, J 29.5, 8.8, 2.4, 
C-1 (3)-H, 3.59 (1 H, ddd, J 23.3, 10.4, 2.2, C-3(1)-H), 3.95-4.07 (2 H, m, 2 C-H), 
4.50 (1 H, dq, J 6.8, 6.8, OCH=CH-CH3), 4.72, 4.84 (2 H, AB, JAB 12.3, CH2Ph), 
4.77, 4.82 (2 H, AB, JAB 12.0, CH2Ph), 4.91 (1 H, dt, J 50.0, 2.4, C-2-H), 6.01 (1 
H, ddd, J 7.0, 1.65, 0.7, OCH=CH-CH3), 7.21-7.66 (10 H, m, CH2Ph)
8C (CDCI3; 68 MHz) 9.24 (q, OCH=CH-CH3), 26.82, 26.92 (2 q, C(CH3)2), 71.52, 
73.37 (2 t, 2 CH2Ph), 74.74 (dd, JC_C_F 15.4, C-1 (3)), 76.74, 76.81, 78.95 (3 d,
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22 Synthesis of 2-deoxy-2-fluoro-/nyo-inositol 1,4,5-trisphosphate
22.1 DL-3,6-Di-0-benzyl-4,5-isopropylidene-1-0-(c/s-prop-1-enyl)-scy//o- 
inositol 173
A solution of 162 (3.16 g, 7.2 mmol) and freshly sublimed potassium tert- 
butoxide (4 g, 3.27 mmol) in dry DMSO (50 ml) was stirred for 2 h at 55°C after 
which tic (hexane / ether 1:1) showed complete conversion of the starting 
material (Rf 0.59) into a product (Rf 0.65). Water (100 ml) was added and the 
mixture was extracted with ether (2 x 100 ml). The organic phase was dried over 
magnesium sulphate and evaporated and the crude product purified by flash 
chromatography (hexane / ether 3:1) to give 173 (3.03 g, 95 %).
m.p. 109-110°C (from hexane)
Found: C, 70.7; H, 7.29. Calc, for C26H320 6 (440.54): C; 70.89; H, 7.32 %.
5h (CDCI3; 270 MHz) 1.46 (6 H, s, 2 CH3), 1.61 (3 H, dd, J 6.8, 1.65, OCH=CH- 
CH3), 2.69 (1 H, d, J 2.4, D20  ex, OH), 3.52-3.75 (6 H, m, 6 C-H), 4.37 (1 H, dq, 
J 6.8, 6.8, OCH=CH-CH3), 4.71, 4.93 (2 H, AB, 11.9, CH2Ph), 4.74, 4.82 (2 
H, AB, 11.7, CH2Ph), 6.18 (1 H, dd, J 6.8, 1.65, OCH=CH-CH3), 7.28-7.39 
(m, 10H ,C H  2Ph)
8C (CDCI3; 68 MHz) 8.99 (q, OCH=CH-CH3), 26.63 (q, CH3) 72.40, 72.62, (2 t, 
CH2Ph), 75.22, 77.75, 78.04, 78.10, 78.43, 85.82 (6 d, inositol ring C), 99.38 (d, 
OCH=CH-CH3), 112.16 (s, (CH3)2C), 127.18, 127.37, 127.54, 127.89, 128.05 (5 
d, CH2Ph), 137.92 (s, CH2Ph), 147.00 (d, OCH=CH-CH3)
m/z (+ve ion FAB) 441 [(M + H)+, 3%], 91 (100)
m/z (-ve ion FAB) 593 [(M + NBA)-, 100%], 399 [(M - CH=CH-CH3)-, 66], 291 
(31), 105 (38)
22.2 DL-3,6-Di-0-benzyl-4,5-isopropylidene-1 -0-(c/s-prop-1 -enyl)-2-0- 
trifluoromethylsulphoxy-scy//o-inositol 174
A mixture of 173 (1.654 g, 3.75 mmol) and dry pyridine (10 ml) in dry 
dichloromethane (50 ml) was cooled to -78°C. Triflic anhydride (1.8 ml, 3 g,
10.62 mmol) was added dropwise to this mixture. After the addition cooling was
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inositol ring C), 81.86 (dd, JC-c-F 17.6, C-3(1)), 90.24 (dd, JC.F 187.3, C-2), 
103.18 (d, OCH=CH-CH3), 112.26 (s, C(CH3)2), 127.50, 127.60, 127.73, 127.86, 
128.18,128.41 (6 d, CH2Ph), 137.52,138.24 (2 s, CH2Ph), 144.95 (d, OCH=CH- 
CH3)
8f  (CDCI3 with reference to CFCI3; 84 MHz) -210.21 (dt, J2_h-F 51.3, Ji{3)-h-f
29.3)
m/z (+ve ion FAB) 443 [(M+H)+, 6 %], 351 (3), 91- (100)
m/z (-ve ion FAB) 595 [(M + NBA)-, 100 %], 488 (20), 401 [(M - CH=CH-CH3)-, 
14], 172(69), 133(56)
22.4 DL-3,6-di-0-benzyl-2-deoxy-2-fluoro-/nyo-inositol 176
175 (801 mg, 1.81 mmol) was heated under reflux in 60 ml of a mixture of 
methanol and 1 M HCI (5:1) for 30 min. The reaction was allowed to cool and 
neutralised with an excess of sodium bicarbonate. The solvents were 
evaporated and the title compound extracted with ethyl acetate to give 176 (451 
mg, 1.24 mmol, 69 %).
m.p. 193-194°C (from ethanol)
Found: C, 66.0; H, 6.40. Calc, for C20H23O5F (362.40): C, 66.29; H, 6.40 %.
5h (d6-DMSO; 270 MHz) 3.21-3.59 (5 H, m, 5 C-H), 4.67 (2 H, AB, CH2Ph), 4.78,
4.82 (2 H, AB, ^  11.7, CH2Ph), 4.85 (1 H, d, J 54.0, C-2-H), 5.09 (1 H, d, J 5.1, 
DzO ex, OH), 5.16 (1 H, d, J 5.0, D20  ex, OH), 5.32 (1 H, d, J 6.0, D20  ex, OH), 
7.21-7.45(10 H, m, CH2P/i)
8C (d6-DMSO; 68 MHz) 69.62 (dd, JC-c-F 15.4, C-1 (3)), 71.29 (t, CH2Ph), 72.14 
(d, inositol ring C), 73.73 (t, CH2Ph), 74.37 (d, inositol ring C), 77.88 (dd, JC_C_F 
17.7, C-3(1)), 81.38 (d, inositol ring C), 92.23 (dd, JC.F 178.5, C-2), 126.92, 
127.21, 127.41, 127.47, 127.80, 128.02 (6 d, CH2P/j), 138.76, 139.50 (2 S, 
CH2Ph)
8f  (d6-DMSO with reference to CFCI3; 84 MHz) - 212.6 (dt, J2.h ,f  51.3, J1 (3 )-h, F
29.3)
m/z (+ve ion FAB) 361 [<M - H)+, 8 %], 91 (100)
m/z (-ve ion FAB) 528 (70 %), 515 [(M + NBA)-, 100], 470 (20), 408 (23), 361 [(M 




176 (185 mg, 510 pmol) and tetrazole (763 mg, 10.9 mmol) were stirred at r.t. in 
dichloromethane (30 ml). 157 was added and stirring continued for 1 h, after 
which 31P-NMR showed three signals at 141.74, 141.60 and 141.47 ppm. The 
mixture was cooled to -78°C and 2,6-lutidine (2 ml) and then ferf-BuOOH (5 ml, 
80 % in tert-butyl alcohol) was added to the mixture. The mixture was allowed to 
warm to r.t. and stirring continued for 1 h. The solution was partitioned between 
chloroform and sat. aqueous NaHC03, the organic phase was dried over 
magnesium sulphate and the solvents were evaporated. The residue was 
chromatographed on silica gel to give 177 (441 mg, 386 pmol, 76 %).
m.p. 129-131 °C
Found: C, 65.2; H, 5.48. Calc, for C62H620 14FP3 (1143.09): C, 65.15; H, 5.47 %. 
5h (CDCI3; 270 MHz) 3.50 (1 H, ddd, J 27.0, 9.8, 1.5, C-3-H), 3.98 (1 H, t, J 9.6, 
C-6-H), 4.28 (1 H, ddt, J 27.0, 9.0, 1.5, C-1-H), 4.50-5.07 (19 H, m, 8 CH2Ph, 3 
C-H), 6.95-7.33 (40 H, m, 8 CH2Ph)
5C (CDCI3; 68 MHz) 69.25, 69.48, 72.07, 74.76 (4 1), 75.54 (dd, JC_C_F 17.6, C-3), 
76.13 (ddd, JC-C-F 17.6, Jc.0-p 5.2, C-1), 76.99, 77.19 (2 dd, JC.0 .P 5.2, C-4 and 
C-5), 78.23 (d, C-6) , 87.12 (dd, JC_F 185.1, C-2), 127.11, 127.21, 127.73,
128.05, 128.22, 128.38, 128.44, 128.54 (8 d, CH2Ph), 135.71, 135.97, 136.81,
137.78 (4 s, CH2P/7)
5P (CDCI3; 36 MHz; 1H-decoupled) -1.61 (1 P), -1.95 (2 P)
8f  (DMSO with reference to CFCI3; 84 MHz) -213.1 (dt, J2-h,f 51.3, Ji(3)-h, f
29.3)
m/z (+ve ion FAB) 1142 [(M - H)+, 4.7 %], 1052 [(M - CH2Ph)+, 1.4], 181 (13), 91 
(100)
m/z (-ve ion FAB) 1049 (13 %), 1015 (1), 959 (2.5), 277 {[0P (0)(0C H 2Ph)2]-, 
100}, 187(14)
22.6 DL-2-deoxy-2-fluoro-/nyo-inositol 1,4,5-trisphosphate 178
Ammonia was condensed into a three neck flask at -78°C. An excess of sodium 
was added to dry the liquid ammonia which was then distilled into a second 
three neck flask and kept at -78°C. Sodium was added until the solution
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remained blue. Compound 177 (79 mg, 69 pmol) was dissolved in dry dioxane (2 
ml) and added to the sodium-liquid ammonia mixture. After stirring for 15 min the 
reaction was quenched with ethanol. Ammonia and ethanol were evaporated, 
the crude product dissolved in water and the solution adjusted to pH 7 with 
Dowex 50-W ion exchanger (H+-form). Purification by ion-exchange 
chromatography on Pharmacia Q Sepharose Fast Flow eluting with a gradient of 
triethylammonium bicarbonate buffer (0.1 M to 1 M), pH 8.0, gave the 
triethylammonium salt of 178 (eluting between 320 mM and 460 mM). Yield 28.3 
pmol (41%).
8h (D20 ; 270 MHz) 3.86 (1 H, ddd, J 28.5, 9.9, 2.0, C-3-H), 3.90 (1 H, t, J 9.5, C- 
6-H), 4.09 (1 H, q, J 9.2, C-4(5)-H), 4.14 (1 H, ddt, J 27.5, 8.4, 1.7, C-1-H), 4.29 
(1 H, q, J 9.2, C-5(4)-H), 5.10 (1 H, dt, J 51.8, 1.5, C-2-H)
8P (D20 , 36 MHz; 1H-coupled) 1.96 (1 P, J 10.1), 1.56 (1 P, J 6.7), 0.37 (1 P, J 
10.1)
8f  (D20  with reference to CFCI3; 84 MHz) -211.8 (dt, ^ - h .f  51  -3» ^1(3)-H, f  36.7) 
m/z (-ve ion FAB) 421 [(M - H)-, 100 %], 401 (6), 339 (14), 325 (13), 311 (19), 
272 (10), 93(10)
Accurate mass calc for C6H130 14FP3 (M - H)- 420.950, found 420.950;
23 Optical Resolution of DL-4,5-Di-0-Acetyl-3-0-allyl-6-0-benzyl-1-0- 
para-methoxybenzyl-myo-inositol
23.1 DL-3-0-Allyl-1,2:4,5-di-Oisopropylidene-/77yo-inositol 179
Allyl bromide (4.8 ml, 6.74 g, 55.7 mmol) was added dropwise to a stirred 
suspension of DL-1,2:4,5-di-0-isopropylidene-myo-inositol 3 (13.02 g, 50 mmol), 
BaO (15.35 g, 100 mmol) and Ba(OH)2 x 8 H20  (1.98 g, 6.25 mmol) in 
dimethylformamide (250 ml) at r.t. Stirring was continued for 60 h after which tic 
(hexane / ethyl acetate 1:1) showed conversion of the starting material (Rf 0.19) 
into two minor products (Rf 0.70 and 0.47) and a major product (Rf 0.44). The 
mixture was diluted with methanol and neutralised with acetic acid / water 1:1. 
The solvents were evaporated and the residue was chromatographed on silica 
gel (petrol ether / ethyl acetate 1:1) to give DL-3-0-allyl-1,2:4,5-di-0-
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isopropylideng-myo-inositol 179 (9.46 g, 31.5 mmol, 63 %).
m.p. 128-130°C (from petrol ether b.p. 60-80°C) (Lit.l136!; 127-129°C)
Found: C, 60.1; H, 8.15. Calc for C15H240 6 (300.35): C, 60.0; H, 8.05 %.
5h (CDCI3; 270 MHz) 1.39, 1.45, 1.47, 1.55 (12 H, 4 s, 4 CH3), 3.31 (1 H, dd, C- 
5-H, J 10.3, 9.5), 3.51 (1 H, br s, D20  ex, OH), 3.81-4.05 (4 H, m, 4 C-H), 4.25, 
4.33 (2 H, AB, d, 12.9, 3J 6.0, CH2CH=CH2), 4.48 (1 H, t, J 4.4, C-2-H), 5.23 
(1 H, d, J 10.3, CH2CH=CH2), 5.32 (1 H, d, J 17.2, CH2CH=CH2), 5.98 (1 H, ddt, 
J 16.9,10.5, 5.7, CH2CW=CH2)
8C (CDCI3; 68 MHz) 25.69, 26.66, 26.76, 27.99 (4 q, 4 CH3), 70.94 (t, 
CH2CH=CH2), 74.02, 74.60, 76.09, 76.81, 78.33, 81.54 (6 d, 6 inositol ring C), 
109.99, 112.16 (2 s, 2 C(CH3)2), 117.97 (t, CH2CH=CH2), 134.41 (d, 
CH2CH=CH2)
m/z (El) 285 (6), 227 (1.4) 113 (100)
m/z (Cl, Iso-butane) 301 (100), 285 (6), 243 (35), 225 (7), 185 (14), 167 (20), 
113(41)
23.2 DL-3,6-Di-0-allyl-1,2:4,5-di-0-isopropylidene-myo-inositol 180:
A second product (Rf 0.70) was also isolated from the reaction mixture obtained 
in experiment 23.1. This product was identified as DL-3,6-di-0-allyl-1 ^^.S-di-O- 
isopropylidene-myo-inositol 180 (Yield 730 mg, 2.1 mmol, 4 %). The 6-O-allyl 
isomer was not isolated.
m.p. 81 -83°C (Lit.!136] 85-87°C)
Found: C, 63.8; H, 8.37. Calc for C18H280 6 (340.42): C, 63.51; H, 8.29 %.
5h (CDCI3; 270 MHz) 1.38, 1.44, 1.46, 1.55 (12 H, 4 s, 4 CH3), 3.34 (1 H, dd, J
10.6, 9.3, C-5-H), 3.66 (1 H, dd, J 10.6, 6.4, C-3(1)-H), 3.80 (1 H, dd, J 10.2, 4.1, 
C-1 (3)-H), 3.98 (1 H, dd, J 9.7, 9.7, C-4(6)-H), 4.09 (1 H, dd, J 6.4, 5.1, C-6(4)- 
H), 4.20-4.37 (4 H, m, CH2CH=CH2), 4.47 (1 H, dd, J 4.6, 4.6, C-2-H), 5.17-5.36 
(4 H, m, 2 CH2CH=CH2), 5.87-6.03 (2 H, m, 2 CH2CH=CH2).
8C (CDCI3; 68 MHz) 25.75, 26.79, 26.86, 27.89 (4 q, 4 CH3), 70.97, 71.06 (2 t, 
CH2CH=CH2 and CH2Ph), 74.60, 76.25, 76.68, 78.40, 79.95, 81.18 (6 d, 6 
inositol ring C), 109.76, 111.90 (2 s, 2 C(CH3)2), 117.12, 117.93 (2 t, 2
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CH2CH=CH2), 134.51, 134.61 (2 d, 2 CH2CH=CH2)
m/z (El) 340 [M+, 1.4 %], 325 (5), 113 (72) 41 (100)
m/z (Cl, Iso-butane) 341 [(M+H)+, 100], 325 (7), 283 (34), 225 (20), 167 (28), 
113(26)
23.3 DL-3-0-Allyl-6-0-benzyM ,2:4,5-di-0-isopropylidene-/nyo-inositol 181
DL-3-0-Allyl-1,2:4,5-di-0-isopropylidine-myo-inositol 179 (21.6 g, 71.9 mmol), 
18-crown-6 (954 mg, 3.6 mmol), potassium hydroxide (48 g) and benzyl chloride 
(102 ml) were heated with vigorous stirring to 120°C, at which point the reaction 
became exothermic. Heating was removed, and after 2 h the reaction mixture 
had cooled to room temperature. Tic (hexane /  ethyl acetate 1:1) showed 
conversion of the starting material (Rf 0.34) into a product (Rf 0.55). Toluene (85 
ml) was added and the mixture was washed with brine, until the aqueous phase 
remained neutral. The toluene layer was dried over magnesium sulphate and 
evaporated at 95°C (high vacuum) to remove remaining solvent. The product 
was recrystallised from methanol to give 181 (25.7 g, 65.8 mmol, 91.5 %).
m.p. 122-123°C
Found: C, 72.83; H, 7.22. Calc for C22H30O6 (390.48): C, 72.66; H, 7.09 %.
§H (CDCI3; 270 MHz) 1.36, 1.39, 1.44, 1.46 (12 H, 4 s, 4 CH3), 3.39 (1 H, dd, J
10.4, 9.3, C-5-H), 3.68 (1 H, dd, J 10.4, 6.5, C-H), 3.79 (1 H, dd, J 10.1, 4.1, C- 
H), 3.96 (1 H, t, J 9.7, C-H), 4.13 (1 H, t, J 5.6, C-H), 4.23, 4.32 (2 H, AB, d,
13.0, J 6.0, CH2CH=CH2), 4.45 (1 H, t, J 4.5, C-2-H), 4.83 (2 H, AB, CW2Ph), 
5.22 (1 H, dd, J 17.2, 1.2, CH2CH=CH2), 5.31 (1 H, dd, J 10.3, 0.8, 
CH2CH=CH2), 5.97 (1 H, ddt, J 16.8, 10.9, 6.4, CH2CW=CH2), 7.24-7.42 (5 H, m, 
CH 2Ph)
8C (CDCI3; 68 MHz) 25.82, 26.86, 26.92, 27.76 (4 q, CH3), 71.00, 71.88 (2 t, 
CH2CH=CH2, CH2Ph), 74.63, 76.25, 76.81, 78.72, 79.82, 81.02 (6 d, inositol ring 
C), 109.79, 111.97 (2 q, C(CH3)2), 117.97 (t, CH2CH=CH2), 127.34, 127.83,
128.05 (3d, CH2P/7), 134.54 (d, CH2CH=CH2), 138.11 (s, CH2P/j)




181 (24.3 g, 62.2 mmol) was heated under reflux in a mixture of methanol (360 
ml) and 1 M HCI (40 ml) for 30 min, after which tic (ethyl acetate) showed 
conversion of the starting material into a product (Rf 0.28). The mixture was 
cooled, neutralised with triethylamine and the solvent was evaporated. The 
product was extracted with ethyl acetate and the' solvent evaporated to give 182 
(16.8 g, 54.1 mmol, 87 %).
m.p. 152-153°C (from ethyl acetate)
Found: C, 61.9; H, 7.21. Calc for C16H220 6 (310.35): C, 61.92; H, 7.15 %.
8h (d6-DMSO; 270 MHz) 3.01 (1 H, dd, J 9.8, 2.4, C-1-H), 3.14 (1 H, dt, J 9.0,
4.8, D20  shake gives t, J 9.1, C-5-H), 3.31 (1 H, m, D20  shake gives dd, J 9.8,
2.5, C-3-H), 3.44 (1 H, t, J 9.2, C-4-H), 3.56 (1 H, dt, J 9.3, 4.8, D20  shake gives 
t, J 9.4, C-6-H), 3.89-3.94 (1 H, m, D20  shake gives t, J 2.5, C-2-H), 4.00-4.17 (2 
H, m, CH2CH=CH2), 4.64-4.83 (6 H, m, D20  shake gives 2 H, AB s at 4.72, 
CH2Ph and 4 OH), 5.15 (1 H, dd, J 10.4, 1.5, CH2CH=CH2), 5.32 ( 1 H, dd, J
17.2, 1.65, CH2CH=CH2), 5.92 (1 H, ddt, J 17.2, 10.4, 5.5, CH2CH=CH2), 7.24- 
7.44 (5 H, m, CH2Ph)
5C (d6-DMSO; 68 MHz) 69.96, 71.58, 72.30, 75.18, 79.59, 81.93 (6 d, inositol 
ring C), 70.1, 73.72 (2 t, CH2CH=CH2, CH2Ph), 116.02 (t, CH2CH=CH2), 127.05,
127.66, 127.97 (3 d, CH2P/?), 136.26 (d, CH2CH=CH2), 140.05 (s, CH2Ph)
m/z (70 eV): 310 (M+, 6 %), 149 (12), 113 (20), 91 (100), 86 (38), 55 (28), 41 
[(C3H5)+, 57]
m/z (Cl, Iso-butane): 310 (M+, 14 %), 219 [(M - C7H7), 22], 131 (98), 107 
[(OC7H7)+, 32], 91 [(C7H7)+, 100], 69 (47)
23.5 DL-3-OAIIyl-6-0-benzyl-1-0-p*methoxybenzyl-/nyo-inositol 183
182 (21.7 g, 70 mmol) and dibutyltin oxide (26.1 g, 105 mmol) in toluene were 
heated under reflux for 3 h in a Dean and Stark apparatus. The reaction mixture 
was cooled and the toluene evaporated to give a syrup which was dried under 
vacuum for 2 h. Caesium fluoride (21.3 g, 140 mmol) was added to the syrup
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and dried for a further hour. Dry DMF (200 ml) was added to the syrup and p- 
methoxybenzyl chloride (11 g, 9.5 ml, 70 mmol) at r.t. After 24 h at r.t. tic (ethyl 
acetate) showed conversion of the starting material (Rf 0.35) into a major 
product (Rf 0.51) and several less polar by-products (Rf 0.65, 0.77 and 0.89). 
The solvents were evaporated under reduced pressure and the residue was 
taken up in dichloromethane. The suspension was washed with water and 1 M 
HCI and the insoluble tin derivatives were removed by filtration through Celite. 
The solution was dried over magnesium sulphate, filtered and evaporated. The 
crude product was chromatographed on silica gel (ethyl acetate) to give 183. 
Yield 24.3 g (81 %).
m.p. 133-135°C (from ethyl acetate)
Found: C, 67.0; H, 7.08. Calc for C24H30O7 (430.50): C, 66.96; H, 7.02 %.
§H (CDCI3; 270 MHz) 2.83 (1 H, brd s, D20  ex, OH), 3.10 (1 H, dd, J 9.6, 2.65, 
C-3(1)-H), 3.35 (1 H, dd, J 9.6, 2.6, C-1(3)-H), 3.40 (1 H, dd, J 9.3, 9.3, C-H), 
3.4-3.5 (2 H, brd, D20  ex, 2 OH), 3.77 (3 H, s, OCH3), 3.79 (1 H, dd, J 9.3, 9.3, 
C-H), 3.90 (1 H, dd, J 9.4, 9.4, C-H), 4.05-4.19 ( 2 H, m, CH2CH=CH2), 4.15 (1 
H, dd, J 2.7, 2.7, C-2-H), 4.61 (2 H, AB, CH2Ph), 4.80, 4.91 (2 H, AB, J 11.2, 
CP2Ph), 5.17 (1 H, dd, J 10.3, 1.3, CH2CH=CH2), 5.26 (1 H, dd, J 17.2, 1.5, 
CH2CH=CH2), 5.91 (1 H, ddt, J 17.2, 10.4, 5.7, CH2CH=CH2), 6.84 (2 H, d, J 8.8, 
CH2P/7), 7.23-7.37 (7 H, m, CH2Ph)
8C (CDCI3; 68 MHz) 55.07 (OCH3), 66.91, 71.65, 74.28, 78.69, 79.30, 80.44 (6 d, 
inositol ring C), 71.16, 72.00, 75.25 (3 t, CH2CH=CH2, CH2Ph), 113.68 (d, 
CH2P/7), 117.64 (t, CH2CH=CH2), 127.40, 127.76, 128.22, 129.35, 129.81 (5 d, 
CH2P/7), 134.48 (d, CH2CH=CH2), 138.72 (s, CH2Ph), 159.16 (s, C-OCH3)
m/z (El): 339 (44 %), 309 (14), 137 (77), 121 (100), 91 (63) 
m/z (Cl, Iso-butane): 429, 339 (11 %), 309 (7), 137 (14), 121 (100)
23.6 DL-3-0-Allyl-6-0-benzyl-4,5-0-isopropylidene-1-0-/HTiethoxybenzyl- 
myo-inositol 184
A mixture of 183 (24 g, 55.7 mmol), p-toluenesulphonic acid monohydrate (2.25 
g, 11.8 mmol) and 2-methoxypropene (19 ml, 14.3 g, 198.4 mmol) in dry DMF
228
(400 ml) was stirred overnight when tic (ether) showed complete conversion of 
the starting material (Rf 0.12) into a product (R, 0.67). Triethylamine (10 ml) was 
added and the solvents were evaporated. The resulting syrup was taken up in 
dichloromethane, washed with water and brine and dried over magnesium 
sulphate. The solvent was evaporated and the crude product purified by flash 
chromatography (petrol ether /  ether 2:3) to give 184 (21.9 g, 46.5 mmol, 84 %).
m.p. 87-89°C (from petrol ether b.p. 60-80°C)
Found: C, 69.1; H, 7.39. Calc for C27H340 7 (470.56): C, 68.92; H, 7.28 %.
8h (CDCI3; 270 MHz) 1.43, 1.45 (6 H, 2 s, 2 CH3), 2.68 (1 H, brd s, D20  ex, 1 
OH), 3.38 (1 H, dd, J 9.7, 9.7, C-H), 3.44 (1 H, dd, J 8.4, 3.1, C-3(1)-H), 3.50 (1 
H, dd, J 10.3, 3.1, C-1(3)-H), 3.78 (3 H, s, OCH3), 3.96 (1 H, dd, J 8.6, 8.4, C-H),
4.02 (1 H, dd, J 9.7, 9.7, C-H), 4.15, 4.26 (2 H, AB, dt, JAB 12.8, J 5.8, 1.5, 
CH2CH=CH2), 4.20 (1 H, dd, J 3.1, 3.1, C-2-H), 4.65, 4.69 (2 H, AB, J 11.35, 
CH2Ph), 4.76, 4.91 (2 H, AB, J 11.6, CH2Ph), 5.18 (1 H, dd, J 10.4, 1.5, 
CH2CH=CH2), 5.28 (1 H, ddt, J 17.3, 1.6, 1.6, CH2CH=CH2), 5.94 (1 H, ddt, J
17.2, 10.4, 5.7, CH2CH=CH2), 6.84 (2 H, d, J 8.8, CHzPh), 7.23-7.41 (7 H, m, 
CH2P/j)
8C (CDCI3; 68 MHz) 26.79, 26.89 (2 q, 2 CH3), 55.07 (q, OCH3), 69.38, 75.96, 
76.71, 78.33, 79.21, 80.41 (6 d, 6 inositol ring C), 70.58, 72.85, 73.21 (3 t, 
CH2CH=CH2 and 2 CH2Ph), 111.51 (s, C(CH3)2), 113.68 (d, CH2P/)OMe), 
117.45 (t, CH2CH=CH2), 127.28, 127.53, 128.09, 129.48, 129.77 (5 d, CH2P/j 
and CH2P/jOMe), 134.44 (d, CH2CH=CH2), 138.66 (s, CH2Ph), 159.22 (s, O  
OCH3)
m/z (+ve ion FAB) 469 [(M-H)+. 3.6 %], 379 (4.9), 349 (3.7), 121 [(C7H6OCH3)+, 
100), 91 (24)
m/z (-ve ion FAB) 622 [(M+NBA)', 66 %], 469 [(M-H)-, 90], 429 (37), 349 [(M - 




A mixture of 184 (470 mg, 1 mmol), (1 S)-(-)-camphanic chloride (433 mg, 2 
mmol) and DMAP (10 mg, 0.08 mmol) in dry pyridine (5 ml) was stirred at r.t. 
overnight, after which tic (hexane / ethyl acetate 1:1) showed conversion of the 
starting material (Rf 0.44) into a product (Rf 0.52). By hptlc there was no visible 
separation of the product spots. The solution was cooled in an ice-bath, water 
(0.5 ml) was added and stirring was continued for 10 min. Ether (50 ml) and 
dichloromethane (25 ml) were added and the organic phase was washed 
successively with saturated aqueous potassium chloride solution, ice-cold 1 M 
HCI, saturated aqueous potassium chloride solution and saturated aqueous 
sodium hydrogen carbonate solution (100 ml each) and then dried over 
magnesium sulphate. Evaporation of the solvents gave a syrup which was co­
evaporated with toluene, then taken up in ether. Petrol ether b.p. 60-80°C was 
added and the solution was kept in the fridge overnight. The crystals were 
filtered off to give 185 as a 1 :1 mixture of the two diastereoisomers. Yield (616 
mg, 0.95 mmol, 95 %). Efforts to separate the diastereoisomers by 
recrystallisation from methanol were also unsuccessful.
m.p. 136-137°C (from ether /  petrol ether) 
m.p. 135-136°C (from methanol)
Found: C, 68.0; H, 7.13. Calc forC37H46O10 (650.77): C, 68.29; H, 7.12 %.
5h (CDCI3; 270 MHz) 0.83 (3 H, s, CH3), 0.90 (3 H, s, CH3), 0.94 (3 H, s, CH3), 
0.98 (3 H, s, CH3), 1.08 (3 H, s, CH3), 1.08 (3 H, s, CH3), 1.45 (6 H, s, CH3), 
1.48 (6 H, s, 2 CH3), 1.62-1.71 (2 H, m, CH2), 1.82-2.07 (4 H, m, 2 CH2), 2.23-
2.42 (2 H, m, CH2), 3.40-3.89 (10 H, m, C-H), overlapping with 3.79 (3 H, s, 
OCH3), 3.80 (3 H, s, OCH3), 4.10-4.14 (4 H, m, CH2-CH=CH2), 4.50-4.65 (4 H, 2 
AB, overlapping, J 11.7, 2 CH2Ph), 4.74-4.92 (4 H, 2 AB, overlapping, J 11.7, 2 
CH2Ph), 5.17 (2 H, ddt, J 10.3, 1.4, 1.4, c/s-CH2-CH=Ctf2), 5.28 (2 H, ddt, J
17.3,1 .6,1 .6, trans-CH2-CH=CH2), 5.80-5.94 (4 H, m, CH2-CH=CH2 and C-2-H),





185 (6.1 g, 9.5 mmol) was heated under reflux in a mixture of methanol (108 ml) 
and 1 M HCI (12 ml) for 30 min, when tic (hexane /  ethyl acetate 1:1) showed 
conversion of the starting material (Rf 0.58) into a product (Rf 0.11). Examination 
by hptlc (ethyl acetate /  hexane 1:1) revealed two product spots only after the 
hptlc plate had been developed three times. The reaction mixture was cooled, 
neutralised with triethylamine and the solvent was evaporated. The residue was 
taken up in hot ether, filtered and kept at -20°C overnight. Crystals appeared, 
however, on filtration at r.t. the compound turned into an oil. Attempts to 
recrystallise from methanol and separate the diastereoisomers by flash 
chromatography (chloroform /  acetone 10:1) were also unsuccessful. Yield of
186 4.8 g, (7.9 mmol, 83 %).
SH (CDCI3; 270 MHz) 0.86, 0.92, 0.98, 1.02, (12 H, 4 s, 4 CH3), 1.08 (6 H, s, 2 
CH3), 1.55-1.72 (2 H, m, Camph-CH2), 1.82-2.1 (4 H, m, Camph-CH2), 2.28-2.46 
(2 H, m, Camph-CH2), 3.2-3.87 (14 H, m, D20  ex gives 10 H, m, 10 inositol ring 
H and 4 OH), 3.78 (6 H, S, 2 OCH3), 3.99-4.22 (4 H, m, CH2CH=CH2), 4.44-4.66 
(4 H, m, 2 CW2Ph), 4.71-4.94 (4 H, m, 2 CH2Ph), 5.18 (2 H, brd d, J 10.4, ds- 
CH2-CH=CH2), 5.28 (2 H, brd d, J 17.0, trans-CH2-CH=CH2), 5.82-5.92 (4 H, m, 
2 CH2CH=CH2 and 2 C-2-H), 6.83, 6.84 (4 H, 2 d, J 8.8, CH2Ph), 7.20-7.33 (14 
H, m, CH2P/j),
8C (CDCI3; 68 MHz) 9.68 (q, 2 Camph-CH3), 16.43, 16.48, 16.72, 16.79 (4 q, 4 
Camph-CH3), 28.95, 30.67 (2 t, Camph), 54.33, 54.91 (2 s, Camph), 55.25 (q, 
OCH3), 70.90, 71.97, 75.23, 75.32 (4 1, CH2CH=CH2 and CH2Ph), 67.71, 67.77, 
72.20, 72.35, 73.94, 76.68, 76.74, 77.55, 77.72, 79.94, 80.34 (11 d, inositol ring 
C), 91.32 (s, Camph), 113.72, 113.75 (2 d, CH2Ph), 117.89, 117.98 (2 t, 
CH2CH=CH2), 127.75, 127.99, 128.09, 128.38, 128.41, 129.74, 129.81 (7 d, 
CH2P/j), 134.05 (d, CH2CH=CH2), 138.39, 138.45 (2 s, CH2Ph), 159.35 (s, C- 
OCH3), 166.62,169.69,178.10,178.22 (4 s, carbonyl)
m/z (+ve ion FAB) 609 [(M-H)+, 1.5 %], 519 [(M-C7H7)+, 4.8], 489 [(M - 
C7H6OCH3) \  2), 121 [(C7H6OCH3)+, 100), 91 (10)
m/z (-ve ion FAB) 763 [(M+NBA)-, 22 %], 656 [(M+NBA - C7H70)-, 13], 609 [(M- 




A mixture of 186 (2.07 g, 3.39 mmol), DMAP (186 mg, 1.37 mmol), acetic 
anhydride (13.8 mg, 12.9 ml, 136.5 mmol) and pyridine (30 ml) was kept for 2 h 
at r.t. when tic (ethyl acetate /  hexane 1:1) showed complete conversion of the 
starting material into a product. Examination by hptlc revealed two product spots 
(Rf = 0.58 and 0.63). The product was precipitated with ice water and taken up in 
chloroform. The solution was washed several times with water and dried over 
magnesium sulphate. Evaporation of the solvents gave a syrup which was 
recrystallised from ethyl acetate /  hexane to give a 1:1 mixture of the two 
diastereoisomers (2.07 g, 2.98 mmol, 88 %). The mixture was taken up in hot 
ether and left overnight at 4°C, the crystals formed were found to be a 2:1 
mixture of the less polar isomer : the more polar isomer. Further 
recrystallisations gave the pure (+)-isomer.
m.p. 142-143°C
[a]D27 = +19.0° (c = 4 in CHCI3);
Found: C, 65.4; H, 6.54. Calc for C38H460 12 (694.78): C, 65.69; H, 6.67 %);
8h (CDCI3; 400 MHz) 0.95 (3 H, s, CH3), 1.115 (3 H, s, CH3), 1.125 (3 H, s, 
CH3), 1.66-1.73 (1 H, m, Camph-CH2), 1.84-2.11 (2 H, m, Camph-CH2), 
overlapping with 1.95 (3 H, s, C(0)CH3), 2.01 (3 H, s, C(0)CH3), 2.36-2.43 (1 H, 
m, Camph-CH2), 3.48 (1 H, dd, J 9.8, 2.7, C-1 (3)-H), 3.60 (1 H, dd, J 9.5, 2.7, C- 
3(1 )-H), 3.73 (1 H, dd, J 9.8, 9.6, C-6-H), 3.79 (3 H, s, OCH3), 3.93, 4.12 (2 H, 
AB, d, Jab 12.9, J 5.4, CH2CH=CH2), 4.48, 4.65 (2 H, AB, 10.5, CH2Ph), 
4.61, 4.80 (2 H, AB, 11.2, CH2Ph), 5.05 (1 H, dd, J 10.0, 10.0, C-5(4)-H),
5.15 (1 H, dd, J 10.7, 1.5, c/s-CH2-CH=CH2), 5.22 (1 H, dd, J 17.6, 1.5 trans- 
CH2-CH=CH2), 5.27 (1 H, dd, J 10.3, 10.3, C-4(5)-H), 5.77 (1 H, ddt, J 17.1, 
10.25, 5.1, CH2CW=CH2), 5.89 (1 H, dd, J 2.7, 2.7, C-2-H), 6.85 (2 H, d, J 8.8, 
CH2Ph), 7.20-7.33 (7 H, m, CU2Ph)
8C (CDCI3; 100 MHz) 9.69,16.39,16.79 (3 q, 3 Camph-CH3), 20.70, 20.74 (2 q, 
2 acetyl-CH3), 29.04, 30.72 (2 t, Camph), 54.46, 54.92 (2 s, Camph), 55.27 (q, 
OCH3), 67.65, 71.18, 72.02, 74.78, 77.45, 78.04 (6 d, 6 inositol ring C), 71.09,
72.18, 75.26 (3 t, CH2CH=CH2 and 2 CH2Ph), 91.29 (s, Camph), 113.83 (d, 
CH2Ph), 117.52 (t, CH2CH=CH2), 127.74, 127.98, 128.33, 129.86 (4 d, CH2Ph),
232
129.26 (s), 133.66 (d, CH2CH=CH2), 137.98 (s, CH2Ph), 159.45 (s, C-OCH3), 
166.51, 169.79,169.99, 178.05 (4 s, carbonyl)
m/z (+ve ion FAB) 693 [(M-H)+, 4 %], 603 [(M-C7H7)+, 10], 121 (100), 91 (34) 
m/z (-ve ion FAB) 847 [(M+NBA)', 40 %], 740 [(M+NBA - C7H70)-, 23], 197 
[(CamphO)-, 100]
23.10 (+)-3-0-Allyl-6-0-benzyl-1-0-/Mnethoxybenzyl-/nyo-inositol 188
187 (2.48 g, 3.57 mmol) was dissolved in 100 ml methanol containing 4 g NaOH. 
The solution was heated under reflux for 30 min when tic (ether) showed 
complete conversion of the starting material into a single product. After cooling, 
the solution was neutralised with solid C 0 2. Water (100 ml) was added and the 
solution extracted twice with 100 ml chloroform each. The organic layers were 
dried over magnesium sulphate and the solvent evaporated to give 188 (1.48 g,
3.43 mmol, 96 %).
m.p. 157-158°C (from ethyl acetate)
[ocfo20 = +19-0° (c = 4 in CHCI3),
Found: C, 67.0; H, 7.02. Calc for C24H30O7 (430.50): C, 66.96; H, 7.02 %. 
m/z (+ve ion FAB) 429 (3 %), 400 (10), 339 (8), 309 (5), 121 [(C7H6OCH3)+, 
100], 91 (8)
m/z (-ve ion FAB) 583 [(M+NBA)-, 100 %], 429 [(M-H)-, 85], 322 [(M - C7H70)-, 
30], 309 [(M - C7H6OCH3)-, 20]
NMR data were identical to 183.
24 Lactonisation
24.1 DL-3,6-Di-0»benzyl-1-O-cyanomethylene-/nyo-inositol 189
A mixture of DL-1,4-di-Obenzyl-/77yo-inositol 124 (8 g, 22.2 mmol) and dibutyltin 
oxide (6 g, 24 mmol) in toluene (240 ml) was heated under reflux in a Dean and 
Stark apparatus for 4 h. The solution was evaporated to dryness in vacuo. 
Caesium fluoride (16.9 g, 111 mmol) was added to the resulting white solid and 
the mixture was dried in vacuo for 2 h. The mixture was then suspended in dry
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DMF (300 ml) under nitrogen, and bromoacetonitrile (3.36 g, 1.95 ml, 28 mmol) 
was added. After stirring for 20 h at room temperature the solvent was 
evaporated. Water (150 ml), 2 M HCI (20 ml) as well as ethyl acetate (300 ml) 
were added to the residue, which was then filtered through Celite to remove tin 
compounds. The organic layers were dried over magnesium sulphate, 
evaporated to dryness and the product was purified by flash chromatography 
using ether / ethyl acetate (2:1) as eluent to give 189 (5.1 g, 12.8 mmol, 58%).
tic (ether / ethyl acetate 1:1) Rf 0.58 
m.p. 141-142°C
Found C, 66.2; H, 6.34; N, 3.53. Calc, for C22H2506N (399.45): C, 66.15; H,
6.31 ;N, 3.51 %.
5h (CDCI3i 270 MHz) 2.90-3.10 (3 H, brd, OH), 3.22 (1 H, dd, J 9.4, 2.2, C-3(1)- 
H), 3.36 (1 H, dd, J 9.4, 2.2, C-1(3)-H), 3.41 (1 H, dd, J 9.4, 9.4, C-H), 3.84 (1 H, 
dd, J 9.5, 9.5, C-H), 3.83, 3.89 (2 H, AB, 9.5, CH2CN), 4.24 (1 H, m, C-H), 
4.31, 4.38 (2 H, AB, 15.8, CH2Ph), 4.65 (1 H, dd, J 3.7, 3.7, C-2-H), 4.81, 
4.92 (2 H, AB, Jab 11-2, CH2Ph), 7.29-7.38 (10 H, m, CH2Ph)
8C (CDCI3, 68 MHz) 56.24 (t, CH2CN), 67.37, 71.84, 74.41, 78.91, 80.24, 80.37 
(6 d, inositol ring C), 72.43, 75.44 (2 t, CH2Ph), 116.21 (CN), 127.83, 127.96,
128.18, 128.48,128.60 (5 d, CH2P/?), 137.27, 138.27 (2 s, CH2P/7),
m/z (70 eV El) 399 (M)+, 308 [(M - C7H7)+, 15 %], 149 (10), 107 [(C7H70 )+, 20], 
91 [(C7H7)+ 100]
m/z (Cl, Isobutane) 442 [(M + C3H7)+, 5 %], 400 [(M + H)+, 25], 308 [(M - C7H7)+, 
20], 181 (40), 107 (55), 91 (100)
24.2 DL-3,6-Di-0-benzyl-1-0-carboxymethylene-/nyo-inositol 190
189 (3.39 g, 8.5 mmol) was dissolved in a solution of NaOH (680 mg, 17 mmol) 
in 25 ml ethanol. The mixture was heated under reflux until no more ammonia 
was formed (4 h). Water was then added and the solution was acidified with 
hydrochloric acid to a pH of 3. The mixture was extracted with ethyl acetate (2 x 
25 ml), the organic fractions were dried (magnesium sulphate) and the solvent 
was evaporated. Recrystallisation of the crude product from ethyl acetate /
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ethanol (10:1) gave 190 (2.86 g, 6.85 mmol, 81 %)
tic (ether / ethyl acetate 1:1) Rf 0.03 
m.p. 185-187°C
Found: C, 62.9; H, 6.50. Calc, for C22H2608 (418.43): C, 63.15; H, 6.26 %.
5h (d6-DMSO, 270 MHz) 3.10 (1 H, dd, J 9.9, 2.2, C-3(1)-H), 3.16 (1 H, dd, J 9.9,
9.9, C-H), 3.27 (1 H, dd, J 9.9, 2.2, C-1(3)-H), 3.38 (1 H, brd, OH), 3.59 (1 H, dd, 
J 9.5, 9.5, C-H), 3.62 (1 H, dd, J 9.5, 9.5, C-H), 4.16, 4.21 (2 H, AB, 16.7, 
CH2COOH), 4.28 (1 H, s, C-2-H), 4.59, 4.66 (2 H, AB, 12.1, CH2Ph), 4.76, 
4.79 (2 H, AB, 11.4, CH2Ph), 4.86 (1 H, brd, OH), 4.95 (1 H, brd, OH), 7.22-
7.44 (10 H, m, CH2Ph), 12.6 (1 H, brd, COOH)
8C (d6-DMSO, 68 MHz) 66.49, 72.04, 74.99, 79.34, 80.76, 81.06 (6 d, inositol 
ring C), 67.27 (t, CH2COOH), 70.94, 74.08 (2 1, CH2Ph), 126.95, 127.01, 127.47, 
127.63, 127.83 (5 d, CH2Ph), 139.02, 139.44 (2 s, CH2Ph), 172.20 (s, COOH)
m/z (+ve ion FAB) 418 (M+, 100 %), 289 (35), 247 (90), 91 (85)
m/z (-ve ion FAB) 570 [(M+NBA - H)-, 60%], 417 [(M - H)-, 100), 326 (25), 272
(30), 167 (42)
v max^ cm 1 (KBr-disc): 1720 (s, carbonyl)
24.3 DL-3,6-di-0-benzyl-(1-0-methylene-2-lacto)-/77yo-inositol 191
a) A mixture of DL-1,4-Di-O-benzyl-myo-inositol 124 (4 g, 11.1 mmol) and 
dibutyltin oxide (3 g, 12 mmol) in toluene (120 ml) was heated under reflux in a 
Dean and Stark apparatus overnight. The solution was evaporated to dryness in 
vacuo. Caesium fluoride (8.44 g, 55.5 mmol) was added to the resulting white 
solid and the mixture was dried in vacuo for 2 h. The mixture was suspended in 
dry DMF (200 ml) under nitrogen and ethyl bromoacetate (6 g, 4 ml, 36 mmol) 
was added. The reaction was stirred at 80°C for 8 h, the solvent was evaporated 
and the residue was taken up in ethyl acetate. After washing with 1 M HCI and 
sat. KCI solution the mixture was stirred for 30 min with a sat. NaHC03 solution 
and the precipitated tin derivatives were removed by filtration through Celite.
The solvent was evaporated and the residue was chromatographed on silica gel
*
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eluting with ether / ethyl acetate to give 191 (700 mg, 1.75 mmol, 16%).
b) A mixture of 190 (1 g, 2.39 mmol), toluene (160 ml) and conc. H2S 04 (20 pi) 
was heated under reflux for 1 h in a Dean and Stark apparatus. The solvent was 
evaporated and the crude product taken up in ethyl acetate. The insoluble solid 
was filtered and the solvent was evaporated. Recrystallisation from ethyl acetate 
/ hexane gave 191 (881 mg, 2.20 mmol, 92 %)
tic (ether /  ethyl acetate 1:1) Rf 0.69 
m.p. 153-155°C
Found: C, 65.80; H, 5.91. Calc, for C22H2407 (400.43): C, 65.99; H, 6.04 %.
5|_| (CDCI3, 270 MHz) 3.03-3.18 (1 H, brd, OH), 3.12-3.26 (1 H, brd, OH), 3.78-
3.86 (2 H, m, C-3-H, C-5-H), 3.94 (1 H, dd, J 5.6, 5.6, C-6-H), 4.07 (1 H, dd, J
6.0, 3.0, C-1-H), 4.20-4.13 (1 H, m, C-4-H), 4.02, 4.30 (2 H, AB, JAB 17.6, 
CH2COOR), 4.61, 4.68 (2 H, AB, JAB 11.2, CH2Ph), 4.74 (2 H, AB, CH2Ph), 4.88 
(1 H, dd, J 3.3, 3.3, C-2-H), 7.25-7.32 (10 H, m, CH2Ph)
8C (C D C I3 , 68 MHz) 61.01 (t, CH2CO), 70.54, 71.13, 73.69, 74.82, 75.63, 76.54, 
(6 d, inositol ring C), 72.23, 73.53 (2 t, CH2Ph), 131.52, 131.59, 131.75, 131.95,
132.01 (5 d, CH2Ph) 136.81 (s, CH2Ph), 166.68 (s, CO)
v max/c m ' 1 (KBr-disc): 1735 (s, carbonyl)




A mixture of 191 (727 mg, 1.74 mmol), DMAP (86 mg, 0.7 mmol), acetic 
anhydride (7.1 mg, 6.6 ml, 70 mmol) and pyridine (15 ml) was stirred for 5 h at 
50°C. The product was precipitated with ice water and taken up in chloroform. 
The solution was washed several times with water and dried over magnesium 
sulphate. Evaporation of the solvents gave a syrup which was recrystallised from 
ethyl acetate / hexane to give 192 (708 mg, 1.46 mmol, 84 %).
236
m.p. 159-163°C
Found C f 64.7; H, 5.78. Calc, for C26H280 9 (484.51): C, 64.46; H, 5.83 %.
8h (CDCI3, 270 MHz) 1.99 (6 H, 2 s, CH3), 3.69 (1 H, dd, J 8.4, 3.3, C-3(1)-H, ), 
3.88 (1 H, dd, J 8.4, 8.4, C-6-H), 3.95 (1 H, dd, J 8.4, 3.1, C-1(3)-H), 4.04, 4.26 
(2 H, AB, 17.6, CH2COOR), 4.63, 4.68 (2 H, AB, 12.1, CP2Ph), 4.65, 
4.70 (2 H, AB, JAB 11.7, CH2Ph), 4.82 (1 H, dd, J 3.1, 3.1, C-2-H), 5.09 (1 H, dd, 
J 9.0, 9.0, C-5-H), 5.39 (1 H, dd, J 9.0, 9.0, C-4-H), 7.28-7.36 (10 H, m, CH2Ph)
8C (CDCI3, 68 MHz) 20.69, 20.76 (2 q, OCOCH3), 66.91, 71.23, 72.52, 76.61, 
78.30, 81.12 (6 d, inositol ring C), 67.85 (t, CH2COOR), 72.56, 75.83 (2 t, 
CH2Ph), 127.76, 127.83, 127.96, 128.18, 128.51, 128.57, 129.74 (7 d, CH2P/j), 
137.04 (s, CH2P/7), 166.29,169.57,169.90 (3 s, CO)
m/z (+ve ion FAB) 969 [(2M+H)+, 1 %], 485 [(M+H)+, 8], 377 [(M-C7H70 )+, 5], 
181 (20), 91 (100)
m/z (-ve ion FAB) 650 (70%), 637 [(M+NBA)-, 100], 530 (50), 483 [(M-H)-, 30] 
vmax/cm ‘1 (KBr-disc): 1770 and 1740 (s, carbonyl)
24.5 (-)-3,6-Di-Obenzyl-4,5-di-0-[(-)-o>-camphanoyl]-(1-0-methylene- 
2-lacto)-/nyo-inositol 193
A mixture of 191 (3.07 g, 7.67 mmol), DMAP (175 mg, 1.43 mmol) and S-(-)- 
camphanic chloride (5 g, 23.15 mmol) in dry pyridine (60 ml) was stirred at r.t. for 
2 h, after which tic (ethyl acetate /  hexane 1:1) showed complete conversion of 
the starting material (Rf 0.32) into a product (Rf 0.81). Water (1 ml) was added 
and the solution stirred for another 30 min. The mixture was then partitioned 
between water and ether (50 ml each) and the ether layer was washed with 
water and sat. NaHC03 solution. The organic phase was then dried over 
magnesium sulphate and the solvent evaporated to give a mixture of the two 
diastereomers of 193 as a syrup (5.43 g, 7.13 mmol, 93 %). Recrystallisation 




[a]D24 = -39.6° (c = 4 in CHCi3)
Found C, 66.7; H, 6.44. Calc, for C42H480 13 (760.84): C 66.30, H 6.36 %.
8h (CDCI3, 400 MHz) 0.81, 0.84, 0.95, 0.98, 1.04, 1.06 (18 H, 6 S, 6 CH3), 1.57-
1.67 (2 H, m, Camph-CH2),1.78-1.95 (4 H, m, Camph-CH2), 2.17-2.27 (2 H, m, 
Camph-CH2), 3.43 (1 H, dd, J 9.8, 2.5, C-3(1)-H), 3.62 (1 H, dd, J 10.0, 2.7, C- 
1(3)-H), 4.12, 4.30 (2 H, AB, J 16.8, CH2COOR), 4.17 (1 H, dd, J 9.8, 9.8, C-6- 
H), 4.38 (1 H, dd, J 2.6, 2.6, C-2-H), 4.57, 4.70 (2 H, AB, J 11.7, CH2Ph), 4.69,
4.87 (2 H, AB, J 11.2, CH2Ph), 5.28 (1 H, dd, J 9.5, 9.5, C-5-H), 5.66 (1 H, dd, J
9.8, 9.8, C-4-H), 7.22-7.33 (10 H, m, CH2P/?)
8C (CDCI3, 100 MHz) 9.60,16.40,16.53,16.64, (4 q, Camph-CH3), 28.75, 28.79, 
31.20 (2 t, Camph), 52.14, 53.66, 53.99, 54.65, 54.74 (5 s, Camph), 66.64, 
72.84, 73.84, 76.79, 78.47, 81.78 (6 d, 6 inositol ring C), 68.23, 72.84, 73.85 (3 
t, CH2COOR and 2 CH2Ph), 90.67, 90.73 (2 s, Camph), 126.96, 127.45, 127.65, 
127.93, 128.29, 128.47 (6 d, CH2Ph) 137.18, 138.13 (s, CH2P/l), 166.64,
166.75,171.56,177.92,178.14 (5 s, 5 CO)
24.6 (+)-3,6-Di-0-benzyl-1-0-carboxymethylene-n7yo-inosItol 194
193 (400 mg, 526 pmol) was dissolved in a solution of NaOH (0.5 g) in 50 ml 
methanol. The mixture was heated under reflux for 30 min. Water was then 
added and the solution was acidified with hydrochloric acid to a pH of 3. The 
mixture was extracted with ethyl acetate (2 x 25 ml), the organic fractions were 
dried (magnesium sulphate) and the solvent was evaporated. Recrystallisation of 
the crude product from ethyl acetate /  ethanol (10:1) gave 194 (197 mg, 473 
mmol, 90 %)
m.p. 308-310°C (with a phase transition between 240 and 255°C)
[a]D23 = + 96° (c = 0.1 in DMF)
Found: C, 62.9; H, 6.50. Calc, for C22H260 8 (418.43): C, 63.15; H, 6.26 %. 
Spectroscopical data were identical to 190.
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25 Elimination / Claisen Rearrangement
25.1 DL-1-0-Allyl-2-0-benzoyl-3,6-di-0-benzyl-4,5-0-isopropylidene- 
scyllo- inositol 195
A solution of 160 (6.06 g, 10.6 mmol), potassium benzoate (5.13 g, 32 mmol) 
and 18-crown-6 (1.32 g, 5 mmol) in DMF (250 ml) was heated at 80°C for 4 h. 
The mixture was cooled, quenched with water (100 ml) and extracted with ether 
(2 x 200 ml). The combined organic layers were washed with brine, dried over 
magnesium sulphate and the solvent was evaporated. Flash chromatography 
(S i02, hexane / ether 3:1) gave 195 (3.9 g, 7.1 mmol, 67 %).
m.p. 141-142°C (ethanol)
Found: C, 72.7; H, 6.62. Calc, for C33H3607 (544.64): C, 72.77; H, 6.66 %.
5h (CDCI3; 270 MHz) 1.48 (6 H, s, 2 CH3), 3.57-3.81 (5 H, m, 5 C-H), 4.03, 4.23 
(2 H, AB, ddd, JAB 12.4, J 5.9,1.65,1.65, CH2CH=CH2), 4.65, 4.80 (2 H, AB, JAB
12.5, CH2Ph), 4.74, 4.91 (2 H, AB, Jab 11-7, CH2Ph), 4.95 (1 H, dq, J 10.8, 1.65, 
CH2CH=CH2), 5.05 (1 H, dq, J 17.2, 1.65, CH2CH=CH2), 5.43 (1 H, dd, J 8.9,
8.9, C-2-H), 5.66 (1 H, ddt, J 16.9, 10.6, 5.7, CH2CH=CH2), 7.11-7.60 (13 H, m, 
CH2P/j and C(0)Ph), 8.02 (2 H, dd, J 7.15,1.3, C(0)Ph)
6C (CDCI3; 68 MHz) 26.95 (q, C(CH3)2), 71.88, 72.95, 74.08 (3 t, 2 CH2Ph and 
CH2CH=CH2), 75.35, 76.42, 78.59, 78.88, 79.40, 81.44 (6 d, 6 inositol ring C), 
112.55 (s, (CH3)2C), 117.06 (t, CH2CH=CH2), 127.28, 127.44, 127.63, 128.02,
128.18, 128.25, 129.71 (7 d, CH2Ph), 132.92 (d, CH2P/?), 134.54 (d, 
CH2CH=CH2), 137.98, 138.30 (2 s, CH2Ph), 165.32 (s, C=0); 
m/z (+ve ion FAB) 545 [(M + H)+, 7 %], 487 [(M - OCH2CH=CH2)+, 15], 91 (100) 
m/z (-ve ion FAB) 697 [(M + NBA)-, 100 %], 560 (42), 485 (55), 440 (55), 322 
(60), 290 (97), 274 (85)
25.2 DL-1-0-Allyl-2-0-benzoyl-3,6-di-0-benzyl-scy//o-inositol 196
195 (990 mg, 1.82 mmol) was heated under reflux in 80 % acetic acid (50 ml) for 
30 min after which tic (ethyl acetate / hexane 1:1) showed complete conversion 
of the starting material (Rf 0.64) into a product (Rf 0.38). The reaction mixture 
was allowed to cool and diluted with water (50 ml). The solution was stored at -
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20°C overnight, the precipitate was collected and recrystallised from ethyl 
acetate / hexane. Yield 813 mg (1.61 mmol, 89 %).
m.p. 158-159°C (ethyl acetate / hexane)
Found: C, 71.6; H, 6.38. Calc, for C30H32O7 (504.58): C, 71.41; H, 6.39 %.
5h (CDCI3; 270 MHz) 3.11 (1 H, brd s, D20  ex, OH), 3.31 (1 H, brd s, D20  ex, 
OH), 3.42-3.65 (5 H, m, 5 C-H), 4.06, 4.22 (2 H, AB, ddd, 12.3, J 6.0, 1.65,
1.65, CH2CH=CH2), 4.67, 4.70 (2 H, AB, J 11.5, CP2Ph), 4.79, 4.90 (2 H, AB, J
11.2, CH2Ph), 4.97 (1 H, dq, J 10.3, 1.65, CH2CH=CH2), 5.05 (1 H, dq, J 17.2,
1.65, CH2CH=CH2), 5.39 (1 H, dd, J 9.3, 9.3, C-2-H), 5.68 (1 H, ddt, J 17.2, 
10.4, 5.9, CH2CH=CH2), 7.13-7.61 (13 H, m, CH2P/7 and C (0 )Ph), 8.04 (2 H, dd, 
J 7.0, 1.5, C(0)P/7))
5C (CDCI3; 68 MHz) 73.79, 73.92, 74.47, 79.86, 80.31, 81.90 (6 d, 6 inositol ring 
C), 74.28, 74.73, 75.44 (3 t, 2 CH2Ph and CH2CH=CH2), 117.35 (t, 
CH2CH=CH2), 127.70, 127.89, 128.02, 128.31, 128.44, 128.54, 129.71 (7 d, 
CH2P/7 and C (0 )Ph)), 133.11 (d, C(0)Ph), 134.48 (d, CH2CH=CH2), 137.82, 
138.34 (2 s, CH2P/7), 165.55 (s, C=0);
m/z (+ve ion FAB) 505 [(M + H)+, 7 %], 413 [(M - CH2Ph)+, 1], 397 [(M - 
OCH2Ph)+, 3], 181 (10), 105 (31), 91 (100)
m/z (-ve ion FAB) 1007 [(2 M - H)-, 19 %], 670 (64), 657 [(M + NBA)-, 100], 550 
(41), 503 [(M -H )-, 46]
25.3 DL-2-0-Benzoyl-1,4-di-0-benzyl-scy//o-inositol 197
196 (2.64 g, 5.23 mmol) and DABCO (118 mg, 1.08 mmol) were heated with 
stirring in a mixture of ethanol, toluene and water (7:3:1, 22 ml). When the 
reaction mixture had reached reflux temperature, tris(triphenylphosphine)- 
rhodium(l) chloride (334 mg, 364 pmol) was added and heating under reflux 
continued for 30 min. Tic (ethyl acetate /  hexane 1:1) showed conversion of the 
starting material (Rf 0.47) into a product (Rf 0.53). 1 M HCI (20 ml) was then 
added and after heating was continued for further 30 min, tic (ethyl acetate / he­
xane 1:1) showed a product (Rf 0.30). The suspension was cooled, neutralised 
with aqueous sodium hydrogen carbonate and extracted with ethyl acetate (2 x
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100 ml). Evaporation of the solvent gave 197 (1.72 g, 3.71 mmol, 71 %) 
m.p. 226-228°C (from ethyl acetate)
Found: C, 69.9; H, 6.14. Calc, for C27H280 7 (464.52): C, 69.81; H, 6.08 %.
5h (d6-DMSO; 270 MHz) 3.26-3.53 (4 H, m, 4 C-H), 3.63 (1 H, ddd, J 9.3, 9.3,
6.0, D20  ex gives dd, J 9.3, 9.3, C-H), 4.54, 4.82 (2 H, AB, JAB 11.5, CH2Ph), 
4.84 (2 H, AB, CH2Ph), 5.10 (1 H, dd, J 9.7, 9.7, C-2-H), 5.14 (1 H, brd s, D20  
ex, OH), 5.31 (1 H, brd s, D20  ex, OH), 5.38 (1 H, d, J 6.0, D20  ex, OH), 7.09-
7.67 (13 H, m, Ph), 8.00 (2 H, dd, J 7.1, 1.5, Ph)
8C (d6-DMSO; 68 MHz) 71.73, 74.00, 74.42, 75.52, 80.36, 82.76 (6 d, 6 inositol 
ring C), 73.72, 73.92 (2 t, 2 CH2Ph), 127.14, 127.18, 127.44, 127.69, 127.91, 
127.99, 128.62, 129.40 (8 d, CH2Ph and C(0)Ph), 130.50 (s, 0 ( 0 )Ph), 133.10 
(d, C(0)P/7), 138.88, 139.68 (2 s, CH2Ph), 165.45 (s, C=0);
m/z (+ve ion FAB) 462 [(M - 2 H)+, 4 %], 413 (13) 
m/z (-ve ion FAB) 355 (100 %), 342, 235
25.4 Elimination
160 (5.7 g, 10 mmol) was dissolved in dry dichloromethane (100 ml) and 1,8- 
diazabicyclo[5.4.0]undec-7-ene (1.52 g, 1.49 ml, 10 mmol) was added to this 
solution. The reaction mixture was stirred for 24 h after which tic (petrol ether 
b.p. 60-80°C / ether 2:1) showed complete conversion of the starting material (Rf 
0.35) into two major products (198, Rf 0.54 and 199, Rf 0.46). The solvent was 
evaporated and the residue separated by flash chromatography (petrol ether 
b.p. 40-60°C /  ether 4:1) to give 198 (1.52 g, 3.6 mmol, 36 %) and 199 (1.39 g, 
3.3 mmol, 33 %).
198:
m.p. 39-41 °C (from ethanol)
Found: C, 74.0; H, 7.18. Calc, for C26H30O5 (422.52): C, 73.91; H, 7.16 %.
5h (CDCI3; 270 MHz) 1.46 (6 H, s, 2 CH3), 3.63 (1 H, dd, J 9.9, 7.7, C-H), 3.73 (1 
H, dd, J 9.7, 8.2, C-H), 4.22-4.31 (4 H, m, CH2CH=CH2 and 2 C-H), 4.63 (1 H, s,
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C-H), 4.65, 4.83 (2 H, AB, J 11.7, Ctf2Ph), 4.81, 4.87 (2 H, AB, J 11.7, C «2Ph), 
5.22 (1 H, dq, J 10.4, 1.5, CH2CH=CH2), 5.33 (1 H, dq, J 17.2, 1.5, 
CH2CH=CH2), 5.96 (1 H, ddt, J17.2, 10.4, 5.3, CH2CH=CH2), 7.24-7.43 (10 H, 
m, CH2P/j)
6C (CDCI3; 68 MHz) 27.02 (q, C(CH3)2), 68.79, 71.45, 72.82 (3 t, 2 CH2Ph and 
CH2CH=CH2), 75.41, 77.23, 79.04, 80.11, 98.34 (5 d, 5 inositol ring C), 111.71 
(S, (CH3)2C), 117.45 (t, CH2CH=CH2), 127.37, 127.47,127.73,128.09, 128.25 (5 
d, CH2P/7), 132.63 (d, CH2CH=CH2), 138.37 (s, CH2Ph), 154.55 (s, inositol ring 
C);
m/z (+ve ion FAB) 421 [(M - H)+, 0.7 %], 365 [(M - OCH2CH=CH2)+, 0.6], 315 [(M 
- OCH2Ph)+, 1.8], 131 (20), 91 (100)
m/z (-ve ion FAB) 575 [(M + NBA)-, 20 %], 437 (31), 381 [(M - CH2CH=CH2)-, 
10), 273 (37), 215 (50), 124 (60), 109 (100)
199:
m.p. 71-73°C (from ethanol)
Found: C, 73.7; H, 7.02. Calc, for C26H30O5 (422.52): C, 73.91; H, 7.16 %.
5h (CDCI3; 270 MHz) 1.49, 1.50 (6 H, 2 s, 2 CH3), 3.78 (1 H. dd, J 10.5, 8.5, C- 
H), 3.92 (1 H, dd, J 10.6, 5.0, C-H), 3.96 (2 H, ddd, J 5.7, 1.5, 1.5, CHz- 
CH=CH2), 4.27-4.33 (2 H, m, 2 C-H), 4.58 (1 H, q, J 1.8, C-H)
4.75, 4.90 (2 H, AB, 11.9, CH2Ph), 4.86, 4.91 (2 H, AB, 12.1, CH2Ph),
5.14 (1 H, dq, J 10.3, 1.65, CH2CH=CH2), 5.21 (1 H, dq, J 17.2, 1.65, 
CH2CH=CH2), 5.84 (1 H, ddt, J 17.1, 10.4, 5.7, CH2CM=CH2), 7.24-7.41 (10 H, 
m, CH2P/j);
5C (CDCi3; 68 MHz) 26.66 (q, C(CH3)2), 69.96, 72.14 (2 t, CH2Ph and 
CH2CH=CH2), 74.02, 80.86, 81.23, 81.54 (4 d, 4 inositol ring C), 94.81 (d, C-2), 
112.32 (S, (CH3)2C), 116.90 (t, CH2CH=CH2), 127.43, 127.53, 127.76, 127.92,
128.18, 128.44 (6 d, CH2Ph), 134.77 (d, CH2CH=CH2), 135.94 (s, CH2P/i), 
138.30 (s, CH2P/7), 153.84 (s, C-3);
m/z (+ve ion FAB) 423 [(M + H)+, 1 %], 365 [(M - OCH2CH=CH2)+, 1], 91 (100)
m/z (-ve ion FAB) 422 (M‘, 2 %), 149 (100), 133 (75)
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25.5 DL-2-Deoxy-2-C-allyl-3,6-di-0-benzyl-4,5-0-isopropylidene-/?7yo-1- 
inosose 200 and DL-2-Deoxy-2-C-allyl-3,6-di-0-benzyl-4,5-0- 
isopropylidene-scy//o-inosose 201
198 (200 mg, 473 pmol) was heated at 200°C for 15 min. After cooling, tic (petrol 
ether b.p. 60-80°C /  ether 2:1) showed complete conversion of the starting 
material (Rf 0.54) into what appeared to be a single product (Rf 0.45). Yield 200 
mg (100 %).
5h (CDCI3; 270 MHz) 1.48, 1.49, 1.51, 1.53 (12 H, 4 s, 4 CH3), 2.14-2.97 (6 H, 
m, CH2CH=CH2, C-1-H), 3.51-4.19 (8 H, m, C-3,4,5,6-H), 4.55-5.03 (12 H, m, 4 
CH2Ph, CH2CH=CH2), 5.54-5.82 (2 H, m, CH2CH=CH2), 7.24-7.63 (20 H, m, 
CH2Ph)
8C (CDCI3; 68 MHz) 26.99 (q, CH3), 29.03, 30.36 (2 t, CH2CH=CH2), 52.67, 
52.97 (2 d, C-1), 71.71, 72.20, 72.36, 72.62 (4 t, CH2Ph), 74.34, 75.18, 77.29,
78.65, 80.44, 81.57, 82.32 (7 d, inositol ring C), 112.68, 112.74 (2 s, C(CH3)2), 
117.25, 117.54 (2 t, CH2CH=CH2), 127.57, 127.73, 127.99, 128.28, 128.35 (5 d, 
CH2P/7), 134.57, 135.22 (2 d, CH2CH=CH2), 137.20, 137.36, 137.65, 137.98 (4 
S, CH2P/7), 203.69, 205.31 (2 s, C=0)
m /z(+  ive ion FAB) 423 [(M+H)+, 8 %], 181 (9), 91 (100) 
v max/c m ' 1 (KBrdisk) 1715 (C = 0 )
25.6 DL-1-0-Allyl-3,6-di-0-benzyl-2-deoxy-2-fluoro-4,5-0-isopropylidene- 
scyllo-inositol 202
Tetrabutylammonium fluoride (3 ml of a 1.1 M solution in THF) was added to 160 
(1.11 g, 1.95 mmol) in THF (20 ml) at r.t. The colour of the reaction mixture 
immediately turned to red / brown. Stirring was continued for a further 30 min, 
the solvent was evaporated and the brown residue taken up in chloroform. After 
washing with water, the organic phase was dried over magnesium sulfate, 
evaporated and the crude product purified by flash chromatography (hexane / 
ether 3:1) to give 202 (595 mg, 1.34 mmol, 69 %) and 199 (60 mg, 0.14 mmol, 7 
%).
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m.p. 111-112°C (from hexane)
Found: C, 70.4; H, 7.04. Calc, for C26H3105F (442.53): C, 70.57; H, 7.06 %.
5h (CDCI3; 270 MHz) 1.42 (s, 6 H, 2 CH3), 3.41-3.63 (4 H, m, 4 C-H), 3.71 (1 H, 
ddd, J 12.8, 9.7, 7.9, C-1-H or C-3-H), 4.24 (2 H, ddd, J 5.9, 1.5, 1.5, CH2- 
CH=CH2), 4.50 (1 H, dt, J 49.3, 7.9, C-2-H), 4.70, 4.85 (2 H, AB, 11.7,
CH2Ph), 4.74, 4.82 (2 H, AB, 11.9, CH2Ph), 5.13 (1 H, ddt, J 10.3, 1.2, 1.2,
CH2-CH=CH2), 5.23 (1 H, ddt, J 17.2, 1.5, 1.5, CH2-CH=CH2), 5.89 (1 H, ddt, J
16.9,10.5, 5.9, CH2-CH=CH2), 7.23-7.39 (10 H, m, CH2P/j);
5C (CDCI3; 68 MHz) 27.64 (q, C(CH3)2), 73.37, 73.82, 74.96 (3 t, 2 CH2Ph and 
CH2CH=CH2), 77.75, 77.85, 78.07 (3 d), 79.22 [dd, JC.C-F 15.4, C-1(3)], 82.99 
[dd, Jc.c.F 17.6, C-3(1)], 98.33 (dd, JC.F 185.1, C-2), 113.52 (s, C(CH3)2), 117.84 
(t, CH2CH=CH2), 128.25, 128.31, 128.38, 128.44, 128.51, 129.00 (6 d, CH2P/j), 
135.48 (d, CH2CH=CH2), 138.73,139.02 (2 s, CH2P/i),
5F (CDCI3 with reference to CFCI3; 84 MHz) 193.9 (dd, J 51.3,14.7)
m/z (+ve ion FAB) 443 [(M + H)+, 7 %], 181 (8), 91 (100)
m/z (-ve ion FAB) 595 [(M + NBA)-, 50 %], 442 (M‘, 29), 182 (72), 167 (100), 93
(85)
The minor product 199 was identical to 199 obtained by the DBU elimination 
reaction performed on 160.
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